WorldWideScience

Sample records for ampliscreen hbv test

  1. [Advanced Testing and Laboratory for HBV, HCV, and HIV Infection].

    Science.gov (United States)

    Deguchi, Matsuo

    2015-06-01

    Most target substances for immunoassay of infectious disease are antigens or antibodies which do not exist in the human body. Therefore, the method to set reference values is different from chemistry or hematology testing. High sensitivity is required for infectious disease testing, particularly for screening. Also, its reference values (cut-off values) are set as low as possible. Therefore, a false-positive reaction can be caused due to slightly non-specific reactions in infectious disease reagents. The specificities for infectious disease reagents were evaluated with 9 kinds of HCV antibody test kit and 9 kinds of HIV screening kit. The frequencies of false-positive results were 0.2-1.8 and 0.2-1.3%, respectively, and even a kit with a high specificity showed a false-positive result for 1 in 500 samples. The sensitivities for infectious disease reagents were evaluated with a newly developed super-high- sensitive HBs antigen assay kit and 8 kinds of chemiluminescence HBs antigen assay kit which are highly sensitive conventional kits. As a result, the super-high-sensitive kit was 10 to 40 times more sensitive than conventional kits. After introducing the super-high-sensitive kit to routine assays, 16 HBV-infected patients, who were not identified with the conventional kits, were detected for six months. On the other hand, we confirmed false-positive results due to contamination between specimens after introducing the super-high-sensitive kit. It is recommended to use the super-high-sensitive kit in a well-controlled environment to prevent contamination between specimens in order to generate highly reliable test results. PMID:26548240

  2. Interpreting Liver Function Test in HIV-HBV Coinfection.

    Directory of Open Access Journals (Sweden)

    Tamal Mukherjee

    2013-08-01

    Such co-infected individuals also face increased risk of hepatotoxicity from anti-retroviral therapy. Individuals with HIV-HBV co-infection should have both the infections completely assessed in order to decide on the best therapeutic option for both viruses. [Natl J Med Res 2013; 3(4.000: 342-345

  3. HBV-DNA positive women postpartum cord blood and breast milk HBV-DNA capacity testing analysis%HBV-DNA阳性孕妇产后脐带血及乳汁中HBV-DNA载量分析

    Institute of Scientific and Technical Information of China (English)

    黄霞; 杨文东

    2013-01-01

    目的 通过荧光定量PCR(FQ-PCR)方法检测血清HBV-DNA阳性产妇产后脐带血及乳汁HBV-DNA载量,探讨胎儿宫内感染HBV及乳汁携带HBV与产妇HBV-DNA载量的相关性.方法 2010年1月至2012年11月,选取在产科住院分娩的HBV-DNA阳性产妇149例,采用FQ-PCR方法检测产妇产前血清、产后脐带血和乳汁HBV-DNA载量.结果 ①选择有HBV感染史产妇304例中149例HBV-DNA阳性,阳性率为49.01%(149/304);②149例HBV-DNA阳性产妇胎儿宫内感染为42.95%;HBV-DNA阳性孕妇乳汁中HBV-DNA阳性率(71.14%)显著高于脐血(42.95%)(P<0.01);HBV-DNA≥1×105组脐带血、初乳及满月乳中HBV-DNA阳性率(61.29%、82.80%、100.00%)显著高于1×103≤HBV-DNA<1×105组(12.50%、51.79%、75.00%)(P< 0.01);满月乳中HBV-DNA阳性率(90.60%)显著高于初乳(71.14%)(P<0.01).结论HBV-DNA阳性孕妇胎儿HBV的宫内感染率及乳汁中携带HBV的阳性率高,与孕妇血清HBV-DNA载量正相关,阻断HBV的宫内感染及减少乳汁携带HBV者,必须有效的降低孕妇血中的HBV-DNA载量水平.

  4. 聚合酶链反应检测血清HBV-DNA的临床价值%Clinical Value of testing Blood HBV-DNA By PCR

    Institute of Scientific and Technical Information of China (English)

    高蓬

    1998-01-01

    @@ 聚合酶链反应(polymerase chain reaction,PCR)是一种体外DNA扩增技术,本文采用PCR技术检测乙型肝炎病毒(HBV-DNA),并与乙肝病毒标志物进行对比,以探讨HBV感染状态及与乙肝标志物(HBV-M)之间的关系.

  5. The Epidemiologic Survey on HBV in Zhangjiakou

    International Nuclear Information System (INIS)

    To investigate the HBV prevalence information and to improve HBV prevention level in Zhangjiakou, the serum HBsAg in patients in Zhangjiakou second hospital from 2001 to 2007 were tested by RIA. The results showed that HBV infection rate had no changes over the years. The HBV infection rate in over 45 years old people was more than that of less 15 years old people, and HBV infection rate in medical workers were more than other vocations. The inoculation of HBV vaccine is modus operandi to prevent HBV infection. The medical workers are HBV infection high risk group. The regular monitoring of HBsAg could cut down HBV infection rate.(authors)

  6. Detection and quantitation of HBV DNA in miniaturized samples: multi centre study to evaluate the performance of the COBAS ® AmpliPrep/COBAS ® TaqMan ® hepatitis B virus (HBV) test v2.0 by the use of plasma or serum specimens.

    Science.gov (United States)

    Berger, Annemarie; Gohl, Peter; Stürmer, Martin; Rabenau, Holger Felix; Nauck, Markus; Doerr, Hans Wilhelm

    2010-11-01

    Laboratory analysis of blood specimens is an increasingly important tool for rapid diagnosis and control of therapy. So, miniaturization of test systems is needed, but reduced specimens might impair test quality. For rapid detection and quantitation of HBV DNA, the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HBV test has proved a robust instrument in routine diagnostic services. The test system has been modified recently for application of reduced samples of blood plasma and for blood serum, too. The performance of this modified COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HBV v2.0 (HBV v2.0 (this test is currently not available in the USA)) test was evaluated by comparison with the former COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HBV v1.0 (HBV v1.0) test. In this study a platform correlation of both assay versions was done including 275 HBV DNA positive EDTA plasma samples. Comparable results were obtained (R(2)=0.97, mean difference -0.03 log(10)IU/ml). The verification of equivalency of the sample matrix (plasma vs. serum samples tested in HBV v2.0 in the same run) showed comparable results for all 278 samples with a R(2)=0.99 and a mean difference of 0.06 log(10)IU/ml. In conclusion, the new test version HBV v2.0 is highly specific and reproducible and quantifies accurately HBV DNA in EDTA plasma and serum samples from patients with chronic HBV infection. PMID:20728470

  7. Development of cost-effective real-time PCR test: to detect a wide range of HBV DNA concentrations in the western amazon region of Brazil

    OpenAIRE

    de Oliveira dos Santos, Alcione; Souza, Luan Felipo Botelho; Borzacov, Lourdes Maria; Villalobos-Salcedo, Juan Miguel; Vieira, Deusilene Souza

    2014-01-01

    Background Currently there is a significant risk of infection with hepatitis B virus (HBV) during blood transfusion in high epidemic area. This is due to the pre-seroconversion window period, immunovariant viral strains and the presence of occult HBV infection (OBI). The aim of this study was to develop an in-house real-time PCR-based method, which was both ultra-sensitive and efficient offering an alternative method for nucleic acid testing (NAT). Methods A precore fragment with 109 bp was c...

  8. Hepatitis B virus DNA is more powerful than HBeAg in predicting peripheral T-lymphocyte subpopulations in chronic HBV-infected individuals with normal liver function tests

    Institute of Scientific and Technical Information of China (English)

    Jing You; Hutcha Sriplung; Alan Geater; Virasakdi Chongsuvivatwong; Lin Zhuang; Hong-Ying Chen; Jun-Hua Huang; Bao-Zhang Tang

    2008-01-01

    AIM: To investigate the peripheral T-lymphocyte subpopulation profile, and its correlations with hepatitis B virus (HBV) replication level in chronic HBV-infected (CHI) individuals with normal liver function tests (LFTs). METHODS: Frequencies of T-lymphocyte subpopulations in peripheral blood were measured by flow cytometry in 216 CHI individuals. HBV markers were detected with ELISA. Serum HBV DNA load was assessed with quantitative real-time PCR. Information of age at HBV infection, and maternal HBV infection status was collected. ANOVA linear trend test and linear regression were used in statistical analysis.RESULTS: CHI individuals had significantly decreased relative frequencies of CD+3, CD+4 subpopulations and CD+4/CD+8 ratio, and increased CD+8 subset percentage compared with uninfected individuals (all P<0.001). There was a significant linear relationship between the load of HBV DNA and the parameters of T-lymphocyte subpopulations (ANOVA linear trend test P<0.01). The parameters were also significantly worse among individuals whose mothers were known to be HBV carriers, and those having gained infection before the age of 8 years. In multiple regressions, after adjustment for age at HBV infection and status of maternal HBV infection, log copies of HBV DNA maintained its highly significant predictive coefficient on T-lymphocyte subpopulations, whereas the effect of HBeAg was not significant.CONCLUSION: HBV DNA correlates with modification in the relative T-lymphocyte subpopulation frequencies. High viral load is more powerful than HBeAg in predicting the impaired balance of T-cell subsets.

  9. Detection of Hepatitis B Virus (HBV) Genomes and HBV Drug Resistant Variants by Deep Sequencing Analysis of HBV Genomes in Immune Cell Subsets of HBV Mono-Infected and/or Human Immunodeficiency Virus Type-1 (HIV-1) and HBV Co-Infected Individuals.

    Science.gov (United States)

    Lee, Z; Nishikawa, S; Gao, S; Eksteen, J B; Czub, M; Gill, M J; Osiowy, C; van der Meer, F; van Marle, G; Coffin, C S

    2015-01-01

    The hepatitis B virus (HBV) and the human immunodeficiency virus type 1 (HIV-1) can infect cells of the lymphatic system. It is unknown whether HIV-1 co-infection impacts infection of peripheral blood mononuclear cell (PBMC) subsets by the HBV. Aims To compare the detection of HBV genomes and HBV sequences in unsorted PBMCs and subsets (i.e., CD4+ T, CD8+ T, CD14+ monocytes, CD19+ B, CD56+ NK cells) in HBV mono-infected vs. HBV/HIV-1 co-infected individuals. Methods Total PBMC and subsets isolated from 14 HBV mono-infected (4/14 before and after anti-HBV therapy) and 6 HBV/HIV-1 co-infected individuals (5/6 consistently on dual active anti-HBV/HIV therapy) were tested for HBV genomes, including replication indicative HBV covalently closed circular (ccc)-DNA, by nested PCR/nucleic hybridization and/or quantitative PCR. In CD4+, and/or CD56+ subsets from two HBV monoinfected cases, the HBV polymerase/overlapping surface region was analyzed by next generation sequencing. Results All analyzed whole PBMC from HBV monoinfected and HBV/HIV coinfected individuals were HBV genome positive. Similarly, HBV DNA was detected in all target PBMC subsets regardless of antiviral therapy, but was absent from the CD4+ T cell subset from all HBV/HIV-1 positive cases (P<0.04). In the CD4+ and CD56+ subset of 2 HBV monoinfected cases on tenofovir therapy, mutations at residues associated with drug resistance and/or immune escape (i.e., G145R) were detected in a minor percentage of the population. Summary HBV genomes and drug resistant variants were detectable in PBMC subsets from HBV mono-infected individuals. The HBV replicates in PBMC subsets of HBV/HIV-1 patients except the CD4+ T cell subpopulation. PMID:26390290

  10. Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients

    OpenAIRE

    Dammermann, Werner; Bentzien, Frank; Stiel, Eva-Maria; Kühne, Claudia; Ullrich, Sebastian; zur Wiesch, Julian Schulze; Lüth, Stefan

    2015-01-01

    Background Interferon gamma release assays (IGRA) have been developed to support easy and fast diagnosis of diseases like tuberculosis, and CMV in transplant patients. IGRAs focus on cellular immunity especially memory T cells and thus also allow rapid screening prior to complex flow cytometric testing. Here, we describe a novel, sensitive whole blood based cytokine release assay capable of assessing T cell responsiveness to HBV antigens in Hepatitis B patients and assessing hepatitis B vacci...

  11. Correlation of quantititive measurements between HBV-DNA and HBV-M%HBV-DNA和HBV-M定量检测的相关性研究

    Institute of Scientific and Technical Information of China (English)

    陈跃琼; 曾婉云

    2010-01-01

    目的 探讨HBV-DNA和乙型肝炎五项(HBV-M)定量检测之间的相关性及其在乙型肝炎感染诊断中的应用价值.方法 收集我院363例乙型肝炎和既往感染HBV患者血清,实时荧光定量PCR检测HBV-DNA,同时以时间分辨免疫荧光技术(TRFIA)定量检测HBV-M,用统计软件分析两者之间的关系.结果 乙型肝炎大三阳(HBsAg、HBeAg、HBcAb阳性)患者外周血HBV-DNA阳性率为92.9%(79/85),平均DNA含量(4.31±1.64)×106 Copies/ml.乙型肝炎小三阳患者(HBsAg、HBeAb、HBcAb阳性)外周血HBV-DNA阳性率为47.7%(105/220),平均DNA含量(2.47±2.21)×104 Copies/ml.HBsAg、HBcAb阳性3例,HBV-DNA均阳性,HBV-DNA为(5.73±1.14)×105Copies/ml.余人群外周血HBV-DNA均阴性.HBV-DNA拷贝量与HBeAg载量呈正相关(r=0.59,P=0.041);HBV-DNA拷贝量与HBsAg含量相关一致性不明显(r=0.221,P=0.077).结论 HBV-M与HBV-DNA之间既有联系又有不同,临床上可以多项检测来估计病情,判断疗效.%Objective To explore the correlation between HBV-DNA and serum HBV markers quantitative detection and determine its diagnosis value in hepatitis B virus infection. Methods The HBV-DNA was measured by fluorescence quantitative PCR and hepatitis B virus was detected by time-resolved fluorescence immunoassay (TRFIA). The relationship between the two tests was analyzed statistically using software. Results Detection of HBV-DNA in the peripheral blood of patients with HBsAg (+), HBeAg (+), HBcAb ( + ) showed 92. 9% (79/85) positive rate,and the average DNA copy number was (4.31 ± 1.64) × 106 copies/ml. While the detection of HBV-DNA in the peripheral blood of patients with HBsAg ( + ), HBeAb ( + ), HBcAb ( + ) showed 47.7% (105/220) positive rate, and the average DNA copy number was (2.47 ± 2. 21 ) × 104 copies/ml. In normal controls,blood HBV-DNA detection was negative. Furthermore, HBV-DNA copy number correlated positively with HbeAg quantitation (r = 0. 59, P = 0. 041 ). However, we found no

  12. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors

    Directory of Open Access Journals (Sweden)

    J.S.F. Pereira

    2006-04-01

    Full Text Available Anti-HBc positivity is a frequent cause of donation rejection at blood banks. Hepatitis B virus (HBV infection may also occur in HBsAg-negative patients, a situation denoted occult infection. Similarly, very low levels of HBV-DNA have also been found in the sera of patients with chronic hepatitis C virus (HCV infection, even in the absence of serum HBsAg. Initially we searched for HBV-DNA in serum of 100 blood donors and 50 HCV-infected patients who were HBsAg negative/anti-HBc positive by nested-PCR and by an HBV monitor commercial test for HBV-DNA. Anti-HBs seroconversion rates were measured in 100 blood donors and in 22 patients with chronic HCV infection after HBV vaccination to determine if the HBV vaccination could eliminate an occult HBV infection in these individuals. Occult HBV infection was detected in proportionally fewer blood donors (6/100 = 6% than chronic hepatitis C patients (12/50 = 24% (P 0.05. All subjects who were HBV-DNA(+ before the first dose of HBV vaccine (D1, became HBV-DNA(- after D1, D2, and D3. Among 22 HCV-positive patients, 10 HBV-DNA(+ and 12 HBV-DNA(-, seroconversion was observed in 9/10 (90% HBV-DNA(+ and in 9/12 (75% HBV-DNA(- subjects (P > 0.05. The disappearance of HBV-DNA in the majority of vaccinated patients suggests that residual HBV can be eliminated in patients with occult infection.

  13. Hepatitis B (HBV)

    Science.gov (United States)

    ... Can I Help a Friend Who Cuts? Hepatitis B (HBV) KidsHealth > For Teens > Hepatitis B (HBV) Print A A A Text Size What's ... There are several different types of hepatitis . Hepatitis B is a type that can move from one ...

  14. HCV and HBV coexist in HBsAg-negative patients with HCV viremia; possibility of coinfection in these patients must be considered in HBV-high endemic area

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Dong Soon [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    1998-01-01

    Hepatocellular carcinoma (HCC) is one of the most common cancers and is highly associated with HBV infection in Korea. It has been suggested that HCV core protein may impair the polymerase activity of HBV in vitro, potentially lowering HBV titre in coinfected patients. The aim of this study was to confirm the coexistence of HBV viremia in HCV infected patients HCC who have apparent HBsAg seronegativity. The serological profiles of HBV and HCV in 616 patients with HCC were analysed and coinfection rate of HBV and HCV investigated. Sera were obtained from 16 patients who were both anti-HCV and HCV RNA positive but HbsAg negative, and tested for HBV BY PCR. As a control group, sera were obtained from 15 patients with HCC and 30 non-A abd non-B chronic hepatitis patients without HCC; both were anti-HCV, HCV-RNA, and HBsAg negative and tested for HBV PCR. Of 616 patients with HCC, 450 (73.1 %) had current HBV infection, 48 (7.8 %) had anti-HCV antibodies, and nine (1.5 %) had viral markers of both HCV abd HBV by serological profiles. Of 27 the patients with HCV viremia and HBsAg seronegativity, 14 (51.9 %) showed HBV viremia by PCR. In contrast, of the 75 patients in the control group who were both HCV PCR negative and HBsAg negative, five (11.1 %) showed HBV viremia by PCR. The PCR for HBV revealed coexistent HBV viremia in HCV viremia patients, despite HBsAg negativity by EIA. In HBV-endemic areas, the possibility of coinfection of HBV in HBsAg-negative patients with HCV viremia should be considered and molecular analysis for HBV-DNA performed. (author). 18 refs., 4 tabs.

  15. HCV and HBV coexist in HBsAg-negative patients with HCV viremia; possibility of coinfection in these patients must be considered in HBV-high endemic area

    International Nuclear Information System (INIS)

    Hepatocellular carcinoma (HCC) is one of the most common cancers and is highly associated with HBV infection in Korea. It has been suggested that HCV core protein may impair the polymerase activity of HBV in vitro, potentially lowering HBV titre in coinfected patients. The aim of this study was to confirm the coexistence of HBV viremia in HCV infected patients HCC who have apparent HBsAg seronegativity. The serological profiles of HBV and HCV in 616 patients with HCC were analysed and coinfection rate of HBV and HCV investigated. Sera were obtained from 16 patients who were both anti-HCV and HCV RNA positive but HbsAg negative, and tested for HBV BY PCR. As a control group, sera were obtained from 15 patients with HCC and 30 non-A abd non-B chronic hepatitis patients without HCC; both were anti-HCV, HCV-RNA, and HBsAg negative and tested for HBV PCR. Of 616 patients with HCC, 450 (73.1 %) had current HBV infection, 48 (7.8 %) had anti-HCV antibodies, and nine (1.5 %) had viral markers of both HCV abd HBV by serological profiles. Of 27 the patients with HCV viremia and HBsAg seronegativity, 14 (51.9 %) showed HBV viremia by PCR. In contrast, of the 75 patients in the control group who were both HCV PCR negative and HBsAg negative, five (11.1 %) showed HBV viremia by PCR. The PCR for HBV revealed coexistent HBV viremia in HCV viremia patients, despite HBsAg negativity by EIA. In HBV-endemic areas, the possibility of coinfection of HBV in HBsAg-negative patients with HCV viremia should be considered and molecular analysis for HBV-DNA performed. (author). 18 refs., 4 tabs

  16. Prevalence of HBV genotypes in South American immigrants affected by HBV-related chronic active hepatitis

    Directory of Open Access Journals (Sweden)

    Emilio Palumbo

    2007-06-01

    Full Text Available This study evaluated the prevalence of HBV infection in a population of South American immigrants in Italy and to determine in patients with detectable serum HBV-DNA the HBVgenotypes. Between April 2005 and April 2006 a total of 130 South American immigrants were tested for HBsAg. In HBsAg positive patients the biochemical and virological activity of infection and the possible presence of co-infections (HCV, HDV, HIV were evaluated. In patients with detectable serum HBV DNA, the HBV genotype was determined by INNOLiPA. Among the 130 subjects tested, 14 (10.7% resulted HBsAg positive. All were men, with a mean age of 22 years (range 19-37 and 12 (85.7 % came from Brazil, while 2 (14.3% came from Ecuador. All patients infected by HBV had elevated alanine-aminotransferase serum levels (mean level was 127 IU/L, range 74-312 and serum HBV DNA detectable by PCR-Real Time (mean level 1,037,652 copies/mL, range 19,876-1,377,648. Genotype distribution was as follow: genotype D, 9 (64.2%, genotype A, 5 (35.8%. All patients infected by genotype D came from Brazil, while among the patients infected by genotype A, three came from Brazil and two from Ecuador. Our study evidences a moderate prevalence of HBV-infection in South American immigrants with the identification of two genotypes, D and A. These genotypes are not the most prevalent in the South America and this is probably the expression of a possible geographical redistribution of HBV genotypes.

  17. Multicenter Evaluation of a Semiautomated, Standardized Assay for Detection of Hepatitis B Virus DNA in Blood Donations

    OpenAIRE

    Romanò, Luisa; Velati, Claudio; Baruffi, Lorella; Fomiatti, Laura; Colucci, Giuseppe; Zanetti, Alessandro R.

    2005-01-01

    We evaluated the COBAS Ampliscreen hepatitis B virus (HBV) test using standards, seroconversion panels, consecutive donations, and samples from patients with abnormal alanine aminotransferase and chronic hepatitis C. Specificity was 100% and sensitivity was 20 IU/ml. In seroconversion panels, HBV DNA was detected up to 4 to 18 days before HBsAg, suggesting that this assay is useful in shortening the infectious window phase.

  18. Pharmacodynamic study of Bay41-4109 in HBV transgenic mouse model

    OpenAIRE

    Xiu-mei LI; Yang-shu CHEN; Guang-ze LIU; Jing-wei LI; Chen, Mei-Juan; Zhou, Jun-Hui; Kong, Xiang-Ping

    2011-01-01

    Objective To study the pharmacodynamics of Bay41-4109,a novel anti-HBV compound,in HBV transgenic mouse model.Methods specific pathogen frce(SPF) level TgM(HBV D1.3)mice were divided into 3 groups: Bay41-4109 group [30mg/(kg·d)],lamivudine group [30mg/(kg·d)] and vehicle group(0.5% sodium carboxymethycellulose),with 32 in each.Antiviral effect of Bay41-4109 was tested in HBV transgenic mice including the analysis of HBcAg changes in liver tissue by immunohistochemistry,and changes in HBV DNA ...

  19. Relationship between serum HBV DNA level and HBV-specific,nonspecific cytotoxic T lymphocytes and natural killer cells in patients with chronic hepatitis B

    Institute of Scientific and Technical Information of China (English)

    GU Xi-bing; YANG Xiao-juan; WANG Dong; HUA Zhong; XU Yue-qin; LU Zhong-hua

    2009-01-01

    Background The response of patients with chronic hepatitis B (CHB) to antiviral therapy against hepatitis B virus (HBV) is related to the base line level of HBV DNA, but the mechanism is not clear. The present study aimed to understand the possible relationship between the level of HBV DNA and HBV-specific, nonspecific cytotoxic T lymphocytes (CTL) and natural killer (NK) cells of CHB patients and the mechanism how the HBV DNA level influences the antiviral therapeutic effect.Methods Totally 100 adult patients with CHB who were positive for HBV DNA, HBeAg and (HLA)-A2 were enrolled into this study. HBV DNA was tested by real time fluorescence quantitative polymerase chain reaction (PCR). HBV specific and nonspecific CTL and NK cells were tested by flowcytometry. Serum alanine aminotransferase (ALT) and total bilirubin (Tbil) were determined for each patient using routine biochemical tests. The 100 cases were assigned to two groups based on their HBV DNA level: group A had 48 cases, their HBV DNA level was 104-105 copies/ml, group B had 52 cases, their HBV DNA level was 106-107 copies/ml. HBV specific CTL, nonspecific CTL, NK cells, ALT and Tbil of the two groups were compared.Results HBV DNA level of groups A and B was (4.81±0.39) log10 copies/ml and (6.81±0.40) log10 copies/ml, respectively (t=25.32, P <0.001). HBV specific CTL and NK cells of group A were significantly higher than those of group B (P <0.001 for both). Nonspecific CTL of group A was significantly lower than that of group B (P <0.01). ALT and Tbil of group A were significantly lower than those of group B (P <0.01 and P <0.05, respectively).Conclusions Serum HBV DNA level of patients with CHB is related to HBV specific CTL, nonspecific CTL and NK cells, which might result in inflammatory reaction of liver and cause more damage to liver function. Mechanism of HBV DNA level affecting the efficacy of anti-viral treatment may be related to the levels of HBV specific CTL and NK cells.

  20. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial.

    Directory of Open Access Journals (Sweden)

    Prudence Ive

    Full Text Available BACKGROUND: Hepatitis B virus (HBV infection is endemic in South Africa however, there is limited data on the degree of liver disease and geographic variation in HIV/HBV coinfected individuals. In this study, we analysed data from the CIPRA-SA 'Safeguard the household study' in order to assess baseline HBV characteristics in HIV/HBV co-infection participants prior to antiretroviral therapy (ART initiation. METHODS: 812 participants from two South African townships Soweto and Masiphumelele were enrolled in a randomized trial of ART (CIPRA-SA. Participants were tested for hepatitis B surface antigen (HBsAg, hepatitis B e antigen (HBeAg, and HBV DNA. FIB-4 scores were calculated at baseline. RESULTS: Forty-eight (5.9% were HBsAg positive, of whom 28 (58.3% were HBeAg positive. Of those with HBV, 29.8% had an HBV DNA<2000 IU/ml and ALT<40 IU/ml ; 83.0% had a FIB-4 score <1.45, consistent with absent or minimal liver disease. HBV prevalence was 8.5% in Masiphumelele compared to 3.8% in Soweto (relative risk 2.3; 95% CI: 1.3-4.0. More participants in Masiphumelele had HBeAg-negative disease (58% vs. 12%, p = 0.002 and HBV DNA levels ≤2000 IU/ml, (43% vs. 6% p<0.007. CONCLUSION: One third of HIV/HBV co-infected subjects had low HBV DNA levels and ALT while the majority had indicators of only mild liver disease. There were substantial regional differences in HBsAg and HbeAg prevalence in HIV/HBV co-infection between two regions in South Africa. This study highlights the absence of severe liver disease and the marked regional differences in HIV/HBV co-infection in South Africa and will inform treatment decisions in these populations.

  1. Animal models for HCV and HBV studies

    Directory of Open Access Journals (Sweden)

    Isabelle Chemin

    2007-02-01

    develop fulminant hepatitis, acute hepatitis, or chronic liver disease after adoptive transfer, and others spontaneously develop hepatocellular carcinoma (HCC. Among HCV transgenic mice, most develop no disease, but acute hepatitis has been observed in one model, and HCC in another. Although mice are not susceptible to HBV and HCV, their ability to replicate these viruses and to develop liver diseases characteristic of human infections provides opportunities to study pathogenesis and develop novel therapeutics In the search for the mechanism of hepatocarcinogenesis in hepatitis viral infection, two viral proteins, the core protein of hepatitis C virus (HCV and the HBx protein of hepatitis B virus (HBV, have been shown to possess oncogenic potential through transgenic mouse studies, indicating the direct involvement of the hepatitis viruses in hepatocarcinogenesis.

    This may explain the very high frequency of HCC in patients with HCV or HBV infection.

    Chimpanzees remain the only recognized animal model for the study of hepatitis C virus (HCV. Studies performed in chimpanzees played a critical role in the discovery of HCV and are continuing to play an essential role in defining the natural history of this important human pathogen. In the absence of a reproducible cell culture system, the infectivity titer of HCV challenge pools can be determined only in chimpanzees.

    Recent studies in chimpanzees have provided new insight into the nature of host immune responses-particularly the intrahepatic responses-following primary and secondary experimental HCV infections. The immunogenicity and efficacy of vaccine candidates against HCV can be tested only in chimpanzees. Finally, it would not have been possible to demonstrate

  2. Anti-HBV effect of TAT- HBV targeted ribonuclease

    Institute of Scientific and Technical Information of China (English)

    Jin Ding; Jun Liu; Cai-Fang Xue; Wei-Dong Gong; Ying-Hui Li; Ya Zhao

    2003-01-01

    AIM: To prepare and purify TAT-HBV targeted ribonuclease fusion protein, evaluate its transduction activity and investigate its effect on HBV replication in 2.2.15 cells.METHODS: The prokaryotic expression vector pTAT containing TR gene was used in transforming E. coli BL21(DE3) LysS and TR was expressed with the induction of IPTG. The TAT-TR fusion protein was purified using Ni-NTA-agrose and PD-10 desalting columns, and analyzed by SDSPAGE. Transduction efficiency of TAT-TR was detected with immunofluorescence assay and the concentration of HBeAg in the supernatant of the 2.2.15 cells was determined via solid-phase radioimmunoassay (spRIA). MTT assay was used to detect the cytotoxicity of TAT-TR.RESULTS: The SDS-PAGE showed that the TAT-TR fusion protein was purified successfully, and the purity of TAT-TR was 90 %. The visualization of TAT-TR by immunofiuorescence assay indicated its high efficiency in transducing 2.2.15 cells.RIA result suggests that TAT-TR could inhibit the replication of HBV effectively, it didn′t affect cell growth and had no cytotoxicity.CONCLUSION: TAT-TR possesses a significant anti-HBV activity and the preparation of TAT-TR fusion protein has laid the foundation for the use of TR in the therapeutic trial of HBV infection.

  3. Know HBV: What Every Asian and Pacific Islander Should Know About Hepatitis B and Liver Cancer

    Science.gov (United States)

    ... Donate! » Get Tested Ask your doctor for these blood tests: HBV Hepatitis B sur face antigen (HBs Ag) : Tells if you ... you are protected against HBV. Only the HBsAg blood test can tell if you have chronic hepatitis B. For more information visit http://liver.stanford.edu » ...

  4. The HBV E Genotype Discover in Dai Nationality in Xishuangbanna, Yunnan Province

    Institute of Scientific and Technical Information of China (English)

    Hai-ping ZHAO; Yuan-ying SHEN; Ru SHEN; Yuan-yi WANG; Mei-ya FU

    2009-01-01

    To investigate the distribution of Hepatitis B virus (HBV) genotypes among the population of Dai nationality in Xishuangbanna, Yurman Province HBV genotypes of the Serum samples were tested by PCR-RFLP. This is the first time to discover the B+E genotypes in China. This finding provides new information for understanding the distribution of HBV genotype in China and a provides a basis for establishing a Chinese gene bank.

  5. Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (- chronic inactive HBV patients from active carriers

    Directory of Open Access Journals (Sweden)

    Gull Sana

    2011-02-01

    Full Text Available Abstract Background and Aims ELISA is still used as primary test for diagnosis HBV disease. However, ELISA-positive patients were marked as HBV inactive after confirmation with PCR and vice versa. Our aim was to assess the performance of new cut-off value of ALT, HBV DNA load and significance of AST as screening tool for HBeAg (- chronic active or inactive patients in Pakistani population. Materials and methods In a cross-sectional, cohort study, 567 HBeAg (- patients followed for one year were selected. Patients with persistent elevated ALT than normal and HBV DNA ≥ 100,000 copies/mL were taken as active chronic. Diagnostic values for ALT, AST and HBV DNA load in HBV HBeAg (- chronic active and inactive patients compared using receiver operation characteristic (ROC curves. Results Of 567 HBeAg (- patients, 228 were classified as chronic inactive and 339 as active. HBV infection was dominant in male. Serum ALT, AST and HBV DNA levels showed significant and high AUROC to differentiate chronic HBeAg (- inactive patients from active. AUROC for Serum ALT, AST and HBV DNA were observed 0.997, 0.969 and 1.000, respectively. For revised cut off value for ALT (30 IU/L for male and 19 IU/L for female and HBV DNA load ≥100,000 copies/mL, a PPV of 97%, NPV of 94%, a sensitivity of 98%, and a specificity of 92% was observed to discriminate active carriers from inactive carriers. We also observed 93.5% specificity, 83.1% sensitivity, 82% PPV and 89.5% NPV for AST ≤20 IU/L to differentiate inactive carriers from active ones in our study group. Conclusions Revised cut off value of ALT and NIH derived HBV DNA value can better discriminate between HBeAg (- chronic active and inactive patients.

  6. Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon

    Science.gov (United States)

    Bivigou-Mboumba, Berthold; François-Souquière, Sandrine; Deleplancque, Luc; Sica, Jeanne; Mouinga-Ondémé, Augustin; Amougou-Atsama, Marie; Chaix, Marie-Laure; Njouom, Richard; Rouet, François

    2016-01-01

    Integrated data on hepatitis B virus (HBV) patterns, HBV genotypes and mutations are lacking in human immunodeficiency virus type 1 (HIV-1) co-infected patients from Africa. This survey was conducted in 2010–2013 among 762 HIV-1-positive adults from Gabon who were predominantly treated with 3TC-based antiretroviral treatment. HBV patterns were identified using immunoassays detecting total antibody to hepatitis B core antigen (HBcAb), hepatitis B surface antigen (HBsAg), IgM HBcAb, hepatitis B e antigen (HBeAg), antibody to HBsAg (HBsAb) and an in-house real-time PCR test for HBV DNA quantification. Occult hepatitis B (OBI) was defined by the presence of isolated anti-HBc with detectable serum HBV DNA. HBV genotypes and HBV mutations were analyzed by PCR-direct sequencing method. Seventy-one (9.3%) patients tested positive for HBsAg, including one with acute hepatitis B (0.1%; 95% CI, 0.0%-0.2%), nine with HBeAg-positive chronic hepatitis B (CHB) (1.2%; 95% CI, 0.6%–2.2%), 16 with HBeAg-negative CHB (2.1%; 95% CI, 1.2%–3.3%) and 45 inactive HBV carriers (5.9%; 95% CI, 4.4%–7.8%). Sixty-one (8.0%; 95% CI, 6.2%–10.1%) patients showed OBI. Treated patients showed similar HBV DNA levels to those obtained in untreated patients, regardless of HBV patterns. Around 15.0% of OBI patients showed high (>1,000 UI/mL) viremia. The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4%) than in HBV/E isolates (0%) (P = .04). Our findings encouraged clinicians to promote HBV vaccination in patients with no exposure to HBV and to switch 3TC to universal TDF in those with CHB. PMID:26764909

  7. HBV And HCV Molecular Evolution

    Directory of Open Access Journals (Sweden)

    Flor H. Pujol

    2007-02-01

    Full Text Available

    Hepatitis B virus (HBV infection is still a significant health concern in in the world, since around 2 billion persons have been infected by this virus (HBV and around 350 millions of them are chronic carriers, in spite of a highly effective vaccine against this virus. Bearing a reverse transcriptase necessary for its replication but with a highly compacted genome, this hepadnavirus exhibits a degree of variability intermediate between DNA and RNA viruses. This plasticiy leads to the generation of several mutants and genotypic variability. HBV mutants develop during the natural course of infection and play an important role in the evasion of the selective pressure applied by the host (immune or chemotherapeutic. Eight HBV genotypes (A-H have been described, based on a minimum divergence of 8% of the complete genome sequences. HBV genotype F is the most divergent of the HBV genotypes, is autochthonous to South America and is highly predominant in the Northen region of South America. The recently described HBV genotype H is closely related to genotype F and seems to be restricted to Central and North America. Recombination among different HBV strains seems to be frequent. Several subgenotypes have also been described inside HBV genotypes, which exhibit a geographic pattern of distribution. The clinical and biologic importance of the genotypic diversity of HBV is of major concern at the present moment and has been studied in Asia and Europe. The origin of HBV is still an open question. Depending on the model used for the phylogenetic analysis, an Asian or an American origin of HBV has been proposed. By revisiting the genotypic diversity of HBV, an alternative explanation is that human HBV genotypes might have emerged by several zoonotic introductions, both in the Old and the New World. Around 170 millions persons in the world are thought to be infected with

  8. Evaluation of the Level of HBV Antibody Titer after HBV Vaccination among Children in Tehran, Iran

    Directory of Open Access Journals (Sweden)

    Seyed Mohammad Javad Hosseini

    2009-06-01

    Full Text Available Background and Aims: Hepatitis B infection is a serious public health problem worldwide. It has been shown that the levels of antibody to hepatitis B surface antigen (anti-HBs decrease after vaccination. The main objective of this study was to assess the level of anti-HBs among children after primary vaccination against hepatitis B virus (HBV in Tehran, Iran.Methods: The study was conducted in four selected healthcare centers in Tehran during a 6-month period from September 2005 to March 2006 in Tehran. Blood samples collected from 165 healthy, 1- to 5-year-old children who had been vaccinated against HBV were tested for anti-HBs using enzyme-linked immunosorbent assay (ELISA.Results: Approximately 47.9 % of the cases were male. Among the cases, the minimum and maximum titers of hepatitis B surface antibodies (HBsAb were zero and 1000 m IU, respectively. The mean level of HBsAb titer in this study was 232.64 m IU, with a standard deviation of 278.711 m IU.Conclusions: The results showed that HBsAb titer may decrease over time after vaccination. Finally, along with prevention and control strategies, ongoing investigation and monitoring of antibody levels against HBV in children and other age ranges is recommended.

  9. A mouse model for HBV immunotolerance and immunotherapy

    OpenAIRE

    Yang, Dan; Liu, Longchao; Zhu, Danming; Peng, Hua; Su, Lishan; Fu, Yang-Xin; Zhang, Liguo

    2013-01-01

    Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV surface antigen (HBsAg). Immunization wit...

  10. If You Have Chronic Hepatitis B Virus (HBV) Infection

    Science.gov (United States)

    ... all your household members see their physicians for hepatitis B testing and vaccination.  Tell your healthcare professionals that you are infected ... of being protected from HBV!  Learn more about hepatitis B so you can make the best decisions ... Action Coalition (651) 647-9009 www.immunize.org ...

  11. High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda.

    Directory of Open Access Journals (Sweden)

    John Rusine

    Full Text Available BACKGROUND: Data on prevalence and incidence of hepatitis B virus (HBV and hepatitis C virus (HCV infection in Rwanda are scarce. METHODS: HBV status was assessed at baseline and Month 12, and anti-HCV antibodies at baseline, in a prospective cohort study of HIV-infected patients in Kigali, Rwanda: 104 men and 114 women initiating antiretroviral therapy (ART at baseline, and 200 women not yet eligible for ART. RESULTS: Baseline prevalence of active HBV infection (HBsAg positive, past or occult HBV infection (anti-HBc positive and HBsAg negative and anti-HCV was 5.2%, 42.9%, and 5.7%, respectively. The active HBV incidence rate was 4.2/1,000 person years (PY. In a multivariable logistic regression model using baseline data, participants with WHO stage 3 or 4 HIV disease were 4.19 times (95% CI 1.21-14.47 more likely to have active HBV infection, and older patients were more likely to have evidence of past exposure to HBV (aRR 1.03 per year; 95%CI 1.01-1.06. Older age was also positively associated with having anti-HCV antibodies (aOR 1.09; 95%CI 1.04-1.14 while having a higher baseline HIV viral load was negatively associated with HCV (aOR 0.60; 95% CI 0.40-0.98. The median CD4 increase during the first 12 months of ART was lower for those with active HBV infection or anti-HCV at baseline. Almost all participants (88% with active HBV infection who were on ART were receiving lamivudine monotherapy for HBV. CONCLUSION: HBV and HCV are common in HIV-infected patients in Rwanda. Regular HBsAg screening is needed to ensure that HIV-HBV co-infected patients receive an HBV-active ART regimen, and the prevalence of occult HBV infection should be determined. Improved access to HBV vaccination is recommended. Active HCV prevalence and incidence should be investigated further to determine whether HCV RNA PCR testing should be introduced in Rwanda.

  12. Overview of HBV whole genome data in public repositories and the Chinese HBV reference sequences

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    The number of Hepatitis B virus (HBV) whole genomic sequences in public nucleotide databases (GenBank, EMBL, and DDBJ) had reached 866 by January 1, 2007. Coming from 46 countries and regions, these sequences were categorized as eight genotypes (A-H). With the statistical and phylogenetic analysis on all available complete genomic data of HBV, we here present an overview of HBV sequences in public databases. From all registered 229 HBV genomes in Chinese regions as well as 59 sequencing data from our research group, we report the establishment of reference sequences of HBV strains prevailing in China. These analyses provide clues for the effects of HBV genotypes in host clinical progressions, geographic distribution of the infection, and the viral evolutionary history. Moreover, the viral sequence reference would be helpful in the identification of various HBV mutations. Based on the analysis of various public databases,we suggest that the Chinese HBV database with the clinical information should be constructed.

  13. HBV and neurological impairment in HIV-infected patients

    Directory of Open Access Journals (Sweden)

    L Manolescu

    2012-11-01

    Full Text Available Objective: HIV can affect CNS in early stages of disease and determine neurological impairment. HBV DNA was found in CSF of HIV co-infected patients, but little is known about the neurotropic character of this virus. Here we assessed the degree of association between HBV infection and neurological impairment in a large cohort of long-term survivors, HIV-infected patients that experienced multiple therapeutic schemes over time. Methods: A total of 462 HIV-1-infected patients were retrospectively followed up for 10 years for HBV infection and neurological impairment. The patients were tested for immune (flow cytometry and virological parameters of HIV infection (Roche Amplicor, version 1.5/ COBAS AmpliPrep/COBAS TaqMan HIV-1 test and for HBV infection markers (HBsAg, anti HBc: Murex Biotech ELISA tests. Many of these patients have experienced between one and six regimens such as: 2 NRTIs, 3 NRTIs, 2 NRTIs+1 NNRTI, 1 NRTI+1 NNRTI+1 PI, 2 NRTIs+2 PIs. Results: After 10 years 29.87% of the patients presented neurological impairment. Out of them 56.52% were HBV-infected. The prevalence of HIV encephalopathy (HE in our studied cohort was 22.7% and 50.4% of these patients were HBV-infected. The median HIV diagnosis age was 7 and the median age of HE diagnosis was 10. In order to establish a possible correlation between HBV infection and HE we first reviewed and excluded the main risk factors associated with HE at the moment of diagnosis: low weight, anemia, constitutional symptoms, low CD4+count, high plasma HIV-RNA load. No patient was infected with HCV. The groups of patients that presented HE and HBsAg and HE without HBsAg were balanced regarding sex, number of deceased patients, number of class C3 patients, but the patients in first group presented lower CD4 values at HE diagnosis vs patients from second group 2: 44.5 vs 95 cells/µL, p=0.3; lower nadir CD4 count: 38 vs 51 cell/µL, p=0.1; and slightly higher HIV viral load: 5.2 vs 5 log10 copies

  14. Co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors in Kathmandu, Nepal

    OpenAIRE

    Shrestha, Ashish Chandra; Ghimire, Prakash; Tiwar, Bishnu Raj; Rajkarnikar, Manita

    2012-01-01

    Background: HIV, HBV, Syphilis and HCV share common modes of transmission. Objective: The study was aimed to determine the co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors. Methods: The study was conducted on blood samples screened as HCV seropositive at Nepal Red Cross Society, Central Blood Transfusion Service, Kathmandu, Nepal. HCV seropositive samples were further tested for HIV, HBV and Syphilis. Results: Eight co-infections were observed in 139 H...

  15. Leukocyte Telomere Length-Related rs621559 and rs398652 Genetic Variants Influence Risk of HBV-Related Hepatocellular Carcinoma

    OpenAIRE

    Wenting Pan; Guangxia Cheng; Huaixin Xing; Juan Shi; Chao Lu; Jinyu Wei; Lichao Li; Changchun Zhou; Qipeng Yuan; Liqing Zhou; Ming Yang

    2014-01-01

    Recent genome-wide association studies (GWAS) have identified eleven leukocyte telomere length (LTL)-related single nucleotide polymorphisms (SNPs). Since LTL has been associated with risk of many malignancies, LTL-related SNPs may contribute to cancer susceptibility. To test this hypothesis in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we genotyped these eleven LTL-related SNPs in a case-control set including 1186 HBV-related HCC cases, 508 chronic HBV carriers and 1308 ...

  16. HBV-DNA in hemodialysis patients infected by HCV

    International Nuclear Information System (INIS)

    End-stage renal disease patients on chronic hemodialysis (HD) patients are at risk for both hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, and they may coexist. To determine the prevalence and clinical impact of HBV and HCV infection, we studied poly chain reaction (PCR) and reverse transcription (RT)-PCR on the blood samples of 90 HD patients in Kerman, Iran. ELISA test was used to detect anti-HBc, anti-HBs and HBs Ag. We found that 30 out of 90 (33.3%) patients were PCR-RT-PCR positive for HCV-RNA. No HBV-DNA (0%) was detected through the PCR study in both positive and negative HCV-RNA patient groups. Though none of the samples was HBsAg positive, 10 (33.3%) HCV-RNA positive patients were anti-HBc positive, and 12 (40.7%) were anti-HBs positive. We conclude that prevalence of hepatitis C infection is high in HD patients in our region, but not associated with active HBV infection. (author)

  17. HBV-DNA in hemodialysis patients infected by HCV

    Directory of Open Access Journals (Sweden)

    Arababadi Mohammad

    2009-01-01

    Full Text Available End-stage renal disease patients on chronic hemodialysis (HD patients are at risk for both hepatitis B virus (HBV and hepatitis C virus (HCV infection, and they may coexist. To de-termine the prevalence and clinical impact of HBV and HCV infection, we studied poly chain reaction (PCR and reverse transcription (RT-PCR on the blood samples of 90 HD patients in Kerman, Iran. ELISA test was used to detect anti-HBc, anti-HBs and HBsAg. We found that 30 out of 90 (33.3% patients were PCR-RT-PCR positive for HCV-RNA. No HBV-DNA (0% was detected through the PCR study in both positive and negative HCV-RNA patient groups. Though none of the samples was HBsAg positive, 10 (33.3% HCV-RNA positive patients were anti-HBc positive, and 12 (40.7% were anti-HBs positive. We conclude that prevalence of hepatitis C infection is high in HD patients in our region, but not associated with active HBV infection.

  18. Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile.

    Science.gov (United States)

    Vargas, Jose Ignacio; Jensen, Daniela; Sarmiento, Valeska; Peirano, Felipe; Acuña, Pedro; Fuster, Felipe; Soto, Sabrina; Ahumada, Rodrigo; Huilcaman, Marco; Bruna, Mario; Jensen, Werner; Fuster, Francisco

    2016-04-01

    HBV-HIV coinfection is prevalent. Frequently, anti-HBc is the only serological marker of HBV, which can be indicative of HBV resolved infection, when found together with anti-HBs reactivity; or present as "isolated anti-HBc," related to HBV occult infection with presence of detectable DNA HBV, more prevalent in HIV-positive individuals. Regional data about this condition are scarce. Anti-HBc rapid test has been used as screening, but its performance has not been described in HIV-positive patients. The aim of this study was determine prevalence of anti-HBc in HIV-positive patients, serological pattern of HBV resolved infection and isolated anti-HBc, evaluating presence of HBV occult infection. Assess anti-HBc rapid test compared to ECLIA. Methods included measurement of anti-HBc and anti-HBs in HIV-positive patients with negative HBsAg. Serum HBV DNA quantification and HBV booster vaccination to "isolated anti-HBc" individuals. Detection of anti-HBc by rapid test and ECLIA. In 192 patients, prevalence of anti-HBc was 42.7% (82/192); associated to male gender, drug use, men-sex-men, positive-VDRL, and longer time HIV diagnosis. 34.4% (66/192) had presence of anti-HBs, mean titers of 637 ui/ml. Isolated anti-HBc in 8.3% (16/192), associated to detectable HIV viral load and no-use of HAART; in them, HBV DNA was undetectable, and 60% responded to HBV vaccination booster. Anti-HBc rapid test showed low sensibility (32.9%) compared to ECLIA. These results show that prevalence of anti-HBc in HIV-positive individuals is high, in most cases accompanied with anti-HBs as HBV resolved infection. Low prevalence of "isolated anti-HBc," with undetectable HBV DNA, and most had anamnestic response to HBV vaccination; suggest low possibility of occult HBV infection. Anti-HBc rapid test cannot be recommended as screening method for anti-HBc. PMID:26381185

  19. Analysis of HBV-DNA Replication Level Distribution in Hepatitis B associated with Liver Cancer of Chongqing%重庆地区乙肝相关性肝癌患者HBV-DNA复制水平分布情况分析

    Institute of Scientific and Technical Information of China (English)

    秦晓波; 胡鹏

    2013-01-01

    Objective To Analyze the HBV-DNA replication level distribution in Hepatitis B associated with Liver Cancer of Chongqing. Methods 238 cases of HCC patients were collected, HBV-DNA replication level detection was tested. Result In 238 cases, HBV-DNA of 202 cases (84.87%) could be detected, except 36 cases (15.13%). The HBV-DNA in 103, 104, 105, 106 copies/mL was the most, that was significantly higher than the others (P<0.05 or 0.01). Conclusion HBV-DNA Replication Level Distribution in Hepatitis B associated with Liver Cancer of Chongqing is higher relatively.%目的:分析重庆地区乙肝相关-原发性肝癌(HBV-HCC)患者HBV-DNA复制水平分布情况。方法收集HBV-HCC患者238例,入选者在确诊肝癌时监测HBV-DNA复制水平。结果238例HBV-HCC患者中,检测出外周血检查出HBV-DNA者202例(84.87%)、未检出者36例(15.13%)。HBV-HCC患者HBV-DNA以103、104、105、106拷贝/mL复制水平分布例数较多,显著高于其他HBV-DNA复制水平组(P<0.05或0.01)。结论重庆地区HBV-HCC患者HBV-DNA复制水平较高。

  20. Pharmacodynamic study of Bay41-4109 in HBV transgenic mouse model

    Directory of Open Access Journals (Sweden)

    Xiu-mei LI

    2011-09-01

    Full Text Available Objective To study the pharmacodynamics of Bay41-4109,a novel anti-HBV compound,in HBV transgenic mouse model.Methods specific pathogen frce(SPF level TgM(HBV D1.3mice were divided into 3 groups: Bay41-4109 group [30mg/(kg·d],lamivudine group [30mg/(kg·d] and vehicle group(0.5% sodium carboxymethycellulose,with 32 in each.Antiviral effect of Bay41-4109 was tested in HBV transgenic mice including the analysis of HBcAg changes in liver tissue by immunohistochemistry,and changes in HBV DNA in liver and serum by quantitative real time PCR analysis.Serum transaminase(ALT and AST and body weight were assayed to evaluate the safety of the compound.Results Oral Bay41-4109 significantly reduced the number of HBV core antigen(HBcAg positive cell nucleus,average area of HBcAg positive cell nucleus and the rate of OD compared with vehicle group after 50 days treatment(P 0.05.However,Bay41-4109 could not significantly reduce HBV-specific DNA in HBV transgenic mice,both in liver and plasma.No significant impact was found on ALT,AST and body weigh of Bay41-4109-treated mice.Conclusions Bay41-4109 can more effectively reduce cytoplasmic HBcAg in liver sections than lamivudine.It is suggested that Bay41-4109,a different mode of action from lamivudine,represents a promising anti-HBV drug candidate with good antiviral effect and safety.

  1. The Prevention of Liver Cancer by HBV Vaccine Program

    Institute of Scientific and Technical Information of China (English)

    TAO Xiong

    2002-01-01

    Objective To recognize the HBV vaccine program for prevention of the hepatic cancer.Methods To discuss the relation between the HBV and hepatic cancer arising, and to discuss the immunology respond of the HBV vaccine (HBV surface antigen protein) in our patient group. Result Our data indicates that the predisposing of the HBV infection is required for the hepatic cancer arising and for the high expression of the AFP gene, and our data indicates that the HBV vaccine can induce highly immuno respond in about 78.8 % of the adult for achieving the HBV prevention status and the hepatic cancer prevention status.

  2. Establishment and use of HBV-replication transgenic mice

    Directory of Open Access Journals (Sweden)

    Xiang-ping KONG

    2011-09-01

    Full Text Available Despite the existence of a preventive vaccine,hepatitis B virus(HBV infection is still a major worldwide health problem,especially in China.As HBV naturally Despite of the existence of a preventive vaccine,hepatitis B virus(HBV infection is still a major worldwide healthy problem,especially in China.As HBV naturally infects only human and chimpanzees,many issues pertaining to the biology and the therapeutic of HBV infection remain unresolved due to the limitation of the establishment of a HBV model.However,the establishment of HBV-replication transgenic mice has greatly improved our understanding of life cycle,immunobiology and pathogensis of HBV.The establishment of HBV transgenic mice and its use in assessing the antiviral potential of pharmacological agents and HBV immunopathogenesis are herewith briefly described in the present paper.

  3. 乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA相关性的比较

    Institute of Scientific and Technical Information of China (English)

    刘晓燕

    2006-01-01

    目的:孕产妇各种血清学标志的乳汁HBV-DNA与血清HBV-DNA相关性的探讨.方法:用全自动荧光定量分析仪对已确认的乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA的检测.结果:85例乙肝孕产妇其各种血清学标志的血清HBV-DNA与乳汁HBV-DNA是一致的.其同一种血清模式的血清HBV-DNA含量高,则乳汁的HBV-DNA相应高.反之,血清HBV-DNA含量低,则乳汁HBV-DNA含量低.

  4. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription

    International Nuclear Information System (INIS)

    Highlights: → LNA-modified oligonucleotides can pass through the plasma membrane of cultured cells even without using transfection machinery. → LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. → LNA-oligonucleotide designed to target nuclear HBV DNA efficiently suppresses HBV replication and transcription in cultured hepatic cells. -- Abstract: Silencing target genes with small regulatory RNAs is widely used to investigate gene function and therapeutic drug development. Recently, triplex-based approaches have provided another attractive means to achieve targeted gene regulation and gene manipulation at the molecular and cellular levels. Nuclear entry of oligonucleotides and enhancement of their affinity to the DNA targets are key points of such approaches. In this study, we developed lipid-based transport of a locked-nucleic-acid (LNA)-modified oligonucleotide for hepatitis B virus (HBV) DNA interference in human hepatocytes expressing HBV genomic DNA. In these cells, the LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. The oligonucleotide specifically targeting HBV DNA clearly interfered with HBV DNA transcription as shown by a block in pregenomic RNA (pgRNA) production. The HBV DNA-targeted oligonucleotide suppressed HBV DNA replication and HBV protein production more efficiently than small interfering RNAs directed to the pgRNA. These results demonstrate that fusion with lipid can carry LNA-modified oligonucleotides to the nucleus where they regulate gene expression. Interfering with HBV DNA transcription by LNA-modified oligonucleotides has strong potential as a new strategy for HBV inhibition.

  5. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription

    Energy Technology Data Exchange (ETDEWEB)

    Sun, Zhen [The State Key Laboratory of Genetic Engineering and The MOE Key Laboratory of Contemporary Anthropology, School of Life Science, Fudan University, Shanghai 200433 (China); Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Xiang, Wenqing; Guo, Yajuan [Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Chen, Zhi [The State Key Laboratory for Infectious Disease, Institute of Infectious Disease, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 (China); Liu, Wei, E-mail: liuwei666@zju.edu.cn [Department of Biochemistry and Molecular Biology, Program in Molecular Cell Biology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058 (China); Lu, Daru, E-mail: drlu@fudan.edu.cn [The State Key Laboratory of Genetic Engineering and The MOE Key Laboratory of Contemporary Anthropology, School of Life Science, Fudan University, Shanghai 200433 (China)

    2011-06-10

    Highlights: {yields} LNA-modified oligonucleotides can pass through the plasma membrane of cultured cells even without using transfection machinery. {yields} LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. {yields} LNA-oligonucleotide designed to target nuclear HBV DNA efficiently suppresses HBV replication and transcription in cultured hepatic cells. -- Abstract: Silencing target genes with small regulatory RNAs is widely used to investigate gene function and therapeutic drug development. Recently, triplex-based approaches have provided another attractive means to achieve targeted gene regulation and gene manipulation at the molecular and cellular levels. Nuclear entry of oligonucleotides and enhancement of their affinity to the DNA targets are key points of such approaches. In this study, we developed lipid-based transport of a locked-nucleic-acid (LNA)-modified oligonucleotide for hepatitis B virus (HBV) DNA interference in human hepatocytes expressing HBV genomic DNA. In these cells, the LNA-modified oligonucleotides passed efficiently across the cell membrane, and lipid-coating facilitated translocation from the cytoplasm to the nucleus. The oligonucleotide specifically targeting HBV DNA clearly interfered with HBV DNA transcription as shown by a block in pregenomic RNA (pgRNA) production. The HBV DNA-targeted oligonucleotide suppressed HBV DNA replication and HBV protein production more efficiently than small interfering RNAs directed to the pgRNA. These results demonstrate that fusion with lipid can carry LNA-modified oligonucleotides to the nucleus where they regulate gene expression. Interfering with HBV DNA transcription by LNA-modified oligonucleotides has strong potential as a new strategy for HBV inhibition.

  6. Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

    Institute of Scientific and Technical Information of China (English)

    JianLin Chen; XiaoJun Lin; Qian Zhou; Ming Shi; ShengPing Li; XiangMing Lao

    2016-01-01

    Background: It remains unclear what the antiviral therapy affects disease‑free survival (DFS) and overall survival (OS) of patients with hepatitis B virus (HBV)‑related hepatocellular carcinoma (HCC) at different tumor stages and baseline HBV DNA levels. In this study, we analyzed the association of antiviral treatment with DFS and OS based on the stratifi‑cation of baseline HBV DNA load in early‑stage (stages I and II) HCC patients. Methods: We included 445 patients with early‑stage HBV‑related HCC who underwent curative resection, and then classified them into four subgroups based on baseline HBV DNA load and antiviral therapy stratification. The Kaplan–Meier and Cox regression analyses were performed to determine the association of clinical characteristics with survival. Results: The median follow‑up period was 74 months. For all patients, cumulative OS rates in the antiviral group were significantly higher than those in the non‑antiviral group (log‑rank test, P = 0.023), whereas no significant differencesin DFS rates were observed. High baseline HBV DNA level was a risk factor associated with short DFS and OS in all patients. In patients with baseline HBV DNA levels ≥2000 IU/mL, antiviral treatment was significantly associated withprolonged DFS and OS (log‑rank test, P or undetectable, antiviral treatment did not show a significant benefit in prolonging DFS and OS. Conclusions: High baseline HBV DNA levels are associated with poor prognosis in the patients with early‑stage HCC, and the antiviral treatment could generate survival benefits for the patients. Therefore, antiviral treatment should be given for these patients. However, the effect of antiviral treatment on the patients with low viral load remains unclear, and further investigation is warranted.

  7. Molecular and Serological Assessment of Chronic HBV Carriers and Additional Burden of Applying Updated Guidelines in Pakistan

    International Nuclear Information System (INIS)

    Objective: To assess the additional burden of the patients eligible for treatment, based on recommendations on viral load, in the light of 2009 version of AASLD guidelines, as compared to 2004 guidelines and to determine the frequency of HBeAg in chronic HBV carriers. Study Design: Descriptive cross-sectional study. Place and Duration of Study: Virology Department, Armed Forces Institute of Pathology, Rawalpindi, from November 2010 to January 2012. Methodology: Persons with chronic HBV infection, reporting for HBV DNA PCR test, were included in the study and blood samples were collected. HBV DNA load was determined by Real Time PCR. HBsAg and HBeAg were tested by ELISA. Results: Out of the 801 subjects positive for HBsAg, 74 (9.24%) were positive for HBeAg. Out of them, 113 (14.1%) had HBV DNA load > 100,000 copies/ml and were eligible for treatment according to AASLD 2004 guidelines. Forty one (5.1%) had HBV load between 10,000 and 100,000 copies/ml, and were additionally eligible for treatment as per AASLD 2009 guidelines. The 5.1% of 4.5 million estimated HBV carries in Pakistan comes to 229500. Conclusion: There was a low HBeAg positivity and HBV DNA positivity in our chronic HBV infected persons. Moreover, there is an increase of 229500 potential candidates for HBV treatment in Pakistan based on viral load testing, according to the AASLD 2009 guidelines when compared with 2004 guidelines. The increase in the number of candidates for treatment may require an additional expenditure of tens of billions of rupees. (author)

  8. A mouse model for HBV immunotolerance and immunotherapy.

    Science.gov (United States)

    Yang, Dan; Liu, Longchao; Zhu, Danming; Peng, Hua; Su, Lishan; Fu, Yang-Xin; Zhang, Liguo

    2014-01-01

    Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV surface antigen (HBsAg). Immunization with the conventional HBV vaccine in the presence of aluminum adjuvant failed to elicit an immune response against HBV in these mice. To identify a vaccine that can potentially circumvent this tolerance, the TLR9 agonist CpG was added to HBsAg as an adjuvant. Vaccination of mice with HBsAg/CpG induced not only clearance of viremia, but also strong antibody production and T-cell responses. Furthermore, both the DNA replication and protein expression of HBV were significantly reduced in the livers of AAV/HBV-infected mice. Accordingly, AAV/HBV-infected mice may be used as a robust model for investigating the underlying mechanism(s) of HBV immunotolerance and for developing novel immunotherapies to eradicate HBV infections. PMID:24076617

  9. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection

    Institute of Scientific and Technical Information of China (English)

    Xiao-Mao Li; Min-Feng Shi; Yue-Bo Yang; Zhong-Jie Shi; Hong-Ying Hou; Hui-Min Shen; Ben-Qi Teng

    2004-01-01

    AIM: To evaluate the efficacy of hepatitis B immunoglobulin (HBIG) in interrupting hepatitis B virus (HBV) intrauterine infection during late pregnancy.METHODS: We allocated 112 HBsAg positive pregnant women into 2 groups randomly. Fifty seven cases in the HBIG group received 200 IU (unit) HBIG intramuscularly every 4 wk from the 28 wk of gestation to the time of delivery, while 55 cases in the control group received no special treatment.HBsAg, HBeAg, HBcAb, HBeAb, HBsAb and HBV DNA levels were tested in the peripheral blood specimens from all of the mothers at 28 wk of gestation, just before delivery, and in blood from their newborns within 24 h before administration of immune prophylaxis.RESULTS: The intrauterine infection rate in HBIG group and control group were 10.5% and 27.3%, respectively, with significant difference (P<0.05). It showed ascendant trend as HBV DNA levels in the peripheral blood increased before delivery.CONCLUSION: HBIG is potent to cut down HBV intrauterine infection rate significantly when administered to pregnant women regularly during late pregnancy. The possibility of HBV intrauterine infection increases if maternal blood HBV DNA ≥ 108 copies/mL.

  10. DIFFERENT COURSES OF HBV INFECTION AFTER LIVER TRANSPLANTATION

    Directory of Open Access Journals (Sweden)

    V. E. Syutkin

    2011-01-01

    Full Text Available To compare clinical and virologic course of de novo and recurrent HBV infection 104 liver graft recipients with 6 months and more follow-up after cadaveric transplantation have been analyzed. Recurred HBV infection occurred in 7 (30.4% out of 23 HBsAg-positive and de novo HBV infection – in 11 out of 81 (13.6% HBsAg- negative recipients. HBeAg and IgM anti-HBc appeared in 8 recipients with de novo and in one case – with recurrent infection. Two recipients with de novo HBV developed acute hepatitis with jaundice and one – chronic hepatitis with graft cirrhosis. Only one recipient with recurrent HBV developed severe acute hepatitis HBV/ HDV, with anti-HBs seroconversion after 12 weeks of peginterferon alfa treatment. Nucleoside analogs (NA were started in all 11 de novo HBV cases and in 5 cases of recurrent HBV infection. Treatment with NA effec- tively suppressed HBV DNA replication in both recurrent and de novo infections; HBsAg clearance occurred in 64% of de novo HBV and in 20% – of recurrent HBV cases. No secondary drug resistance occurred. De novo HBV infection is a self-limited disease in most cases, and preemptive NA treatment is the best treatment choice. Recurrent HBV infection is usually chronic, and pegylated interferon may be under consideration as well as NA. 

  11. A randomized control trial on interruption of HBV transmission in uterus

    Institute of Scientific and Technical Information of China (English)

    朱启镕; 于广军; 俞蕙; 吕晴; 顾新焕; 董左权; 张秀珍

    2003-01-01

    Objective To study the interruptive effect of hepatitis B virus (HBV) specific immunolobulin (HBIG) before delivery in attempt to prevent intrauterine transmission of HBV.Methods Nine hundred and eighty HBsAg carrier pregnant women were randomly divided into HBIG group and control group. Each subject in the HBIG group received 200 IU or 400 IU of HBIG intramuscularly at 3, 2 and 1 month before delivery. The subjects in the control group did not receive any specific treatment. All newborn infants received 100 IU of HBIG intramascularty after venous blood samples were taken at birth and 2 weeks after birth, followed by 30 μg plasma-derived HB vaccine or 5 μg recombinant yeast-derived hepatitis B vaccine at 1, 2 and 7 months of age. Blood tests were performed for all the lying-in women and their neonates. Blood specimens were tested for HBsAg and HBeAg by enzyme immunoassay. All infants were followed up for 1 year.Results In the HBIG group, 491 neonates were born to 487 HBV carrier mothers; and in the control group, 496 neonates were born to 493 HBV carrier mothers. The rates of intrauterine transmission in the two groups were 14.3% and 5.7% respectively (χ2=20.280, P<0.001), and the rates of chronic hepatitis B in the two groups were 2.2% and 7.3% respectively (χ2=13.696, P<0.001). The high risk factors of intrauterine HBV infection included HBsAg HBeAg double positive and HBV DNA positive in the peripheral blood of pregnant women.Conclusion HBV infection in the uterus may be interrupted by injecting multiple intramuscular HBIG injections before delivery without causing any side-effects.

  12. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection

    OpenAIRE

    Lascar, R. M.; Gilson, R. J.; Lopes, A. R.; Bertoletti, A.; Maini, M K

    2003-01-01

    Liver-related mortality is an increasing problem in human immunodeficiency virus (HIV)/hepatitis B virus (HBV)-coinfected patients receiving highly active antiretroviral therapy (HAART). In HIV-negative patients, HBV chronicity is associated with a reduction in specific T cell responses that can be partially restored by treatment with lamivudine. We studied 5 HIV/HBV-coinfected patients treated with HAART, either with or without addition of a drug with specific anti-HBV activity. Our data sho...

  13. Analysis of serum 9 HBV marks in 183 HBV infected patients detected synchronously

    International Nuclear Information System (INIS)

    The purpose of this analyse is to investigate the significance of detecting serum 9 HBV marks on judging the replication and the activity of HBV, so as to direct the clinical treatment of anti-virus. 183 HBV infected patients were selected, and the five indexes of hepatitis B, Pre-S2, PHSA-R, HBsAg-IgM and HBV-DNA, were detected synchronously. The occurrence of HBV-DNA, Pre-S2, PHSA-R, HBsAg-IgM are 86.36%, 96.97%, 93.94%, 95.45% respectively when HBeAg is positive, and they are 15.79%, 44.74%, 39.47%, 48.68% respectively when both HBeAg and HBsAg are negative. So it was concluded that HBV-DNA, Pre-S2, PHSA-R, HBsAg-IgM and HBeAg can all be regarded as replication indexes. Pre-S2, PHSA-R and HBsAg-IgM are all surface albumen, the replication and infectivity are in positive proportion to their quantity. Virus can still be replicated when HBeAg and HBsAg are negative

  14. Poly(I:C/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting.

    Directory of Open Access Journals (Sweden)

    Xia Chuai

    Full Text Available BACKGROUND: Virus-specific cellular immune responses play a critical role in virus clearance during acute or chronic HBV infection. Currently, the commercially available HBV vaccine is combined with alum adjuvant, which stimulates mainly Th2 immune responses. Therefore, development of new therapeutic HBV vaccine adjuvants and immune strategies that also promote Th1 and CTL responses is urgently needed. METHODOLOGY/PRINCIPAL FINDINGS: To improve the immunity induced by the novel HBSS1 HBV vaccine, we evaluated the ability of adjuvants, including alum, CpG and polyriboinosinic polyribocytidylic acid [poly(I:C], to enhance the response when boosted with the recombinant adenoviral vector vaccine rAdSS1. The immune responses to different adjuvant combinations were assessed in C57BL/6 mice by enzyme-linked immunosorbent assay (ELISA, ELISpot and cytokine release assays. Among the combinations tested, a HBV protein particle vaccine with CpG/alum and poly(I:C/alum priming combinations accelerated specific seroconversion and produced high antibody (anti-PreS1, anti-S antibody titres with a Th1 bias. After boosting with recombinant adenoviral vector vaccine rAdSS1, both groups produced a strong multi-antigen (S and PreS1-specific cellular immune response. HBSS1 immunisation with poly(I:C/alum priming also generated high-level CD4(+ and CD8(+ T cell responses in terms of Th1 cytokines (IFN-γ and IL-2. CONCLUSIONS: The protein-vaccine HBSS1 with mixed poly(I:C/alum adjuvant priming, followed by a rAdSS1 vaccine boost, maximises specific antibody and Th1-biased cellular immune responses. This regime might prove useful in the development of HBV therapeutic vaccines. Furthermore, this promising strategy might be applied to vaccines against other persistent infections, such as human immunodeficiency virus and tuberculosis.

  15. Clinical Characteristics in Patients with Liver Cirrhosis Induced by HBV Infection and Combined with Mild Alcohol Intake

    Institute of Scientific and Technical Information of China (English)

    2014-01-01

    Objective To investigate the differences of clinical and biochemical characteristics between patients with liver cirrhosis induced by HBV infection combined with and without mild alcohol intake. Methods Data of patients with liver cirrhosis who were hospitalized in the First Hospital Afifliated to Xinjiang Medical University were retrospectively analyzed. Patients were divided into three groups: patients with liver cirrhosis induced by HBV infection and combined with mild alcohol intake, patients with HBV-related cirrhosis, and patients with alcohol-related cirrhosis. Biochemical detections including liver function, fasting lipid proifles, lipoprotein, kidney function, glucose, uric acid and regular blood tests were carried out and results were compared among three groups. Data were analyzed through STATA software and co-variant analysis. Results Total of 2 350 patients with liver cirrhosis were included, 732 patients had cirrhosis induced by HBV infection combined with mild alcohol intake, 1 316 patients had HBV-related liver cirrhosis, 302 patients had alcohol-related cirrhosis. The highest mean level of white cell count, mean corpuscular volume,γ-glutamyltranspeptidase and uric acid were observed in HBV infection combined with mild alcohol intake group. Multivariate regression analysis revealed that HBV infection, excessive alcohol intake, male and age were risk factors for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Conclusions HBV infection combined with mild alcoholic-related liver cirrhosis group showed the highest oxidative stress compared with alcoholic liver cirrhosis group, which suggested that mild alcohol intake may increase the incidence of liver cirrhosis in HBV infected patients and may not increase the incidence of HCC.

  16. Leukocyte telomere length-related rs621559 and rs398652 genetic variants influence risk of HBV-related hepatocellular carcinoma.

    Directory of Open Access Journals (Sweden)

    Wenting Pan

    Full Text Available Recent genome-wide association studies (GWAS have identified eleven leukocyte telomere length (LTL-related single nucleotide polymorphisms (SNPs. Since LTL has been associated with risk of many malignancies, LTL-related SNPs may contribute to cancer susceptibility. To test this hypothesis in hepatitis B virus (HBV-related hepatocellular carcinoma (HCC, we genotyped these eleven LTL-related SNPs in a case-control set including 1186 HBV-related HCC cases, 508 chronic HBV carriers and 1308 healthy controls at the discovery stage. The associations of HCC risk with these SNPs were further confirmed in an independent case-control set. We found that 1p34.2 rs621559 and 14q21 rs398652 were significantly associated with HBV-related HCC risk (both P<0.005 after Bonferroni corrections. There was no significant difference of either rs621559 or rs398652 genotypes between chronic HBV carriers and healthy controls, demonstrating that the association was not due to predisposition to HBV infection. In the pooled analyses (1806 HBV-related HCC cases and 1954 controls, we observed a decreased HCC risk, 0.72-times, associated with the 1p34.2 rs621559 AA genotype compared to the GG genotype (P = 1.6×10(-6. Additionally, there was an increased HCC risk, 1.27-fold, associated with the rs398652 GG genotype (P = 3.3×10(-6. A statistical joint effect between the rs621559 GG and rs398652 GG genotypes may exist in elevating risk of HBV-related HCC. We show, for the first time, that rs398652 and rs621559 might be marker genetic variants for risk of HBV-related HCC in the Chinese population.

  17. HBV Vaccination in Chronic Renal Failure Patients

    OpenAIRE

    Mir-davood Omrani; Mohammad Hassan Khadem Ansari

    2006-01-01

    HBV infection in chronic renal failure (CRF) becomes chronic in 30 to 60% compared with less than 10% in nonuremic patients. Immunological dysfunction in patients on hemodialysis may be related to imbalanced cytokine systems, such as tumor necrosis factor (TNF-|α|) and interleukin (IL) 6,1 by retention of renal metabolite in uremia and chronic inflammation and have a poor immunological reaction to T-cell-dependent antigens, like hepatitis B vaccination. Immunocompromised patients who are unre...

  18. Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants

    OpenAIRE

    Hong Kim; Bum-Joon Kim

    2015-01-01

    Occult hepatitis B virus infection (HBV) is characterized by HBV DNA positivity but HBV surface antigen (HBsAg) negativity. Occult HBV infection is associated with a risk of HBV transmission through blood transfusion, hemodialysis, and liver transplantation. Furthermore, occult HBV infection contributes to the development of cirrhosis and hepatocellular carcinoma. We recently reported the characteristic molecular features of mutations in the preS/S regions among Korean individuals with occult...

  19. Co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors in Kathmandu, Nepal

    Directory of Open Access Journals (Sweden)

    Ashish Chandra Shrestha

    2012-02-01

    Full Text Available Background: HIV, HBV, Syphilis and HCV share common modes of transmission. Objective: The study was aimed to determine the co-infection rate of HIV, HBV and Syphilis among HCV seropositive identified blood donors. Methods: The study was conducted on blood samples screened as HCV seropositive at Nepal Red Cross Society, Central Blood Transfusion Service, Kathmandu, Nepal. HCV seropositive samples were further tested for HIV, HBV and Syphilis. Results: Eight co-infections were observed in 139 HCV seropositives with total co-infection rate of 5.75% (95% CI = 2.52-11.03. Conclusion: Co-infection of HIV, HBV and Syphilis with HCV is prevalent in the healthy looking blood donors of Kathmandu, Nepal.

  20. HBV X-gene: A new serum marker for anti-HBV therapy monitoring

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Objective: To address HBV serum nucleic acid markers for stages without apparent replication. Methods: DNA and RNA sequence segments from the X, C and pre C/C regions produced successively during replication were used as targets for quantitative PCR and RT/PCR. Results: The assays confirmed the preferential formation of intermediates blocked at early stages. They persisted as the only detectable type of serum HBV DNA even after one year of therapy. At reentry into viral replication due to emergence of drug resistant mutants, lamivudine resistance produced exclusively incomplete DNA minus strands, whereas the wild type virus immediately synthesized complete DNA minus strands. Conclusion:PCR assays used for monitoring complete suppression of HBV replication must target the X gene region.

  1. A rare HBV subgenotype D4 with unique genomic signatures identified in north-eastern India--an emerging clinical challenge?

    Directory of Open Access Journals (Sweden)

    Priyanka Banerjee

    Full Text Available BACKGROUND/AIMS: HBV has been classified into ten genotypes (A-J and multiple subgenotypes, some of which strongly influence disease outcome and their distribution also correlate with human migration. HBV infection is highly prevalent in India and its diverse population provides an excellent opportunity to study the distinctiveness of HBV, its evolution and disease biology in variegated ethnic groups. The North-East India, having international frontiers on three sides, is one of the most ethnically and linguistically diverse region of the country. Given the paucity of information on molecular epidemiology of HBV in this region, the study aimed to carry out an in-depth genetic characterization of HBV prevailing in North-East state of Tripura. METHODS: From sera of chronically HBV infected patients biochemical/serological tests, HBV DNA quantification, PCR-amplification, sequencing of PreS/S or full-length HBV genomes were done. HBV genotype/subgenotype determination and sequence variability were assessed by MEGA5-software. The evolutionary divergence times of different HBV subgenotypes were estimated by DNAMLK/PHYLIP program while jpHMM method was used to detect any recombination event in HBV genomes. RESULTS: HBV genotypes D (89.5%, C (6.6% and A (3.9% were detected among chronic carriers. While all HBV/A and HBV/C isolates belonged to subgenotype-A1 and C1 respectively, five subgenotypes of HBV/D (D1-D5 were identified including the first detection of rare D4. These non-recombinant Indian D4 (IndD4 formed a distinct phylogenetic clade, had 2.7% nucleotide divergence and recent evolutionary radiation than other global D4. Ten unique amino acids and 9 novel nucleotide substitutions were identified as IndD4 signatures. All IndD4 carried T120 and R129 in ORF-S that may cause immune/vaccine/diagnostic escape and N128 in ORF-P, implicated as compensatory Lamivudine resistance mutation. CONCLUSIONS: IndD4 has potential to undermine vaccination

  2. Hepatitis B virus (HBV status of children born to HIV/HBV co-infected women in a French hospital: a cross-sectional study

    Directory of Open Access Journals (Sweden)

    Pierre Sellier

    2014-11-01

    Full Text Available Introduction: Human Immunodeficiency Virus (HIV Mother-To-Child-Transmission (MTCT and prevention by combined antiretroviral therapy (cART have been extensively studied. Hepatitis B Virus (HBV MTCT from HIV/HBV co-infected women and prevention by antiretroviral therapy with dual activity have been poorly studied. The aim of the study was to assess HBV MTCT from HIV/HBV co-infected women in a developed country with a large access to cART. Materials and Methods: HIV/HBV co-infected pregnant women attending the Obstetrics Department from 1st January 2000 to 1st January 2012 could be included in the study (NCT02044068. Antiretroviral therapy during pregnancy, injection of immunoglobulin and/or vaccine to newborns was retrospectively recorded. We assessed HBV status of children at least as old as two years. Results: Forty nine (9.2% from 530 HIV-infected women followed in the hospital were HIV/HBV co-infected. 34 (69.4% had given birth to 57 children in the hospital. 13 of these women (22 children were lost-to-follow-up, 21 women (35 children could be studied. Twenty six children (74.3% had HBs Ab at a protective level, 22 of them had received immunoglobulin at birth; 24 had received a complete vaccine schedule during the first six months of life (with immunoglobulin in 21 cases. The women had been given lamivudine or tenofovir/emtricitabine during eight and nine pregnancies respectively. Eight children (22.8% were tested negative for HBs Ag, HBs Ab and HBc Ab: 4 (11.4% had received immunoglobulin and a complete vaccine schedule; in two children, immunoglobulin was uncertain; in one child, the vaccine schedule was incomplete; in the last one, data about immunoglobulin and the vaccine schedule were lacking. The women had been given lamivudine or tenofovir/emtricitabine during five and two pregnancies respectively. One child had HBc Ab and HBs Ab, immunoglobulin was uncertain and the vaccine schedule was incomplete. The woman had been given lamivudine

  3. Functional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans.

    Science.gov (United States)

    Powell, Eleanor A; Boyce, Ceejay L; Gededzha, Maemu P; Selabe, Selokela G; Mphahlele, M Jeffrey; Blackard, Jason T

    2016-07-01

    Occult hepatitis B is defined by the presence of hepatitis B virus (HBV) DNA in the absence of hepatitis B surface antigen (HBsAg). Occult HBV is associated with the development of hepatocellular carcinoma, reactivation during immune suppression, and virus transmission. Viral mutations contribute significantly to the occult HBV phenotype. Mutations in the 'a' determinant of HBsAg are of particular interest, as these mutations are associated with immune escape, vaccine escape and diagnostic failure. We examined the effects of selected occult HBV-associated mutations identified in a population of HIV-positive South Africans on HBsAg production in vitro. Mutations were inserted into two different chronic HBV backbones and transfected into a hepatocyte-derived cell line. HBsAg levels were quantified by enzyme-linked immunosorbent assay (ELISA), while the detectability of mutant HBsAg was determined using an HA-tagged HBsAg expression system. Of the seven mutations analysed, four (S132P, C138Y, N146D and C147Y) resulted in decreased HBsAg expression in one viral background but not in the second viral background. One mutation (N146D) led to a decrease in HBsAg detected as compared to HA-tag, indicating that this mutation compromises the ability of the ELISA to detect HBsAg. The contribution of occult-associated mutations to the HBsAg-negative phenotype of occult HBV cannot be determined adequately by testing the effect of the mutation in a single viral background, and rigorous analysis of these mutations is required. PMID:27031988

  4. The use of HBV model for flash flood forecasting

    OpenAIRE

    Kobold, M.; Brilly, M.

    2006-01-01

    The standard conceptual HBV model was originally developed with daily data and is normally operated on daily time step. But many floods in Slovenia are usually flash floods as result of intense frontal precipitation combined with orographic enhancement. Peak discharges are maintained only for hours or even minutes. To use the HBV model for flash flood forecasting, the version of HBV-96 has been applied on the catchment with complex topography with the time step of one hour. ...

  5. Leukocyte telomere length-related rs621559 and rs398652 genetic variants influence risk of HBV-related hepatocellular carcinoma.

    Science.gov (United States)

    Pan, Wenting; Cheng, Guangxia; Xing, Huaixin; Shi, Juan; Lu, Chao; Wei, Jinyu; Li, Lichao; Zhou, Changchun; Yuan, Qipeng; Zhou, Liqing; Yang, Ming

    2014-01-01

    Recent genome-wide association studies (GWAS) have identified eleven leukocyte telomere length (LTL)-related single nucleotide polymorphisms (SNPs). Since LTL has been associated with risk of many malignancies, LTL-related SNPs may contribute to cancer susceptibility. To test this hypothesis in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we genotyped these eleven LTL-related SNPs in a case-control set including 1186 HBV-related HCC cases, 508 chronic HBV carriers and 1308 healthy controls at the discovery stage. The associations of HCC risk with these SNPs were further confirmed in an independent case-control set. We found that 1p34.2 rs621559 and 14q21 rs398652 were significantly associated with HBV-related HCC risk (both PHCC cases and 1954 controls), we observed a decreased HCC risk, 0.72-times, associated with the 1p34.2 rs621559 AA genotype compared to the GG genotype (P = 1.6×10(-6)). Additionally, there was an increased HCC risk, 1.27-fold, associated with the rs398652 GG genotype (P = 3.3×10(-6)). A statistical joint effect between the rs621559 GG and rs398652 GG genotypes may exist in elevating risk of HBV-related HCC. We show, for the first time, that rs398652 and rs621559 might be marker genetic variants for risk of HBV-related HCC in the Chinese population. PMID:25365256

  6. Detection of Hepatitis B Virus (HBV) in Blood Serum By Means of PCR (Polymerase Chain Reaction) Technique

    International Nuclear Information System (INIS)

    Research for detecting the presence of HBV DNA in serum with PCR technique by using two pairs of oligonucleotide primers, has been carried out. Ten serum consisted of 5 HBsAg positive serum, I HBsAg weak positive serum, 3 HBsAg negative serum, and I sampel with negative HBV DNA as a previous PCR product trom another laboratory, were used to purify and to extract the DNA of virus, the sample pretreatment was done with Boom method. The two pairs of primers used for the- PCR process, were PC1 and PC2 and P1 and P2. The amplification process by means of PC1 and PC2 primer was carried out with two treatments, l.a. and l.b treatments of 5 HBsAg positive serum samples, 3 were positive for HBV DNA by PCR test with l.a. treatment. The PCR test by means of either the same primer but different treaunent (l.b treatment) or different pair of primer (pI and P2 pimer), revealed the presence of HBV DNA in all of HBsAg serum mentioned above of HBsAg negative Seruln, I serum was positive for HBV DNA and it was an amplification product of PCR test by using PI and P2 primer. The amplification products of PCR processwith either l.b treatment or PI and P2 primer, showed the positive results for I HBV positive serum as a previous PCR product trom another laboratory. All of the PCR test in this research provided the negative HBV DNA result in the HBsAg weak positive serum. The DNA amplification process by means of PI and P2 primer was more sensitive compared with PC I and PC2 primer

  7. Defective Natural Killer cell antiviral capacity in paediatric HBV infection

    DEFF Research Database (Denmark)

    Heiberg, Ida Louise; Laura J., Pallett; Winther, Thilde Nordmann;

    2015-01-01

    Natural Killer (NK) cells exhibit dysregulated effector function in adult chronic HBV infection (CHB), which may contribute to virus persistence. The role of NK cells in children infected perinatally with HBV is less studied. Access to a unique cohort enabled the cross-sectional evaluation of NK...

  8. HBV vaccine efficacy and detection and genotyping of vaccineé asymptomatic breakthrough HBV infection in Egypt

    Science.gov (United States)

    Abushady, Eman AE; Gameel, Magda MA; Klena, John D; Ahmed, Salwa F; Abdel-Wahab, Kouka SE; Fahmy, Sanya M

    2011-01-01

    AIM: To evaluate the impact of mass vaccination against the hepatitis B virus (HBV) in Egypt, and to search for vaccinee asymptomatic breakthrough HBV infection and its genotype. METHODS: Seven hundred serum samples from vaccinated children and adults (aged 2-47 years) were used for quantitative and qualitative detection of HBsAb by ELISA. Three hundred and sixty serum samples representing undetectable or low or high HBsAb were screened for markers of active HBV infection (HBsAg, HBcAb (IgG) and HBeAb by ELISA, plus HBsAg by AxSYM) and HBV-DNA genotyping by nested multiplex PCR and by DNA sequencing. RESULTS: It was found that 65% of children aged 2-4 years, and 20.5% aged 4-13 years, as well as 45% adults were good responders to HBV vaccination mounting protective level HBsAb. Poor responders were 28%, 59.5% and 34%, and non-responders were 7%, 20% and 21% respectively, in the three studied groups. Markers of asymptomatic HBV infections were HBsAg detected by ELISA in 2.5% vs 11.39% by AxSYM. Other markers were HBcAb (IgG) in 1.38%, HBeAb in 0.83%, and HBV-DNA in 7.8%. All had HBV genotype E infection. CONCLUSION: It is concluded that HBV vaccine is efficient in controlling HBV infection among children and adults. The vaccine breakthrough infection was by HBV genotype E. A booster dose of vaccine is recommended, probably four years after initial vaccination. PMID:21860674

  9. HIV, HBV and HCV Coinfection Prevalence in Iran - A Systematic Review and Meta-Analysis.

    Directory of Open Access Journals (Sweden)

    Fahimeh Bagheri Amiri

    Full Text Available worldwide, hepatitis C and B virus infections (HCV and HCV, are the two most common coinfections with human immunodeficiency virus (HIV and has become a major threat to the survival of HIV-infected persons. The review aimed to estimate the prevalence of HIV, HBV, HCV, HIV/HCV and HIV/HBV and triple coinfections in different subpopulations in Iran.Following PRISMA guidelines, we conducted a systematic review and meta-analysis of reports on prevalence of HIV, HBV, HCV and HIV coinfections in different subpopulations in Iran. We systematically reviewed the literature to identify eligible studies from January 1996 to March 2012 in English or Persian/Farsi databases. We extracted the prevalence of HIV antibodies (diagnosed by Elisa confirmed with Western Blot test, HCV antibodies and HBsAg (with confirmatory laboratory test as the main primary outcome. We reported the prevalence of the three infections and coinfections as point and 95% confidence intervals.HIV prevalence varied from %0.00 (95% CI: 0.00-0.003 in the general population to %17.25 (95% CI: 2.94-31.57 in people who inject drugs (PWID. HBV prevalence ranged from % 0.00 (95% CI: 0.00-7.87 in health care workers to % 30.9 (95% CI: 27.88-33.92 in PWID. HCV prevalence ranged from %0.19 (95% CI: 0.00-0.66 in health care workers to %51.46 (95% CI: 34.30-68.62 in PWID. The coinfection of HIV/HBV and also HIV/HCV in the general population and in health care workers was zero, while the most common coinfections were HIV/HCV (10.95%, HIV/HBV (1.88% and triple infections (1.25% in PWID.We found that PWID are severely and disproportionately affected by HIV and the other two infections, HCV and HBV. Screenings of such coinfections need to be reinforced to prevent new infections and also reduce further transmission in their community and to others.

  10. Application of CRISPR/Cas9 Technology to HBV

    Directory of Open Access Journals (Sweden)

    Guigao Lin

    2015-11-01

    Full Text Available More than 240 million people around the world are chronically infected with hepatitis B virus (HBV. Nucleos(tide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA, which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV.

  11. Study on correlation of hepatitis B maternal serum HBV-DNA with HBV-DNA in milk%乙肝孕产妇血清HBV-DNA与乳汁HBV-DNA相关性的比较

    Institute of Scientific and Technical Information of China (English)

    李国航; 庄桂龙; 瞿志军; 骆欢

    2012-01-01

    目的 探讨乙型病毒性肝炎(乙肝)孕产妇血清HBV-DNA与乳汁HBV-DNA的相关性,以期指导乙肝产妇的喂养方式.方法 选取2008年12月至2009年12月收治的70例血清HBV抗原阳性孕产妇(乙肝组)及20例健康产妇(对照组)为研究对象,采用酶联免疫吸附试验(ELISA)检测血清及乳汁中免疫血清学标志物;采用荧光定量PCR法(FQ-PCR)检测血清及乳汁中HBV-DNA含量情况,并对所检测的指标进行相关性分析.结果 采用ELISA检测到乙肝组产妇大三阳18例,小三阳27例,HBsAg、HBcAb均为阳性的有35例,乳汁HBV-DNA在各组中的检出的阳性率、病毒载量均小于血清HBV-DNA,但两者无显著性差异(P>0.05).乳汁HBV-DNA的含量随血清HBV-DNA含量的升高而增大(P 0.05 ). The level of HBV - DNA in milk was elevated following the increase of serum level of HBV - DNA, P <0.05. Conclusion The choice of feeding mode should be selected according to milk and serum levels of HBV -DNA, and breast feeding can be taking only at the time when HBV - DNA in milk and serum of mother turned to negative level.

  12. Detection of HBsAg, HBcAg, and HBV DNA in ovarian tissues from patients with HBV infection

    Institute of Scientific and Technical Information of China (English)

    Li-Zhang Chen; Xue-Gong Fan; Jian-Ming Gao

    2005-01-01

    AIM: To investigate the presence of HBsAg, HBcAg, and HBV DNA in ovarian tissues from patients with HBV infection.METHODS: HBsAg and HBcAg were examined in ovarian biopsy tissues from 26 patients with HBV infection by immunocytochemistry, and HBV DNA was detected in ovarian tissues by PCR.RESULTS: HBsAg and HBcAg were present with the same positive rate of 34.6% (9/26). The total positive rate was 46.2% (12/26). HBsAg and HBcAg were positive in 6 (23.1%) of the 26 patients. Brown positive particles were diffusely distributed in ovarian cells. The positive rate of HBV DNA was 58.3% (7/12).CONCLUSION: HBsAg, HBcAg, and HBV DNA can be detected in ovarian tissues from patients with HBV infection. The presence of HBsAg and HBcAg in ovarian tissues does not correlate with the HBV markers in serum.

  13. The Early Results of a New Health Care Program Implementation in HBV Screening: an Iranian Experience

    Science.gov (United States)

    Sharifian, Afsaneh; Naderi, Nostratollah; Sanati, Azar; Mohebi, Seyed Reza; Azimzadeh, Pedram; Golmohamadi, Ali; Nori, Simin; Khanyaghma, Mahsa; Sheikhesmaeili, Farshad; Zali, Mohamad Reza

    2015-01-01

    BACKGROUND According to the reports of World Health Organization (WHO) and Centers for Disease Control and Prevention, the prevalence of chronic hepatitis B infection in Iran has decreased from 2-7% in 2001 to 1.3-0.8% in children aged 2-14 years. In 2010 the Institute of Medicine recommended more comprehensive screening by primary care physicians (PCPs) for evaluation, vaccination, and management of infected patients for further decrease in the prevalence of chronic HBV infection. Thus, with contribution of the Health Department, we developed a practical flowchart for PCPs to start active screening of hepatitis B virus (HBV) in all visited patients and refer the positive cases for further evaluation and management to Taleghani Hospital. METHODS With collaboration of Health Department of Shahid Beheshti University of Medical Sciences), physicians of health centers were asked to screen all their patients for HBsAg. Positive cases were referred to Taleghani Hospital. They were first registered and educated about their disease, life style, and prevention methods. Their first degree families were screened for HBV infection too and were referred for vaccination if needed. According to the results of lab tests, appropriate management was done by a hepatologist. RESULTS Since implementation of this program, we have encountered a significant rise in patient detection (even in high risk groups). Many of them were not aware of their disease and most of those who were aware of their disease were not managed appropriately. Family screening and vaccination were inadequate and need more emphasis. CONCLUSION Although health system is active about screening of HBV infection in high risk populations, it is not perfect. It seems that health system needs to upgrade the screening and management programs of HBV infection. PMID:26609351

  14. Differential distribution of age and HBV serological markers in liver cirrhosis and non-cirrhotic patients with primary liver cancer

    Directory of Open Access Journals (Sweden)

    XU Xiuhua

    2013-03-01

    Full Text Available ObjectiveTo compare the age distributions and presence of hepatitis B virus (HBV serological markers between primary hepatic cancer (PHC patients with and without liver cirrhosis. MethodsA total of 547 PHC cases were analyzed retrospectively. After dividing into two groups according to liver cirrhosis status, the between-group differences in age and HBV serological markers, such as hepatitis B e antigen (HBeAg status, were statistically compared using the Chi-squared test. ResultsThe number of cirrhotic and non-cirrhotic PHC patients was 265 and 282, respectively. HBV infection was present in 221 cirrhotic PHC patients and 256 non-cirrhotic PHC patients (834% vs. 90.8%. There was a substantial bias in the proportion of males to females in the cirrhotic PHC patients (7.83∶1. The number of PHC patients <60 years old was similar between the cirrhotic and non-cirrhotic groups, but the non-cirrhotic group had significantly more patients >60 years old (P<0.005. In cirrhotic PHC patients, the HBV infection rate was highest in the <40 years old age group (96.7% and the HBeAg serological conversion rate was highest in the 40-60 years old age group (89.5%. In non-cirrhotic PHC patients, the 40-60 years old age group showed the highest HBV infection rate (90.3% but the lowest HBeAg serological conversion rate (80.0%. ConclusionPHC with liver cirrhosis mainly occurred in males, with the HBV infection rate being higher in individuals <60 years old. Non-cirrhotic PHC patients were more often >60 years old. Many of the HBV-infected PHC patients with cirrhosis had high HBeAg serological conversion rate.

  15. [Risk Management of HBV Reactivation: Construction of Check System].

    Science.gov (United States)

    Tanaka, Yasuhito

    2015-09-01

    In recent years, reactivation of HBV in patients receiving cancer chemotherapy or immunosuppressive therapy has been a problem. Generally, HBV-DNA levels are elevated prior to HBsAg concentration, and then hepatic dysfunction is observed in the process of hepatitis by HBV reactivation. Therefore, the monitoring of HBV-DNA is useful for the prediction of hepatic dysfunction, and nucleoside/nucleoside analogue (NA) administration is able to prevent this HBV reactivation. According to these facts, "Guidelines for the Prevention of HBV Reactivation in Patients Receiving Immunosuppressive Therapy or Chemotherapy", 2009 (revised as "JSH Guidelines for the Management of Hepatitis B Virus Infection", 2013) is established, and the diagnostic algorithm of HBsAg, anti-HBc, anti-HBs, and HBV-DNA has relevant descriptions. Combination therapy with rituximab and steroid for malignant lymphoma has a high risk of leading to fulminant hepatitis and, consequently, the guidelines are widely followed in such cases. We introduced the improvement of electronic medical recording and ordering systems in collaboration with hepatologists, and such a system has been widely used. Although the monitoring of HBV-DNA levels is required every 1-3 months, the guidelines are not followed strictly in cases such as rheumatoid disease and solid tumors only with chemotherapy or steroid treatment. Since a DNA assay is complicated and expensive, cost-effective, time-saving, and highly sensitive/specific measurements are required as well. Therefore, Lumipulse HBsAg-HQ (CLIA method) with high sensitivity is expected to be used for the monitoring of HBV reactivation. PMID:26731893

  16. The detection of HBV DNA with gold nanoparticle gene probes

    Institute of Scientific and Technical Information of China (English)

    Dong Xi; Xiaoping Luo; Qin Ning; Qianghua Lu; Kailun Yao; Zuli Liu

    2007-01-01

    Objective:Gold nanoparticle Hepatitis B virus (HBV) DNA probes were prepared, and their application for HBV DNA measurement was studied. Methods:Alkanethiol modified oligonucleotide was bound with self-made Au nanoparticles to form nanoparticle HBV DNA gene probes, through covalent binding of Au-S. By using a fluorescence-based method, the number of thiol-derivatized, single-stranded oligonucleotides and their hybridization efficiency with complementary oligonucleotides in solution was determined. With the aid of Au nanoparticle-supported mercapto-modified oligonucleotides serving as detection probes, and oligonucleotides immobilized on a nylon membrane surface acting as capturing probes,HBV DNA was detected visually by sandwich hybridization based on highly sensitive aggregation and silver staining. The modified nanoparticle HBV DNA gene probes were also used to detect the HBV DNA extracted from serum in patients with hepatitis B. Results:Compared with bare Au nanoparticles, oligonucleotide modified nanoparticles had a higher stability in NaCl solution or under high temperature environment and the absorbance peak of modified Au nanoparticles shifted from 520nm to 524nm. For Au nanoparticles, the maximal oligonucleotide surface coverage of hexaethiol 30-mer oligonucleotide was (132 ± 10) oligonucleotides per nanoparticle, and the percentage of hybridization strands on nanoparticles was (22 ± 3% ). Based on a two-probe sandwich hybridization/nanoparticle amplification/silver staining enhancement method, Au nanoparticle gene probes could detect as low as 10-11 mol/L composite HBV DNA molecules on a nylon membrane and the PCR products of HBV DNA visually. As made evident by transmission electron microscopy, the nanoparticles assembled into large network aggregates when nanoparticle HBV DNA gene probes were applied to detect HBV DNA molecules in liquid. Conclusion:Our results showed that successfully prepared Au nanoparticle HBV DNA gene probes could be used to

  17. Establishment and detection of HBV transgenic mice with YMDD mutation

    OpenAIRE

    Yu-qin YOU; Yang-shu CHEN; Guang-ze LIU; Fu-qiang YANG; Chen, Mei-Juan; Xiu-mei LI; Zhou, Jun-Hui; Kong, Xiang-Ping

    2011-01-01

    Objective To establish the hepatitis B virus(HBV) transgenic mice with YMDD mutation,and provide an animal model for research of HBV prevention and therapeutic approach.Methods 1.3 copies HBV genome containing YMDD mutation associated with lamivudine resistance was injected into the zygote of FVB/N female mice by microinjection.Integration and passage of exogenous gene in transgenic mice was confirmed by PCR.The expression of HBsAg in liver and kidney tissues in transgenic mice was identified...

  18. A Novel Hydrodynamic Injection Mouse Model of HBV Genotype C for the Study of HBV Biology and the Anti-Viral Activity of Lamivudine

    OpenAIRE

    Li, Xiumei; Liu, Guangze; Chen, Meijuan; Yang, Yang; Xie, Yong; Kong, Xiangping

    2016-01-01

    Background: Absence of an immunocompetent mouse model of persistent hepatitis B virus (HBV) infection has hindered the research of HBV infection and the development of antiviral medications. Objectives: In the present study, we aimed to develop a novel HBV genotype C mouse model by hydrodynamic injection (HI) and then used it to evaluate the antiviral activity of lamivudine. Materials and Methods: A quantity of 15 μg of HBV plasmid [pcDNA3.1 (+)-HBV1.3C], adeno-associated virus-HBV1.3C (pAAV-...

  19. Serum Levels of IL-10 and IL-17A in Occult HBV-Infected South-East Iranian Patients

    Directory of Open Access Journals (Sweden)

    Gholamhossein Hassanshahi

    2010-01-01

    Full Text Available Background and Aims: Occult hepatitis B infected (OBI patients can not completely eradicate hepatitis B virus-DNA (HBV-DNA from their liver and peripheral blood. The main aim of this study was to investigate the Interleukin (IL-10 and IL-17A serum levels in patients suffering from OBI.Methods: In this observational study, plasma samples of 3700 blood donors were tested for hepatitis B surface antigen (HBsAg and antibodies to the hepatitis B core antigen (anti-HBc, using enzyme-linked immunosorbent assay (ELISA. The HBsAg-/anti-HBc+ samples were selected and screened for HBV-DNA, using the polymerase chain reaction (PCR. HBV-DNA positive samples were assigned as OBI cases and IL-10 and IL-17 serum levels were detected using ELISA.Results: The results demonstrated that, 352 (9.5% out of 3700 blood samples were HBsAg-/anti-HBc+ and HBV-DNA was detected in 57/352 (16.1% of the HBsAg-/anti-HBc+ samples. Our results showed that the IL-10 and IL-17A serum levels increased significantly in the OBI cases in comparison to the controls (P < 0.001.Conclusions: According to the results of this study the higher level of IL-10 production may suppress the functioning of the immune system against HBV in OBI patients. The elevated IL-17A serum level also indicates a long period of infection in the patients observed.

  20. Seroprevalences of HBV, HCV and HIV among healthcare workers in a state hospital

    OpenAIRE

    Tekin, Alicem; Deveci, Özcan

    2010-01-01

    Objectives: In present study was aimed to investigate the seroprevalences of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among healthcare workers in Mardin Obstetric and Children Hospital between 2008 and 2009. Methods: In sera samples obtained from 180 healthcare workers, hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), HCV antibody (anti-HCV) and HIV antibody (anti-HIV) markers were tested by chemiluminescent immun...

  1. Seroprevalences of HBV, HCV and HIV among healthcare workers in a state hospital

    OpenAIRE

    Özcan Deveci; Alicem Tekin

    2010-01-01

    Objectives: In present study was aimed to investigate the seroprevalences of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among healthcare workers in Mardin Obstetric and Children Hospital between 2008 and 2009.Methods: In sera samples obtained from 180 healthcare workers, hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), HCV antibody (anti-HCV) and HIV antibody (anti-HIV) markers were tested by chemiluminescent immunoassa...

  2. Construction and Immunological Evaluation of Multivalent Hepatitis B Virus (HBV) Core Virus-Like Particles Carrying HBV and HCV Epitopes▿

    OpenAIRE

    Sominskaya, Irina; Skrastina, Dace; Dislers, Andris; Vasiljev, Denis; Mihailova, Marija; Ose, Velta; Dreilina, Dzidra; Pumpens, Paul

    2010-01-01

    A multivalent vaccine candidate against hepatitis B virus (HBV) and hepatitis C virus (HCV) infections was constructed on the basis of HBV core (HBc) virus-like particles (VLPs) as carriers. Chimeric VLPs that carried a virus-neutralizing HBV pre-S1 epitope corresponding to amino acids (aa) 20 to 47 in the major immunodominant region (MIR) and a highly conserved N-terminal HCV core epitope corresponding to aa 1 to 60 at the C terminus of the truncated HBcΔ protein (N-terminal aa 1 to 144 of f...

  3. HBV Vaccination in Chronic Renal Failure Patients

    Directory of Open Access Journals (Sweden)

    Mir-davood Omrani

    2006-12-01

    Full Text Available HBV infection in chronic renal failure (CRF becomes chronic in 30 to 60% compared with less than 10% in nonuremic patients. Immunological dysfunction in patients on hemodialysis may be related to imbalanced cytokine systems, such as tumor necrosis factor (TNF-|α| and interleukin (IL 6,1 by retention of renal metabolite in uremia and chronic inflammation and have a poor immunological reaction to T-cell-dependent antigens, like hepatitis B vaccination. Immunocompromised patients who are unresponsive to hepatitis B vaccination seem to be unable to enhance IL-10 synthesis for control of monokine overproduction. Moreover, human leukocyte antigen (HLA genes, which play a major role in the antigen presentation to immunocompetent cells, have also been shown to modulate this immune response. Unfortunately, seroconversion to anti-HBS has been reported to occur in only 40 to 50% of the vaccine, a significantly lower rate than that observed in healthy adults. Various methods including adjutants such as zinc, gamma interferon, thymopentine, GM-CSF and Levamisol for improving immune responses have been advised. Experience with Pres1/s2, third-generation vaccines is limited and they have not been proven more effective than intradermally (ID administered second-generation S antigen vaccines. Both intramuscular (IM and intradermal (ID vaccinations against hepatitis B have variable efficiency in hemodialysis and non-responders should be retreated by ID route.

  4. Clinical Observation of Pregnant Woman Quantitative HBV-DNA and Mother to Infant Vertical Transmission%孕妇HBV-DNA定量与母婴垂直传播的临床观察

    Institute of Scientific and Technical Information of China (English)

    高卓; 俞洋

    2015-01-01

    目的:探讨HBV-DNA定量与孕妇母婴阻断后的HBV宫内感染的临床观察。方法:将286例HBsAg阳性孕妇分为研究组143例,其中乙肝大三阳46例,乙肝小三阳45例,HBsAg阳性者52例,HBV-DNA定量均高于正常值或几倍不等;对照组143例,其中乙肝大三阳47例,乙肝小三阳50例,HBsAg阳性者46例,HBV-DNA定量均在正常范围内。两组均于孕28、32、36周分别肌注HBIG 200 IU,采用酶联免疫吸附试验检测两组新生儿的五项指标。结果:研究组、对照组新生儿脐血检测结果HBsAg阳性率分别为34.2%、11.2%,两组比较差异有统计学意义(P0.05)。结论:HBV-DNA含量均在正常范围内,HBIG能够有效阻断HBsAg阳性和乙肝小三阳的母婴传播,但不能阻断乙肝大三阳和HBV-DNA定量异常的乙肝小三阳和HBsAg阳性患者的母婴传播。%Objective:To investigate the clinical observation on HBV intrauterine infection of maternal and child block after the implementation of quantitative HBV-DNA with pregnant women.Method:In this paper,286 cases of HBsAg positive pregnant women were divided into the study group(n=143), 46 cases of HBsAg,HBeAg,and HBcAb test positive,45 cases of hepatitis B small Sanyang,52 cases of HBsAg positive,quantitative HBV-DNA was higher than the normal value ora few times ranging from.The control group(n=143),47 cases of HBsAg,HBeAg,and HBcAb test positive,50 cases of hepatitis B small Sanyang,46 cases of HBsAg positive,quantitative HBV-DNA were within the normal range.Among them,the study group and the control group were injected with 200 IU of hepatitis B immunoglobulin for 1 injection at 28th,32th,and 36th weeks of pregnancy respectively.The samples of cord blood from the newborns were collected and tested for HBsAg,HBsAb,HBeAg,HBeAb and HBcAb by ElISA and FQ-PCR.Result:The study group and the control group positive rates of detection results of neonatal cord blood HBsAg were 34.2%,11.2%,there was

  5. Mutation analyses of integrated HBV genome in hepatitis B patients

    Institute of Scientific and Technical Information of China (English)

    Peilin Wang; Xiuhai Wang; Shuying Cong; Hongming Ma; Xuecheng Zhang

    2008-01-01

    Little has been learnt in the last 30 years about detection of HBV genome as well as its mutation analysis between hepatitis B fathers (HBF) and their children. In this study, we used nest polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and DNA sequencing analysis, to examine the integrated HBV genome in paraffin-embedded testis tissues, which were taken as samples from HBF, and in peripheral blood mononuclear cells (PBMC) from 74 cases of HBFs and their children who were born after their fathers' HBV infection (caHBF). We found that HBV DNA existed in testis tissues, mainly in the basilar parts of the seminiferous tubules, and also in PBMC of HBF. It was also documented that there were point mutations of poly-loci, insertions and deletions of nucleotides in integrated HBV genomes, and the types of gene mutations in the HBFs were similar to those in caHBF. This study addresses the major types of gene mutations in integrated HBV genome in human patients and also presents reliable evidence of possible genetic transmission of hepatitis B.

  6. Automated Triplex (HBV, HCV and HIV) NAT Assay Systems for Blood Screening in India

    Science.gov (United States)

    2016-01-01

    This review is confined to triplex nucleic acid testing (NAT) assays to be used on fully automated platform. Around the world, these assays are being used at various transfusion medicine centres or blood banks to screen blood units for HBV, HCV and HIV. These assay systems can screen up to 1000 blood units for HBV, HCV and HIV simultaneously in a day. This area has been dominated by mainly two manufacturers: M/s Gen-Probe-Novartis and M/s Roche Molecular Systems. The triplex NAT assay systems of both manufacturers are licensed by United States Food and Drug Administration. There is not much awareness about the technology and procedures used in these assays. The main objective of this review is to create awareness about the technology and procedure of these assays. PMID:27042485

  7. Design and choice of TFO binding and cleaving HBV core promoter

    Institute of Scientific and Technical Information of China (English)

    光丽霞; 袁发焕; 任平; 奚敏; 艾友平

    2003-01-01

    Objective: To screen a triple helix-forming oligodeoxyribonucleotide (TFO) that can bind HBV core promoter at target site with high affinity and specificity, and to observe the ability of manganese porphyrin modified TFO to combine and cleave HBV DNA.Methods: Similar homopurine domain (1 734-1 754) in HBV core promoter was selected as target sequence.Several corresponding TFOs were synthesized.The affinities and specificities of TFOs binding target sequence were tested with electrophoretic mobility shift and DNase Ⅰ footprinting assays.The selected best TFO was modified with manganese porphyrin and acridine.The ability of the TFO derivative to cleave HBV DNA was observed with cleavage experiment.Results: Under the condition of 37℃ and pH 7.4, the TFO consisting of cytidylate and thymidylate (CT-TFO) and the parallel TFO consisting of guanylate and thymidylate (GT-TFOp) bound the target sequence weakly with Kd values much more than 10-6 mol/L.The affinities of anti-parallel GT-TFO (GT-TFOap) and short TFO consisting of adenine nucleotide and guanylate (AG-TFOsh) binding the target sequence were higher than those of the formers, with Kd values of 5×10-7 mol/L and 2.5×10-8 mol/L respectively.Long AG-TFO (AG-TFOl) had the highest binding affinity with a Kd value of 3×10-9 mol/L among all the TFOs studied for sequence specificity.In the presence of potassium monopersulfate, KHSO5, TFO modified with manganese porphyrin and acridine cleaved the target sequence where the triplex DNA formed.Conclusion: TFO containing AG or GT binds homopurine in HBV core promoter in adverse parallel direction to form triple helix.AG-TFOl has the highest binding affinity among all the TFOs studied.After modified with manganese porphyrin, AG-TFOl completely binds and cleaves the target HBV DNA sequence where triplex DNA is formed.

  8. Prevalence of HBV and HBV vaccination coverage in health care workers of tertiary hospitals of Peshawar, Pakistan

    OpenAIRE

    Ali Ijaz; Khan Shahid; Ayaz Sultan; Naseemullah,; Khan Sanaullah; Attaullah Sobia; Hoti Naseruddin; Siraj Sami

    2011-01-01

    Abstract Background Hepatitis B Virus (HBV) may progress to serious consequences and increase dramatically beyond endemic dimensions that transmits to or from health care workers (HCWs) during routine investigation in their work places. Basic aim of this study was to canvass the safety of HCWs and determine the prevalence of HBV and its possible association with occupational and non-occupational risk factors. Hepatitis B vaccination coverage level and main barriers to vaccination were also ta...

  9. Evaluation of the Procleix Ultrio Plus ID NAT assay for detection of HIV 1, HBV and HCV in blood donors

    Directory of Open Access Journals (Sweden)

    Raj Nath Makroo

    2015-01-01

    Full Text Available Introduction: The Procleix Ultrio Plusassay is a new-generation qualitative in vitro nucleic acid amplification test used to screen for human immunodeficiency virus type 1 (HIV-1 RNA, hepatitis C virus (HCV RNA and hepatitis B virus (HBV DNA in blood donors. This study was performed to compare the Procleix Ultrio assay with the new-generation Procleix Ultrio Plus Nucleic Acid Test (NAT assays. Materials and Methods: Ten thousand three hundred and two donor samples were run in parallel for ID NAT using the Procleix Ultrio and the Procleix Ultrio Plus assay. Simultaneously, enzyme-linked immunosorbent assay testing was performed on an EVOLIS Walk away System for HIV, HCV, HBsAg and anti-HBc. Reactive samples were confirmed using polymerase chain reaction. Results: In the 10,302 samples tested during the study period, we identified 15 NAT yields, and all these revealed HBV DNA in the discriminatory assays. Eight of these were exclusive yields from the Ultrio Plus assay and the remaining seven cases were determined as HBV NAT yield, both by the Procleix Ultrio as well as the Ultrio Plus assays, i.e. "Combined" yields. No HCV or HIV 1 yields were detected during the study period by either of two assays. Conclusion: With an overall yield rate of 1 in 687 and an exclusive yield rate of 1 in 1287, the Procleix Ultrio Plus assay proved to be highly sensitive in detecting occult HBV infections.

  10. 腹水细胞HBV DNA荧光PCR检测方法的建立及意义研究%Studying and the significance of the HBV DNA from ascite cells with time fluoresceence quantitative PCR

    Institute of Scientific and Technical Information of China (English)

    李妍; 马洪滨; 朱剑功; 王海滨; 洪炜; 庞君丽; 王大刚; 杨宁; 李永利; 刘立明; 王雪飞; 陈厦

    2011-01-01

    Objective:The Cyto- megalovirus CMV Lysis Solution , which can extraction the HBV DNA from ascite cells, has been used in detecting HBV DNA with time fluoresceence quantitative PCR , and then we can study the change and the clinical significance. Methods: 10 ml ascite from cirrhosis patients originating hepatitis B infection centrifuged immediately by 1500 g for 5 minutes. The liquid supernatant was discarded thoroughly. The HBV DNA in ascite cells from the bottom of tube is detected with real time PCR technology. Results:The detected numerical attain abilities was 102 IU/ml, which using fluorescence PCR technology testing ascite cell HBV DNA it showed theoretical gradient according to the terms of diluted times. and then the Correlation coefficient is 0.91, making it clear that the method has a good sensitivity. By making repeated study we find that the 5 repeated times leafs CV is 14.4% ,9.8% and 11.2%, and the declination meet the NCCL Requirements. There is about 0.5 to 1. 5 LOG of HBV DNA in different ascite cells from patients with cirrhosis,which explaining ascite cells not only contains a lot of HBV, but also has much individual differences apparently. The HBV DNA in three times of dynamic detecting in one case of hepatocellular carcinoma is gradually decreased both in ascite and ascite cells along with the deterioration of disease. Conclusion:Our real - time PCR system of HBV DNA detection from ascite cells by the Cyto - megalo virus CMV Lysis Solution , can provide an accurate and highly sensitive rapid method to quantify Hepatitis B virus with low artificial positive and lower negative artificial results. It is suitable for studying the significance of HBV DNA from ascite cells in clinic.%目的:采用细胞病毒裂解液快速提取腹水细胞内的HBV DNA,建立实时荧光定量PCR检测HBV DNA的技术,并初步研究其临床意义.方法:采用乙肝肝硬化患者腹水10 ml,1500 g/min离心5 min,全部吸出上清,对沉渣细胞进

  11. Prevalence of genotype D in chronic liver disease patients with occult HBV infection in northern region of India

    Directory of Open Access Journals (Sweden)

    Meher Rizvi

    2014-01-01

    Full Text Available Background: Etiology of nearly 30% cases of chronic viral hepatitis remains undetected. Occult HBV infection (OBI has emerged as an important clinical entity in this scenario. Apart from prevalence and clinical outcome of OBI patients genotype was determined in northern region of India. Materials and Methods: A total of 847 patients with chronic liver disease (CLD were screened for common viral etiologies and others serological markers of HBV. Amplification of surface, precore and polymerase genes of HBV was performed in patients negative for other etiologies. Genotyping and sequencing of the precore region was performed for OBI cases. Results: Twenty-nine (7.61% cases of OBI were identifiedof which 9 had chronic liver disease (CHD, 11 liver cirrhosis (LC and 9 hepatocellular carcinoma (HCC. Majority of OBI cases were detected by amplification of surface gene 26 (89.6%, followed by pre-core gene 12 (41.3%. Their liver functions tests were significantly deranged in comparison to overt HBV cases. IgG anti HBc was present in 8 (27.6% OBI cases. Mutation was observed in 8 (32% in pre-core region at nt. 1896 of overt HBV cases. Genotype D was the predominant genotype. In conclusion: OBI in our study was characterized by predominance of genotype D and more severe clinical and biochemical profile in comparison to overt HBV. IgG anti HBc positivity could be utilized as a marker of OBI. We recommend use of sensitive nested PCR for diagnosis of OBI, amplifying at least surface and precore gene.

  12. Chemoprevention of HBV-related hepatocellular carcinoma by the combined product of resveratrol and silymarin in transgenic mice

    Directory of Open Access Journals (Sweden)

    Wen-Chuan Hsieh

    2013-09-01

    Full Text Available ABSTRACTBackground: Patients with chronic hepatitis B virus (HBV infection are at a high risk to develop hepatocellular carcinoma (HCC. Recently, metabolic syndrome has been found to carry a risk for HCC development. Considering the limitation of chemotherapeutic drugs for HCCs, the development of chemopreventive agents for high risk chronic HBV carriers is urgently demanded. In this study, we used combined silymarin and resveratrol extract which have been shown to exhibit biologic effects on activating peroxisome proliferator activated receptors (PPAR and inhibiting mTOR signaling in a transgenic mice model harboring HBV viral oncoproteins.Methods: The transgenic mice model harboring HBx and pre-S2 mutant constructs which develop HCC was adopted. First, we in vitro tested the ideal combination dosages of the silymarin and resveratrol product, and then we fed the natural product to the transgenic mice.The chemopreventive effects on preventing the development of HCC were evaluated.Results: MTT assay showed an enhanced effect of the combined silymarin and resveratrol product on the reduction of cell proliferation in two hepatoma cell lines, Huh-7 and Hep G2. In vitro reporter assay and Western blot analyses revealed that the combined product couldactivate PPAR/PGC-1 signaling and inhibit mTOR expression. In vivo, the combined products could significantly ameliorate fatty liver and reduce HCCs in transgenic miceharboring HBV oncoproteins.Conclusions: The combined silymarin and resveratrol product exhibits a synergistic effect on the reduction of HCC development in transgenic mice model and may represent a potential agent for the prevention of HCC in high risk chronic HBV carriers.Key words: HBV, HCC, Transgenic mice, Chemoprevention

  13. Anti-HBV activity of TRL mediated by recombinant adenovirus

    Institute of Scientific and Technical Information of China (English)

    Wei-Dong Gong; Ya Zhao; Jun Yi; Jin Ding; Jun Liu; Cai-Fang Xue

    2005-01-01

    AIM: To investigate the inhibitive effect of hepatitis B virus (HBV)-TRL on HBV replication. METHODS: Based on previously constructed pcDNA3.1 (-)/TRL, TR, TRmut, HBV core protein (HBVc) and hEDN, interest gene sequences TRL, TR, HBVc and hEDN were inserted into adenovirus shuttle plasmid pDC316 respectively and co-transfected HEK293 cells with rescue plasmid pBHGlox(delta)E1,3Cre to acquire RAd/TRL, TR, HBVcand hEDN. And then RAds were identified, amplified and the titers in HEK293 cells were determined. RAd/TRL and TR were named as the experimental groups, and others were control ones. After HepG2.2.15 cells were infected, RAd/TRL expression was identified by indirect immunofluorescence staining. Supernatant HBV-DNA content was determined by fluorescent quantification PCR. Meanwhile, metabolism of HepG2.2.15 cells was evaluated by MTT colorimetry.RESULTS: RAd vectors with distinct interest gene sequence were successfully constructed. Effective expression of RAd/TRL in HepG2.2.15 cells resulted in a significant decrease of supernatant HBV-DNA content compared to RAd/TR (0.63±0.14 vs 1.60±0.47, P = 0.0266, <0.05) andother control groups (0.63±0.14 vs 8.50±2.78, 8.25±2.26,8.25±2.29, 8.50±1.51, 8.57±1.63, P<0.01). MTT assaysuggested that there were no significant differences in cell metabolic activity between groups (P>0.05).CONCLUSION: The construction and expression of RAd/TRL has been achieved and it could inhibit HBV replication successfully, which has laid the foundation for further research on anti-HBV activity in vivo.

  14. [Establishment of hepatitis B virus (HBV) chronic infection mouse model by in vivo transduction with a recombinant adeno-associated virus 8 carrying 1. 3 copies of HBV genome (rAAN8-1. 3HBV)].

    Science.gov (United States)

    Dong, Xiao-Yan; Yu, Chi-Jie; Wang, Gang; Tian, Wen-Hong; Lu, Yue; Zhang, Feng-Wei; Wang, Wen; Wang, Yue; Tan, Wen-Jie; Wu, Xiao-Bing

    2010-11-01

    In this report, we developed a HBV infection model in C57BL/6 mouse line by in vivo injection of a recombinant adeno-associated virus 8 vector carrying 1. 3 copies of HBV genome (ayw subtype) (rAAV8-1. 3HBV). We firstly prepared and purified the rAAV8-1. 3HBV and then injected it into three C57BL/6 mice with the dose of 2 x 10e11vg, respectively. HBsAg and HBeAg were assayed in sera collected at different time points post injection. Ten weeks post injection, the three mice were sacrificed and blood and liver tissue were taken for assay. Copies of HBV DNA were detected by real time PCR and the way of HBV DNA replication was identified by PCR. Subsequently, detection of HBV antigen by immunohistochemistry and pathology analysis of liver tissue of mice were performed. The results suggested that expression of HBsAg and HBeAg lasted for at least 10 weeks in mice sera. Among mice injected with rAAV8-1. 3HBV, HBsAg levels were showed an 'increasing-decreasing-increasing' pattern (the lowest level at the 4th week post injection), while HBeAg levels were kept high and relatively stable. HBV DNA copies were 4.2 x 10(3), 3.6 x 10(3), 2.5 x 10(3) copies/mL in sera and 8.0 x 10(6), 5.7 x 10(6), 2.6 x 10(6) copies/g in hepatic tissues of three mice, respectively. We found that the linear 1. 3HBV DNA in the rAAV8-1. 3HBV could self form into circular HBV genome and replicate in livers of HBV transfected mice. HBsAg and HBcAg were both positive in liver tissue of mice injected with rAAV8-1. 3HBV and no obvious pathological characters were found in liver of mice injected with rAAV8-1. 3HBV. In conclusion, we successfully developed a HBV chronic infection model in C57BL/6 mouse line by in vivo transduction with the recombinant virus rAAV8-1. 3HBV, in which HBV genes could be continuously expressed and replicated over 10 weeks, and paved a way for further characterization of the human chronic hepatitis B virus infection and evaluation of vaccine and anti-HBV agents. PMID:21344744

  15. Effect of previous exposure to hbv on liver histology and treatment response in chc patients

    International Nuclear Information System (INIS)

    Objective: To analyze the influence of previous exposure to HBV on liver histology and treatment outcomes in chronic hepatitis C (CHC) patients. Study Design: Case control study. Place and Duration of Study: Rawalian Liver Clinic, Department of Medicine, Holy Family Hospital, Rawalpindi, from January 2011 to December 2012. Methodology: Medical records of CHC patients attending the Rawalian Liver Clinic were retrospectively analyzed. Virological and treatment responses along with histological changes were compared between cases (anti-HBc positive) and controls (anti-HBc negative). Significance was determined through chi-square test at p < 0.05. Results: Among the 592 CHC patients, 254 (42.9%) had serological evidence of a positive anti-HBc (cases) and 338 (57.1%), patients had negative anti-HBc (controls). No significant difference was found between ETR, SVR and treatment responses (n=220) between the two groups. Out of 65 patients whose liver biopsy data was available, cases were more likely to respond in the absence of fibrosis (63.2%, (n=24) vs. 36.8%, (n=14), p=0.001). The controls responded more in the presence of fibrosis (100% (n=9) vs. 0, p=0.001). There was no significant effect of anti-HBc positivity on grades of inflammation and consequent treatment response (p=0.14). Conclusion: There are a significant number of CHC patients with markers of previous HBV infection in Pakistani population. Previous HBV (anti-HBc positive) does not seem to have an adverse effect on liver histology and treatment responses in HBV infection. (author)

  16. Seroprevalence of HBV, HCV & HIV co-infection and risk factors analysis in Tripoli-Libya.

    Directory of Open Access Journals (Sweden)

    Mohamed A Daw

    Full Text Available BACKGROUND: In 1998 Libya experienced a major outbreak of multiple blood borne viral hepatitis and HIV infections. Since then, no studies have been done on the epidemic features and risk factors of HBV, HCV, HIV and co-infection among the general population. METHODS: A prospective study was carried out using a multi-centre clustering method to collect samples from the general population. The participants were interviewed, and relevant information was collected, including socio-demographic, ethnic, and geographic variables. This information was correlated with the risk factors involved in the transmission of HBV, HCV and HIV. Blood samples were collected and the sera were tested for HBsAg, anti-HCV and anti-HIV using enzyme immunoassay. RESULTS: A total of 9,170 participants from the nine districts of Tripoli were enrolled. The average prevalence of HBsAg was 3.7%, anti-HCV 0.9%, anti-HIV 0.15% and co-infection 0.02%. The prevalence varied from one district to another. HBV was more prevalent among those aged over 50 years and was associated with family history. Anti-HCV and anti-HIV were more prevalent among those aged 20-40 years. Intravenous drug use and blood transfusion were the main risk factors for HCV and HIV infection. CONCLUSION: HBV, HCV, HIV and co-infection are relatively common in Libya. High prevalence was associated with geographic, ethnic and socioeconomic variability within the community. HCV and HIV infections among the younger age groups are becoming an alarming issue. Regulations and health care education need to be implemented and longer term follow-up should be planned.

  17. Relationship between serum HBV DNA level and follicular helper T lymphocyte in patients with chronic hepatitis B and its significance%慢性乙型肝炎患者血清HBV DNA水平与滤泡辅助性T淋巴细胞的关系和意义

    Institute of Scientific and Technical Information of China (English)

    王娟华; 顾锡炳; 朱银芳; 华忠; 王栋; 杨小娟; 徐月琴; 陆忠华

    2013-01-01

    目的 探讨慢性乙型肝炎(CHB)患者HBV DNA水平与外周血滤泡辅助性T淋巴细胞(Tfh)的关系和意义.方法 179例HBV DNA阳性、HBeAg阳性、人白细胞抗原(HLA)-A2阳性的CHB患者,用实时荧光定量PCR检测HBV DNA,流式细胞术检测Tfh、HBV特异性CTL,并作IL-21的检测.将179例CHB患者根据HBV DNA水平分为甲、乙两组,甲组86例,HBV DNA水平为104 ~105拷贝/ml,乙组93例,HBV DNA水平为106 ~ 107拷贝/ml,对两组患者进行以上检测指标的比较.结果 甲组HBV DNA水平为(4.85±0.37) log10拷贝/ml,乙组HBV DNA水平为(6.83±0.31) log10拷贝/ml,t=27.31,P<0.001,甲组Tfh(5.96±1.59)%,高于乙组(3.71±2.15)%,t=4.92,P<0.01,IL-21(42.61 ±15.11)ng/L,高于乙组(14.91 ±3.15) ng/L,t=8.62,P<0.01,HBV特异性CTL(0.36±0.08)%,高于乙组(0.18±0.06)%,=19.99,P<0.001.结论 CHB患者血清HBVDNA水平与外周血Tfh水平有关:HBV DNA水平低者,Tfh水平高,IL-21水平和HBV特异性CTL水平也高.HBV DNA水平高者,Tfh水平低,IL-21水平和HBV特异性CTL水平也低.基线HBV DNA水平影响抗病毒疗效的机制可能与Tfh水平有关.%Objective To explore relationship between HBV DNA level and peripheral blood follicular helper T lymphocyte (Tfh) in patients with chronic hepatitis B (CHB) and its significance.Methods HBV DNA levels of 179 cases of CHB patients with positive HBV DNA,positive HBeAg and positive human leukocyte antigen (HLA)-A2 were tested with real time fluorescent quantitative PCR.Tfh and HBV specific CTL were tested with flow cytometry.IL-21 was also tested.179 cases of CHB patients were divided into group A and group B based on HBV DNA levels,86 cases in group A,HBV DNA levels were 104-105copies/ml,93 cases in group B,HBV DNA levels were 106-107 copies/ml.Above testing indexes of the two groups were compared.Results HBV DNA levels of group A were (4.85 ± 0.37) log10 copies/ml,HBV DNA levels of group B were(6.83 ±0.31) log10copies/ml,t =27.31,P <0

  18. Differences in antiproliferative effect of STAT3 inhibition in HCC cells with versus without HBV expression

    International Nuclear Information System (INIS)

    Chronic infection with hepatitis B virus (HBV) plays an important role in the etiology of hepatocellular carcinoma (HCC). Signal transducer and activator of transcription 3 (STAT3) inactivation could inhibit the tumor growth of HCC. In this study, differential antiproliferative effect of STAT3 inhibition was observed with HBV-related HCC cells being more resistant than non-HBV-related HCC cells. Resistance of HBV-related HCC cells to STAT3 inhibition was positively correlated to the expression of HBV. Enhanced ERK activation after STAT3 blockade was detected in HBV-related HCC cells but not in non-HBV-related HCC cells. Combined ERK and STAT3 inhibition eliminates the discrepancy between the two types of HCC cells. Moderate reduced HBV expression was found after STAT3 inhibition. These findings disclose a discrepancy in cellular response to STAT3 inhibition between non-HBV-related and HBV-related HCC cells and underscore the complexity of antiproliferative effect of STAT3 inactivation in HBV-related HCC cells. - Highlights: • HBV endows HCC cells with resistance to STAT3 inactivation on proliferation. • Abnormal ERK activation after STAT3 inhibition in HBV-related HCC cells. • Combined ERK and STAT3 inhibition eliminates the discrepancy. • STAT3 inhibition moderately reduces HBV expression

  19. Differences in antiproliferative effect of STAT3 inhibition in HCC cells with versus without HBV expression

    Energy Technology Data Exchange (ETDEWEB)

    Hong, Yun; Zhou, Lin; Xie, Haiyang; Wang, Weilin [Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Zheng, Shusen, E-mail: shusenzheng@zju.edu.cn [Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China); Key Laboratory of Combined Multi-organ Transplantation of Ministry of Public Health, Qingchun Road 79, Hangzhou, Zhejiang 310003 (China)

    2015-06-05

    Chronic infection with hepatitis B virus (HBV) plays an important role in the etiology of hepatocellular carcinoma (HCC). Signal transducer and activator of transcription 3 (STAT3) inactivation could inhibit the tumor growth of HCC. In this study, differential antiproliferative effect of STAT3 inhibition was observed with HBV-related HCC cells being more resistant than non-HBV-related HCC cells. Resistance of HBV-related HCC cells to STAT3 inhibition was positively correlated to the expression of HBV. Enhanced ERK activation after STAT3 blockade was detected in HBV-related HCC cells but not in non-HBV-related HCC cells. Combined ERK and STAT3 inhibition eliminates the discrepancy between the two types of HCC cells. Moderate reduced HBV expression was found after STAT3 inhibition. These findings disclose a discrepancy in cellular response to STAT3 inhibition between non-HBV-related and HBV-related HCC cells and underscore the complexity of antiproliferative effect of STAT3 inactivation in HBV-related HCC cells. - Highlights: • HBV endows HCC cells with resistance to STAT3 inactivation on proliferation. • Abnormal ERK activation after STAT3 inhibition in HBV-related HCC cells. • Combined ERK and STAT3 inhibition eliminates the discrepancy. • STAT3 inhibition moderately reduces HBV expression.

  20. Reliable timescale inference of HBV genotype A origin and phylodynamics.

    Science.gov (United States)

    Zehender, Gianguglielmo; Svicher, Valentina; Gabanelli, Elena; Ebranati, Erika; Veo, Carla; Lo Presti, Alessandra; Cella, Eleonora; Giovanetti, Marta; Bussini, Linda; Salpini, Romina; Alteri, Claudia; Lai, Alessia; Tanzi, Elisabetta; Perno, Carlo Federico; Galli, Massimo; Ciccozzi, Massimo

    2015-06-01

    The worldwide distributed Hepatitis B virus (HBV) genotype A is classified into three subgenotypes, and one quasi-subgenotype. The majority of HBV-A subgenotypes are widespread in Africa and in ethnic groups that have relatively recently emigrated from African countries, whereas HBV-A2 is highly prevalent among subjects at high risk for sexual exposure to HBV in north-western Europe and the USA. The aim of this study was to reconstruct the origin and dispersion of HBV-A subgenotypes on a reliable timescale using short-term calibration based on heterochronous sampling for HBV-A2, and long-term calibration based on historical data for the other subgenotypes. To this aim, we analysed 113 newly characterised HBV-A isolates with 247 reference sequences retrieved from a public database. The phylodynamic reconstruction was performed by a Bayesian framework. The common ancestor of the currently circulating A subgenotypes was placed in west-central Africa a mean 1057 years ago. The genotype diverged into two main clades at the beginning of the 13th century: one including all of the west-central African quasi-subgenotypes and the other corresponding to subgenotype A1, originating in east Africa and further segregating into two main subclades: an "African" and a "cosmopolitan" clade. It is likely that the slave trade was the main source the spread of cosmopolitan HBV-A1, which was exported to Asia in the 17th century as a result of Arab or Portuguese trade, and to Latin America in the 18th centuries through the trans-Atlantic slave trade. The origin of the currently circulating A2 strains dates back to the first decades of the 20th century, and the evolutionary demography analysis suggests an exponential growth of infections, between 1970s and the mid-1990s. In conclusion, the very different epidemiological and evolutionary histories of HBV-A subgenotypes justify the use of different calibration approaches to reconstruct their reciprocal phylodynamics. PMID:25784568

  1. People with multiple tattoos and/or piercings are not at increased risk for HBV or HCV in The Netherlands.

    Directory of Open Access Journals (Sweden)

    Anouk T Urbanus

    Full Text Available BACKGROUND: Although published results are inconsistent, it has been suggested that tattooing and piercing are risk factors for HBV and HCV infections. To examine whether tattooing and piercing do indeed increase the risk of infection, we conducted a study among people with multiple tattoos and/or piercings in The Netherlands who acquired their tattoos and piercings in The Netherlands and/or abroad. METHODS: Tattoo artists, piercers, and people with multiple tattoos and/or piercings were recruited at tattoo conventions, shops (N = 182, and a biannual survey at our STI-outpatient clinic (N = 252 in Amsterdam. Participants were interviewed and tested for anti-HBc and anti-HCV. Determinants of HBV and HCV infections were analysed using logistic regression analysis. RESULTS: The median number of tattoos and piercings was 5 (IQR 2-10 and 2 (IQR 2-4, respectively. Almost 40% acquired their tattoo of piercing abroad. In total, 18/434 (4.2%, 95%CI: 2.64%-6.46% participants were anti-HBc positive and 1 was anti-HCV positive (0.2%, 95%CI: 0.01%-1.29%. Being anti-HBc positive was independently associated with older age (OR 1.68, 95%CI: 1.03-2.75 per 10 years older and being born in an HBV-endemic country (OR 7.39, 95%CI: 2.77-19.7. Tattoo- and/or piercing-related variables, like having a tattoo or piercing in an HBV endemic country, surface percentage tattooed, number of tattoos and piercings etc., were not associated with either HBV or HCV. CONCLUSIONS: We found no evidence for an increased HBV/HCV seroprevalence among persons with multiple tattoos and/or piercings, which might be due to the introduction of hygiene guidelines for tattoo and piercing shops in combination with the low observed prevalence of HBV/HCV in the general population. Tattoos and/or piercings, therefore, should not be considered risk factors for HBV/HCV in the Dutch population. These findings imply the importance of implementation of hygiene guidelines in other countries.

  2. The use of HBV model for flash flood forecasting

    Directory of Open Access Journals (Sweden)

    M. Kobold

    2006-01-01

    Full Text Available The standard conceptual HBV model was originally developed with daily data and is normally operated on daily time step. But many floods in Slovenia are usually flash floods as result of intense frontal precipitation combined with orographic enhancement. Peak discharges are maintained only for hours or even minutes. To use the HBV model for flash flood forecasting, the version of HBV-96 has been applied on the catchment with complex topography with the time step of one hour. The recording raingauges giving hourly values of precipitation have been taken in calibration of the model. The uncertainty of simulated runoff is mainly the result of precipitation uncertainty associated with the mean areal precipitation and is higher for mountainous catchments. Therefore the influence of number of raingauges used to derive the areal precipitation by the method of Thiessen polygons was investigated. The quantification of hydrological uncertainty has been performed by analysis of sensitivity of the HBV model to error in precipitation input. The results show that an error of 10% in the amount of precipitation causes an error of 17% in the peak of flood wave. The polynomial equations showing the relationship between the errors in rainfall amounts and peak discharges were derived for two water stations on the Savinja catchment. Simulated discharges of half-yearly runs demonstrate the applicability of the HBV model for flash flood forecasting using the mesoscale meteorological forecasts of ALADIN/SI model as input precipitation data.

  3. 分析乙肝血清学检验中的三种不常见现象%Analysis of HBV Serological Test Three of the Unusual Phenomenon

    Institute of Scientific and Technical Information of China (English)

    杜琼; 涂云贵

    2015-01-01

    Objective Hepatitis B serology three of the unusual phenomenon. Explore the use of different reagents whether it will affect the test results. Methods Randomly selected in January 2012 to January 2015, January serological examination hospital 200 cases of hepatitis B patients as research subjects. All patients taking 3ml venous blood as the test sample, the same samples were taken to two different ELISA reagents for clinical testing. Analysis of the test results and, and statistical probability of the occur-rence is not common. Results A set of test results showed that a total of 10 patients had three hepatitis B serological testing is not a common phenomenon, Group B test results showed that nine patients had three hepatitis B serological testing is not a common phenomenon. Using statistical software comparison of the two test results showed no significant difference in contrast showed no statistically significant (P>0.05) between the two groups. In which a total of 10 patients had unusual phenomenon, 5.0%of the total number of cases. Conclusion Different reagents will not have hepatitis B serology unusual phenomenon affecting, for hepatitis B serology is not a common phenomenon, should be combined with clinical symptoms and other clinical indicators detect a compre-hensive analysis and review, rule out the possibility everything for interference, for in order to increase the accuracy and reliability of test results.%目的 分析研究乙肝血清学检验中的三种不常见现象. 探究使用试剂的不同是否会对检测结果造成影响. 方法 随机选取2012年1月-2015年1月于该院进行血清学检验的200例乙肝患者作为研究对象. 所有患者取3 mL静脉血作为检验样本,同一样本分别采取两种不同的ELISA试剂进行临床检验. 分析检测结果,并统计不常见现象的发生几率. 结果 A组检测结果显示共有10例患者出现三种乙肝血清检测不常见现象,B组检测结果显示共有9例患者

  4. Combination and cleavage of HBV DNA fragments by triple helix-forming oligonucleotides modified with manganese porphyrin in vitro

    Institute of Scientific and Technical Information of China (English)

    光丽霞; 袁发焕; 奚敏; 赵聪敏; 刘立; 温恩懿; 艾友萍

    2003-01-01

    Objective To observe the ability of triple helix-forming oligonucleotides (TFOs) modified with manganese porphyrin to combine with and cleave HBV DNA fractions. Methods TFO were modified with manganese porphyrin and acridines, and then reacted with the 32P labeled HBV DNA fragments at 37℃ in vitro (pH 7.4). Electrophoretic mobility shift assays and Dnase Ⅰ footprinting tests were used to show the affinity and specificity of TFO to bind to target sequences. The ability of TFO to cleave HBV DNA fragments was tested by cleavage experiments. Results TFO modified with manganese porphyrin and acridine could bind to the target sequence in a sequence-dependent manner, with a Kd value of 3.5×10-7 mol/L and a relative affinity of 0.008. In the presence of potassium monopersulfate (KHSO5), TFO modified with manganese porphyrin and acridine could cleave the target sequence where the triplex DNA was formed. Conclusion In the presence of KHSO5, TFO modified with manganese porphyrin and acridine could bind and cleave the target HBV-DNA in a sequence-dependent manner.

  5. Prevalence of HBV and HBV vaccination coverage in health care workers of tertiary hospitals of Peshawar, Pakistan

    Directory of Open Access Journals (Sweden)

    Ali Ijaz

    2011-06-01

    Full Text Available Abstract Background Hepatitis B Virus (HBV may progress to serious consequences and increase dramatically beyond endemic dimensions that transmits to or from health care workers (HCWs during routine investigation in their work places. Basic aim of this study was to canvass the safety of HCWs and determine the prevalence of HBV and its possible association with occupational and non-occupational risk factors. Hepatitis B vaccination coverage level and main barriers to vaccination were also taken in account. Results A total of 824 health care workers were randomly selected from three major hospitals of Peshawar, Khyber Pakhtunkhwa. Blood samples were analyzed in Department of Zoology, Kohat University of Science and Technology Kohat, and relevant information was obtained by means of preset questionnaire. HCWs in the studied hospitals showed 2.18% prevalence of positive HBV. Nurses and technicians were more prone to occupational exposure and to HBV infection. There was significant difference between vaccinated and non-vaccinated HCWs as well as between the doctors and all other categories. Barriers to complete vaccination, in spite of good knowledge of subjects in this regard were work pressure (39.8%, negligence (38.8% un-affordability (20.9%, and unavailability (0.5%. Conclusions Special preventive measures (universal precaution and vaccination, which are fundamental way to protect HCW against HBV infection should be adopted.

  6. Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice

    Institute of Scientific and Technical Information of China (English)

    Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Jing-Yuan Fang; Yu-Lin Song; Zhao-Hui Shen; Ai-Ping Cao

    2004-01-01

    AIM: To study the inhibitory effect of oxymatrine on serum hepatitis B virus (HBV) DNA in HBV transgenic mice.METHODS: HBV transgenic mice model was established by microinjection, and identified by HBV DNA integration and replication. Transgenic mice with replicating HBV were divided into 3 groups, and injected with normal saline (group A, n=9), 50 mg/kg (group B, n=8) and 100 mg/kg (group C, n=9) oxymatrine intraperitoneally once a day for 30 d, respectively. Quantitation of serum HBV DNA in HBV transgenic mice was performed by competitive polymerase chain reaction (PCR) in combination with DNA hybridization quantitative detection technique before and after treatment.RESULTS: Compared with pre-treatment, the serum HBV DNA in group A (F=1.04, P=0.9612) and group B (F=1.13,P=0.8739) had no changes after treatment. However, in group C serum HBV DNA was significantly decreased (F=13.97,P=0.0012). The serum HBV DNA after treatment was lower in group C than in groups B and A (F=8.65, P=0.0068;F=12.35, P=0.0018; respectively). The serum HBV DNA after treatment was lower in group B than in group A, but there was no statistical significance (F=1.43, P=0.652).CONCLUSION: Oxymatrine has inhibitory effects on serum HBV DNA in HBV transgenic mice.

  7. Application of CRISPR/Cas9 Technology to HBV

    OpenAIRE

    Guigao Lin; Kuo Zhang; Jinming Li

    2015-01-01

    More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustai...

  8. Hematological and biochemical indexes in blood of HBV transgenic mice

    OpenAIRE

    Feng-jiao ZHENG; Fu, Yong-Hang; Guang-ze LIU; Zhang, Jian; Xiu-mei LI; Chen, Mei-Juan; Kong, Xiang-Ping

    2011-01-01

    Objective To study the effects of gene integration of HBV on the biochemical and hematological indices in blood of transgenic mice.Methods The venous blood was collected from orbital venous plexus of 28 normal mice born in the same brood(HBsAg negative) and 50 HBV transgenic mice(HBsAg positive),6-8 weeks in age.The blood routine examination was performed,including white blood cells(WBC),red blood cells(RBC),hemoglobin(Hb),platelets(PLT),lymphocyte percentage(L%),intermediate cell percentage(...

  9. Study on the relationship between semen HBV-DNA load and offspring-paternal-vertical-transmission of HBV%HBV感染者精液HBV-DNA载量对子代垂直传播的影响

    Institute of Scientific and Technical Information of China (English)

    张荣莲; 王梅颖; 陈起燕; 任坤海; 修晓燕; 邱丽茵; 黄艳红

    2014-01-01

    Objective To explore the relationship between HBV-DNA load and the offspring vertical transmission of HBV.Methods 138 families who had taken the examination between August 2009 and November 2011 but the HBsAg of the housewife was negative,were chosen as research objects.Blood from the couples and sperms from the husbands during pregnancy were followed and collected for detection on related indicators.Cord blood was sampled after delivery for HBVM and HBV-DNA quantification.Those with HBV-DNA load ≥5 × 102 copies/ml were chosen as cases while those <5 × 102 copies/ml were formed as controls,respectively.Results 1) The positive rates of HBV-DNA was 34.8% (48/138) in the neonatal cord blood while the positive rates of cord blood HBsAg and HBeAg were 28.3% (39/138) and 15.2% (21/138) respectively.2) The positive rate of semen HBV-DNA was 21.0% (29/138) while the positive rates of paternal serum HBV-DNA and HBeAg were 76.8% (106/138)and 42.8% (59/138).3)Among the positive ones on paternal serum HBV-DNA,paternal serum HBeAg,semen HBV-DNA,items as measures taken for HBV vertical transmission and prevention on the fathers and the first class family histories on HBV appeared to be the risk factors for HBV paternal transmission (P<0.05).4)Data from Multivariate analysis showed that positivities on patemal serum HBV-DNA,paternal serum HBeAg and semen HBV-DNA were risk factors for HBV paternal transmission (OR=5.7,95%CI:1.1-29.1 ; OR=4.2,95%CI:1.7-10.0; OR=6.7,95% CI:2.4-18.9).5)Dose-response relationships were seen between levels of paternal serum HBV-DNA load and cord blood HBV-DNA load,between levels of paternal serum HBV-DNA load and semen HBV-DNA load,between levels of semen HBV-DNA load and cord blood HBV-DNA load.6)Results from the analysis on ROC curve showed that paternal serum HBV-DNA load level (105 copies/ml) and semen HBV-DNA load level (103 copies/ml)were better demarcation points to forecast the occurrence of paternal transmission of

  10. Expression and Purification of a Novel Computationally Designed Antigen for Simultaneously Detection of HTLV-1 and HBV Antibodies.

    Directory of Open Access Journals (Sweden)

    Hafez Heydari Zarnagh

    2015-04-01

    Full Text Available Computational tools are reliable alternatives to laborious work in chimeric protein design. In this study, a chimeric antigen was designed using computational techniques for simultaneous detection of anti-HTLV-I and anti-HBV in infected sera. Databases were searched for amino acid sequences of HBV/HLV-I diagnostic antigens. The immunodominant fragments were selected based on propensity scales. The diagnostic antigen was designed using these fragments. Secondary and tertiary structures were predicted and the B-cell epitopes were mapped on the surface of built model. The synthetic DNA coding antigen was sub-cloned into pGS21a expression vector. SDS-PAGE analysis showed that glutathione fused antigen was highly expressed in E. coli BL21 (DE3 cells. The recombinant antigen was purified by nickel affinity chromatography. ELISA results showed that soluble antigen could specifically react with the HTLV-I and HBV infected sera. This specific antigen could be used as suitable agent for antibody-antigen based screening tests and can help clinicians in order to perform quick and precise screening of the HBV and HTLV-I infections.

  11. The prognosis and management of inactive HBV carriers.

    Science.gov (United States)

    Invernizzi, Federica; Viganò, Mauro; Grossi, Glenda; Lampertico, Pietro

    2016-01-01

    Patients with chronic hepatitis B virus (HBV) infection lacking the serum hepatitis B e antigen (HBeAg) and with antibodies against HBeAg (anti-HBe), are the prevalent subgroup of HBV carriers worldwide. The prognosis of these patients is different from inactive carriers (ICs), who are characterized by persistently normal serum alanine aminotransferase (ALT) and low (Fibroscan of <5 kPa. Antiviral treatment is not indicated in ICs since the prognosis for the progression of liver disease is favourable if there are no cofactors of liver damage such as alcohol abuse, excess weight or co-infection with the hepatitis C virus or delta virus. Moreover, spontaneous HBsAg loss frequently occurs (1-1.9% per year) in these patients while the development of hepatocellular carcinoma (HCC) is rare, at least in Caucasian patients. However, an emerging issue reinforcing the need for clinical surveillance of ICs is the risk of HBV reactivation in patients who undergo immunosuppressive therapy without receiving appropriate antiviral prophylaxis. After diagnosis, management of ICs includes monitoring of ALT and HBV DNA every 12 months with periodic measurement of serum HBsAg levels to identify viral clearance. PMID:26725905

  12. Expression and immunoreactivity of HCV/HBV epitopes

    Institute of Scientific and Technical Information of China (English)

    Xin-Yu Xiong; Xiao Liu; Yuan-Ding Chen

    2005-01-01

    AIM: To develop the epitope-based vaccines to prevent Hepatitis C virus (HCV)/Hepatitis B virus (HBV) infections.METHODS: The HCV core epitopes C1 STNPKPQRKTKRNTNRRPQD (residuals aa2-21) and C2 VKFPGGGQIVGGVYLLPRR (residuals aa22-40), envelope epitope E GHRMAWDMMMNWSP (residuals aa315-328) and HBsAg epitope S CTTPAQGNSMFPSCCCTKPTDGNC (residuals aa124-147) were displayed in five different sites of the flock house virus capsid protein as a vector, and expressed in E. coli cells (pET-3 system).Immunoreactivity of the epitopes with anti-HCV and anti-HBV antibodies in the serum from hepatitis C and hepatitis B patients were determined.RESULTS: The expressed chimeric protein carrying the HCV epitopes C1, C2, E (two times), L3C1-I2E-L1C2-L2E could react with anti-HCV antibodies. The expressed chimeric protein carrying the HBV epitopes S, I3S could react with anti-HBs antibodies. The expressed chimeric proteins carrying the HCV epitopes C1, C2, E plus HBV epitope S, L3C1-I2E-L1C2-L2E-I3S could react with antiHCV and anti-HBs antibodies.CONCLUSION: These epitopes have highly specific and sensitive immunoreaction and are useful in the development of epitope-based vaccines.

  13. Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan-based HBV vaccine.

    Directory of Open Access Journals (Sweden)

    Hong Chen

    Full Text Available BACKGROUND: A therapeutic vaccine for chronic hepatitis B virus (HBV infection that enhances virus-specific cellular immune responses is urgently needed. The "prime-boost" regimen is a widely used vaccine strategy against many persistence infections. However, few reports have addressed this strategy applying for HBV therapeutic vaccine development. METHODOLOGY/PRINCIPAL FINDINGS: To develop an effective HBV therapeutic vaccine, we constructed a recombinant vaccinia virus (Tiantan containing the S+PreS1 fusion antigen (RVJSS1 combined with the HBV particle-like subunit vaccine HBVSS1 to explore the most effective prime-boost regimen against HBV. The immune responses to different prime-boost regimens were assessed in C57BL/C mice by ELISA, ELISpot assay and Intracellular cytokine staining analysis. Among the combinations tested, an HBV protein particle vaccine priming and recombinant vaccinia virus boosting strategy accelerated specific seroconversion and produced high antibody (anti-PreS1, anti-S antibody titres as well as the strongest multi-antigen (PreS1, and S-specific cellular immune response. HBSS1 protein prime/RVJSS1 boost immunization was also generated more significant level of both CD4+ and CD8+ T cell responses for Th1 cytokines (TNF-α and IFN-γ. CONCLUSIONS: The HBSS1 protein-vaccine prime plus RVJSS1 vector boost elicits specific antibody as well as CD4 and CD8 cells secreting Th1-like cytokines, and these immune responses may be important parameters for the future HBV therapeutic vaccines.

  14. Knowledge of HBV and HCV and individuals' attitudes toward HBV- and HCV-infected colleagues: a national cross-sectional study among a working population in Japan.

    Directory of Open Access Journals (Sweden)

    Hisashi Eguchi

    Full Text Available Prejudice and discrimination in the workplace regarding the risk of transmission of Hepatitis B virus (HBV and Hepatitis C virus (HCV are increased by excess concerns due to a lack of relevant knowledge. Education to increase knowledge about HBV and HCV and their prevention could be the first step to reduce prejudice and discrimination. This study aimed to determine the association between the level of knowledge and negative attitudes toward HBV- and HCV-infected colleagues among the Japanese working population. An online anonymous nationwide survey involving about 3,000 individuals was conducted in Japan. The questionnaire consisted of knowledge of HBV and HCV, and attitudes toward HBV- and HCV-infected colleagues in the workplace. Knowledge was divided into three categories: "ensuring daily activities not to be infected"; "risk of infection"; and "characteristics of HBV/HCV hepatitis", based on the result of factor analysis. Multiple logistic regression analysis was applied. A total of 3,129 persons responded to the survey: 36.0% reported they worried about the possibility of transmission of HBV and HCV from infected colleagues; 32.1% avoided contact with infected colleagues; and 23.7% had prejudiced opinions about HBV and HCV infection. The participants were classified into tertiles. A higher level of knowledge of HBV and HCV was significantly associated with these three negative attitudes (P for trend < 0.005. This study suggests that increasing knowledge may decrease individuals' negative attitudes towards HBV- and HCV-infected colleagues. Thus, we should promote increased knowledge of HBV and HCV in stages to reduce negative attitudes toward HBV- and HCV-infected colleagues.

  15. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients.

    Directory of Open Access Journals (Sweden)

    Hie-Won Hann

    Full Text Available Serum liver enzymes are frequently tested in clinics to aid disease diagnosis. Large observational studies indicated that these enzymes might predict cancer risk and mortality. However, no prospective study has reported on their relationships with the risk of HBV-related hepatocellular carcinoma (HCC.We evaluated the predictive values of four routinely tested liver enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and gamma-glutamyltransferase [GGT] in HCC risk in a prospectively enrolled clinical cohort of 588 Korean American HBV patients. For all four enzymes, the baseline level as well as the average and maximum levels during the first 1 or 2 years of follow-up were analyzed using multivariate Cox proportional hazards model. Patients were categorized into a normal or an elevated group based on the clinical cut-off of each enzyme. During a median follow-up of 7.5 years, 52 patients (incidence rate, 8.8% developed HCC. The incidence rates were higher in the elevated groups for all four enzymes. The most significant finding was for GGT, with the highest incidence rate of 16.4% in the elevated group compared to 4.6% in the normal group (P<0.001. Compared to patients with normal baseline GGT, those with elevated GGT exhibited a significantly increased HCC risk with a hazards ratio (HR of 2.60 (95% confidence interval [CI], 1.41-4.77, P = 0.002. Further analyses revealed a cumulative effect between baseline GGT and ALP (HR = 3.41, 95% CI 1.54-7.56, P = 0.003.Serum GGT might predict HCC risk in HBV patients individually or jointly with other enzymes.

  16. Molecular analysis of hepatitis B virus (HBV in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy

    Directory of Open Access Journals (Sweden)

    Costantini Andrea

    2011-11-01

    Full Text Available Abstract Background Occult hepatitis B virus (HBV infection (OBI is characterized by HBV DNA persistence even though the pattern of serological markers indicates an otherwise resolved HBV infection. Although OBI is usually clinically silent, immunocompromised patients may experience reactivation of the liver disease. Case presentation We report the case of an individual with human immunodeficiency virus (HIV infection and anti-HBV core antibody positivity, who experienced severe HBV reactivation after discontinuation of lamivudine-including antiretroviral therapy (ART. HBV sequencing analysis showed a hepatitis B surface antigen escape mutant whose presence in an earlier sample excluded reinfection. Molecular sequencing showed some differences between two isolates collected at a 9-year interval, indicating HBV evolution. Resumption of ART containing an emtricitabine/tenofovir combination allowed control of plasma HBV DNA, which fell to undetectable levels. Conclusion This case stresses the ability of HBV to evolve continuously, even during occult infection, and the effectiveness of ART in controlling OBI reactivation in HIV-infected individuals.

  17. Safety of breast-feeding with HBV-DNA positive breast milk%HBV-DNA阳性乳汁喂养的安全性探讨

    Institute of Scientific and Technical Information of China (English)

    周冬生; 林秋香; 蒋就喜

    2013-01-01

    Objective To investigate the safety of breast-feeding by puerpera with HBV-DNA positive breast milk.Methods 117 puerpera with HBV-DNA positive breast milk (2 cases with twins) were studied.119 infants were given with HBV active and passive immunization.34 infants were provided with breast feeding and 85 infants were provided with artificial-feeding.Results 34 out of 119 infants (28.57%) were found to have chronic HBV infection.The rate of HBV infection in the breast-feeding group (32.35%,11/34) was similar to artificial-feeding froup (27.06%,23/85) (P>0.05).However,it has statistical significant difference that the amount of breast milk HBV-DNA loads between the group of chronic HBV infection in infants and the group of no infection(P<0.05).Conclusions Chronic HBV infection in infants is correlated with the amount of HBV-DNA in maternal milk.Breast-feeding with HBV-DNA positive breast milk may not increase the risk of chronic HBV infection in infants.%目的 探讨乳汁HBV-DNA阳性产妇母乳喂养的安全性.方法 乳汁HBV-DNA阳性产妇117例(双胞2例),119例幼儿出生时均接受HBV主动+被动免疫,自由选择喂养方式,其中母乳喂养34例(母乳喂养组),人工喂养85例(人工喂养组),观察两组幼儿慢性感染HBV情况.结果 119例幼儿慢性感染HBV 34例,慢性感染率为28.57%;其中母乳喂养组幼儿慢性感染率为32.35%(11/34),人工喂养组为27.06%(23/85),差异无统计学意义(P>0.05);但幼儿HBV慢性感染组与未感染组母亲乳汁HBV-DNA水平差异有统计学意义(P<0.05).结论 幼儿慢性感染HBV与产妇乳汁HBV-DNA载量有关,但母乳喂养并未增加感染HBV的风险.

  18. Associated factors for recommending HBV vaccination to children among Georgian health care workers

    Directory of Open Access Journals (Sweden)

    Butsashvili Maia

    2012-12-01

    Full Text Available Abstract Background Most cases of hepatitis B virus (HBV infection and subsequent liver diseases can be prevented with universal newborn HBV vaccination. The attitudes of health care workers about HBV vaccination and their willingness to recommend vaccine have been shown to impact HBV vaccination coverage and the prevention of vertical transmission of HBV. The purpose of this study was to ascertain the factors associated with health care worker recommendations regarding newborn HBV vaccination. Methods A cross-sectional study of prevalence and awareness of hepatitis B and hepatitis B vaccine was conducted among randomly selected physicians and nurses employed in seven hospitals in Georgia in 2006 and 2007. Self-administered questionnaires included a module on recommendations for HBV, HCV and HIV. Results Of the 1328 participants included in this analysis, 36% reported recommending against hepatitis B vaccination for children, including 33% of paediatricians. Among the 70.6% who provided a reason for not recommending HBV vaccine, the most common concern was an adverse vaccine event. Unvaccinated physicians and nurses were more likely to recommend against HBV vaccine (40.4% vs 11.4%, PR 3.54; 95% CI: 2.38, 5.29. Additionally, health care worker age was inversely correlated with recommendations for HBV vaccine with older workers less likely to recommend it. Conclusion Vaccinating health care workers against HBV may provide a dual benefit by boosting occupational safety as well as strengthening universal coverage programs for newborns.

  19. Study on HBV Vertical Transmission via the in vitro Fertilization(IVF)Technique

    Institute of Scientific and Technical Information of China (English)

    Jing-ning YANG; Qing-bin LUO; Chang-jun ZHANG; Hua WANG

    2009-01-01

    Objective To study the hepatitis B virus(HB V)vertical transmission via infected spermatozoa.Methods Eighteen male patients with HBV infection who underwent in vitro fertilization (IVF)were studied,5 HBV negative patients were selected as the control.Fluorescence in situ hybridization(FISH)analysis using the partial-length HBV DNA as the hybridization probe was performed to explore the existence of HBV DNA in the sperm and in the host embryonic genome.Results FISH showed that 5 of 18 patients' sperm presented positive signals and 2 of 18 embryos presented positive signals,while no positive signals were found in control group.Conclusion The HBV DNA was found in human sperm and embryos of HBV patients.These results provide direct evidence that HBV DNA could transmit to foetus via human infected spermatozoa.

  20. HBV influence on Response to Antiretroviral Therapy in Horizontally HIV-HBV Coinfected Patient during Early Childhood

    Science.gov (United States)

    Niculescu, Irina; Cupşa, A.M.; Stoian, Andreea Cristina; Dumitrescu, FLorentina; Giubelan, L.I.; Alexandru, D.O.

    2013-01-01

    Background: There are few studies on pediatric HIV-HBV coinfection, so evidences about relationships between the two viruses are scarce. Objectives: influence of HBV infection on virological and immunological response to antiretroviral therapy (ART) in antiretroviral-naïve horizontally HIV-HBV coinfected subjects during early childhood. Material and methods: observational study on 826 HIV+ subjects in evidence of Craiova Regional Centre (CRC); we analyzed the immunological and virological response at 6-12 months after starting first antiretroviral regimens compared in 2 groups: horizontally HIV-HBV coinfected subjects during early childhood (CoS) versus horizontally HIV infected subjects during early childhood without HBV infection (non-CoS). Results: Number of subjects: CoS-66 subjects, non-CoS-132 subjects. Demographic data: CoS-gender ratio F:M=0.886, the majority lived in rural area (57.58%), mean age on diagnosis-9.288±4.607 years, non-CoS-gender ratio F:M=0.859, the majority lived in urban area (53.79%), mean age on diagnosis-10.742±5.107 years. At baseline, HIV category was: CoS-A-1.52%, B-80.30%, C-18.18%, non-CoS-A-2.27%, B-70.45%, C-27.27% (p Chi2=0.332), the mean CD4+ cell count was: CoS-148.33±148.10 cells/ml, non-CoS-163.17±155.39 cells/ml (p Student=0.521) and the mean HIV viral load (HIV VL) was: CoS-5.06±0.80 lgcopies/ml (for 29 subjects), non-CoS-5.04±0.84 lgcopies/ml (for 61 subjects) (p Student=0.978). At the end of the studied period, the mean increase in CD4+ cell count was: CoS-177.068±141.676 cells/ml, non-CoS-176.015±191.751 cells/ml (p Student=0.969) and the mean decrease in HIV VL was: CoS-5.04±0.79 lgcopies/ml, non-COS-4.69±2.04 lgcopies/ml (p Student=0.911). Conclusions: The presence of HBV coinfection does not influence immunological or virological response to ART. PMID:24778861

  1. Justification for screening programs for early detection of HBV infections

    OpenAIRE

    Małgorzata Leźnicka; Krzysztof Gierlotka; Tomasz Prycel

    2014-01-01

    Background: The objective of the study was to collect the data on undetected hepatitis B virus (HBV) in the frequently hospitalized (at least twice in the last 5 years) population of the Kujawsko-Pomorskie voivodship. The study results could be used by occupational health services and local governments to take preventive actions. Material and Methods: The study focused on empirical data derived from hepatitis B Screening Programme in the Kujawsko-Pomorskie voivodship. The study comprised 6332...

  2. HBV infection in relation to consistent condom use: a population-based study in Peru.

    Directory of Open Access Journals (Sweden)

    Antonio Bernabe-Ortiz

    Full Text Available BACKGROUND: Data on hepatitis B virus (HBV prevalence are limited in developing countries. There is also limited information of consistent condom use efficacy for reducing HBV transmission at the population level. The study goal was to evaluate the prevalence and factors associated with HBV infection in Peru, and the relationship between anti-HBc positivity and consistent condom use. METHODS AND FINDINGS: Data from two different surveys performed in 28 mid-sized Peruvian cities were analyzed. Participants aged 18-29 years were selected using a multistage cluster sampling. Information was collected through a validated two-part questionnaire. The first part (face-to-face concerned demographic data, while the second part (self-administered using handheld computers concerned sexual behavior. Hepatitis B core antibody (anti-HBc was tested in 7,000 blood samples. Prevalences and associations were adjusted for sample strata, primary sampling units and population weights. Anti-HBc prevalence was 5.0% (95%CI 4.1%-5.9%, with the highest prevalence among jungle cities: 16.3% (95%CI 13.8%-19.1%. In the multivariable analysis, Anti-HBc positivity was directly associated with geographic region (highlands OR = 2.05; 95%CI 1.28-3.27, and jungle OR = 4.86; 95%CI 3.05-7.74; compared to coastal region; and inversely associated with age at sexual debut (OR = 0.90; 95%CI 0.85-0.97. Consistent condom use, evaluated in about 40% of participants, was associated with reduced prevalence (OR = 0.34; 95%CI 0.15-0.79 after adjusting for gender, geographic region, education level, lifetime number of sex partners, age at sexual debut and year of survey. CONCLUSION: Residence in highlands or jungle cities is associated with higher anti-HBc prevalences, whereas increasing age at sexual debut were associated with lower prevalences. Consistent condom use was associated with decreased risk of anti-HBc. Findings from this study emphasize the need of primary

  3. The intracellular dynamics of hepatitis B virus (HBV) replication with reproduced virion "re-cycling".

    Science.gov (United States)

    Nakabayashi, Jun

    2016-05-01

    Hepatitis B virus (HBV) is a causative agent of hepatitis. Clinical outcome of hepatitis type B depends on the viral titer observed in the peripheral blood of the patient. In the chronic hepatitis patient, production of HBV virion remains low level. On the other hand, the viral load prominently increases in fulminant hepatitis patient as compared with that in the chronic hepatitis patient. We previously proposed a mathematical model describing the intracellular dynamics of HBV replication. Our model clarified that there are two distinguishable replication patterns of HBV named "arrested" and "explosive" replication. In the arrested replication, the amount of virion newly reproduced from an infected cell remains low level, while the amount of virion extremely increases in the explosive replication. Viral load is drastically changed by slight alteration of expression ratio of 3.5kb RNA to 2.4kb mRNA of HBV. Though our model provided the switching mechanism determining the replication pattern of HBV, HBV dynamics is determined by not only the expression pattern of viral genes. In this study, "recycling" of HBV virion in the replication cycle is investigated as a new factor affecting the intracellular dynamics of HBV replication. A part of newly produced virion of HBV is reused as a core particle that is a resource of HBV replication. This recycling of HBV virion lowers the threshold for the explosive replication when waiting time for the next cycle of the replication is large. It is seemingly contradicting that prominent production of HBV is caused by large recycling rate and small release rate of HBV virion from infected cell to extracellular space. But the recycling of HBV virion can contribute to the positive feedback cycle of HBV replication for the explosive replication to accumulate the core particle as a resource of HBV replication in an infected cell. Accumulation of core particle in the infected cell can be risk factor for the exacerbation of hepatitis rather

  4. Hepatitis B Test

    Science.gov (United States)

    ... limited. Home Visit Global Sites Search Help? Hepatitis B Testing Share this page: Was this page helpful? Also known as: HBV Tests; Hep B; anti-HBs; Hepatitis B Surface Antibody; HBsAg; Hepatitis ...

  5. Long-term hepatitis B virus (HBV response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.

    Directory of Open Access Journals (Sweden)

    Woottichai Khamduang

    Full Text Available Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV. In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known.HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials.gov NCT00433030 and initiating a 3TC-containing-HAART regimen were included. HBV-DNA, HIV-RNA, CD4+ T-cell counts and alanine transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. Kaplan-Meier analysis was used to estimate the cumulative rates of patients who achieved and maintained HBV-DNA suppression. Of 30 co-infected patients, 19 were positive for HBe antigen (HBeAg. At initiation of 3TC-containing-HAART, median HBV DNA and HIV RNA levels were 7.35 log(10 IU/mL and 4.47 log(10 copies/mL, respectively. At 12 months, 67% of patients achieved HBV DNA suppression: 100% of HBeAg-negative patients and 47% of HBeAg-positive. Seventy-three percent of patients had HIV RNA below 50 copies/mL. The cumulative rates of maintained HBV-DNA suppression among the 23 patients who achieved HBV-DNA suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. Of 17 patients who maintained HBV-DNA suppression while still on 3TC, 4 (24% lost HBsAg and 7 of 8 (88% HBeAg-positive patients lost HBeAg at their last visit (median duration, 59 months. HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L.All HBeAg-negative patients and 63% of HBeAg-positive HIV-HBV co-infected patients achieved long-term HBV DNA suppression while on 3TC-containing-HAART. This study provides information useful for the management of co-infected patients

  6. Effects of interferon-α/β on HBV replication determined by viral load.

    Directory of Open Access Journals (Sweden)

    Yongjun Tian

    2011-07-01

    Full Text Available Interferons α and β (IFN-α/β are type I interferons produced by the host to control microbial infections. However, the use of IFN-α to treat hepatitis B virus (HBV patients generated sustained response to only a minority of patients. By using HBV transgenic mice as a model and by using hydrodynamic injection to introduce HBV DNA into the mouse liver, we studied the effect of IFN-α/β on HBV in vivo. Interestingly, our results indicated that IFN-α/β could have opposite effects on HBV: they suppressed HBV replication when viral load was high and enhanced HBV replication when viral load was low. IFN-α/β apparently suppressed HBV replication via transcriptional and post-transcriptional regulations. In contrast, IFN-α/β enhanced viral replication by inducing the transcription factor HNF3γ and activating STAT3, which together stimulated HBV gene expression and replication. Further studies revealed an important role of IFN-α/β in stimulating viral growth and prolonging viremia when viral load is low. This use of an innate immune response to enhance its replication and persistence may represent a novel strategy that HBV uses to enhance its growth and spread in the early stage of viral infection when the viral level is low.

  7. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.

    Science.gov (United States)

    Beaumont, Elodie; Roingeard, Philippe

    2015-02-18

    The development of an effective, affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. The recently described chimeric HBV-HCV subviral envelope particles could potentially be used for this purpose, as they could be produced by industrial procedures adapted from those established for the hepatitis B virus (HBV) vaccine. We show here, in an animal model, that pre-existing immunity acquired through HBV vaccination does not influence the immunogenicity of the HCV E2 protein presented by these chimeric particles. Thus, these chimeric HBV-HCV subviral envelope particles could potentially be used as a booster in individuals previously vaccinated against HBV, to induce protective immunity to HCV. PMID:25596457

  8. Prevalence of HBV Infection and Knowledge of Hepatitis B Among Patients Attending Primary Care Clinics in Poland.

    Science.gov (United States)

    Ganczak, Maria; Dmytrzyk-Daniłów, Gabriela; Korzeń, Marcin; Drozd-Dąbrowska, Marzena; Szych, Zbigniew

    2016-06-01

    It is well known that community awareness of hepatitis B (HB) can lead to vaccination and testing. The study objectives were to assess the prevalence of HBV infection and knowledge of HB among adult patients attending randomly selected primary care clinics. A cross-sectional sero-survey was conducted in March 2013 in the Zgorzelec region, Poland, with the use of an investigator-developed questionnaire containing 22 questions regarding HB knowledge. Serum samples were assayed for anti-HBc total and anti-HBs with enzyme immunoassay. The prevalence of anti-HBc total among 410 participants (median age 56 years) was 10.3 % (95 % CI 7.6-13.8 %), nobody was aware of an infection. The main sources of HB knowledge were the media and medical staff. The mean knowledge score was 14.8 ± 4.9; 76.7 % of the respondents had scores >50 %. Particular gaps were detected relating to knowledge of unprotected sexual intercourse and MTCT; 45.6 % patients were not aware of the potential asymptomatic course of HBV infection, 41.2 % about chronic HB treatment. A patient's low educational level was negatively associated with a high knowledge level; the willingness for further education on HB and HBV vaccination in the past were independently associated with good knowledge. In conclusion, the HBV infection remains a public health threat in Poland, since the prevalence of infection markers in asymptomatic adult patients was high. Knowledge gaps call for awareness campaigns which may increase testing and diagnosis, audiences representing lower education level should be targeted first. Knowledge on HB might serve as an effective tool in decision making regarding vaccination. PMID:26699149

  9. Seroprevalence of HIV, HBV, HCV and syphilis in blood donors in Southern Haryana.

    Science.gov (United States)

    Arora, Dimple; Arora, Bharti; Khetarpal, Anshul

    2010-01-01

    Blood transfusion is an important mode of transmission of infections to recipients. The aim of the study was to assess the prevalence of transfusion-transmissible infections among blood donors. For this, a 3.5-year retrospective study, from October 2002 to April 2006 was conducted at the blood transfusion centre of Maharaja Agrasen Medical College, Agroha (Hisar) Haryana. Donors were screened for seroprevalence of HIV, HBV, HCV and syphilis. A total of 5849 donors were tested, out of which 4010 (68.6%) were replacement donors and 1839 (31.4%) were voluntary donors. The seroprevalence of HIV was 0.3% in the donors. No voluntary donor was found to be positive for HIV. The low sero-positivity among donors is attributed to pre-donation counseling in donor selection. The seroprevalence of HBV, HCV and syphilis was 1.7%, 1.0% and 0.9% respectively in total donors. The seroprevalence of hepatitis and syphilis was more in replacement donors as compared to voluntary donors. PMID:20551540

  10. Hiv/hbv, hiv/hcv and hiv/htlv-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in iran

    International Nuclear Information System (INIS)

    To assess the prevalence and risk factors for HBV, HCV and HTLV-I co-infection in the Iranian HIV positive Injecting Drug Users (IDU) patients admitted in hospital. Analyses were based on 154 male IDU patients admitted in Infectious disease ward of Razi Hospital, Ahwaz, Iran, from April 2001 to March 2003. All of them had been tested for HIV infection (Elisa-antibody and Western blot), HBV surface antigen, HCV antibody and HTLV-1 antibody. One hundred and four patients (67.53%) were identified as HIV infected. Among HIV infected, HB surface antigen, HCV antibody and HTLV-I antibody were positive in 44.23% and 74.04% and 16.33% patients respectively. HCV/HBV/HIV and HCV/HBV/HIV/HTLV-1 co-infection were 20.20% and 8.65% respectively. Co-infection with HBV or HCV or HTLV-1 is common among hospitalized HIV-infected IDU patients in the region of study. HIV disease outcomes appear to be adversely affected by HBV/HCV/HTLV-I co-infection, so identification of these viral infections is recommended as routine tests for this population. (author)

  11. Development of fatal acute liver failure in HIV-HBV coinfected patients

    Institute of Scientific and Technical Information of China (English)

    Albert; M; Anderson; Marina; B; Mosunjac; Melody; P; Palmore; Melissa; K; Osborn; Andrew; J; Muir

    2010-01-01

    Coinfection with hepatitis B virus(HBV) is not uncommon in human immunodeficiency virus(HIV)-infected individuals and patients with HIV-HBV coinfection are at high risk for progression of liver disease.Current guidelines regarding the treatment of HIV infection recommend that patients who are coinfected with HIV and HBV receive highly active antiretroviral therapy(HAART) with activity against hepatitis B.While HIVHBV coinfected patients often experience liver enzyme elevations after starting antiretroviral ...

  12. Development of a Multiplex Real-Time PCR Assay for the Detection of Treponema pallidum, HCV, HIV-1, and HBV.

    Science.gov (United States)

    Zhou, Li; Gong, Rui; Lu, Xuan; Zhang, Yi; Tang, Jingfeng

    2015-01-01

    Treponema pallidum, hepatitis C virus (HCV), human immunodeficiency virus (HIV)-1, and hepatitis B virus (HBV) are major causes of sexually transmitted diseases passed through blood contact. The development of a sensitive and efficient method for detection is critical for early diagnosis and for large-scale screening of blood specimens in China. This study aims to establish an assay to detect these pathogens in clinical serum specimens. We established a TaqMan-locked nucleic acid (LNA) real-time polymerase chain reaction (PCR) assay for rapid, sensitive, specific, quantitative, and simultaneous detection and identification. The copy numbers of standards of these 4 pathogens were quantified. Standard curves were generated by determining the mean cycle threshold values versus 10-fold serial dilutions of standards over a range of 10(6) to 10(1) copies/μL, with the lowest detection limit of the assay being 10(1) copies/μL. The assay was applied to 328 clinical specimens and compared with enzyme-linked immunosorbent assay (ELISA) and commercial nucleic acid testing (NAT) methods. The assay identified 39 T. pallidum-, 96 HCV-, 13 HIV-1-, 123 HBV-, 5 HBV/HCV-, 1 T. pallidum/HBV-, 1 HIV-1/HCV-, and 1 HIV-1/T. pallidum-positive specimens. The high sensitivity of the assay confers strong potential for its use as a highly reliable, cost-effective, and useful molecular diagnostic tool for large-scale screening of clinical specimens. This assay will assist in the study of the pathogenesis and epidemiology of sexually transmitted blood diseases. PMID:25866106

  13. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection

    Directory of Open Access Journals (Sweden)

    Raul Carlos Wahle

    2015-10-01

    Full Text Available ABSTRACTIn coinfected HBV/HCV patients, HBV replication is usually suppressed by HCV over the time. No study to date has evaluated the HBV viremia in long-term follow-up after HCV treatment in hemodialysis patients with HBV/HCV coinfection. This study aimed to assess the evolution of HBV viremia after HCV treatment in this special population. Ten hemodialysis patients with HBV/HCV coinfection with dominant HCV infection (HBV lower than 2000 IU/mL and significant fibrosis were treated with interferon-alpha 3 MU 3×/week for 12 months and could be followed for at least 36 months after HCV treatment. Six cases of HBV reactivation (60% during follow-up were observed and 5/6 had been successfully treated for HCV. Patients with HBV reactivation received anti-HBV therapy. Our preliminary findings indicate that treatment of hepatitis C in HBV/HCV coinfected hemodialysis patients may favor HBV reactivation. Thus, continued monitoring of HBV viremia must be recommended and prompt anti-HBV therapy should be implemented.

  14. How immigration can change the prevalence of HBV infection in an urban area of Northern Italy

    OpenAIRE

    Massimo De Paschale; Maria Teresa Manco; Luisa Belvisi; Carlo Magnani; Tiziana Re; Paolo Viganò; Sara Biagiotti; Francesca Capelli; Antonino Mazzone; Maria Pia Baldacci; Aldo Ferrara; Anna Lisa Neri; Carlo Maria Guastoni; Riccardo Armando Bonazzina; Bruno Brando

    2011-01-01

    The introduction of HBV vaccination in Italy has led to a decline in new HBV infections. Increasing immigration over recent years suggests a change in short-term epidemiology of HBV. The aim of this study was to assess the prevalence of HBV infection in the general population living in the catchment area of Legnano Hospital (Northern Italy). In the period 2007-2008, 22,758 inpatients and outpatients were examined for Hepatitis B surface antigen (HBsAg), of whom 1,654 (7.3%) were of foreign or...

  15. Anti-sense expression of a metallopeptidase gene enhances nuclear entry of HBV-DNA

    International Nuclear Information System (INIS)

    Although several putative hepatitis B virus (HBV) receptors have been identified, none of them is capable of initiating HBV replication in a non-permissive human cell line. Using an Epstein-Barr virus-based extrachromosomal replication system, we have screened through a human liver cDNA library and successfully identified a clone capable of facilitating nuclear transport of HBV-DNA during the early phase of HBV infection. This clone contained a cDNA encoding a metallopeptidase-like protein in anti-sense orientation. Pretreatment of naive HepG2 cells with 1,10-phenanthroline, an inhibitor for liver metallopeptidases, led to nuclear entry of HBV-DNA after HBV infection. However, cccDNA was still undetectable in the nuclei, indicating other cellular factors required to complete the replication cycle were still missing. Our present data suggest that in the initial stage of HBV infection, liver metallopeptidase constitutes a barrier for effective nuclear entry of HBV genomic DNA. Attenuation of metallopeptidase activity may facilitate HBV infection

  16. Preparation and identification of 1.3 copies C-type HBV transgenic mice

    OpenAIRE

    Chen, Mei-Juan; Yu-qin YOU; Guang-ze LIU; Tong, Ming-Hua; Jing-wei LI; Xiu-mei LI; Kong, Xiang-Ping

    2011-01-01

    Objective To prepare 1.3 copies C-type HBV transgenic mice for providing a better model for the prevention and treatment of hepatitis B.Methods The HBV transgenic mice were generated by microinjection of 1.3 copies C-type HBV genome into the pronucleus of FVB /N zygotes.PCR,ELISA,RT-PCR and immunohistochemistry were used to detect the integration,replication and expression of HBV gene in the transgenic mice.Results Tow thousand two hundred and eighty-two fertilized eggs were injected and a to...

  17. 核酸检测在血液HBV筛查中的应用研究%Application of NAT detection for HBV in blood screening

    Institute of Scientific and Technical Information of China (English)

    王芳; 金钊; 林松峰; 栾燕; 刘显智

    2010-01-01

    目的:了解沈阳地区乙型肝炎病毒表面抗原(HBsAg)阴性献血者中乙型肝炎病毒(hepatitis B virus,HBV)感染状况,探讨HBV核酸扩增检测(nucleic acid amplification testing,NAT)技术应用于血液筛查的意义.方法:在酶联免疫法(enzyine immunoassay,EIA)检测的基础上,应用TaqMan实时荧光聚合酶链式反应(PCR)方法对HBsAg EIA阴性血液标本进行HBV DNA的NAT检测.对NAT阳性标本进一步做乙型肝炎病毒血清标志物(HBV Marker,HBV-M)及核酸定量检测.结果:共检测了105,152例HBsAg阴性的血液标本,检出HBV DNA阳性标本15例,阳性率0.014%.Abbott酶联免疫试剂检测发现,15例标本中有6例标本的HBV-M五项指标检测全部阴性,9例为HBsAg阴性但其它标志物阳性.其中10例HBV DNA阳性标本再经Roche试剂进行核酸定量检测,HBV DNA核酸含量最高为149 IU/ml.结论:在HBsAg ELA阴性献血者中仍有极少数的HBV感染者;核酸扩增检测和酶联免疫检测互补,能够缩短血液筛查中HBV检测窗口期,特别是对提高HBsAg阴性血液标本中HBV感染检出率具有重要价值.

  18. Combined Detection of Hepatitis B five,Pre S1 antigen and HBV-DNA Value in Clinical Application%联合检测乙型病毒性肝炎五项、前S1抗原与HBV-DNA的临床应用价值

    Institute of Scientific and Technical Information of China (English)

    刘绮婷; 黎阳成; 何秋贤

    2015-01-01

    目的 探讨联合检测乙型病毒性肝炎五项、前S1抗原与乙型肝炎病毒脱氧核糖核酸(HBV-DNA)的临床关系,评估其在乙型肝炎病毒(HBV)检测中的临床价值.方法 将2011年9月至2013年9月于我院接受治疗的100例乙型病毒性肝炎表面抗原阳性患者作为研究对象,收集其临床资料,采集所有患者肘静脉血液,并选用定量法与酶联免疫吸附试验进行乙型病毒性肝炎五项、前S1抗原及HBV-DNA检测,评估其临床价值.结果 在不同的乙型病毒性肝炎五项模式下,前S1抗原与HBV-DNA检测结果比较差异无统计学意义(P>0.05);两组患者HBV-DNA与乙型病毒性肝炎前S1抗原检出符合率比较差异无统计学意义(P>0.05).结论 选用乙型病毒性肝炎前S1抗原与HBV-DNA联合检测能提高乙型病毒性肝炎的检出率,指导其治疗与预后有重要意义.%Objective To investigate the combined detection of hepatitis B five,pre-S1 antigen clinical relationship with HBV-DNA to assess the clinical value of hepatitis B virus(HBV)detection.Methods The September 2011 to September 2013 in our hospital treated 100 cases of hepatitis B surface antigen-positive patients as research subjects,the colection of clinical data colected for al patients cubital vein blood,and the choice of method and quantitative enzyme-linked immunosorbent assay the hepatitis B five,pre-S1 antigen and HBV-DNA detection method to assess the clinical relationship.Results Hepatitis B in five different models,pre-S1 antigen and HBV-DNA test results showed no significant difference(P>0.05);patients were HBV-DNA and HBV pre-S1 antigen detection rate is relatively consistent with the difference was not statisticaly significant(P>0.05).Conclusion Pre-selection of hepatitis B antigen and HBV-DNA S1 joint detection of hepatitis B to improve the detection rate,to guide their treatment and prognosis are important.

  19. HBV carriage in children born from HIV-seropositive mothers in Senegal: The need of birth-dose HBV vaccination.

    Science.gov (United States)

    Gueye, Sokhna Bousso; Diop-Ndiaye, Halimatou; Lo, Gora; Mintsa, Sandrine; Guindo, Ibrahima; Dia, Aminata; Sow-Sall, Amina; Gaye-Diallo, Aissatou; Mboup, Souleymane; Touré-Kane, Coumba

    2016-05-01

    Hepatitis B is a major public health problem in Senegal, a country with high prevalence and a transmission occurring mainly during infancy. Only, one 6-8 weeks vaccination campaign was initiated in 2005 and it was part of the expanded program of immunization. The aim of this study was to determine the prevalence of HBsAg in children born from HIV-seropositive mothers by using dried blood specimens. Specimens were collected between July 2007 and November 2012 from children aged 2-48 weeks in Dakar and decentralized sites working on HIV mother-to-child transmission prevention. HBsAg detection was performed using Architect HBsAg Qualitative II kit (Abbott Diagnostics, Ireland) and for all reactive samples confirmation was done using Architect HBsAg Qualitative II Confirmatory kit (Abbott Diagnostics, Ireland). Nine hundred thirty samples were collected throughout the country with 66% out of Dakar, the capital city. The median age was 20 weeks and 88% of children were less than 1 year of age with a sex ratio of 1.27 in favor of boys. HBsAg was detected in 28 cases giving a global prevalence of 3%. According to age, HBsAg prevalences were 5.1% for children less than 6 weeks, 4.1% and 4.6%, respectively, for those aged 12-18 weeks and 18-24 weeks of age. The HIV prevalence was 2.6% with no HIV/HBV co-infection. This study showed a high rate of HBV infection in children under 24 months, highlighting the need to promote birth-dose HBV vaccination as recommended by WHO. J. Med. Virol. 88:815-819, 2016. © 2015 Wiley Periodicals, Inc. PMID:26488892

  20. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study

    Directory of Open Access Journals (Sweden)

    Asare Isaac

    2008-03-01

    Full Text Available Abstract Background Prisons are known to be high-risk environments for the spread of bloodborne and sexually transmitted infections. Prison officers are considered to have an intermittent exposure potential to bloodborne infectious diseases on the job, however there has been no studies on the prevalence of these infections in prison officers in Ghana. Methods A national multicenter cross-sectional study was undertaken on correlates of human immunodeficiency virus (HIV, hepatitis B virus (HBV, hepatitis C virus (HCV, and syphilis infections in sample of prison inmates and officers from eight of ten regional central prisons in Ghana. A total of 1366 inmates and 445 officers were enrolled between May 2004 and December 2005. Subjects completed personal risk-factor questionnaire and provided blood specimens for unlinked anonymous testing for presence of antibodies to HIV, HCV and Treponema pallidum; and surface antigen of HBV (HBsAg. These data were analyzed using both univariate and multivariate techniques. Results Almost 18% (1336 of 7652 eligible inmates and 21% (445 of 2139 eligible officers in eight study prisons took part. Median ages of inmates and officers were 36.5 years (range 16–84 and 38.1 years (range 25–59, respectively. Among inmates, HIV seroprevalence was 5.9%, syphilis seroprevalence was 16.5%, and 25.5% had HBsAg. Among officers tested, HIV seroprevalence was 4.9%, HCV seroprevalence was 18.7%, syphilis seroprevalence was 7.9%, and 11.7% had HBsAg. Independent determinants for HIV, HBV and syphilis infections among inmates were age between 17–46, being unmarried, being illiterate, female gender, being incarcerated for longer than median time served of 36 months, history of homosexuality, history of intravenous drug use, history of sharing syringes and drug paraphernalia, history of participation in paid sexual activity, and history of sexually transmitted diseases. Independent determinants for HIV, HBV, HCV and syphilis

  1. Rocks along the road to the control of HBV and HCC.

    Science.gov (United States)

    Beasley, R Palmer

    2009-04-01

    Hepatitis B vaccine is one of the best human vaccines ever developed; it is safe, cheap, and highly immunogenic, stimulates long lasting protective efficacy, and is the first human cancer vaccine. Remarkably, HBV vaccine works even when administered to newborns, timing which is necessary because of mother to infant transmission. Countrywide HBV immunization programs were initiated in Taiwan and Thailand in the 1980s. HBV vaccine has been part of the WHO global immunization since 199x and with at-birth immunization programs in xxx countries resulting in major declines in acute sequelae of HBV infection. Of far greater significance, HBV vaccination prevents hepatocellular carcinoma (HCC) and its use is reducing mother to infant transmission, the driving force behind the HBV carrier state worldwide. These benefits are just being realized since decades elapse between perinatal transmission at birth and the onset of HCC decades later. Studies in Taiwan and Thailand are showing declines in HCC incidence as a result of country wide at-birth HBV immunization programs initiated in the 1980s. Many investigators from many countries have contributed to the understanding of HBV and its role as the major cause of HCC. This article briefly summarizes the work of my University of Washington laboratory in Taipei, Taiwan where I lived and worked from 1972 and 1986 because of the very high HBV carrier rates of HBV in Taiwan. During those 14 years we discovered vertical transmission, its timing and mechanism, and the predictive value of HBeAg. We went on to establish the efficacy of HBIG for prevention of vertical transmission. In later studies we established the efficacy and timing of HBV vaccine and HBIG and HBV vaccine in combination for optimum preventive efficacy. Of greatest significance, our studies showed that chronic HBV infection is the commonest cause of HCC. Worldwide, mothers are the driving force behind the infections that lead to HCC because the HBV carrier state is

  2. Sleeping Beauty transposon-based system for rapid generation of HBV-replicating stable cell lines.

    Science.gov (United States)

    Wu, Yong; Zhang, Tian-Ying; Fang, Lin-Lin; Chen, Zi-Xuan; Song, Liu-Wei; Cao, Jia-Li; Yang, Lin; Yuan, Quan; Xia, Ning-Shao

    2016-08-01

    The stable HBV-replicating cell lines, which carry replication-competent HBV genome stably integrated into the genome of host cell, are widely used to evaluate the effects of antiviral agents. However, current methods to generate HBV-replicating cell lines, which are mostly dependent on random integration of foreign DNA via plasmid transfection, are less-efficient and time-consuming. To address this issue, we constructed an all-in-one Sleeping Beauty transposon system (denoted pTSMP-HBV vector) for robust generation of stable cell lines carrying replication-competent HBV genome of different genotype. This vector contains a Sleeping Beauty transposon containing HBV 1.3-copy genome with an expression cassette of the SV40 promoter driving red fluorescent protein (mCherry) and self-cleaving P2A peptide linked puromycin resistance gene (PuroR). In addition, a PGK promoter-driven SB100X hyperactive transposase cassette is placed in the outside of the transposon in the same plasmid.The HBV-replicating stable cells could be obtained from pTSMP-HBV transfected HepG2 cells by red fluorescence-activated cell sorting and puromycin resistant cell selection within 4-week. Using this system, we successfully constructed four cell lines carrying replication-competent HBV genome of genotypes A-D. The replication and viral protein expression profiles of these cells were systematically characterized. In conclusion, our study provides a high-efficiency strategy to generate HBV-replicating stable cell lines, which may facilitate HBV-related virological study. PMID:27091097

  3. Reactive oxygen species promote heat shock protein 90-mediated HBV capsid assembly

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Yoon Sik, E-mail: yumshak@naver.com; Seo, Hyun Wook, E-mail: suruk@naver.com; Jung, Guhung, E-mail: drjung@snu.ac.kr

    2015-02-13

    Hepatitis B virus (HBV) infection induces reactive oxygen species (ROS) production and has been associated with the development of hepatocellular carcinoma (HCC). ROS are also an important factor in HCC because the accumulated ROS leads to abnormal cell proliferation and chromosome mutation. In oxidative stress, heat shock protein 90 (Hsp90) and glutathione (GSH) function as part of the defense mechanism. Hsp90 prevents cellular component from oxidative stress, and GSH acts as antioxidants scavenging ROS in the cell. However, it is not known whether molecules regulated by oxidative stress are involved in HBV capsid assembly. Based on the previous study that Hsp90 facilitates HBV capsid assembly, which is an important step for the packing of viral particles, here, we show that ROS enrich Hsp90-driven HBV capsid formation. In cell-free system, HBV capsid assembly was facilitated by ROS with Hsp90, whereas it was decreased without Hsp90. In addition, GSH inhibited the function of Hsp90 to decrease HBV capsid assembly. Consistent with the result of cell-free system, ROS and buthionine sulfoximine (BS), an inhibitor of GSH synthesis, increased HBV capsid formation in HepG2.2.15 cells. Thus, our study uncovers the interplay between ROS and Hsp90 during HBV capsid assembly. - Highlights: • We examined H{sub 2}O{sub 2} and GSH modulate HBV capsid assembly. • H{sub 2}O{sub 2} facilitates HBV capsid assembly in the presence of Hsp90. • GSH inhibits function of Hsp90 in facilitating HBV capsid assembly. • H{sub 2}O{sub 2} and GSH induce conformation change of Hsp90.

  4. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line

    Institute of Scientific and Technical Information of China (English)

    Wei He; Li-Xia Li; Qing-Jiao Liao; Chun-Lan Liu; Xu-Lin Chen

    2011-01-01

    AIM: To analyze the antiviral mechanism of Epigallocatechin gallate (EGCG) against hepatitis B virus (HBV) replication. METHODS: In this research, the HBV-replicating cell line HepG2.117 was used to investigate the antiviral mechanism of EGCG. Cytotoxicity of EGCG was analyzed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Hepatitis B virus e antigen (HBeAg) and hepatitis B virus surface antigen (HBsAg) in the supernatant were detected by enzyme-linked immunosorbent assay. Precore mRNA and pregenomic RNA (pgRNA) levels were determined by semi-quantitative reverse transcription polymerase chain reaction (PCR) assay. The effect of EGCG on HBV core promoter activity was measured by dual luciferase reporter assay. HBV covalently closed circular DNA and replicative intermediates of DNA were quantified by real-time PCR assay. RESULTS: When HepG2.117 cells were grown in the presence of EGCG, the expression of HBeAg was suppressed, however, the expression of HBsAg was not affected. HBV precore mRNA level was also downregulated by EGCG, while the transcription of precore mRNA was not impaired. The synthesis of both HBV covalently closed circular DNA and replicative intermediates of DNA were reduced by EGCG treatment to a similar extent, however, HBV pgRNA transcripted from chromosome-integrated HBV genome was not affected by EGCG treatment, indicating that EGCG targets only replicative intermediates of DNA synthesis. CONCLUSION: In HepG2.117 cells, EGCG inhibits HBV replication by impairing HBV replicative intermediates of DNA synthesis and such inhibition results in reduced production of HBV covalently closed circular DNA.

  5. Reactive oxygen species promote heat shock protein 90-mediated HBV capsid assembly

    International Nuclear Information System (INIS)

    Hepatitis B virus (HBV) infection induces reactive oxygen species (ROS) production and has been associated with the development of hepatocellular carcinoma (HCC). ROS are also an important factor in HCC because the accumulated ROS leads to abnormal cell proliferation and chromosome mutation. In oxidative stress, heat shock protein 90 (Hsp90) and glutathione (GSH) function as part of the defense mechanism. Hsp90 prevents cellular component from oxidative stress, and GSH acts as antioxidants scavenging ROS in the cell. However, it is not known whether molecules regulated by oxidative stress are involved in HBV capsid assembly. Based on the previous study that Hsp90 facilitates HBV capsid assembly, which is an important step for the packing of viral particles, here, we show that ROS enrich Hsp90-driven HBV capsid formation. In cell-free system, HBV capsid assembly was facilitated by ROS with Hsp90, whereas it was decreased without Hsp90. In addition, GSH inhibited the function of Hsp90 to decrease HBV capsid assembly. Consistent with the result of cell-free system, ROS and buthionine sulfoximine (BS), an inhibitor of GSH synthesis, increased HBV capsid formation in HepG2.2.15 cells. Thus, our study uncovers the interplay between ROS and Hsp90 during HBV capsid assembly. - Highlights: • We examined H2O2 and GSH modulate HBV capsid assembly. • H2O2 facilitates HBV capsid assembly in the presence of Hsp90. • GSH inhibits function of Hsp90 in facilitating HBV capsid assembly. • H2O2 and GSH induce conformation change of Hsp90

  6. 皖北地区乙型肝炎患者HBV血清标志物与HBV-DNA定量检测的比较%Comparison of HBV-M and HBV-DNA detection in HBV infectors in the North of Anhui

    Institute of Scientific and Technical Information of China (English)

    昝丽娜; 石秀芳; 孙峰

    2013-01-01

    Objective: To compare the detection results of HBV-M and HBV-DNA. Methods: All 388 HBV patients were detected for the HBV-M by ELISA and HBV-DNA by FQ-PCR. Results:The positive rate of HBV-DNA in the group of HBsAg(+)/HBeAg(+)/ HBcAb(+) was 91.25% ,and the majority of the virus replication was 107 IU/ml; while the majority of the virus replication in the group of HBsAg(+)/HBeAb(+)/ HBcAb(+) was 103 IU/ml. The positive rate of HBV-DNA in the group of HBsAgAb(+)/ HBeAg(+)/HBc(+) was higher than that in the group of HBsAg(+)/HBeAb(+)/HBcAb(+) (P <0.05) . The positive rate of HBV-DNA in the group of HBsAg(+)/HBeAg(±)/ HBc(+) Ab was 66. 67% . The majority of the virus replication was 105 IU/ml and 106 IU/ml in patients with positive HBsAg(+)/HBeAg(+)/HBc(-) Ab. The positive rate of HBV-DNA in the group of HBsAg (+)/HBeAg(-)/HBcAb(+) was 30.77%. Conclusions: Patients with HBeAg(+) have the highest replication level in all the groups,which is closely associated with HBV-DNA. Virus replication in patients with HBeAb(+) and HBcAb(+) does not stop completely, but obviously decreases. Combination detection of HBV-M and HBV-DNA may display the immune status and virus replication level of patients with hepatitis B, which would provide experimental basis for clinical monitoring and drug administration.%目的:比较乙型肝炎病毒血清标志物(HBV-M)与HBV-DNA定量检测的结果.方法:采用酶联免疫法检测388例患者血清HBV-M,同时用荧光定量-聚合酶链反应检测其HBV-DNA含量.结果:乙型肝炎大三阳组患者血清HBV-DNA阳性率为91.25%,阳性患者中HBV拷贝数为107 IU/ml的所占比例最多,小三阳组阳性患者中HBV拷贝数以103 IU/ml为主,大三阳组患者血清HBV-DNA阳性率高于小三阳组(P<0.05);HBsAg(+)、HBeAg(±)、抗-HBc(+)组阳性率为66.67%;HBsAg(+)、HBeAg(+)、抗HBc(-)组阳性患者中以105 IU/ml和106 IU/ml为主;HBsAg(+)、HBeAg(-)、HBcAb(+)组阳性率为30.77%.结论:乙型肝炎患者中HBeAg(+)者

  7. Virus and Host Testing to Manage Chronic Hepatitis B.

    Science.gov (United States)

    Wong, Grace Lai-Hung; Wong, Vincent Wai-Sun; Chan, Henry Lik-Yuen

    2016-06-01

    Chronic hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma worldwide. The past 50 years have seen rapid developments in HBV testing. Beginning from traditional serologic tests, the availability of sensitive HBV DNA assays allows a thorough understanding of the virology and natural history of chronic HBV infection. Quantification of hepatitis B surface antigen levels reflects the amount and transcriptional activities of covalently closed circular DNA in the liver and may be used to evaluate the stage of disease and guide antiviral therapy. The natural history of chronic HBV infection is also a manifestation of the interaction between the host and the virus, and recent genomic works have shed light on the host-virus relationship and may provide novel tests in the future. This review highlights recent advances in the application of HBV tests in the management of chronic hepatitis B. PMID:27190319

  8. RPB5-Mediating Protein Suppresses Hepatitis B Virus (HBV Transcription and Replication by Counteracting the Transcriptional Activation of Hepatitis B virus X Protein in HBV Replication Mouse Model

    Directory of Open Access Journals (Sweden)

    Zhou

    2015-09-01

    Full Text Available Background RPB5-Mediating protein (RMP is associated with the RNA polymerase II subunit RPB5. This protein functionally counteracts the transcriptional activation of Hepatitis B Virus X protein (HBx by competitively binding to the RPB5; however, the effects of RMP on Hepatitis B virus (HBV transcription and replication remain unknown. Objectives The purpose of this study was to investigate the effect of RMP on viral transcription and replication in vivo by using the hydrodynamic-based HBV replication mouse model. Materials and Methods Male balb/c mice were transfected with wild type (1.2 wt or the HBx minus HBV plasmids (1.2x (- with or without HBx and RMP, to establish an HBV replication mouse model by hydrodynamic injection through the tail vein. The HBV RNA and HBV DNA replication intermediates (RI were analyzed in the liver. Results RPB5-Mediating protein could inhibit HBV transcription and replication in groups transfected with the 1.2 wt and HBx. The inhibitory effect disappeared in the 1.2x (- groups, yet it reappeared in the groups co-transfected with 1.2x (- and HBx. An inhibitory effect was indicated at a low dose of RMP (0.3 ug, 0.5 ug and 0.7 ug compared to the control group and groups that had received high doses of RMP. Conclusions Our study demonstrated that a low dose of RMP could inhibit HBV transcription and replication, which is dependent on the appearance of HBx in vivo.

  9. Sieropositivitá per HIV, HBV e HCV negli utenti del Servizio di Tossicodipendenza di Formia (ASL di Latina

    Directory of Open Access Journals (Sweden)

    G. La Torre

    2003-05-01

    Full Text Available

    Obiettivi: valutare la prevalenza sieropositività per HIV, HBV e HCV nei tossicodipendenti afferenti al Ser.T di Formia (LT.

    Materiali e metodi: sono state consultate le cartelle cliniche degli afferenti al Ser.T. nel 2002, estraendo dati relativi ai parametri socio-demografici ed alle sieropositività. L’analisi statistica ha previsto l’impiego del test del χ2 e della regressione logistica multipla.

    Risultati: sono stati presi in considerazione 135 tossicodipendenti, di cui 103 (76.3% maschi e 32 (23.7% femmine. L’età mediana dell’inizio della tossicodipendenza e della presa in carico presso il servizio erano, rispettivamente, di 18 e di 23 anni. Il 94.1% dei tossicodipendenti risulta dipendente primariamente da eroina, il 5.2% da cocaina e lo 0.7% da alcol. Relativamente alle positività per i virus considerati, 7 soggetti (5.2% sono risultati positivi all’HIV, 23 (17% sieropositivi per HBV e 50 (37% sieropositivi per HCV. L’analisi multivariata mostra che sono associate alla sieropositività per HCV la sieropositività per HBV (OR = 3.87 e l’età della presa in carico presso il servizio superiore a 25 anni (OR = 1.88; alla sieropositività per HBV l’occupazione saltuaria (OR = 4.58, la HCV positività (OR = 4.41 e la HIV positività (OR = 5.39; alla sieropositività per HIV l’età della presa in carico presso il servizio superiore a 25 anni (OR = 4.94.

    Discussione: l’indagine ha messo in evidenza prevalenze di sieropositività per HCV, HBV e HIV decisamente inferiori a quelle registrate in altre realtà italiane ed internazionali. Una possibile spiegazione potrebbe essere ricercata nei bassi livelli di sieropositività per questi virus nella popolazione generale del Basso Lazio, o nella scarsa abitudine di scambiarsi le siringhe fra tossicodipendenti di questa area geografica.

  10. Cloning analysis of HBV-specific CD8 T cell receptor gene in patients with acute hepatitis B

    Directory of Open Access Journals (Sweden)

    Ning DING

    2011-05-01

    Full Text Available Objective To investigate the molecular mechanism of T cell receptor(TCR in CD8 T cell-mediated immune response to HBV in patients with acute hepatitis B(AHB.Methods Peripheral blood mononuclear cells(PBMCs were collected from HLA-A2-positive AHB patients.To determine HBsAg183-191 and HBsAg335-343-specific CD8 T cell frequencies,the PBMCs were stained by fluorescence-labeled anti-CD3,anti-CD8 and pentamers,and analyzed by flow cytometry.PBMCs from 6 patients were stimulated with epitopic peptide HBsAg335-343 in vitro for 3 to 4 weeks.HBV-specific CD8 T cells were isolated by magnetic activated cell sorting followed by flow florescence activated cell sorting.The mRNA of sorted cells was extracted after expanding by IL-2,anti-CD3 and anti-CD8.The full-length gene fragments of variable region of TCR α and β chains were gained by 5’-RACE,and then cloned and sequenced(≥50 clones for single chain of each sample.The gene families of TCR α and β chains were identified and the sequence characters of CDR3 were compared.Results Analysis of more than 600 cloned gene sequences of TCR α and β chains showed that the proliferated HBV-specific CD8 T cells from 6 AHB patients presented a predominant expression in TCR α and chains,with 2-4 α chain families and 1-4 chain families in each case.The α2,α14,α15,β3,β13 and 23 families were detected in more than one case.The chain genes were all 13 for all tested clones in one case.For the same α chain or-chain family,CDR3 sequences tended to be identical in one case but different among cases.Conclusions HBV-specific CD8 T cells with antigenic peptide-induced proliferation present predominance in the usage of TCR α and β chains.This property might be one of the important molecular factors influencing anti-HBV immunity.

  11. HBV Genotype B/C and Response to Lamivudine Therapy: A Systematic Review

    Directory of Open Access Journals (Sweden)

    Xiu-Li Chen

    2013-01-01

    Full Text Available A number of nucleoside analogues such as lamivudine (LAM, actually used for the treatment of chronic hepatitis B, can suppress HBV DNA replication, improve transaminase level and liver histology, and enhance the rate of hepatitis B e antigen (HBeAg clearance. The responses to LAM therapy involve HBeAg clearance and HBV DNA conversion of negative. However, the associations between HBV genotype B/C and response to LAM therapy remain ambiguous. The aim of this meta-analysis is to determine more precise estimations of the relationship. All the publications on the associations between HBV genotype B/C and response to LAM (HBeAg clearance and HBV DNA conversion of negative through June 2013 were collected. Relative risk (RR with 95% confidence intervals (95% CI was calculated in fixed or random model, was calculated to examine heterogeneity, and funnel plots were plotted to examine small study effects with Stata 11 software. Overall, for HBeAg clearance and genotype B/C, the RR (95% CI was 1.27 (0.94–1.71, while for HBV DNA conversion of negative and genotype B/C, the RR (95% CI was 1.07 (0.98–1.17. HBV genotype B/C shows no significance associations with response to lamivudine therapy (HBeAg clearance and HBV DNA conversion of negative.

  12. Influence of serum HBV-DNA content on the expression of TGF-β1 and TNF-α in patients with chronic hepatitis B

    International Nuclear Information System (INIS)

    Objective: To study the relationship between the serum HBV-DNA content and levels of transforming growth factor β1 (TGF-β1), tumor necrosis factor-α (TNF-α) as well as the degree of hepatic fibrosis in patients with chronic hepatitis B. Methods: Serum HBV-DNA content quantification was determined with PCR-real time fluorescence method; TGF-β1 and TNF-α with ELISA and the hepatic fibrosis indicators HA, LN, IV-C, P-III with RIA. Altogether 89 patients with clinical chronic hepatitis B of various degrees (mild 25, moderate 35, advanced 29) were tested. Results: With the progress of hepatic injury, the serum contents of HBV-DNA, TGF-β1, TNF-α were correspondingly increased with significant differences among the patients groups (p<0.01). The TGF-β1, TNF-α, HA, IV-C, PC III, levels were positively correlated to the degree of hepatic injury with r=0.9561, 0.8123, 0.8561, 0.7723, 0.7150 respectively and p<0.01; for LN it was r=0.542 and p<0.05. Conclusion: In patients with chronic hepatitis B, hepatic fibrosis is the fundamental process in the pathogenesis of liver cirrhosis. High concentration of HBV is the crucial factor for development of hepatic fibrosis, which works synergically with many cytokines especially TGF-β1 and TNF-α

  13. Prevalence, attitudes and knowledge about HIV HBV and HCV infections among inmates in prisons Prilep and Bitola--a pilot study.

    Science.gov (United States)

    Jovanovska, Tanja; Kocic, Biljana; Stojcevska, Viktorija P

    2014-06-01

    Prisons are associates as facilities liable of high risk of infection disease, as a result of the possibility of transmission of infections in prisons surroundings. Investigations carried out in correctional facilities around the world have shown a high prevalence of blood borne hepatitis viruses and HIV. The study was aimed at confirming prevalence of HIV hepatitis B and hepatitis C among prisoners in Bitola's, and Prilep's prisons, existing of co-infection as well to assess knowledge and attitudes related to HIV, HBV and HCV infections. In this cross-sectional study 200 prisoners have participated, providing answers to structured questionnaire and in order to analyze blood for HIV, HBV and HCV, rapid blood tests in detecting antibodies has been used. Prevalence of HCV is 0.20, HBV 0.17 and HIV prevalence is 0. Co-infection prevalence of HCV/HBV is 0.07 from the total number of examinees. As for the manner of infection with HIV virus 22% are familiar with the fact that persons cannot be infected by HIV if they have only one sexual partner who is not infected and have no other partners, and for the protection of HIV and Hepatitis B by correct use of condoms-58% have given correct answers. PMID:25144968

  14. Hepatitis B (HBV), Hepatitis C (HCV) and Hepatitis Delta (HDV) Viruses in the Colombian Population—How Is the Epidemiological Situation?

    Science.gov (United States)

    Alvarado-Mora, Mónica Viviana; Gutierrez Fernandez, María Fernanda; Gomes-Gouvêa, Michele Soares; de Azevedo Neto, Raymundo Soares; Carrilho, Flair José; Pinho, João Renato Rebello

    2011-01-01

    Background Viral hepatitis B, C and delta still remain a serious problem worldwide. In Colombia, data from 1980s described that HBV and HDV infection are important causes of hepatitis, but little is known about HCV infection. The aim of this study was to determine the currently frequency of HBV, HCV and HDV in four different Colombian regions. Methodology/Principal Findings This study was conducted in 697 habitants from 4 Colombian departments: Amazonas, Chocó, Magdalena and San Andres Islands. Epidemiological data were obtained from an interview applied to each individual aiming to evaluate risk factors related to HBV, HCV or HDV infections. All samples were tested for HBsAg, anti-HBc, anti-HBs and anti-HCV markers. Samples that were positive to HBsAg and/or anti-HBc were tested to anti-HDV. Concerning the geographical origin of the samples, the three HBV markers showed a statistically significant difference: HBsAg (p = 0.033) and anti-HBc (pAmazonas and Magdalena departments. Isolated anti-HBs (a marker of previous vaccination) frequencies were: Chocó (53.26%), Amazonas (32.88%), Magdalena (17.0%) and San Andrés (15.33%) - pAmazonas department showed the highest frequency for anti-HCV marker (5.68%), while the lowest frequency was found in San Andrés Island (0.66%). Anti-HDV was found in 9 (5.20%) out of 173 anti-HBc and/or HBsAg positive samples, 8 of them from the Amazonas region and 1 from them Magdalena department. Conclusions/Significance In conclusion, HBV, HCV and HDV infections are detected throughout Colombia in frequency levels that would place some areas as hyperendemic for HBV, especially those found in Amazonas and Magdalena departments. Novel strategies to increase HBV immunization in the rural population and to strengthen HCV surveillance are reinforced by these results. PMID:21559488

  15. Dynamics of an HBV Model with Drug Resistance Under Intermittent Antiviral Therapy

    Science.gov (United States)

    Zhang, Ben-Gong; Tanaka, Gouhei; Aihara, Kazuyuki; Honda, Masao; Kaneko, Shuichi; Chen, Luonan

    2015-06-01

    This paper studies the dynamics of the hepatitis B virus (HBV) model and the therapy regimens of HBV disease. First, we propose a new mathematical model of HBV with drug resistance, and then analyze its qualitative and dynamical properties. Combining the clinical data and theoretical analysis, we demonstrate that our model is biologically plausible and also computationally viable. Second, we demonstrate that the intermittent antiviral therapy regimen is one of the possible strategies to treat this kind of complex disease. There are two main advantages of this regimen, i.e. it not only may delay the development of drug resistance, but also may reduce the duration of on-treatment time compared with the long-term continuous medication. Moreover, such an intermittent antiviral therapy can reduce the adverse side effects. Our theoretical model and computational results provide qualitative insight into the progression of HBV, and also a possible new therapy for HBV disease.

  16. Relationship between heterogeneity of HBV preS/S gene and intrauterine transmission

    Institute of Scientific and Technical Information of China (English)

    LI Duan; YAN Yong-ping; XU De-zhong; ZHANG Jing-xia

    2002-01-01

    Objective: To study the relationship of the mutation of HBV preS/S gene in HBsAg carrying pregnant women and intrauterine transmission. Methods: Polymerase chain reaction (PCR) was used to amplify HBV preS/S gene from sera of 8 HBsAg carrying pregnant women, 4 women's neonates infected with HBV,and the other's neonates non-infected with. The PCR products were cloned and 5 clones were chosen from every woman for DNA sequencing. Results: Heterogeneity of HBV preS/S gene in HBsAg carrying pregnant women having intrauterine transmission was much higher than that from having not intrauterine transmission, and the divergence rate of nucleotide sequences also higher strikingly. Conclusion: High heterogeneity of HBV preS/S gene of HBsAg positive pregnant women may be relative to high rate of intrauterine transmission.

  17. Effects of temporal variability on HBV model calibration

    Directory of Open Access Journals (Sweden)

    Steven Reinaldo Rusli

    2015-10-01

    Full Text Available This study aimed to investigate the effect of temporal variability on the optimization of the Hydrologiska Byråns Vattenbalansavedlning (HBV model, as well as the calibration performance using manual optimization and average parameter values. By applying the HBV model to the Jiangwan Catchment, whose geological features include lots of cracks and gaps, simulations under various schemes were developed: short, medium-length, and long temporal calibrations. The results show that, with long temporal calibration, the objective function values of the Nash-Sutcliffe efficiency coefficient (NSE, relative error (RE, root mean square error (RMSE, and high flow ratio generally deliver a preferable simulation. Although NSE and RMSE are relatively stable with different temporal scales, significant improvements to RE and the high flow ratio are seen with longer temporal calibration. It is also noted that use of average parameter values does not lead to better simulation results compared with manual optimization. With medium-length temporal calibration, manual optimization delivers the best simulation results, with NSE, RE, RMSE, and the high flow ratio being 0.563 6, 0.122 3, 0.978 8, and 0.854 7, respectively; and calibration using average parameter values delivers NSE, RE, RMSE, and the high flow ratio of 0.481 1, 0.467 6, 1.021 0, and 2.784 0, respectively. Similar behavior is found with long temporal calibration, when NSE, RE, RMSE, and the high flow ratio using manual optimization are 0.525 3, −0.069 2, 1.058 0, and 0.980 0, respectively, as compared with 0.490 3, 0.224 8, 1.096 2, and 0.547 9, respectively, using average parameter values. This study shows that selection of longer periods of temporal calibration in hydrological analysis delivers better simulation in general for water balance analysis.

  18. Relationship between single nucleotide polymorphism of chemokine CXCL10 G-210A and the chronicity and severity of HBV infection

    Directory of Open Access Journals (Sweden)

    Li-ming LIU

    2011-01-01

    Full Text Available Objective To investigate the single nucleotide polymorphism(SNP in the promoter of chemokine CXCL10 G-201A,and explore the relationship between the SNP and the chronicity and severity of hepatitis B virus(HBV infection.Methods Blood samples were collected from 792 patients with HBV infection,including 200 with acute hepatitis B(AHB,200 with mild/moderate chronic hepatitis B(CHB-M,192 with severe chronic hepatitis B(CHB-S and 200 with acute liver failure of chronic hepatitis(ACLF,and 300 healthy people were enrolled as normal control(NC.DNA were extracted and subjected to PCR amplification of fragment containing C-1596 site that links with G-201 variation,followed by restriction fragment length polymerase(RFLP analysis.Simultaneously,400 samples were randomly extracted from various groups for direct sequencing of G-201 variation.The consistency of SNP typing results of the two methods was analyzed.Results Variation rates of G-201A were 17.77% for AHB group,25.26% for CHB-M group,26.59% for CHB-S group,21.28% for ACLF group,and 13.82% for NC group.The overall P value obtained from the general χ2 test among the 5 groups was 0.0037.The correlation test(P=0.0015 demonstrated that the variation rate was related to different disease status,and the linear trend test(P=0.0029,Z=-2.9748 indicated an increasing trend of variation rate with the disease progression.Paired comparison showed that the differences in variation rate between CHB-M and NC(P=0.0024,CHB-S and NC(P=0.0007,ACLF and NC(P=0.0428,as well as CHB-S and CHB(P=0.0488 were statistically significant.Direct PCR sequencing showed 98.68% identity with the results from PCR-RFLP.Kappa test(U=58.425,P < 0.05 indicated that the consistency of the two assays met the statistical requirements.Conclusion The G-201A variation in CXCL10 promoter is related to chronicity of HBV infection,and the relations between the variation and the severity of HBV infection remains to be further clarified.

  19. Serum Levels of IL-10 and IL-17A in Occult HBV-Infected South-East Iranian Patients

    OpenAIRE

    Gholamhossein Hassanshahi; Abdollah Jafarzadeh; Mohammad Kazemi Arababadi; Ali Akbar Pourfathollah2

    2010-01-01

    Background and Aims Occult hepatitis B infected (OBI) patients can not completely eradicate hepatitis B virus-DNA (HBV-DNA) from their liver and peripheral blood. The main aim of this study was to investigate the Interleukin (IL)-10and IL-17A serum levels in patients suffering from OBI. Material and Methods In this observational study, plasma samples of 3700 blood donors were tested for hepatitis Bsurface antigen (HBsAg) and antibodies to the hepatitis B core antigen (anti-HBc), using enzyme-...

  20. HBV, HCV and HIV seroprevalence among blood donors in Istanbul, Turkey: how effective are the changes in the national blood transfusion policies?

    Directory of Open Access Journals (Sweden)

    Ali Acar

    2010-02-01

    Full Text Available The national blood transfusion policies have been changed significantly in recent years in Turkey. The purpose of this study was to determine the prevalence of HBV, HCV, and HIV in blood donors at the Red Crescent Center in Istanbul and to evaluate the effect of changes in the national blood transfusion policies on the prevalence of these infections. The screening results of 72695 blood donations at the Red Crescent Center in Istanbul between January and December 2007 were evaluated retrospectively. HBsAg, anti-HCV, and anti-HIV-1/2 were screened by microparticle enzyme immunoassay (MEIA method. Samples found to be positive for anti-HIV 1/2 and anti-HCV were confirmed by Inno-Lia HCV Ab III and Inno-Lia HIV I/II Score, respectively. The seropositivity rates for HBsAg, anti-HCV, and anti-HIV-1/2 were determined as 1.76%, 0.07%, and 0.008%, respectively. Compared to the previously published data from Red Crescent Centers in Turkey, it was found that HBV and HCV seroprevalances decreased and HIV seroprevalance increased in recent years. In conclusion, we believe that the drop in HBV and HCV prevalence rates are likely multifactorial and may have resulted from more diligent donor questioning upon screening, a higher level of public awareness on viral hepatitis as well as the expansion of HBV vaccination coverage in Turkey. Another factor to contribute to the decreased prevalence of HCV stems from the use of more sensitive confirmation testing on all reactive results, thereby eliminating a fair amount of false positive cases. Despite similar transmission routes, the increase in HIV prevalence in contrast to HBV and HCV may be linked to the increase in AIDS cases in Turkey in recent years.

  1. Association of an HLA-G 14-bp Insertion/Deletion polymorphism with high HBV replication in chronic hepatitis.

    Science.gov (United States)

    Laaribi, A B; Zidi, I; Hannachi, N; Ben Yahia, H; Chaouch, H; Bortolotti, D; Zidi, N; Letaief, A; Yacoub, S; Boudabous, A; Rizzo, R; Boukadida, J

    2015-10-01

    Identification of an HLA-G 14-bp Insertion/Deletion (Ins/Del) polymorphism at the 3' untranslated region of HLA-G revealed its importance in HLA-G mRNA stability and HLA-G protein level variation. We evaluated the association between the HLA-G 14-bp Ins/Del polymorphism in patients with chronic Hepatitis B virus (HBV) infection in a case-control study. Genomic DNA was extracted from 263 patients with chronic HBV hepatitis and 246 control subjects and was examined for the HLA-G 14-bp Ins/Del polymorphism by PCR. The polymorphic variants were genotyped in chronic HBV seropositive cases stratified according to HBV DNA levels, fibrosis stages and in a control population. There was no statistical significant association between the 14-bp Ins/Del polymorphism and increased susceptibility to HBV infection neither for alleles (P = 0.09) nor for genotypes (P = 0.18). The stratification of HBV patients based on HBV DNA levels revealed an association between the 14-bp Ins/Del polymorphism and an enhanced HBV activity with high HBV DNA levels. In particular, the Ins allele was significantly associated with high HBV DNA levels (P = 0.0024, OR = 1.71, 95% CI 1.2-2.4). The genotype Ins/Ins was associated with a 2.5-fold (95% CI, 1.29-4.88) increased risk of susceptibility to high HBV replication compared with the Del/Del and Ins/Del genotypes. This susceptibility is linked to the presence of two Ins alleles. No association was observed between the 14-bp Ins/Del polymorphism and fibrosis stage of HBV infection. We observed an association between the 14-bp Ins/Del polymorphism and high HBV replication characterized by high HBV DNA levels in chronic HBV patients. These results suggest a potential prognostic value for disease outcome evaluation. PMID:25619305

  2. High Seroprevalence of HBV and HCV Infection in HIV-Infected Adults in Kigali, Rwanda

    OpenAIRE

    Rusine, John; Ondoa, Pascale; Asiimwe-Kateera, Brenda; Boer, Kimberly R.; Uwimana, Jean Marie; Mukabayire, Odette; Zaaijer, Hans; Mugabekazi, Julie; Reiss, Peter; van de Wijgert, Janneke H.

    2013-01-01

    Background Data on prevalence and incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in Rwanda are scarce. Methods HBV status was assessed at baseline and Month 12, and anti-HCV antibodies at baseline, in a prospective cohort study of HIV-infected patients in Kigali, Rwanda: 104 men and 114 women initiating antiretroviral therapy (ART) at baseline, and 200 women not yet eligible for ART. Results Baseline prevalence of active HBV infection (HBsAg positive), past or occu...

  3. HIV, HBV and HCV Coinfection Prevalence in Iran - A Systematic Review and Meta-Analysis

    OpenAIRE

    Fahimeh Bagheri Amiri; Ehsan Mostafavi; Ali Mirzazadeh

    2016-01-01

    Background worldwide, hepatitis C and B virus infections (HCV and HCV), are the two most common coinfections with human immunodeficiency virus (HIV) and has become a major threat to the survival of HIV-infected persons. The review aimed to estimate the prevalence of HIV, HBV, HCV, HIV/HCV and HIV/HBV and triple coinfections in different subpopulations in Iran. Method Following PRISMA guidelines, we conducted a systematic review and meta-analysis of reports on prevalence of HIV, HBV, HCV and H...

  4. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis:A comparative study

    Institute of Scientific and Technical Information of China (English)

    Ioan; Sporea; Roxana; Sirli; Alexandra; Deleanu; Adriana; Tudora; Alina; Popescu; Manuela; Curescu; Simona; Bota

    2010-01-01

    AIM:To assess the values of liver stiffness (LS) in pa-tients with hepatitis B virus (HBV) chronic hepatitis and to compare them with those in patients with hepatitis C virus (HCV) chronic hepatitis. METHODS: The study included 140 patients with HBV chronic hepatitis, and 317 patients with HCV chronic hepatitis, in which LS was measured (FibroScan-Echo-sens) and liver biopsy was performed in the same session (assessed according to the Metavir score). RESULTS:According to the Metavir score of the 140 HBV p...

  5. HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.

    Science.gov (United States)

    Kim, H N; Scott, J; Cent, A; Cook, L; Morrow, R A; Richardson, B; Tapia, K; Jerome, K R; Lule, G; John-Stewart, G; Chung, M H

    2011-10-01

    Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV-infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty-seven (6.9%) were HBsAg positive and anti-HBs negative, 24 were HBeAg negative, and 18 had HBV DNA levels ≤ 10,000 IU/mL. Sustained HBV suppression to <100 IU/mL occurred in 89% of 19 evaluable patients. Resistance occurred in only two subjects, both with high baseline HBV DNA levels. Lamivudine resistance can emerge in the setting of incomplete HBV suppression but was infrequently observed among HIV-HBV coinfected patients with low baseline HBV DNA levels. PMID:21914062

  6. Detection of HBV - DNA content in serum and breast milk of parturient women carrying HBV and its clinical significance%HBV携带产妇血清及乳汁中HBV- DNA含量检测及其临床意义

    Institute of Scientific and Technical Information of China (English)

    黄珍贞

    2012-01-01

    目的:探讨HBV携带产妇的血清及乳汁中HBV -DNA含量,以期指导母乳喂养.方法:选取HBV携带产妇100例,采用荧光定量PCR技术检测其血清、乳汁中HBV -DNA含量.结果:HBsAg、HBeAg双阳性组和HBsAg单阳性组中血清HBV-DNA含量、阳性率均高于乳汁,差异有统计学意义(P<0.05),且乳汁HBV-DNA阳性率随着母血清HBV-DNA含量的增加而增加;100例产妇中乳汁HBV-DNA检测阴性及血清病毒含量<104 copy/ml的母乳喂养儿未见婴儿发生乙肝病毒感染.结论:HBV携带产妇乳汁具有一定的传染性,但乳汁的传染性低于血液,血清HBV-DNA阳性产妇在哺乳时应进行HBV -DNA检测,以保证婴儿的安全哺乳环境.%Objective: To explore the contents of HBV - DNA in serum and breast milk of parturient women carrying HBV, in order to direct breast feeding. Methods: 100 parturient women carrying HBV were selected, fluorescence quantitative PCR technique was used to detect the contents of HBV - DNA in serum and breast milk. Results; In positive HBsAg + positive HBeAg group and positive HBsAg group, the contents and positive rates of HBV - DNA in serum were significantly higher than those in breast milk (P < 0.05 ) . The positive rate of HBV - DNA in breast milk increased with the increase of HBV - DNA content in maternal serum; 100 infants who were bom by the parturient women with negative HBV - DNA in breast milk and serum viral content < 104 copy/ml were not found with HBV infection. Conclusion; The breast milk of parturient women carrying HBV have infectivity, but the infectivity of breast milk is lower than that of serum, the parturient women with positive HBV - DNA in serum should receive HBV - DNA detection when they suckle their infants to ensure a safe lactation environment of infants.

  7. Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognoses

    International Nuclear Information System (INIS)

    Housekeeping genes are routinely used as endogenous references to account for experimental differences in gene expression assays. However, recent reports show that they could be de-regulated in different diseases, model animals, or even under varied experimental conditions, which may lead to unreliable results and consequently misinterpretations. This study focused on the selection of suitable reference genes for quantitative PCR in human hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) with different clinical outcomes. We evaluated 6 commonly used housekeeping genes' expression levels in 108 HBV-related HCCs' matched tumor and non-tomor tissue samples with different clinical outcomes and 26 normal liver specimens by real-time PCR. The expression stability of the 6 genes was compared using the software programs geNorm and NormFinder. To show the impact of reference genes on data analysis, we took PGK1 as a target gene normalized by each reference gene, and performed one-way ANOVA and the equivalence test. With the geNorm and NormFinder software programs, analysis of TBP and HPRT1 showed the best stability in all tissue samples, while 18s and ACTB were less stable. When 18s or ACTB was used for normalization, no significant difference of PGK1 expression (p > 0.05) was found among HCC tissues with and without metastasis, and normal liver specimens; however, dramatically differences (p < 0.001) were observed when either TBP or the combination of TBP and HPRT1 were selected as reference genes. TBP and HPRT1 are the most reliable reference genes for q-PCR normalization in HBV-related HCC specimens. However, the well-used ACTB and 18S are not suitable, which actually lead to the misinterpretation of the results in gene expression analysis

  8. Characteristics of co-infections by HCV and HBV among Brazilian patients infected by HIV-1 and/or HTLV-1

    Directory of Open Access Journals (Sweden)

    Marcia Moreira

    2013-12-01

    Full Text Available BACKGROUND: The human retroviruses HIV-1 and HTLV-1 share the routes of infection with hepatitis viruses B and C. Co-infection by these agents are a common event, but we have scarce knowledge on co-infection by two or more of these agents. OBJECTIVE: To evaluate the characteristics and risk factors for co-infections by HBV and HCV in patients infected by HIV-1 or/and HTLV-1, in Salvador, Brazil. METHODS: In a case-control study we evaluated patients followed in the AIDS and HTLV clinics of Federal University of Bahia Hospital. Clinical and epidemiological characteristics were reviewed, and patients were tested for the presence of serological markers of HBV and HCV infections. HCV-infected patients were tested by PCR to evaluate the presence of viremia. RESULTS: A total of 200 HIV-1, 213 HTLV-1-infected, and 38 HIV-HTLV-co-infected individuals were included. HIV-infected patients were more likely to have had more sexual partners in the lifetime than other patients' groups. HIV-HTLV-co-infected subjects were predominantly male. Patients infected by HTLV or co-infected had a significantly higher frequency of previous syphilis or gonorrhea, while HIV infection was mainly associated with HPV infection. Co-infection was significantly associated to intravenous drug use (IVDU. HBV and/or HCV markers were more frequently found among co-infected patients. HBV markers were more frequently detected among HIV-infected patients, while HCV was clearly associated with IVDU across all groups. AgHBs was strongly associated with co-infection by HIV-HTLV (OR = 22.03, 95% CI: 2.69-469.7, as well as confirmed HCV infection (p = 0.001. Concomitant HCV and HBV infection was also associated with retroviral co-infection. Patients infected by HTLV-1 had a lower chance of detectable HCV viremia (OR = 0.04, 95% CI: 0.002-0.85. CONCLUSIONS: Infection by HCV and/or HBV is frequent among patients presenting retroviral infection, but risk factors and prevalence for each

  9. Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

    Science.gov (United States)

    2012-04-24

    PHENYTOIN/SORAFENIB [VA Drug Interaction]; Liver Neoplasms; Carcinoma, Hepatocellular; Digestive System Neoplasms; Neoplasms by Site; Liver Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]; HBV

  10. Know HBV: What Every Asian and Pacific Islander Should Know About Hepatitis B and Liver Cancer

    Science.gov (United States)

    ... the skin or eyes) appear, it is often too late for treatment to be effective. » T ransmitted just like HIV 1. A mother-to-child infection For Asians, HBV is commonly transmitted from a chronically infected ...

  11. Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients

    Institute of Scientific and Technical Information of China (English)

    Timothée Noterdaeme; Luc Longrée; Christian Bataille; Arnaud Deroover; Anne Lamproye; Jean Delwaide; Yves Beguin; Pierre Honoré; Olivier Detry

    2011-01-01

    Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure. Liver transplantation (LT) currently remains the only definitive treatment option for such cases, but is generally denied to patients suffering from malignancy. Here, the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure arising from HBV reactivation induced by chemotherapy for advanced stage lymphoma. These 2 cases, and some other reports in the literature, may suggest that patients suffering from hematologic malignancies and terminal liver disease can be considered for LT if the prognosis of their hematologic malignancy is good.

  12. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDT protein chip technology

    Institute of Scientific and Technical Information of China (English)

    Xiao-Dong Zhu; Wei-Hua Zhang; Cheng-Lin Li; Yang Xu; Wei-Jiang Liang; Po Tien

    2004-01-01

    AIM: To find new serum biomarkers for liver cirrhosis (LC)in chronic carriers of hepatitis B virus (HBV).METHODS: Surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry was used to discover biomarkers for differentiating HBV induced LC from non-cirrhotic cohorts. A training population of 25 patients with HBV-induced LC, 20 patients with HCC, and 25 closely age-matched healthy men, was studied.RESULTS: Two biomarkers with Mr 7 772 and 3 933 were detected in sera of non-cirrhotic cohorts, but not in patients with HBV-induced LC. A sensitivity of 80% for all LC patients,a specificity of 81.8% for all non-cirrhotic cohorts and a positive predictive value of 75% for the study population were obtained.CONCLUSION: These two serum biomarkers for HBVinduced LC might be used for diagnosis and assessment of disease progression.

  13. Basis of HBV persistence and new treatment options.

    Science.gov (United States)

    Thursz, Mark

    2014-09-01

    The majority of the morbidity and mortality associated with hepatitis B virus infection is due to viral persistence and its consequences. The heterogeneity of outcomes from HBV infection suggests that both viral and host factors influence the development of chronic infection. Study of host genetic susceptibility has revealed a number of genes including MHC class II loci and cytokine receptors, which decrease the risk of persistence. On the viral side, the replication system is adapted to generate high levels of virions without stimulating the innate immune system. Secreted viral proteins (HBsAg and HBeAg) suppress innate responses through inhibition of TLR signaling, which leads to a weak adaptive immune response with an exhausted phenotype that is incapable of inducing viral elimination. However, even when the adaptive immune system begins to take effect after HBe seroconversion, the ability of the virus to mutate and evade T and B cell-mediated responses helps to sustain persistent infection. Understanding the mechanisms of persistence is important for the design of therapeutic strategies. Although there are currently no specific drugs that target the viral minichromosome (cccDNA), it is expected that in the future we will be able to use existing drugs more effectively to eliminate the infection. PMID:26201329

  14. The Dual Role of an ESCRT-0 Component HGS in HBV Transcription and Naked Capsid Secretion.

    Directory of Open Access Journals (Sweden)

    Shu-Fan Chou

    2015-10-01

    Full Text Available The Endosomal Sorting Complex Required for Transport (ESCRT is an important cellular machinery for the sorting and trafficking of ubiquitinated cargos. It is also known that ESCRT is required for the egress of a number of viruses. To investigate the relationship between ESCRT and hepatitis B virus (HBV, we conducted an siRNA screening of ESCRT components for their potential effect on HBV replication and virion release. We identified a number of ESCRT factors required for HBV replication, and focused our study here on HGS (HRS, hepatocyte growth factor-regulated tyrosine kinase substrate in the ESCRT-0 complex. Aberrant levels of HGS suppressed HBV transcription, replication and virion secretion. Hydrodynamic delivery of HGS in a mouse model significantly suppressed viral replication in the liver and virion secretion in the serum. Surprisingly, overexpression of HGS stimulated the release of HBV naked capsids, irrespective of their viral RNA, DNA, or empty contents. Mutant core protein (HBc 1-147 containing no arginine-rich domain (ARD failed to secrete empty virions with or without HGS. In contrast, empty naked capsids of HBc 1-147 could still be promoted for secretion by HGS. HGS exerted a strong positive effect on the secretion of naked capsids, at the expense of a reduced level of virions. The association between HGS and HBc appears to be ubiquitin-independent. Furthermore, HBc is preferentially co-localized with HGS near the cell periphery, instead of near the punctate endosomes in the cytoplasm. In summary, our work demonstrated the importance of an optimum level of HGS in HBV propagation. In addition to an effect on HBV transcription, HGS can diminish the pool size of intracellular nucleocapsids with ongoing genome maturation, probably in part by promoting the secretion of naked capsids. The secretion routes of HBV virions and naked capsids can be clearly distinguished based on the pleiotropic effect of HGS involved in the ESCRT-0 complex.

  15. Preparation and identification of 1.3 copies C-type HBV transgenic mice

    Directory of Open Access Journals (Sweden)

    Mei-juan CHEN

    2011-09-01

    Full Text Available Objective To prepare 1.3 copies C-type HBV transgenic mice for providing a better model for the prevention and treatment of hepatitis B.Methods The HBV transgenic mice were generated by microinjection of 1.3 copies C-type HBV genome into the pronucleus of FVB /N zygotes.PCR,ELISA,RT-PCR and immunohistochemistry were used to detect the integration,replication and expression of HBV gene in the transgenic mice.Results Tow thousand two hundred and eighty-two fertilized eggs were injected and a total of 2024 survived.The survival rate of injection was 88.7%.The injected eggs were transplanted into 72 pseudo pregnant female mice,among which 59 became pregnant.The pregnancy rate was 81.9%.One hundred and eighty-five F0 offsprings were produced with 19 positive mice as detected by PCR,and the positive rate was 10.3%.RT-PCR revealed that HBV DNA replication of 102-103 copies/ml existed in serum of 6 mice.Ninety-six F1 offsprings were produced,of which 33 were positive for HBV DNA replication as detected by PCR,the positive rate was 34.4%.RT-PCR showed that HBV DNA replication was observed in 10 mice with 102-103 copies/ml.Three mice were randomly chosen from each of F0 and F1 generations to detect the HBsAg expression in livers and kidneys by immunohistochemistry.The results showed that HBsAg expressed in both livers and kidneys,and it was stronger in kidneys than in livers.Conclusion The 1.3 copies C-type HBV gene can not only replicate and express in the transgenic mice produced,but it also can be transmitted to the next generation of these mice.

  16. Cortical signature of patients with HBV-related cirrhosis without overt hepatic encephalopathy: a morphometric analysis.

    Science.gov (United States)

    Wu, Xiu; Lv, Xiao-Fei; Zhang, Yu-Ling; Wu, Hua-Wang; Cai, Pei-Qiang; Qiu, Ying-Wei; Zhang, Xue-Lin; Jiang, Gui-Hua

    2015-01-01

    Previous studies have shown that patients with hepatitis B virus-related cirrhosis (HBV-RC) without overt hepatic encephalopathy (OHE) are associated with a varying degree of cognitive dysfunction. Several resting-state functional magnetic resonance imaging (fMRI) studies have been conducted to explore the neural correlates of such cognitive deficits, whereas little effort has been made to investigate the cortical integrity in cirrhotic patients without OHE. Here, using cortical thickness, surface area and local gyrification index (lGI), this study performed a comprehensive analysis on the cortical morphometry of patients with HBV-RC without OHE (HBV-RC-NOHE) vs. matched healthy controls. Compared with healthy controls, we found significantly increased cortical thickness in the bilateral lingual and parahippocampal gyrus, right posterior cingulate cortex, precuneus, peri-calcarine sulcus and fusiform gyrus in patient with HBV-RC-NOHE, which may closely relate to be the low-grade brain edema. Cortical gyrification analysis showed significantly increased lGI in the left superior and inferior parietal cortex as well as lateral occipital cortex, which was speculated to be associated with disruptions in white matter connectivity and sub-optimal intra-cortical organization. In addition, the mean cortical thickness/lGI of the regions with structural abnormalities was shown to be negatively correlated with psychometric hepatic encephalopathy score (PHES) of the patients with HBV-RC-NOHE. These morphological changes may serve as potential markers for the preclinical diagnosis and progression of HBV-RC-NOHE. PMID:26106307

  17. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.

    Science.gov (United States)

    Peng, Cheng; Lu, Mengji; Yang, Dongliang

    2015-10-01

    Hepatitis B virus (HBV) infection remains a major global health problem because current therapies rarely eliminate HBV infections to achieve a complete cure. A different treatment paradigm to effectively clear HBV infection and eradicate latent viral reservoirs is urgently required. In recent years, the development of a new RNA-guided gene-editing tool, the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) system, has greatly facilitated site-specific mutagenesis and represents a very promising potential therapeutic tool for diseases, including for eradication of invasive pathogens such as HBV. Here, we review recent advances in the use of CRISPR/Cas9, which is designed to target HBV specific DNA sequences to inhibit HBV replication and to induce viral genome mutation, in cell lines or animal models. Advantages, limitations and possible solutions, and proposed directions for future research are discussed to highlight the opportunities and challenges of CRISPR/Cas9 as a new, potentially curative therapy for chronic hepatitis B infection. PMID:26511989

  18. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV

    Institute of Scientific and Technical Information of China (English)

    Cheng; Peng; Mengji; Lu; Dongliang; Yang

    2015-01-01

    Hepatitis B virus(HBV) infection remains a major global health problem because current therapies rarely eliminate HBV infections to achieve a complete cure. A different treatment paradigm to effectively clear HBV infection and eradicate latent viral reservoirs is urgently required. In recent years, the development of a new RNA-guided gene-editing tool, the CRISPR/Cas9(clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) system, has greatly facilitated site-specific mutagenesis and represents a very promising potential therapeutic tool for diseases, including for eradication of invasive pathogens such as HBV. Here, we review recent advances in the use of CRISPR/Cas9, which is designed to target HBV specific DNA sequences to inhibit HBV replication and to induce viral genome mutation, in cell lines or animal models. Advantages, limitations and possible solutions, and proposed directions for future research are discussed to highlight the opportunities and challenges of CRISPR/Cas9 as a new, potentially curative therapy for chronic hepatitis B infection.

  19. HBV X Gene Transfection Upregulates IL-1β and IL-6 Gene Expression and Induces Rat Glomerular Mesangial Cell Proliferation

    Institute of Scientific and Technical Information of China (English)

    Hongzhu LU; Jianhua ZHOU

    2008-01-01

    The X gene of HBV encodes a 17-KD protein, termed HBx, which has been shown to function as a transcriptional trans-activator of a variety of viral and cellular promoter/enhancer elements. The aim of this study was to investigate the effect of HBx on gene expression of interleukin (IL)-1β and IL-6, and proliferation of rat mesangial cells in vitro. The X gene of HBV was amplified by PCR assay, and inserted into the eukaryotic expression vector pCI-neo. The structure of recombinant pCI-neo-X plasmid was proved by restrict endonuclease digestion and sequencing analysis. pCI-neo-X was transfected into cultured rat mesangial cell line in vitro via liposome. HBx expression in transfected mesangial cells was detected by Western blot. The IL-1β and IL-6 mRNA expression in those cells was assayed by semiquantitative RT-PCR. Mesangial cell proliferation was tested by MTT. The results showed that HBx was obviously expressed in cultured mesangial cell line at 36th and 48th h after transfection. The expression of IL-1β and IL-6 mRNA was simultaneously increased. The cell proliferation was also obvious at the same time. It was concluded that HBx gene transfection could induce IL-1β and IL-6 gene expression and mesangial cell proliferation. HBx may play a critical role in mesangial cell proliferation through upregulation of the IL-1β and IL-6 gene expression.

  20. ORIGINAL ARTICLE: Blood Donor’s Status of HIV, HBV, HCV and Syphilis in this Region of Marathwada, India

    Directory of Open Access Journals (Sweden)

    Rangrao H. Deshpande

    2012-07-01

    Full Text Available Aims & Objectives: Blood transfusion can cause the transmission of infections to recipients. This is an important mode of infection. The aim of study was to assess the prevalence of such type of infections among blood donors and to compare the seroprevalence of transfusion transmitted diseases in voluntary donors and replacement donors. Retrospective study of five years from Jan. 2007 to Dec. 2011 was done. This study was conducted at Blood bank, MIMSR Medical College Latur, Govt. Medical College, Latur and Bhalchandra Blood bank, Latur. Material & Methods: Total 10, 4925 donors were tested. Donors were screened for seroprevalence of HIV, HBC, HCV and Syphilis. Screening of HIV, HBV & HCV was done by ELISA method & Syphilis was screened by RPR type. Results: The comparison of seroprevalence of HIV, HBV, HCV & Syphilis in voluntary donors and replacement donors showed significant difference only for HIV in the years 2007, 2010, and 2011. Conclusion: The seroprevalence of transfusion transmitted diseases in the study is very low or negligible in voluntary donors as compared to replacement donors. There was a declining trend of seroprevalence for all the disease screened. But in our study the difference is not significant, which indicates that the selection of donors is of low quality. The selection of high quality voluntary donors should be achieved by creation of awareness by education of the prospective donor populations.

  1. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration

    Science.gov (United States)

    Hunt, Christine M; Beste, Lauren A; Lowy, Elliott; Suzuki, Ayako; Moylan, Cynthia A; Tillmann, Hans L; Ioannou, George N; Lim, Joseph K; Kelley, Michael J; Provenzale, Dawn

    2016-01-01

    AIM: To evaluate pretreatment hepatitis B virus (HBV) testing, vaccination, and antiviral treatment rates in Veterans Affairs patients receiving anti-CD20 Ab for quality improvement. METHODS: We performed a retrospective cohort study using a national repository of Veterans Health Administration (VHA) electronic health record data. We identified all patients receiving anti-CD20 Ab treatment (2002-2014). We ascertained patient demographics, laboratory results, HBV vaccination status (from vaccination records), pharmacy data, and vital status. The high risk period for HBV reactivation is during anti-CD20 Ab treatment and 12 mo follow up. Therefore, we analyzed those who were followed to death or for at least 12 mo after completing anti-CD20 Ab. Pretreatment serologic tests were used to categorize chronic HBV (hepatitis B surface antigen positive or HBsAg+), past HBV (HBsAg-, hepatitis B core antibody positive or HBcAb+), resolved HBV (HBsAg-, HBcAb+, hepatitis B surface antibody positive or HBsAb+), likely prior vaccination (isolated HBsAb+), HBV negative (HBsAg-, HBcAb-), or unknown. Acute hepatitis B was defined by the appearance of HBsAg+ in the high risk period in patients who were pretreatment HBV negative. We assessed HBV antiviral treatment and the incidence of hepatitis, liver failure, and death during the high risk period. Cumulative hepatitis, liver failure, and death after anti-CD20 Ab initiation were compared by HBV disease categories and differences compared using the χ2 test. Mean time to hepatitis peak alanine aminotransferase, liver failure, and death relative to anti-CD20 Ab administration and follow-up were also compared by HBV disease group. RESULTS: Among 19304 VHA patients who received anti-CD20 Ab, 10224 (53%) had pretreatment HBsAg testing during the study period, with 49% and 43% tested for HBsAg and HBcAb, respectively within 6 mo pretreatment in 2014. Of those tested, 2% (167/10224) had chronic HBV, 4% (326/7903) past HBV, 5% (427

  2. Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma.

    Directory of Open Access Journals (Sweden)

    Te-Sheng Chang

    Full Text Available The expression of cancer stemness is believed to reduce the efficacy of current therapies against hepatocellular carcinoma (HCC. Understanding of the stemness-regulating signaling pathways incurred by a specific etiology can facilitate the development of novel targets for individualized therapy against HCC. Niche environments, such as virus-induced inflammation, may play a crucial role. However, the mechanisms linking inflammation and stemness expression in HCC remain unclear. Here we demonstrated the distinct role of inflammatory mediators in expressions of stemness-related properties involving the pluripotent octamer-binding transcription factor 4 (OCT4 in cell migration and drug resistance of hepatitis B virus-related HCC (HBV-HCC. We observed positive immunorecognition for macrophage chemoattractant protein 1 (MCP-1/CD68 and OCT4/NANOG in HBV-HCC tissues. The inflammation-conditioned medium (inflamed-CM generated by lipopolysaccharide-stimulated U937 human leukemia cells significantly increased the mRNA and protein levels of OCT4/NANOG preferentially in HBV-active (HBV+HBsAg+ HCC cells. The inflamed-CM also increased the side population (SP cell percentage, green fluorescent protein (GFP-positive cell population, and luciferase activity of OCT4 promoter-GFP/luciferase in HBV-active HCC cells. Furthermore, the inflamed-CM upregulated the expressions of insulin-like growth factor-I (IGF-I/IGF-I receptor (IGF-IR and activated IGF-IR/Akt signaling in HBV-HCC. The IGF-IR phosphorylation inhibitor picropodophyllin (PPP suppressed inflamed-CM-induced OCT4 and NANOG levels in HBV+HBsAg+ Hep3B cells. Forced expression of OCT4 significantly increased the secondary sphere formation and cell migration, and reduced susceptibility of HBV-HCC cells to cisplatin, bleomycin, and doxorubicin. Taking together, our results show that niche inflammatory mediators play critical roles in inducing the expression of stemness-related properties involving IGF

  3. Pharmacokinetics of anti-HBV polyoxometalate in rats.

    Directory of Open Access Journals (Sweden)

    Juan Wang

    Full Text Available Polyoxometalates are non-nucleoside analogs that have been proven to exhibit broad-spectrum antiviral activity. In particular, Cs2K4Na[SiW9Nb3O40].H2O 1 shows low toxicity and high activity against HBV. The preclinical pharmacokinetics of Compound 1 in rats were characterized by establishing and applying inductively coupled plasma-mass spectrometry method to determine the concentration of W in plasma, urine, feces, bile and organ samples. The quantitative ICP-MS method demonstrated good sensitivity and application in the pharmacokinetics study of polyoxometalates. The pharmacokinetic behavior of Compound 1 after intravenous or oral administration fit a two-compartment model. Tmax ranges from 0.1 h to 3 h and the T1/2 of Compound 1 is between 20 h and 30 h. The absolute bioavailability of Compound 1 at 45, 180 and 720 mg/kg groups were 23.68%, 14.67% and 11.93%, respectively. The rates of plasma protein binding of Compound 1 at 9, 18 and 36 mg/ml of Compound 1 are 62.13±9.41%, 71.20±24.98% and 49.00±25.59%, respectively. Compound 1 was widely distributed throughout the body, and high levels of compound 1 were found in the kidney and liver. The level of Compound 1 in excretion was lower: 30% for urine, 0.28% for feces and 0.42% for bile, respectively. For elaborate pharmacokinetic characteristics to be fully understood, the metabolism of Compound 1 needs to be studied further.

  4. Prevalence of HBV in pregnant women from areas of different endemicity in Peru

    International Nuclear Information System (INIS)

    The present study was performed to estimate the prevalence of HBV in pregnant women (mean age among groups 25,0 ± 6,9) who live in areas of different endemicity, and located in the Department of Lima, Junin, Apurimac, and Ayacucho in Peru. All studies were carried out using radioimmunological techniques. In the Instituto Materno Perinatal in Lima, located in a low endemic area, 2086 pregnant women whose ages ranged between 14 and 44 years old were evaluated (for laboratory tests) at their first prenatal examination. A prevalence of 0,38% (HBsAg+), 0,38% (Ratio), and 3,18% (HBsAg+, anti-HBsAg+) was found, corresponding to 107 HBsAg+ pregnant women whose treated newborn would prevent the HBV chronic infection of approximate 21 newborn each year. 63% HBsAg+ pregnant women were born in Departments other than Lima. In the Hospital de Apoyo La Merced, located in Chanchamayo, Junin, which is a medium endemic area, 217 pregnant women whose ages ranged between 14 and 48 years old were evaluated. T he prevalence found in this hospital was of 1,38% (HBsAg+), 1,2% (Ratio), and 17,*% (HBsAg+, anti-HBs+). All positive HBsAg were negative for HBeAg. The projection of results corresponded to a total of 9 HbsAg+ pregnant women and 2 newborn preventive of chronic disease per year. In the Guillermo Diaz de la Vega Hospital in Abancay, Apurimac, located in a medium to high endemic area, 221 pregnant women whose ages ranged between 15 and 46 years old were evaluated. A prevalence of 1,36% (HBsAg+), 1,0% (Ratio), and 36.16% (HBsAg+, anti-HBs+) was found. All positive HBsAg were negative for HBeAg. Projected results corresponded to a total of 37 HBsAg+ pregnant carriers and 7 newborn preventive of chronic disease per year. The Hospital General de Huanta, in Ayacucho, located in a high endemicity area, presented a prevalence of 3,2% (HBsAg+), 1,9% (Ratio), and 76, 2% (HBsAg+, anti-HBs+) from 126 pregnant women evaluated with ages between 15 and 48 years old. These results gave a total

  5. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.

    Directory of Open Access Journals (Sweden)

    Edouard Tuaillon

    Full Text Available BACKGROUND: The decline in hepatitis B virus surface antigen (HBsAg may be an early predictor of the viral efficacy of Hepatitis B virus (HBV therapy. The HBsAg levels obtained by different immunoassays now need comparing and the relationships between levels of HBsAg and HBV DNA alongside HBsAg and genotype must be evaluated. METHODOLOGY/PRINCIPAL FINDINGS: HBsAg levels were compared among 80 patients using the Abbott Architect assay, a commercial immunoassay approved for HBsAg detection and quantitation, and three other assays derived from immunoassays approved for HBsAg detection (manufactured by Diasorin, Bio-Rad and Roche. Good correlation was found between the Abbot vs. Diasorin, Bio-Rad and Roche assays with narrow 95% limits of agreement and small mean differences: -0.06 to 0.11, -0.09 log(10 IU/mL; -0.57 to 0.64, -0.04 log(10 IU/mL; -0.09 to 0.45, -0.27 log(10 IU/mL, respectively. These agreements were not affected by genotypes A or D. HBsAg was weakly correlated with HBV DNA, whatever the HBsAg assay used: Abbott, ρ = 0.36 p = 0.001, Diasorin ρ = 0.34, p = 0.002; Bio-Rad ρ = 0.37, p<0.001; or Roche ρ = 0.41, p<0.001. This relationship between levels of HBsAg and HBV DNA seemed to depend on genotypes. Whereas HBsAg (Abbott assay tended to correlate with HBV DNA for genotype A (ρ = 0.44, p = 0.02, no such correlation was significant for genotypes D (ρ = 0.29, p = 0.15. CONCLUSION/SIGNIFICANCE: The quantitation of HBsAg in routine clinical samples is comparable between the reference assay and the adapted assays with acceptable accuracy limits, low levels of variability and minimum discrepancy. While HBsAg quantitation is not affected by HBV genotype, the observed association between levels of HBsAg and HBV DNA seems genotype dependent.

  6. Detection of hepatitis G virus-RNA (HGV-RNA) in serum of patients with HBV hepatitis

    International Nuclear Information System (INIS)

    Objective: To investigate the incidence of HGV infection in patients with HBV hepatitis and any possible adverse effect of the superinfection. Methods: Serum HGV-RNA expression was examined with PCR in 1104 patients with HBV hepatitis and 251 controls. Results: The positive rate of HGV-RNA in HBV hepatitis patients was not significantly different from that in controls (3.17% vs 2.79%, P>0.05). Among the patients with HBV hepatitis, HGV-RNA positive rate in patients with chronic hepatitis was significantly higher than that in patients with acute hepatitis (4.78% vs 0.96, P<0.05). Conclusion: HGV infection might be presented as non-symptomatic carriers or other mild form of hepatitis. The incidence of HGV infection was not especially high in HBV hepatitis patients, however, concomitant HGV and HBV infection might predispose to development of chronicity. (authors)

  7. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.

    Science.gov (United States)

    Seeger, Christoph; Sohn, Ji A

    2016-08-01

    Hepatitis B virus (HBV) causes chronic infections that cannot yet be cured. The virus persists in infected hepatocytes, because covalently closed circular DNA (cccDNA), the template for the transcription of viral RNAs, is stable in nondividing cells. Antiviral therapies with nucleoside analogues inhibit HBV DNA synthesis in capsids in the cytoplasm of infected hepatocytes, but do not destroy nuclear cccDNA. Because over 200 million people are still infected, a cure for chronic hepatitis B (CHB) has become one of the major challenges in antiviral therapy. As a first step toward the development of curative therapies, we previously demonstrated that the CRISPR/Cas9 system can be used to functionally inactivate cccDNA derived from infectious HBV. Moreover, some evidence suggests that certain cytokines might induce an APOBEC-mediated cascade leading to the destruction of cccDNA. In this report we investigated whether a combination of the two mechanisms could act synergistically to inactivate cccDNA. Using next generation sequencing (NGS), we determined the complete spectrum of mutations in cccDNA following Cas9 cleavage and repair by nonhomologous end joining (NHEJ). We found that over 90% of HBV DNA was cleaved by Cas9. In addition our results showed that editing of HBV DNA after Cas9 cleavage is at least 15,000 times more efficient that APOBEC-mediated cytosine deamination following treatment of infected cells with interferon alpha (IFNα). We also found that a previously used method to detect cytosine deaminated DNA, termed 3D-PCR, overestimates the amount and frequency of edited HBV DNA. Taken together, our results demonstrated that the CRISPR/Cas9 system is so far the best method to functionally inactivate HBV cccDNA and provide a cure for CHB. PMID:27203444

  8. How immigration can change the prevalence of HBV infection in an urban area of Northern Italy

    Directory of Open Access Journals (Sweden)

    Massimo De Paschale

    2011-11-01

    Full Text Available The introduction of HBV vaccination in Italy has led to a decline in new HBV infections. Increasing immigration over recent years suggests a change in short-term epidemiology of HBV. The aim of this study was to assess the prevalence of HBV infection in the general population living in the catchment area of Legnano Hospital (Northern Italy. In the period 2007-2008, 22,758 inpatients and outpatients were examined for Hepatitis B surface antigen (HBsAg, of whom 1,654 (7.3% were of foreign origin. Of the 488 patients who were positive for HBsAg (2.1%, 381 (1.8% were Italian and 107 (6.5% were born in other countries. In terms of age, the prevalence of HBsAg was significantly higher among non- Italians in every age group (other than those aged >60 and <11 years, and in many of the selected subgroups: the inpatients of some departments (35.4% vs 17.2%, pregnant women (5.3% vs 0.3%, blood donors (4.7% vs 0.1%, and hospital staff (6.4% vs 1.3%. Non- Italians were affected by 16.7% of acute infections and 24.3% of chronic infections; they also accounted for 42.6% of subjects with carrier state, 16.0% of patients with chronic hepatitis, and 12.2% of patients with cirrhosis. In our area, the overall prevalence of HBsAg among Italians is less than 2% (as expected following the introduction of HBV vaccination, but it is significantly higher among patients from areas highly endemic for HBV infection who represent a new reservoir for HBV infection.

  9. Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice.

    Science.gov (United States)

    Xu, Long; Yin, Wenwei; Sun, Rui; Wei, Haiming; Tian, Zhigang

    2013-10-15

    The liver plays a critical role in inducing systemic immune tolerance, for example, during limiting hypersensitivity to food allergy and in rendering acceptance of allotransplant or even hepatotropic pathogens. We investigated the unknown mechanisms of liver tolerance by using an established hepatitis B virus (HBV)-carrier mouse model, and found that these mice exhibited an antigen-specific tolerance toward peripheral HBsAg vaccination, showing unenlarged draining lymph node (DLN), lower number of germinal centers (GC), and inactivation of GC B cells and follicular T helper (Tfh) cells. Both in vivo and in vitro immune responses toward HBsAg were suppressed by mononuclear cells from HBV-carrier mice, which were CD4(+) Foxp3(-) type 1 regulatory T (Tr1)-like cells producing IL-10. Using recipient Rag1(-/-) mice, hepatic Tr1-like cells from day 7 of HBV-persistent mice acquired the ability to inhibit anti-HBV immunity 3 d earlier than splenic Tr1-like cells, implying that hepatic Tr1-like cells were generated before those in spleen. Kupffer cell depletion or IL-10 deficiency led to impairment of Tr1-like cell generation, along with breaking HBV persistence. The purified EGFP(+)CD4(+) T cells (containing Tr1-like cells) from HBV-carrier mice trafficked in higher numbers to DLN in recipient mice after HBsAg vaccination, and subsequently inactivated both Tfh cells and GC B cells via secreting IL-10, resulting in impaired GC formation and anti-HB antibody production. Thus, our results indicate Tr1-like cells migrate from the liver to the DLN and inhibit peripheral anti-HBV immunity by negatively regulating GC B cells and Tfh cells. PMID:24089450

  10. HBVPathDB: A database of HBV infection-related molecular interaction network

    Institute of Scientific and Technical Information of China (English)

    Yi Zhang; Xiao-Chen Bo; Jing Yang; Sheng-Qi Wang

    2005-01-01

    AIM: To describe molecules or genes interaction between hepatitis B viruses (HBV) and host, for understanding how virus' and host's genes and molecules are networked to form a biological system and for perceiving mechanism of HBV infection.METHODS: The knowledge of HBV infection-related reactions was organized into various kinds of pathways with carefully drawn graphs in HBVPathDB. Pathway information is stored with relational database management system (DBMS), which is currently the most efficient way to manage large amounts of data and query is implemented with powerful Structured Query Language (SQL). The search engine is written using Personal Home Page (PHP) with SQL embedded and web retrieval interface is developed for searching with Hypertext Markup Language (HTML).RESULTS: We present the first version of HBVPathDB,which is a HBV infection-related molecular interaction network database composed of 306 pathways with 1050molecules involved. With carefully drawn graphs, pathway information stored in HBVPathDB can be browsed in an intuitive way. We develop an easy-to-use interface for flexible accesses to the details of database. Convenient software is implemented to query and browse the pathway information of HBVPathDB. Four search page layout options-category search, gene search, description search,unitized search-are supported by the search engine ofthe database. The database is freely available at http://www.bio-inf, net/HBVPathDB/HBV/.CONCLUSION: The conventional perspective HBVPathDB have already contained a considerable amount of pathway information with HBV infection related, which is suitable for in-depth analysis of molecular interaction network of virus and host. HBVPathDB integrates pathway data-sets with convenient software for query, browsing,visualization, that provides users more opportunity to identify regulatory key molecules as potential drug targets and to explore the possible mechanism of HBV infection based on gene expression datasets.

  11. KIR : HLA association with clinical manifestations of HBV infection in Madurai, south India

    Indian Academy of Sciences (India)

    Narayanan Kalyanaraman; Lakshmikanthan Thayumanavan; Mariakuttikan Jayalakshmi

    2016-03-01

    The antiviral action of natural killer (NK) cells is regulated by a wide repertoire of germ-line encoded membrane receptors which recognize the expression of certain self-molecules on target cells. Among the receptors, killer cell immunoglobulinlikereceptor (KIR) which recognizes the expression of human leukocyte antigen (HLA) class I has a predominant role in regulating the effector functions of NK cells, particularly in viral infections. We studied a total of 128 hepatitis B virus (HBV)patients (15 acute, 43 asymptomatic, 27 chronic and 43 with other liver diseases) while attending the Department of Medical Gastroenterology, Government Rajaji Hospital, Madurai, India, and 128 ethnic matched control to find the association between the KIR : HLA genes and differential manifestations of HBV. KIR and its ligand HLA polymorphism were identified by DNAPCR methods. The activatory receptor KIR-2DS1 was significantly elevated in various disease categories, namely asymptomatic, chronic and other HBV, except acute HBV infection. Whereas, KIR 2DS3 in acute and chronic patients and KIR 2DS5 and 3DS1 in asymptomatic individuals. Among various KIR–HLA combinations, homozygous 2DS2:C1 and individuals with 3DSI:BW4 (OR = 3.23, CI = 1.55–6.7, Pc = 0.02) are associated with HBV asymptomatism, while most of the two domain inhibitory receptors with their ligands showed significant risk in other liver diseases. Further, KIR3DL1 : HLA Bw4Iso80 (OR = 3.89, 95% CI = 1.58–9.55, Pc = 0.004) is related with higher risk for asymptomatic infection when compared with chronic HBV. Thus, the select KIR : HLA alleles and combinations seem to direct the NK cell activities and immune response in different directions resulting in varied symptoms and manifestations in the subgroups of HBV-infected patientsstudied.

  12. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial.

    Science.gov (United States)

    Pande, C; Sarin, S K; Patra, S; Kumar, A; Mishra, S; Srivastava, S; Bhutia, K; Gupta, E; Mukhopadhyay, C K; Dutta, A K; Trivedi, S S

    2013-11-01

    Vertical transmission of Hepatitis B virus HBV can result in a state of chronic HBV infection and its complications. HBV vaccination with or without hepatitis B immunoglobulin (HBIG) prevents transmission of overt infection to the babies. However, whether it also prevents occult HBV infection in babies is not known. Consecutive pregnant women of any gestation found to be HBsAg positive were followed till delivery, and their babies were included in the study. Immediately after delivery, babies were randomized to receive either HBIG or placebo in addition to recombinant HBV vaccine (at 0, 6, 10 and 14 weeks). The primary end-point of the study, assessed at 18 weeks of age, was remaining free of any HBV infection (either overt or occult) plus the development of adequate immune response to vaccine. The babies were further followed up for a median of 2 years of age to determine their eventual outcome. Risk factors for HBV transmission and for poor immune response in babies were studied. Of the 283 eligible babies, 259 were included in the trial and randomized to receive either HBIG (n=128) or placebo (n=131) in addition to recombinant HBV vaccine. Of the 222 of 259 (86%) babies who completed 18 weeks of follow-up, only 62/222 (28%) reached primary end-point. Of the remaining, 6/222 (3%) developed overt HBV infection, 142/222 (64%) developed occult HBV infection, and 12/222 (5%) had no HBV infection but had poor immune response. All 6 overt infections occurred in the placebo group (P=0.030), while occult HBV infections were more common in the HBIG group (76/106 [72%] vs. 66/116 [57%]; P=0.025). This may be due to the immune pressure of HBIG. There was no significant difference between the two groups in frequency of babies developing poor immune response or those achieving primary end-point. The final outcome of these babies at 24 months of age was as follows: overt HBV infection 4%, occult HBV infection 42%, no HBV infection but poor immune response 8% and no HBV

  13. Genotyping the hepatitis B virus with a fragment of the HBV DNA polymerase gene in Shenyang, China

    OpenAIRE

    Juan Feng; Ding Yang; Ma Ying; Dou Xiao

    2011-01-01

    Abstract The hepatitis B virus (HBV) has been classified into eight genotypes (A-H) based on intergenotypic divergence of at least 8% in the complete nucleotide sequence or more than 4% in the S gene. To facilitate the investigation of the relationship between the efficacy of drug treatment and the mutation with specific genotype of HBV, we have established a new genotyping strategy based on a fragment of the HBV DNA polymerase gene. Pairwise sequence and phylogenetic analyses were performed ...

  14. Seroprevalences of HBV, HCV and HIV among Children who examined Before Elective Surgery in Mardin province

    Directory of Open Access Journals (Sweden)

    Tekin A et al.

    2011-10-01

    Full Text Available Objectives: The aim of this study was to investigate the seroprevalence of hepatitis B virus (HBV, hepatitis C virus (HCV and human immunodeficiency virus (HIV among children who examined before elective surgery in Mardin province. Materials and Methods: Between 01 November 2008 and 30 April 2010, a total of 556 patients aged 0–16 years, who planned to be operated, were investigated for viral hepatitis seroprevalences in the Mardin Women and Pediatrics Hospital. Children’s blood samples were tested for hepatitis B surface antigen (HBsAg, hepatitis B surface antibody (anti-HBs, HCV antibody (anti-HCV and HIV antibody (anti-HIV markers by chemiluminescent immunoassay with Advia Centaur (Siemens autoanalyser. Results: A total of 556 children (441 boys, 115 girls age under 16 years who planned to be underwent elective surgery were included. We found positive HBsAg and negative anti-HBs in 3 patients (0.5%; Negative HBsAg and positive anti-HBs were found in 473 children (85.1%; Negative HBsAg and negative anti-HBs were observed in 80 children (14.4%. None of the patients had positive HCV and HIV antibody. Conclusion: HBsAg positivity rate was lower and anti-HBs positivity rate was higher than expected levels. This study indicated that vaccination was successful in our region.

  15. Non-association of IL-12 +1188 and IFN-γ +874 polymorphisms with cytokines serum level in occult HBV infected patients

    Directory of Open Access Journals (Sweden)

    Mohammad K Arababadi

    2011-01-01

    Full Text Available Background/Aim: Occult hepatitis B infection (OBI is identified as a form of hepatitis in which despite the absence of detectable HBsAg, HBV-DNA is observed in peripheral blood of patients. The main aim of this study has been to investigate the association between polymorphisms in +874 of IFN-γ and +1188 of IL-12 with their serum level in patients suffering from OBI. Materials and Methods: In this experimental study, plasma samples of 3700 blood donors were tested for the presence of hepatitis B surface antigen (HBsAg and anti-HBc by ELISA. The HBsAg - /anti-HBc + samples were selected and screened for HBV-DNA by PCR. HBV-DNA positive samples were assigned as OBI cases and ARMS-PCR techniques were performed to examine the two known polymorphisms within IL-12 and IFN-γ. In addition, the serum levels of IL-12 and IFN-γ were also determined by ELISA. Results: Results of this study demonstrated that, 352 (9.5% out of 3700 blood samples were HBsAg - /anti-HBc + and HBV-DNA was detected in 57/352 (16.1% of HBsAg - /anti-HBc + samples. Our results showed that groups showed significant difference in CC allele of +1188 region of IL-12 and no difference was observed in the other evaluated genes. Our results also showed that the alleles of +1188 region of IL-12 and alleles of +874 of IFN-γ were also not associated with serum level of cytokines. Conclusion: According to the results of this study, it may be concluded that the polymorphisms in +1188 region of IL-12 and +874 region of IFN-γ would not affect the expression of both cytokines at serum level in OBI patients.

  16. The Anti-Hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-Viremia SCID Mice

    OpenAIRE

    Le-Mei Hung; Yiu-Kay Lai; Thomas Ta-Tung Yuan; Kai-Ling Huang; Jia-Ming Chang

    2010-01-01

    Boehmeria nivea extract (BNE) is widely used in southern Taiwan as a folk medicine for hepato-protection and hepatitis treatment. In previous studies, we demonstrated that BNE could reduce the supernatant hepatitis B virus (HBV) DNA in HBV-producing HepG2 2.2.15 cells. In the present study, we established an animal model of HBV viremia and used it to validate the efficacy of BNE in vivo. In this animal model, serum HBV DNA and HBsAg were elevated in accordance with tumor growth. To evaluate t...

  17. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients

    Institute of Scientific and Technical Information of China (English)

    Hai-Ying Lu; Zhong-Hou Han; Yong Chen; Li-Wei Zhuang; Yan-Yan Yu; Hadad Ivan; Chong-Wen Si; Zheng Zeng; Jun Li; Dong-Ming Hou; Xin-Yue Chen

    2007-01-01

    AIM:To evaluate the effect of antiviral agents on intrahepatic HBV DNA in HBeAg-positive chronic hepatitis B patients.METHODS: Seventy-one patients received treatment with lamivudine, interferon alpha (IFN-α2b) or sequential therapy with lamivudine-IFN-α2b for 48 wk. All subjects were followed up for 24 wk. Serum and intrahepatic HBV DNA were measured quantitatively by PCR. HBV genotypes were analyzed by PCR-RFLP.RESULTS: At the end of treatment, the intrahepatic HBV DNA level in 71 patients decreased from a mean of (6.1 ± 1.0) log10 to (4.9 ± 1.4) log10. Further, a larger decrease was seen in the intrahepatic HBV DNA level in patients with HBeAg seroconversion. Intrahepatic HBV DNA level (before and after treatment) was not significantly affected by the patients'HBV genotype, or by the probability of virological flare after treatment.CONCLUSION: Intrahepatic HBV DNA can be effectively lowered by antiviral agents and is a significant marker for monitoring antivirus treatment. Low intrahepatic HBV DNA level may achieve better efficacy of antivirus treatment.

  18. Correlation analysis between the load levels of paternal semen HBV-DNA and vertical transmission of HBV from father to infant%父亲精液HBV-D NA载量与HBV父婴垂直传播的相关性分析

    Institute of Scientific and Technical Information of China (English)

    陈顺萍; 张荣莲; 任坤海; 王梅颖

    2014-01-01

    Aim:To explore the impact of the load levels of paternal semen HBV-DNA on vertical transmission of HBV from HBsAg-positive father to infant.Methods:52 families of pregnant women with negative HBsAg and HBV-DNA and husbands with positive,serum HBsAg were selected.Clinical data and blood samples of the parents and their newborns、semen samples of the husbands were collected.Ser-um HBVM and the load levels of paternal blood and semen HBV-DNA were determined.In case-control study,based on the results of neonatal cord blood HBV-DNA detection,1 1 newborns with cord blood posi-tive HBV-DNA were selected as subiects,and 41 newborns with negative HBV-DNA as controls.Results:①The positive rate of neonatal cord blood HBV-DNA was found to be 21.2%(11/52),and that of se-men HBV-DNA was 26.9%(14/52).②The incidence of vertical transmission of HBV in infants with paternal positive semen HBV-DNA was found significantly higher than that in infants with paternal nega-tive semen HBV-DNA(P<0.01).③There was a positive rank correlation between semen and serum of HBV-DNA load levels,while the load levels of semen HBV-DNA was lower than that of serum HBV-DNA load levels.④The analysis of ROC curve showed that the prediction accuracy of semen HBV-DNA in the occurrence of vertical transmission were more accurate than that based on serum HBV-DNA load.Con-clusion:Paternal positive semen HBV-DNA is one of the risk fators for vertical transmission of HBV;re-ducing HBV-DNA load levels in paternal blood and semen before pregnancy may be a way to block father-fetal transmisson of HBV.%目的:探讨乙肝表面抗原(HBsAg)阳性父亲精液乙型肝炎病毒脱氧核糖核酸(HBV-DNA)载量对其新生儿发生HBV父婴垂直传播的影响,以期寻找阻断HBV父婴垂直传播的有效方法.方法:在知情同意的原则,以丈夫血清HBsAg阳性、孕母HBsAg及HBV-DNA均阴性的52个家庭作为研究对象,收集父母及其新生儿的相关资料及血液标

  19. Abstract efficacy of combined vaccine for the prevention of HBV transmission in highly viremic HBeAg+ mothers and the HBV markers' dynamic change of babies in follow-up%乙型肝炎病毒e抗原阳性孕妇所生婴儿联合免疫接种后乙型肝炎病毒血清学标志物的动态变化

    Institute of Scientific and Technical Information of China (English)

    江红秀; 韩国荣; 王翠敏; 岳欣; 王根菊

    2011-01-01

    followup.Methods HBeAg + mothers with HBV DNA≥1.0×6log10 copies/ml were enrolled and their babies were followed up until 12 months old.The infants received HBIG 200 IU IM in 24 hrs and on day 15,and 20 μg recombinant anti-HBV vaccine at 0,land 6months.The HBV markers and HBV DNA were tested at birth day,and 1,7,12 months after birth respectively.The vertical transmission rate at birth and intrauterine infection rate,the HBsAb positive rate and the HBV markers' dynamic changes during follow up were evaluated.Results (1) 29 out of 127 infants with HBsAg (+) at birth,11 of which were HBV DNA (+),HBV perinatal transmission rate was 22.83%.2 infants' HBsAg were positive at monthl and became negative at month 7 and 10 infants were still HBsAg (+) and HBV DNA (+).HBV intrauterine infection rate was 7.87%.(2) The positive rate of HBeAg and HBcAb in uninfected infants were 96.58% and 98.29% respectively,which declined gradually to undetectable level after immunization.No infants were HBeAb (+).(3) Infants uninfected produced effective HBsAb after vaccination.The level of HBsAb elevated gradually,and the level of HBeAg decreased quickly even to undetectable.Conclusion The combination vaccination of 200 IU HBIG with 20 μg recombinant anti-HBV vaccine in the Infants delivered by HBeAg + and highly viremic mothers reduced obviously the rate of perinatal transmission of HBV,enhanced largely the production of antibody against HBV surface antigen and dropped the maternal HBeAg and HBcAb in infants or even to negative.

  20. Prevalence of occult HBV infection in haemodialysis patients with chronic HCV

    Institute of Scientific and Technical Information of China (English)

    Vedat Goral; Hamza Ozkul; Selahattin Tekes; Dede Sit; Ali Kemal Kadiroglu

    2006-01-01

    AIM: To study the prevalence and clinical effects of occult HBV infection in haemodialysis patients with chronic HCV.METHODS: Fifty chronic hemodialysis patients with negative HbsAg, and positive anti-HCV were included in the study. These patients were divided into two groups:HCV-RNA positive and HCV-RNA negative, based on the results of HCV-RNA PCR. HBV-DNA was studied using the PCR method in both groups.RESULTS: None of the 22 HCV-RNA positive patients and 28 HCV-RNA negative patients revealed HBV-DNA in serum by PCR method. The average age was 47.2 ± 17.0 in the HCV-RNA positive group and 39.6 ± 15.6 in the HCV-RNA negative group.CONCLUSION: The prevalence of occult HBV infection is not high in haemodialysis patients with chronic HCV in our region. This result of our study has to be evaluated in consideration of the interaction between HBsAg positivity (8%-10%) and frequency of HBV mutants in our region.

  1. Quantifying anti-HBV effect of targeted ribonuclease by real-time fluorescent PCR

    Institute of Scientific and Technical Information of China (English)

    Jun Liu; Ying-Hui Li; Jin Ding; Wei-Dong Gong; Cai-Fang Xue; Ya Zhao; Yu-Xiao Huang

    2004-01-01

    AIM: To quantify the inhibition of HBV replication by targeted ribonuclease by using real-time fluorescent PCR.METHODS: Targeted ribonuclease was introduced into 2.2.15cells by liposome-mediated transfection or HIV-TAT mediated protein transduction. Forty-eight hours after the transfection and 24 h after the transduction, supernatants of 2.2.15 cells were collected and HBV DNA in the supernatants was quantified by real-time fluorescent PCR with a commercial kit.RESULTS: HBV DNA concentrations in the supernatants of2.2.15 cells transfected or transducted with targeted ribonuclease were 4.9±2.4×108 copies/L and 8.3±4.0×108copies/L, respectively. Compared with controls, transfection or transduction of targeted ribonuclease reduced HBV DNA concentration in the supernatants of 2.2.15 cells by 90.4%and 90.1%, respectively (P<0.05).CONCLUSION: Targeted ribonuclease can inhibit HBV replication in 2.2.15 cells.

  2. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma.

    Directory of Open Access Journals (Sweden)

    Vinod Kumar

    Full Text Available MHC class I polypeptide-related chain A (MICA molecule is induced in response to viral infection and various types of stress. We recently reported that a single nucleotide polymorphism (SNP rs2596542 located in the MICA promoter region was significantly associated with the risk for hepatitis C virus (HCV-induced hepatocellular carcinoma (HCC and also with serum levels of soluble MICA (sMICA. In this study, we focused on the possible involvement of MICA in liver carcinogenesis related to hepatitis B virus (HBV infection and examined correlation between the MICA polymorphism and the serum sMICA levels in HBV-induced HCC patients. The genetic association analysis revealed a nominal association with an SNP rs2596542; a G allele was considered to increase the risk of HBV-induced HCC (P = 0.029 with odds ratio of 1.19. We also found a significant elevation of sMICA in HBV-induced HCC cases. Moreover, a G allele of SNP rs2596542 was significantly associated with increased sMICA levels (P = 0.009. Interestingly, HCC patients with the high serum level of sMICA (>5 pg/ml exhibited poorer prognosis than those with the low serum level of sMICA (≤5 pg/ml (P = 0.008. Thus, our results highlight the importance of MICA genetic variations and the significance of sMICA as a predictive biomarker for HBV-induced HCC.

  3. HLA-DRB多态性与HBV感染的相关性研究%The correlation between HLA-DRB polymorphism and HBV infection

    Institute of Scientific and Technical Information of China (English)

    邢文斌; 郭晓楠; 徐慧宁

    2015-01-01

    Objective To analyze the HBV infection status and their HLA-DRB polymorphism among male patients with chronic hepatitis B, meanwhile their spouses and children were collected, to identify the correlation between HLA-DRB and HBV. Methods The serum markers of hepatitis B were tested by ELISA, different HLA-DRB1 allelic fragments in the patients with HBV and their spouses and children were ampliifed by ampliifcation, and the gene fragments were separated by agar gel electrophoresis, UV transmittance reflectance analyzer determine the type of HLA-DRB1. Results The patients with chronic hepatitis B and HBV carriers carrying HLA-DRB1*0201, 0301 genes were signiifcantly higher than those of healthy control group. The frequency of HLA-DRB1*1301 allele in healthy control group were higher than those in HBV patients and carriers. There was no significant difference between the recovery group and healthy control group with HLA-DRB1*0201, 0301, 0701 and 1301 alleles. The frequency of HLA-DRB1*0201, 0301, 0701 and 1301 alleles between the patients with chronic hepatitis B and HBV carriers were no significant difference. The frequency of HLA-DRB1*0201, 0301 and 0701 alleles in the hepatitis group was higher, and HLA-DRB1*1301 allele in recovery group was higher. Conclusions HLA-DRB1*0701, 0301 and 0201 alleles were related to HBV chronic infection, and HLA-DRB1*1301 allele was related to the clearance of HBV.%目的:通过对慢性乙型肝炎男性患者的配偶和子女HBV感染状况及其HLA-DRB多态性分析,揭示HLA-DRB与HBV感染的相关性。方法采用ELISA方法筛查HBV血清标志物,采用PCR/SSP技术扩增HBV感染者及易感人群HLA-DRB1不同位点等位基因片段,琼脂凝胶电泳分离基因片段,紫外透射反射分析仪判定HLA-DRB1型别。结果慢性乙型肝炎患者及HBV携带者携带HLA-DRB1*0201、0301基因显著高于健康对照组;HLA-DRB1*1301在健康对照组的携带率显著高于慢性乙型肝炎患

  4. Asymmetric PCR method in generation of HBV ssDNA for pyrosequencing

    Institute of Scientific and Technical Information of China (English)

    Nian-cai Peng; Chun-lin Wang; Li-li Zhang; Mao-li Lu; Zhen-xi Zhang

    2009-01-01

    Objective To explore the optimal primer ratio and concentration of asymmetric polymerase chain reaction (A-PCR) in producing hepatitis B virus (HBV) single-stranded DNA (ssDNA) for pyrosequencing. Methods A-PCR was carried out to generate HBV ssDNA with forward to reverse primers of different ratios (50 : 1, 100 : 1) and concentrations (13. 0 pmol/25μL and 0.14 pmol/25μL, 19. 5 pmol/25μL and 0. 21 pmol/25μL), and the product yield and quality were compared respectively. Results The forward to reverse primer ratio of 50 : 1 provided better yield and concentration of 19. 5 pmol/25μL and 0. 21 pmol//25μL generated a clearer band. Conclusion A simple and feasible method to produce HBV ssDNA for pyrosequencing in batch is established.

  5. Age-dependent immune events during HBV infection from birth to adulthood: an alternative interpretation

    Directory of Open Access Journals (Sweden)

    Antonio eBertoletti

    2014-09-01

    Full Text Available Immune responses change during the life of an individual. While this concept has been well accepted for adaptive immunity, only recently it is becoming clear that the innate immune responses also acquire distinct features in different phases of life. We believe that this concept can offer a different interpretation of the pathological manifestations that can be observed in HBV-infected subjects during the patient’s life. Here, we will review the age-related immunopathological features of HBV infection and discuss how the different virological and clinical manifestations might be linked to the developmental pathway of the immune system from newborns to adults. We will discuss how the age of patients can affect the degree of inflammatory responses, but not the levels of antiviral specific immunity. We then propose that the different clinical manifestations occurring during the natural history of HBV infection are related to the host ability to trigger an inflammatory immune response.

  6. Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma

    Directory of Open Access Journals (Sweden)

    Yong-dong Niu

    2011-08-01

    Full Text Available Farnesoid X receptor (FXR, also termed nuclear receptor NR1H4 is critically involved in the regulation of nascent bile formation and bile acid enterohepatic circulation. FXR and bile acids have been shown to play roles in liver regeneration and inflammatory responses. There is increasing evidence suggesting that FXR and the FXR signaling pathway are involved in the pathophysiology of a wide range of liver diseases, such as viral hepatitis, cirrhosis, and hepatocellular carcinoma (HCC. Here we discuss the latest discoveries of FXR functions with relevance to bile acid metabolism and HBV-associated HCC. More specifically, the goal of this review is to discuss the roles of FXR and bile acids in regulating HBV replication and how disregulation of the FXR-bile acid signaling pathway is involved in HBV-associated hepatocarcinogenesis.

  7. Immune memory responses to HBV vaccine 13-18 years after primary vaccination.

    Science.gov (United States)

    Hou, L; Li, W; Wei, X; Zhou, Y; Zhuo, Y; Wu, H; Shen, B

    2015-01-01

    The aim of this study was to evaluate the immune memory response 13-18 years after an hepatitis B virus (HBV) vaccine by performing a specific in vitro stimulation experiment. Thirty healthy volunteers who had been inoculated 13-18 years ago with the HBV vaccine were collected from the physical examination center. Peripheral blood mononuclear cells were stimulated with 50 ng/mL recombinant HBsAg. An ELISA kit was used for the detection of antibodies that were produced by these cells in vitro. It was found that even 13-18 years after inoculation with the HBV vaccine, an anamnestic antibody response still existed, and was not correlated with the serum antibody levels (r = -0.177, P = 0.377). In conclusion, our data showed that the individuals after inoculation, including those with anti-HBs B cells. PMID:26345774

  8. HBV and HIV co-infection: Impact on liver pathobiology andtherapeutic approaches

    Institute of Scientific and Technical Information of China (English)

    Mohammad Khalid Parvez

    2015-01-01

    The consequences of hepatitis B virus (HBV) andhuman immunodeficiency virus (HIV) co-infection onprogression of severe liver diseases is a serious publichealth issue, worldwide. In the co-infection cases,about 90% of HIV-infected population is seropositivefor HBV where approximately 5%-40% individuals arechronically infected. In HIV co-infected individuals, liverrelatedmortality is estimated over 17 times higher thanthose with HBV mono-infection. The spectrum of HIVinducedliver diseases includes hepatitis, steatohepatitis,endothelialitis, necrosis, granulomatosis, cirrhosis andcarcinoma. Moreover, HIV co-infection significantlyalters the natural history of hepatitis B, and thereforecomplicates the disease management. Though severalstudies have demonstrated impact of HIV proteins onhepatocyte biology, only a few data is available oninteractions between HBV and HIV proteins. Thus,the clinical spectrum as well as the complexity of theco-infection offers challenging fronts to study theunderlying molecular mechanisms, and to designeffective therapeutic strategies.

  9. Baseline characteristics of HIV & hepatitis B virus (HIV/HBV) co-infected patients from Kolkata, India

    Science.gov (United States)

    Sarkar, Jayeeta; Saha, Debraj; Bandyopadhyay, Bhaswati; Saha, Bibhuti; Kedia, Deepika; Guha Mazumder, D.N.; Chakravarty, Runu; Guha, Subhasish Kamal

    2016-01-01

    Background & objectives: Hepatitis B virus (HBV) and HIV co-infection has variable prevalence worldwide. In comparison to HBV mono-infection, the course of chronic HBV infection is accelerated in HIV/HBV co-infected patients. The present study was carried out to analyse the baseline characteristics (clinical, biochemical, serological and virological) of treatment naïve HIV/HBV co-infected and HIV mono-infected patients. Methods: Between July 2011 and January 2013, a total number of 1331 HIV-seropositive treatment naïve individuals, enrolled in the ART Centre of Calcutta School of Tropical Medicine, Kolkata, India, were screened for hepatitis B surface antigen (HBsAg). A total of 1253 HIV mono-infected and 78 HIV/HBV co-infected patients were characterized. The co-infected patients were evaluated for HBeAg and anti-HBe antibody by ELISA. HIV RNA was quantified for all co-infected patients. HBV DNA was detected and quantified by real time-PCR amplification followed by HBV genotype determination. Results: HIV/HBV co-infected patients had proportionately more advanced HIV disease (WHO clinical stage 3 and 4) than HIV mono-infected individuals (37.1 vs. 19.9%). The co-infected patients had significantly higher serum bilirubin, alanine aminotransferase (ALT), alkaline phosphatase and ALT/platelet ratio index (APRI). CD4 count was non-significantly lower in co-infected patients. Majority (61.5%) were HBeAg positive with higher HIV RNA (PHIV/HBV co-infected patients had significantly higher serum bilirubin, ALT, alkaline phosphatase and lower platelet count. HBeAg positive co-infected patients had higher HIV RNA and HBV DNA compared to HBeAg negative co-infected patients. Prior to initiation of antiretroviral treatment (ART) all patients should be screened for HBsAg to initiate appropriate ART regimen. PMID:27488008

  10. Cortical Signature of Patients with HBV-related Cirrhosis without Overt Hepatic Encephalopathy: a Morphometric Analysis

    Directory of Open Access Journals (Sweden)

    Xiu Wu

    2015-06-01

    Full Text Available Previous studies have shown that patients with hepatitis B virus-related cirrhosis (HBV-RC without overt hepatic encephalopathy (OHE are associated with a varying degree of cognitive dysfunction. Several resting-state functional magnetic resonance imaging (fMRI studies have been conducted to explore the neural correlates of such cognitive deficits, whereas little effort has been made to investigate the cortical integrity in cirrhotic patients without OHE. Here, using cortical thickness, surface area and local gyrification index (lGI, this study performed a comprehensive analysis on the cortical morphometry of patients with HBV-RC without OHE (HBV-RC-NOHE versus matched healthy controls. Compared with healthy controls, we found significantly increased cortical thickness in the bilateral lingual and parahippocampal gyrus, right posterior cingulate cortex, precuneus, peri-calcarine sulcus and fusiform gyrus in patient with HBV-RC-NOHE, which may closely relate to be the low-grade brain edema. Cortical gyrification analysis showed significantly increased lGI in the left superior and inferior parietal cortex as well as lateral occipital cortex, which was speculated to be associated with disruptions in white matter connectivity and sub-optimal intra-cortical organization. In addition, the mean cortical thickness/lGI of the regions with structural abnormalities was shown to be negatively correlated with psychometric hepatic encephalopathy score (PHES of the patients with HBV-RC-NOHE. These morphological changes may serve as potential markers for the preclinical diagnosis and progression of HBV-RC-NOHE.

  11. HIV, HBV, and HCV molecular epidemiology among trans (transvestites, transsexuals, and transgender) sex workers in Argentina.

    Science.gov (United States)

    Carobene, Mauricio; Bolcic, Federico; Farías, María Sol Dos Ramos; Quarleri, Jorge; Avila, María Mercedes

    2014-01-01

    Commercial sex work is frequent among male-to-female transvestites, transsexuals and transgenders in Argentina, leading to high susceptibility to HIV, HBV, and HCV among other sexually transmitted infections. In a global context of scarce data on the trans sex workers population, this study was aimed to study the genomic characterization of these viruses. Plasma presence of HIV, HBV, and HCV genomic material was evaluated in samples from 273 trans sex workers. Genomic sequences of HIV-gag, pol, and vif-vpu genes, HBV-S gene, and HCV-5'UT and NS5B genes were obtained. Molecular characterization involved phylogenetic analysis and several in silico tools. Resistance-associated mutations in HIV and HBV pol genes were also analyzed. The HIV genomic characterization in 62 trans sex workers samples showed that 54.8% of the isolates corresponded to BF intersubtype recombinants, and 38.7% to subtype B. The remaining were classified as subtypes C (4.8%) and A (1.6%). HBV and HCV co-infection prevalence among HIV positive trans sex workers yielded rates of 3.2% and 6.5% respectively. Drug resistance-associated mutations were found in 12/62 (19%) HIV pol sequences, but none among HBV. Based on phylogenetic relationships, HIV isolates characterized as subtypes BF and B appeared intermingled with those from other high-risk groups. Despite trans sex workers declared not to have received antiviral treatment, complex drug resistance-associated mutation patterns were found in several HIV isolates. Planned prevention, screening, and treatment are needed to reduce further transmission and morbidity. PMID:24123155

  12. Interleukin-22 as a molecular adjuvant facilitates IL-17-producing CD8+ T cell responses against a HBV DNA vaccine in mice

    OpenAIRE

    Wu, Bing; Zou, Qiang; Hu, Yanxin; Wang, Bin

    2013-01-01

    Interleukin-22 (IL-22) is mainly produced by activated Th1 cells, Th17 cells and NK cells and promotes anti-microbial defense, pro-inflammatory and tissue remodeling responses. However, its potential use as a vaccine adjuvant has not been tested. In this study, we tested if a DNA construct expressing IL-22 (pVAX-IL-22) could be used as a molecular adjuvant to enhance host immune responses induced by HBV DNA vaccination (pcD-S2). After immunizing mice with pcD-S2 combined with pVAX-IL-22, we d...

  13. Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC

    Directory of Open Access Journals (Sweden)

    Charing Ching-Ning Chong

    2016-03-01

    Full Text Available There have been major advances recently on the therapeutic approaches of hepatitis B virus (HBV-related hepatocellular carcinoma (HCC. Surgical treatments are the key curative treatments of HCC, whereas local ablative treatments may also achieve clinical remission in selected cases. Trans-arterial locoregional therapies are regarded as palliative but still lead to improved survival. There have been major breakthroughs in the systemic therapies for HCC. The first marketed targeted therapy, sorafenib, was shown to improve survival in patients with advanced HCC. Studies on other targeted therapies also showed promising results. Suppressing HBV with effective antiviral treatment would also benefit HCC patients by reducing recurrence and improving liver function.

  14. The association of complex liver disorders with HBV genotypes prevalent in Pakistan

    Directory of Open Access Journals (Sweden)

    Qureshi Huma

    2007-11-01

    Full Text Available Abstract Background Genotyping of HBV is generally used for determining the epidemiological relationship between various virus strains and origin of infection mostly in research studies. The utility of genotyping for clinical applications is only beginning to gain importance. Whether HBV genotyping will constitute part of the clinical evaluation of Hepatitis B patients depends largely on the availability of the relevance of the evidence based information. Since Pakistan has a HBV genotype distribution which has been considered less virulent as investigated by earlier studies from south East Asian countries, a study on correlation between HBV genotypes and risk of progression to further complex hepatic infection was much needed Methods A total of 295 patients with HBsAg positive were selected from the Pakistan Medical Research Council's (PMRC out patient clinics. Two hundred and twenty six (77% were males, sixty nine (23% were females (M to F ratio 3.3:1. Results Out of 295 patients, 156 (53.2% had Acute(CAH, 71 (24.2% were HBV Carriers, 54 (18.4% had Chronic liver disease (CLD Hepatitis. 14 (4.7% were Cirrhosis and HCC patients. Genotype D was the most prevalent genotype in all categories of HBV patients, Acute (108, Chronic (39, and Carrier (53. Cirrhosis/HCC (7 were HBV/D positive. Genotype A was the second most prevalent with 28 (13% in acute cases, 12 (22.2% in chronics, 14 (19.7% in carriers and 5 (41.7 in Cirrhosis/HCC patients. Mixed genotype (A/D was found in 20 (12.8% of Acute patients, 3 (5.6% of Chronic and 4 (5.6% of carriers, none in case of severe liver conditions. Conclusion Mixed HBV genotypes A, D and A/D combination were present in all categories of patients except that no A/D combination was detected in severe conditions. Genotype D was the dominant genotype. However, genotype A was found to be more strongly associated with severe liver disease. Mixed genotype (A/D did not significantly appear to influence the clinical outcome.

  15. Asymmetric PCR method in generation of HBV ssDNA for pyrosequencing

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    Objective To explore the optimal primer ratio and concentration of asymmetric polymerase chain reaction (A-PCR) in producing hepatitis B virus (HBV) single-stranded DNA (ssDNA) for pyrosequencing. Methods A-PCR was carried out to generate HBV ssDNA with forward to reverse primers of different ratios (50∶1, 100∶1) and concentrations (13.0 pmol/25μL and 0.14 pmol/25μL, 19.5 pmol/25μL and 0.21 pmol/25μL), and the product yield and quality were compared respectively. Results The forward to reverse primer ratio ...

  16. Osteopontin promotes dendritic cell maturation and function in response to HBV antigens

    Directory of Open Access Journals (Sweden)

    Cui GY

    2015-06-01

    Full Text Available Guangying Cui,1,2 Jianing Chen,1,2 Jianqin He,1,2 Chong Lu,1,2 Yingfeng Wei,1,2 Lin Wang,1,2 Xuejun Xu,3 Lanjuan Li,1,2 Toshimitsu Uede,4 Hongyan Diao1,2 1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 3Department of Oral Orthodontics, Affiliated Stomatology Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 4Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan Purpose: Dendritic cells (DCs play critical roles in promoting innate and adaptive immunity in microbial infection. Functional impairment of DCs may mediate the suppression of viral-specific T-cell immune response in chronic hepatitis B (CHB patients. Osteopontin (OPN is involved in several liver diseases and infectious diseases. However, whether OPN affects DC function in hepatitis B virus (HBV infection is unknown.Methods: Twenty CHB patients and 20 healthy volunteers were recruited. OPN secreted by DCs was compared. Peripheral blood mononuclear cells cultured with OPN antibody were examined to study the costimulatory molecular expression and interleukin (IL-12 production of DCs after HBV antigenic stimulation. OPN-deficient mice were used to investigate the influence of OPN on DC maturation and function after HBV antigenic stimulation in vitro and in vivo. Exogenous OPN was administrated to further verify the functioning of DCs from CHB patients upon HBV antigenic stimulation.Results: We found that OPN production of DCs from CHB patients was significantly lower than those from healthy volunteers. The absence of OPN impaired IL-12 production and costimulatory molecular expression of DCs upon stimulation with HBV antigens. Defective DC function led to reduced activation of Th1 response to

  17. Assimilating H-SAF and MODIS Snow Cover Data into the Conceptual Models HBV and SRM

    Science.gov (United States)

    Sensoy, Aynur; Schwanenberg, Dirk; Sorman, Arda; Akkol, Bulut; Alvarado Montero, Rodolfo; Uysal, Gokcen

    2014-05-01

    Conceptual hydrological models are widely used for operational and scientific water resources management applications in mountain catchments. However, current model-based forecasting approaches are jeopardized by input data and model uncertainties. Data assimilation provides a suitable tool to merge information from remotely sensed observations and hydrological model predictions for improving the lead time performance of streamflow forecasts in the context of operational hydrological forecasting systems. In this study, we present a novel variational approach based on Moving Horizon Estimation (MHE). It includes a highly flexible formulation of distance metrics for penalizing the introduction of noise into the model and enforcing the agreement between simulated and observed variables. Furthermore, the MHE setup shows a high robustness regarding non-equidistant, noisy and sometimes missing data and enables the modification of model input as well as state variables. In situ snowpack measurements are sparsely distributed in mountainous regions. Therefore the data limitations in combination with snowpack heterogeneity prevent a detailed understanding of the variability of snow cover and melt. Remotely sensed images offer an opportunity to supplement ground measurements for performing runoff predictions during the snowmelt season. In this context, EUMETSAT initiated the H-SAF (Satellite Application Facility on Support to Operational Hydrology and Water Management) project for deriving novel products from satellite data and applying it to operational hydrology. This research contributes to the H-SAF product validation by applying a generic data assimilation test bed for H-SAF snow products in comparison to snow cover data of MODIS. A preliminary performance assessment of the data assimilation framework using the conceptual models HBV and SRM with satellite derived snow data is evaluated for a snow dominated test site of 10250 km2 at the headwaters of Euphrates River in

  18. Moving horizon estimation for assimilating H-SAF remote sensing data into the HBV hydrological model

    Science.gov (United States)

    Montero, Rodolfo Alvarado; Schwanenberg, Dirk; Krahe, Peter; Lisniak, Dmytro; Sensoy, Aynur; Sorman, A. Arda; Akkol, Bulut

    2016-06-01

    Remote sensing information has been extensively developed over the past few years including spatially distributed data for hydrological applications at high resolution. The implementation of these products in operational flow forecasting systems is still an active field of research, wherein data assimilation plays a vital role on the improvement of initial conditions of streamflow forecasts. We present a novel implementation of a variational method based on Moving Horizon Estimation (MHE), in application to the conceptual rainfall-runoff model HBV, to simultaneously assimilate remotely sensed snow covered area (SCA), snow water equivalent (SWE), soil moisture (SM) and in situ measurements of streamflow data using large assimilation windows of up to one year. This innovative application of the MHE approach allows to simultaneously update precipitation, temperature, soil moisture as well as upper and lower zones water storages of the conceptual model, within the assimilation window, without an explicit formulation of error covariance matrixes and it enables a highly flexible formulation of distance metrics for the agreement of simulated and observed variables. The framework is tested in two data-dense sites in Germany and one data-sparse environment in Turkey. Results show a potential improvement of the lead time performance of streamflow forecasts by using perfect time series of state variables generated by the simulation of the conceptual rainfall-runoff model itself. The framework is also tested using new operational data products from the Satellite Application Facility on Support to Operational Hydrology and Water Management (H-SAF) of EUMETSAT. This study is the first application of H-SAF products to hydrological forecasting systems and it verifies their added value. Results from assimilating H-SAF observations lead to a slight reduction of the streamflow forecast skill in all three cases compared to the assimilation of streamflow data only. On the other hand

  19. IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection.

    Science.gov (United States)

    Liu, Yun; Cheng, Li-Sha; Wu, Sheng-di; Wang, Si-Qi; Li, Lei; She, Wei-Min; Li, Jing; Wang, Ji-Yao; Jiang, Wei

    2016-06-01

    Non-specific immune responses to antigens have been demonstrated as being enhanced during chronic hepatitis B virus (HBV) infection. Here, we evaluated the role of interleukin-10 (IL-10)-producing regulatory B-cells (Bregs) in the pathogenesis of HBV-related liver fibrosis (HBV-LF) and assessed their immunoregulatory effects. Sixty-seven patients diagnosed with chronic hepatitis B (CHB) were enrolled in this study. Numbers and frequencies of peripheral B-cells (memory CD19(+)CD24(hi)CD27(+) cells, immature/transitional CD19(+)CD24(hi)CD38(hi) cells, mature CD19(+)CD24(int)CD38(int) cells) were tested and analysed. Flow cytometry-sorted CD4(+)T cells were cultured with autologous Bregs to elucidate the effects of Bregs on CD4(+)T cells, including effector T and regulatory T-cells (Tregs). The potential immunoregulatory mechanism of Bregs was also investigated. The numbers of total B-cells and Bregs were enriched in CHB patients. The frequency of Bregs was negatively correlated with elevated alanine aminotransferase (ALT) and histological inflammation grades (G), but positively correlated with advanced histological fibrosis stages (S) and enhanced HBV replication. The phenotype of Bregs was predominantly characterized as CD19(+)CD24(hi)CD38(hi) In co-culture with Bregs, CD4(+)CD25(-)T cells from CHB patients produced less interferon-γ (IFN-γ) and IL-17 but more IL-4 than CD4(+)CD25(-)T cells alone, whereas their conversions into Tregs and IL-10(+)T cells were enhanced. In addition, Breg depletion in CHB samples dramatically decreased Treg numbers and expression of cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), IL-10 and transforming growth factor-β (TGF-β). Moreover, the observed regulatory effect was partly dependent on IL-10 release and cell-to-cell contact. Elevated Bregs can suppress effector T but enhance Treg functions, which might influence immune tolerance in chronic HBV infection. PMID:26980345

  20. Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi

    Science.gov (United States)

    Liao, Xiwen; Han, Chuangye; Qin, Wei; Liu, Xiaoguang; Yu, Long; Lu, Sicong; Chen, Zhiwei; Zhu, Guangzhi; Su, Hao; Mo, Zengnan; Qin, Xue; Peng, Tao

    2016-01-01

    Objective: The genome-wide association approach was employed to explore the association between single nucleotide polymorphisms (SNPs) and TP53 expression in the HBV-related hepatocellular carcinoma (HCC) of Chinese patients in Guangxi. Methods: 403 HBV-related HCC patients were recruited into this study and classified according to the TP53 expression in the cancer by immunohistochemistry. DNA was extracted from the cancer and genotyped with the Human ExomeBeadChip 12v1-1 system; quality control and principal-component analysis (PCA) were applied for data analysis. Results: The Genome-wide association analysis indicated that rs2797992 with a P value of 4.35 × 10-5 locus in PLCE1 gene and rs6950826 with a P value of 2.2 × 10-3 locus in EGFR gene were associated with TP53 expression in the HCC. A allele of rs2797992 predicted a decreased risk for TP53 expression in HCC. In contrast, A allele of rs6950826 increased the risk for TP53 expression. There was no strong LD locus in the tested regions. PLCE1 and EGFR were associated with TP53 in pathway and at HCC mRNA level. Conclusion: rs2797992 of PLCE1 gene and rs6950826 of EGFR gene are associated with TP53 expression, but not with the prognosis of HBV-related HCC in HBV-related HCC of Chinese patients in Guangxi. PMID:27186304

  1. Serum testosterone levels and androgen receptor CAG polymorphism correlate with hepatitis B virus (HBV-related acute liver failure in male HBV carriers.

    Directory of Open Access Journals (Sweden)

    Bao-Yan Xu

    Full Text Available BACKGROUND: Augmentation of androgen/androgen receptor (AR pathway may influence chronic hepatitis B (CHB more likely in males. AR activity is modulated by a polymorphic CAG repeat sequence in AR exon 1. This study aimed to investigate the relationship between serum testosterone levels, CAG repeat numbers and hepatitis B virus (HBV-related acute liver failure (ALF. METHODS: Three hundred and seventy eight male CHB patients with ALF and 441 asymptomatic HBV carriers (AsCs were recruited. AR CAG repeats numbers were analyzed. The serum testosterone levels of AsCs, ALFs and patients with hepatitis B flare groups, and sequential serum samples, were assessed quantitatively. RESULTS: The median CAG repeat (M-CAG frequency was significantly higher in ALF patients than AsCs (P<0.001. Patients with M-CAG alleles (P<0.001, OR 3.0, 95% CI 2.1-4.2 had the highest risk for ALF. Serum testosterone levels were significantly higher (P<0.001 at hepatitis flare point (8.2 ± 3.0 ng/mL than inactive phase (6.4 ± 2.0 ng/mL. CHB (8.30 ± 2.71 ng/mL, P = 7.6 × 10(-6 and ALF group (2.61 ± 1.83 ng/mL, P = 1.7 × 10(-17 had significantly different levels of testosterone in comparison with AsCs group (6.56 ± 2.36 ng/mL. The serum testosterone levels sharply decreased from hepatitis flare phase to liver failure phase, and tended to be normal at the recovery phase. Male AsCs with M-CAG alleles had significantly lower serum testosterone levels (P<0.05. CONCLUSIONS: There was a serum testosterone fluctuation during hepatitis B flare and HBV-related ALF, and the median CAG repeats in AR gene exon 1 were associated with lower serum testosterone levels in asymptomatic HBV carriers and an increased susceptibility to HBV-related ALF.

  2. Inhibition of Hepatitis B Virus Replication by Rheum palmatum L. Ethanol Extract in a Stable HBV-producing Cell

    Institute of Scientific and Technical Information of China (English)

    Yan SUN; Li-jun LI; Jing LI; Zhi LI

    2007-01-01

    Hepatitis B virus(HBV) infection is a severe health problem in the world.However,there is still not a satisfactory therapeutic strategy for the HBV infection.To search for new anti-HBV agents with higher efficacy and less side-effects,the inhibitory activities of traditional Chinese medicine Rheum palmatum L.ethanol extract(RPE) against HBV replication were investigated in this study.Quantitative real-time polymerase chain reaction(PCR) was employed to analyze the inhibitory activity of RPE against HBV-DNA replication in a stable HBV-producing cell line HepAD38; the expression levels of HBV surface antigen(HBsAg) and e antigen(HBeAg) were also determined by enzyme linked immunosorbent assay(ELISA) after RPE treatment.RPE could dose-dependently inhibit the production of HBV-DNA and HBsAg.The concentration of 50% inhibition(IC50) was calculated at 209.63,252.53 μg/mL,respectively.However,its inhibitory activity against HBeAg expression was slight even at high concentrations.RPE had a weak cytotoxic effect on HepAD38 cells(CC50 = 1 640 μg/mL) and the selectivity index(SI) was calculated at 7.82.Compared with two anthraquinone derivatives emodin and rhein,RPE showed higher ability of anti-HBV and weaker cytotoxicity.So Rheum palmatum L.might possess other functional agents which could effectively inhibit HBV-DNA replication and HBsAg expression.Further purification of the active agents,identification and modification of their structures to improve the efficacy and decrease the cytotoxicity are required.

  3. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

    OpenAIRE

    Cavenaugh, James S; Dorka Awi; Maimuna Mendy; Hill, Adrian V. S.; Hilton Whittle; McConkey, Samuel J.

    2011-01-01

    BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secondary goal was to characterize the immune responses. METHODS: Firstly 32 HBV e antigen negative (eAg(-)) participants were randomly assigned to one of four groups: to receive vaccines alone, lamivud...

  4. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV

    Institute of Scientific and Technical Information of China (English)

    Di-Peng Ou; Lian-Yue Yang; Geng-Wen Huang; Yi-Ming Tao; Xiang Ding; Zhi-Gang Chang

    2005-01-01

    AIM: To comprehend the risk factors of recurrence of hepatocellular carcinoma (HCC) and its relationship with the infection patterns of hepatitis B virus (HBV). METHODS: All materials of 270 cases of postoperative HCC were statistically analyzed by SPSS software. Recurrence and metastasis were classified into early (≤2 years) and late phase (>2 years). Risk factors for recurrence and metastasis after surgery in each group were analyzed.RESULTS: Out of 270 cases of HCC, 162 cases were followed up in which recurrence and metastasis occurred in 136 cases. There were a lot of risk factors related to recurrence and metastasis of HCC; risk factors contributing to early phase recurrence were serum AFP level, vascular invasion, incisal margin and operative transfusion, gross tumor classification and number of intrahepatic node to late phase recurrence. The HBV infective rate of recurrent HCC was 94.1%, in which "HBsAg, HBeAb, HBcAb" positive pattern reached 45.6%. The proportion of HBV infection in solitary large hepatocellular carcinoma (SLHCC) evidently decreased compared to nodular hepatocellular carcinoma (NHCC) (P<0.05).CONCLUSION: The early and late recurrence and metastasis after hepatectomy of HCC were associated with different risk factors. The early recurrence may be mediated by vascular invasion and remnant lesion, the late recurrence by tumor's clinical pathology propert, as multicentric carcinogenesis or intrahepatic carcinoma denovo. HBV replication takes a great role in this process. From this study, we found that SLHCC has more satisfactory neoplasm biological behavior than NHCC.

  5. Modeling and Analyzing the Transmission Dynamics of HBV Epidemic in Xinjiang, China.

    Directory of Open Access Journals (Sweden)

    Tailei Zhang

    Full Text Available Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV which affects livers. In this paper, we formulate a hepatitis B model to study the transmission dynamics of hepatitis B in Xinjiang, China. The epidemic model involves an exponential birth rate and vertical transmission. For a better understanding of HBV transmission dynamics, we analyze the dynamic behavior of the model. The modified reproductive number σ is obtained. When σ 1, the disease-free equilibrium is unstable and the disease is uniformly persistent. In the simulation, parameters are chosen to fit public data in Xinjiang. The simulation indicates that the cumulated HBV infection number in Xinjiang will attain about 600,000 cases unless there are stronger or more effective control measures by the end of 2017. Sensitive analysis results show that enhancing the vaccination rate for newborns in Xinjiang is very effective to stop the transmission of HBV. Hence, we recommend that all infants in Xinjiang receive the hepatitis B vaccine as soon as possible after birth.

  6. Effect of vector-expressed siRNA on HBV replication in hepatoblastoma cells

    Institute of Scientific and Technical Information of China (English)

    Jun Liu; Ying Guo; Cai-Fang Xue; Ying-Hui Li; Yu-Xiao Huang; Jin Ding; Wei-Dong Gong; Ya Zhao

    2004-01-01

    AIM: To study the effect of siRNA expressed from DNA vector on HBV replication.METHODS: Human U6 promoter was amplified from genomic DNA and cloned into plasmid pUC18 to construct a mammalian siRNA expression vector pUC18U6. Then oligonucleotides coding for a short hairpin RNA against HBV were cloned into pUC18U6 to form pUC18U6HBVsir which was introduced into 2.2.15 cells by using liposome-mediated transfection.2.2.15 cells transfected by pUC18U6 and pUC18U6GFPsir which expressed siRNA against green fluorescent protein and mock-transfected 2.2.15 cells were used as controls.Concentration of HBsAg in the supernatant of the transfected cells was measured by using solid-phase radioimmunoassay.RESULTS: A mammalian siRNA expression vector pUC18U6was constructed successfully. Compared with controls,pUC18U6HBVsir which expressed siRNA against HBV decreased concentration of HBsAg significantly by 44%(P<0.05).CONCLUSION: HBV replication in 2.2.15 cells is inhibited by siRNA expressed from the DNA vector.

  7. Identification of novel HBV core-interacting partners PRMT5 and MEP50

    Czech Academy of Sciences Publication Activity Database

    Lubyová, Barbora; Hodek, Jan; Prouzová, Hana; Hubálek, Martin; Weber, Jan

    Ontario: American Society for Virology, 2015. P29-03. [ASV 2015. Annual Meeting of the American Society for Virology /34./. 11.07.2015-15.07.2015, Ontario] R&D Projects: GA MŠk(CZ) LK11207 Institutional support: RVO:61388963 Keywords : HBV core protein * arginine methyltransferase * protein-protein interactions Subject RIV: EE - Microbiology, Virology

  8. Study on the risk factors related vertical transmission of HBV positive couples to their infant

    Institute of Scientific and Technical Information of China (English)

    张荣莲

    2013-01-01

    Objective To explore the risk factors and the rate of HBV vertical transmission from HBsAg-positive couple to their infant. Methods 46 families who had antenatal examination at Fujian Provincial Maternal and Child Health Hospital during August 2010 and November 2011 were

  9. Blocking peptides against HBV: PreS1 protein selected from a phage display library

    Energy Technology Data Exchange (ETDEWEB)

    Wang, Wei; Liu, Yang; Zu, Xiangyang; Jin, Rui [State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071 (China); Xiao, Gengfu, E-mail: xiaogf@wh.iov.cn [State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071 (China)

    2011-09-09

    Highlights: {yields} Successfully selected specific PreS1-interacting peptides by using phage displayed library. {yields} Alignment of the positive phage clones revealed a consensus PreS1 binding motif. {yields} A highly enriched peptide named P7 had a strong binding ability for PreS1. {yields} P7 could block PreS1 attachment. -- Abstract: The PreS1 protein is present on the outermost part of the hepatitis B virus (HBV) surface and has been shown to have a pivotal function in viral infectivity and assembly. The development of reagents with high affinity and specificity for PreS1 is of great significance for early diagnosis and treatment of HBV infection. A phage display library of dodecapeptide was screened for interactions with purified PreS1 protein. Alignment of the positive phage clones revealed a putative consensus PreS1 binding motif of HX{sub n}HX{sub m}HP/R. Moreover, a peptide named P7 (KHMHWHPPALNT) was highly enriched and occurred with a surprisingly high frequency of 72%. A thermodynamic study revealed that P7 has a higher binding affinity to PreS1 than the other peptides. Furthermore, P7 was able to abrogate the binding of HBV virions to the PreS1 antibody, suggesting that P7 covers key functional sites on the native PreS1 protein. This newly isolated peptide may, therefore, be a new therapeutic candidate for the treatment of HBV. The consensus motif could be modified to deliver imaging, diagnostic, and therapeutic agents to tissues affected by HBV.

  10. Synergistic Action of Clonorchiasis,HBV Infection and Alcohol Consumption on Primary Hepatocellular Carcinoma

    Institute of Scientific and Technical Information of China (English)

    Shengkui Tan; Xiaoqiang Qiu; Hongping Yu; Xiaoyun Zeng; Zengming Xiao; Lequn Li; Qiuan Zhong

    2009-01-01

    OBJECTIVE It has been recognized that HBV infection and alcohol consumption are two important risk factors for primary hepatocellular carcinoma(HCC).Recently,the role of clonorchiasis as a risk factor for HCC is controversial.We aimed to investigate whether these factors increase the risk of HCC in Guangxi,China.METHODS A hospital-based,case-control study of HCC was conducted from July 2005 to July 2007.We enrolled 500consecutive patients with HCC as an experimental group and 500patients without tumor in liver as a control group.nle risk factors that the patients were exposed to were assessed.RESULTS Comparing the risks of developing the HCC,we found out the following results.The risk of developing HCC for the patients with clonorchiasis was 5 folds of that for the patients without clonorchiasis(OR=5.0;95%CI:3.1-8.1),and the risk for the patients with alcohol consumption was 3 folds of that for the patients without drinking alcohol(OR=3.4;95%CI:2.3-4.9),and similarly,the risk for the patients with HBV infection was 21 times of that for the patients without HBV infection (OR=20.6;95% CI:14.3-29.7).According to crossover analysis,there was significant interaction among clonorchiasis,HBV infection and alcohol consumption,with synergistic indices greater than 1.The etiologic fractions attributed to these interactions [EF(A x B)] are 0.7465,0.5789 and 0.5506,respectively.CoNCLUSION Clonorchiasis,HBV infection and heavy alcohol consumption are independent risk factors for developing HCC in our population in Guangxi,and as they can interact synergistically,the risk of developing HCC is increased.Data from this study may indicate new prevention strategies of developing HCC in hish-risk individuals.

  11. Blocking peptides against HBV: PreS1 protein selected from a phage display library

    International Nuclear Information System (INIS)

    Highlights: → Successfully selected specific PreS1-interacting peptides by using phage displayed library. → Alignment of the positive phage clones revealed a consensus PreS1 binding motif. → A highly enriched peptide named P7 had a strong binding ability for PreS1. → P7 could block PreS1 attachment. -- Abstract: The PreS1 protein is present on the outermost part of the hepatitis B virus (HBV) surface and has been shown to have a pivotal function in viral infectivity and assembly. The development of reagents with high affinity and specificity for PreS1 is of great significance for early diagnosis and treatment of HBV infection. A phage display library of dodecapeptide was screened for interactions with purified PreS1 protein. Alignment of the positive phage clones revealed a putative consensus PreS1 binding motif of HXnHXmHP/R. Moreover, a peptide named P7 (KHMHWHPPALNT) was highly enriched and occurred with a surprisingly high frequency of 72%. A thermodynamic study revealed that P7 has a higher binding affinity to PreS1 than the other peptides. Furthermore, P7 was able to abrogate the binding of HBV virions to the PreS1 antibody, suggesting that P7 covers key functional sites on the native PreS1 protein. This newly isolated peptide may, therefore, be a new therapeutic candidate for the treatment of HBV. The consensus motif could be modified to deliver imaging, diagnostic, and therapeutic agents to tissues affected by HBV.

  12. Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion

    Directory of Open Access Journals (Sweden)

    Panigrahi Rajesh

    2010-08-01

    Full Text Available Abstract Background Occult hepatitis B virus (HBV infection might transmit viremic units into the public blood supply if only hepatitis B surface antigen (HBsAg testing is used for donor screening. Our aim was to evaluate the prevalence of occult HBV infection among the HBsAg negative/antiHBc positive donations from a highly HIV prevalent region of India. Methods A total of 729 HBsAg negative donor units were included in this study. Surface gene and precore region were amplified by in house nucleic acid test (NAT for detection of occult HBV infection and surface gene was analyzed after direct sequencing. Results A total of 220 (30.1% HBsAg negative donors were antiHBc positive, of them 66 (30% were HBV DNA positive by NAT. HBV DNA positivity among 164 antiHBc only group, was 27.1% and among 40 antiHBs positive group was 30.0%. HBV/D (93.3% was predominant and prevalence of both HBV/C and HBV/A was 3.3%. Single or multiple amino acids substitutions were found in 95% samples. Conclusion Thus, a considerable number of HBV infected donors remain undiagnosed, if only HBsAg is used for screening. Addition of antiHBc testing for donor screening, although will lead to rejection of a large number of donor units, will definitely eliminate HBV infected donations and help in reducing HBV transmission with its potential consequences, especially among the immunocompromised population. The HBV genetic diversity found in this donor population are in accordance with other parts of India.

  13. TGF-β suppression of HBV RNA through AID-dependent recruitment of an RNA exosome complex.

    Directory of Open Access Journals (Sweden)

    Guoxin Liang

    2015-04-01

    Full Text Available Transforming growth factor (TGF-β inhibits hepatitis B virus (HBV replication although the intracellular effectors involved are not determined. Here, we report that reduction of HBV transcripts by TGF-β is dependent on AID expression, which significantly decreases both HBV transcripts and viral DNA, resulting in inhibition of viral replication. Immunoprecipitation reveals that AID physically associates with viral P protein that binds to specific virus RNA sequence called epsilon. AID also binds to an RNA degradation complex (RNA exosome proteins, indicating that AID, RNA exosome, and P protein form an RNP complex. Suppression of HBV transcripts by TGF-β was abrogated by depletion of either AID or RNA exosome components, suggesting that AID and the RNA exosome involve in TGF-β mediated suppression of HBV RNA. Moreover, AID-mediated HBV reduction does not occur when P protein is disrupted or when viral transcription is inhibited. These results suggest that induced expression of AID by TGF-β causes recruitment of the RNA exosome to viral RNP complex and the RNA exosome degrades HBV RNA in a transcription-coupled manner.

  14. The prevalence of HBV infection in the cohort of IDPs of war against terrorism in Malakand Division of Northern Pakistan

    Directory of Open Access Journals (Sweden)

    Akbar Haji

    2011-06-01

    Full Text Available Abstract Background Hepatitis B is an important public health problem in the Pakistani population and is the major cause of chronic hepatitis, cirrhosis, fibrosis and hepatocellular carcinoma. High prevalence of HBV infections has been observed especially in areas of low economic status. In spite of effective immunization programs, no significant change has been observed in the epidemiology of HBV in the rural areas of Pakistan (~67.5% of the total population mainly due to lack of interest from government authorities and poor hygienic measures. The current study was aimed at estimating the prevalence and risk factors associated with HBV infection within internally displaced persons (IDPs due to war against terrorism in the Malakand Division of Northern Pakistan. Methods Blood samples from 950 IDPs suspected with HBV infection (including both males and females were collected and processed with commercial ELISA kits for HBsAg, Anti HBs, HBeAg, Anti HBe antibodies. The samples positive by ELISA were confirmed for HBV DNA by real-time PCR analysis. Results The overall prevalence of HBV observed was 21.05% of which 78.5% were males and 21.5% were females. Most confirmed HBV patients belong to the Malakand and Dir (lower district. High-risk of infection was found in the older subjects 29.13% (46-60 years, while a lower incidence (11.97% was observed in children aged Conclusion The present study, revealed for the first time a high degree of prevalence of HBV infection in rural areas of Northern Pakistan. The noticed prevalence is gender- and age-dependent that might be due to their high exposures to the common risk factors. To avoid the transmission of HBV infection proper awareness about the possible risk factors and extension of immunization to the rural areas are recommended.

  15. Species association of hepatitis B virus (HBV in non-human apes; evidence for recombination between gorilla and chimpanzee variants.

    Directory of Open Access Journals (Sweden)

    Sinéad Lyons

    Full Text Available Hepatitis B virus (HBV infections are widely distributed in humans, infecting approximately one third of the world's population. HBV variants have also been detected and genetically characterised from Old World apes; Gorilla gorilla (gorilla, Pan troglodytes (chimpanzee, Pongo pygmaeus (orang-utan, Nomascus nastusus and Hylobates pileatus (gibbons and from the New World monkey, Lagothrix lagotricha (woolly monkey. To investigate species-specificity and potential for cross species transmission of HBV between sympatric species of apes (such as gorillas and chimpanzees in Central Africa or between humans and chimpanzees or gorillas, variants of HBV infecting captive wild-born non-human primates were genetically characterised. 9 of 62 chimpanzees (11.3% and two from 11 gorillas (18% were HBV-infected (15% combined frequency, while other Old world monkey species were negative. Complete genome sequences were obtained from six of the infected chimpanzee and both gorillas; those from P. t .ellioti grouped with previously characterised variants from this subspecies. However, variants recovered from P. t. troglodytes HBV variants also grouped within this clade, indicative of transmission between sub-species, forming a paraphyletic clade. The two gorilla viruses were phylogenetically distinct from chimpanzee and human variants although one showed evidence for a recombination event with a P.t.e.-derived HBV variant in the partial X and core gene region. Both of these observations provide evidence for circulation of HBV between different species and sub-species of non-human primates, a conclusion that differs from the hypothesis if of strict host specificity of HBV genotypes.

  16. Immune Exhaustion and Immune Senescence – Two Distinct Pathways for HBV Vaccine Failure during HCV and/or HIV Infection

    OpenAIRE

    Yao, Zhi Q.; Moorman, Jonathan P.

    2013-01-01

    Given the shared risk factors for transmission, co-infection of hepatitis B virus (HBV) with hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV) is quite common, and may lead to increases in morbidity and mortality. As such, HBV vaccine is recommended as the primary means to prevent HBV super-infection in HCV- and/or HIV-infected individuals. However, vaccine response (sero-conversion with a hepatitis B surface antibody titer >10 IU/L) in this setting is often blunted, with poor...

  17. HBV父婴垂直传播水平与HBV-DNA载量的相关研究%A correlation analysis between the rate of vertical transmission of HBV and HBsAg-positive father to infant and the rate of neonatal cord blood HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    张荣莲; 罗颖; 谢婧娴; 陈起燕; 成玲; 郭胜斌; 黄欣欣

    2010-01-01

    Objective To study the influence of HBV-DNA with different load levels of HBsAg-positive among fathers on the rate of neonatal cord blood HBV-DNA.Methods Using HBsAg and HBV-DNA as screening indicators for pregnant women and their husbands from an obstetric clinic.161 pregnant women whose HBsAg and HBV-DNA were negative,but HBsAg was positive among their husbands and their newborns,were selected.Blood samples from those pregnant women,their husbands and their newborns were collected to detect the related indicators.Using ELISA to detect hepatitis B virus markers(HBVM),and FQ-PCR to detect the levels of HBV-DNA load.According to neonatal cord blood HBV-DNA detection guideline,newborns with cord blood HBV-DNA positive were selected as cases,others as controls.Results(1)Result of the study showed that there was a dose-response relationship between paternal serum HBV-DNA load levels and neonatal cord blood HBV-DNA positive rates in newborns(trend χ~2=64.117,P=0.000).The rate of vertical transmission of HBV from HBsAg-positive father to infant in the paternal serum HBV-DNA>1.0×107 copies/ml group was significantly higher than HBV-DNA<1.0×107 copies/ml group(χ~2=71.539,P=0.000).(2)There was a positive rank correlation between semen positive HBeAg and vertical transmission of HBV from HBsAg-positive father to infant(χ~2=6.892,P=0.009).Conclusion There was a dose-response relationship between paternal serum HBV-DNA load levels and neonatal cord blood HBV-DNA positive in newborns.Paternal serum HBV-DNA≥1.0×107 copies/ml and with HBeAg positive status were risk factors of vertical transmission of HBV from HBsAg-positive father to infant.%目的 探讨HBsAg阳性父亲血HBV-DNA的不同载量水平对其新生儿发生HBV父婴垂直传播的影响.方法 对161例HBsAg阳性的父亲及其新生儿(母亲血清HBVM全阴性或仅HBsAb阳性及HBV-DNA均为阴性)HBV感染状况进行调查分析.采用ELISA检测HBVM,FQ-PCR法检测血清HBV DNA

  18. HBV携带产妇的血清及乳汁HBV-DNA载量的差异与母乳喂养安全性的研究%Load of HBV DNA in serum and breast milk of HBV carried mother and safety of breast-fed infants

    Institute of Scientific and Technical Information of China (English)

    马力; 王兆荃; 赵桂珍; 梁争论; 王心竹

    2007-01-01

    目的 探讨HBV携带产妇的血清、乳汁中HBV-DNA不同裁量与实施母乳喂养安全性的关系及对母婴传播阻断效果的影响.方法 应用荧光定量聚合酶链反应和酶免疫测定(EIA)技术对91例HBsAg、HBeAg双阳性产妇血清、乳汁及婴儿24月龄血标本进行HBV-DNA定量和HBVM检测.32例婴儿采用母乳喂养,59例采用人工喂养.对两种喂养方式的婴儿做3(T3)、9(T9)、12(T12)、24(T24)个月追踪检测观察.结果 HBsAg、HBeAg双阳性产妇的血清、乳汁中HBV-DNA阳性率为100%、49.45%(P<0.005),HBV-DNA平均含量(拷贝数/毫升的对数,(-x)±s)为(7.43±1.81)、(4.02±1.01);初乳HBV-DNA的检出率随母血HBV-DNA载量的增加而增加,两者呈正相关.母乳和人工两种方式喂养的婴儿HBV感染率为15.63%和13.56%,统计学处理X2=0.022,P>0.05差异无显著性;母乳喂养组抗体几何平均滴度(GMT)明显高于人工喂养组;发生HBV-DNA感染的13例婴儿T24血标本HBV-DNA载量为(3.24±0.23).结论 HBsAg、HBeAg双阳性产妇血清HBV-DNA载量大于109cps/mL的婴儿是母婴传播的高危易感人群.HBV感染的婴儿HBV-DNA水平较低,病毒载量<104cps/mL.乳汁HBV-DNA阳性率和病毒载量明显低于血清,HBV携带产妇的婴儿接受正规乙肝基因工程疫苗(Hbice)全程免疫或Hbice和HBIG(乙肝免疫球蛋白)的主、被动联合免疫后,母乳喂养不影响母婴传播阻断效果,母乳喂养有助于提高婴儿抗-HBs的GMT水平.%[Objective]To investigate the relationship between the load of HBV-DNA in serum and breast milk of pregnant women carrying HBV and the safety of breast-feeding and to explore the blocking effect on the mother-infant transmission of HBV.[Methods]Content of HBV-DNA and/or HBVM in serum and breast milk specimens of 91 pregnant women with positive HBsAg and HBeAg and in serum specimens of their 24 month old infants were detected by Real-time quantitative polymerase chain reaction(RQ-PCR)and/or EIA at

  19. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy

    Directory of Open Access Journals (Sweden)

    Laura Camoni

    2010-03-01

    Full Text Available We estimated the prevalence of HIV, HBV and HCV infections among injecting and non-injecting drug users treated within public drug-treatment centres in Italy to determine the correlates of infection. In the sample of 1330 drug users, the prevalence of HIV was 14.4% among drug injectors and 1.6% among non-injectors; the prevalence of HBV was 70.4% among injecting drug users and 22.8% among non-injectors and of HCV was 83.2% among injecting drug users and 22.0% among non-injectors. Old age, unemployment, and intravenous drug use were significantly correlated with each of the infections, as well as a longer history of injecting drug use. The results indicate that these infections continue to circulate among drug users, highlighting the need for monitoring of this group in Italy.

  20. Discovery and Development of Anti-HBV Agents and Their Resistance

    Directory of Open Access Journals (Sweden)

    Baik-Lin Seong

    2010-08-01

    Full Text Available Hepatitis B virus (HBV infection is a prime cause of liver diseases such as hepatitis, cirrhosis and hepatocellular carcinoma. The current drugs clinically available are nucleot(side analogues that inhibit viral reverse transcriptase activity. Most drugs of this class are reported to have viral resistance with breakthrough. Recent advances in methods for in silico virtual screening of chemical libraries, together with a better understanding of the resistance mechanisms of existing drugs have expedited the discovery and development of novel anti-viral drugs. This review summarizes the current status of knowledge about and viral resistance of HBV drugs, approaches for the development of novel drugs as well as new viral and host targets for future drugs.

  1. Management of Vaccination Failure in a Case of HIV - HBV Co-infection: A Case Report

    Directory of Open Access Journals (Sweden)

    Andre Small

    2014-06-01

    Full Text Available Background: A 60-year-old African American female patient, with chronic HIV infection since 1999, presented with markers of acute hepatities B virus (HBV infection for the past 15 months. The patient was previously vaccinated for HBV. Immunoglobulin dysfunction was hypothesized, but electrophoresis yielded no conclusive result. Results: Investigation suggests that the patient is a non-responder: someone who fails to sero-convert to standard vaccinations. This condition can be linked to B-cell dysfunction due to chronic HIV infection. Conclusion: It is suggested that non-responders may require a 6-dose regimen to achieve sero-conversion for vaccination. Prevention of co-infection should be the mainstay of treatment, which is achieved by vaccination. However, immune system dysfunction can lead to complications.

  2. Seroprevalencia de VHB, VHC y VIH en donadores de sangre en Irapuato, México Seroprevalence of HBV, HCV and HIV in blood donors in Irapuato, Mexico

    Directory of Open Access Journals (Sweden)

    Miguel Angel Carreto-Vélez

    2003-01-01

    General Hospital No. 2 Family Medicine Unit, of the Mexican Social Security Institute in Irapuato, Mexico. MATERIAL AND METHODS: A cross-sectional descriptive study. Data was recorded on blood bank forms, and risk factors and illnesses were studied in the 7,056 blood donors at the General Hospital No. 2 Family Medicine Unit, of the Mexican Social Security Institute in Irapuato, Guanajuato, Mexico, over a period of two years (from July 1998 to June 2000. A sample of 4,010 donors was obtained, each of whom underwent serological tests for HBV, HCV and HIV, serotypes 1 and 2, using an enzymatic immunoassay of third generation in serum or human plasma; seroprevalence rate of seropositive donors was calculated and stratified by age and sex. RESULTS: The combined seroprevalence for HBV, HCV and HIV was 2.5% (101; HCV was 1.14% (46, HBV, 1.12% (45, and HIV, 0.24% (10. In males, HBV was 1.04% (33, HCV 1.07% (34, and HIV, 0.28% (9. In females, HBV was 1.42% (12, HCV was 1.42% (12, and HIV was 0.11% (1. Seropositive males had a 2.4 higher rate as compared to females. CONCLUSIONS: The seroprevalence of viral markers was greater than that reported in previous studies carried out in Mexico, which suggests that sexual transmission was the principal mechanism of infection; this reflects poor health education and the need to carefully select potential donors.

  3. The Impact of Gender Differences in Attitudes and Beliefs Concerning HBV Vaccination and Screening in the Lao Community.

    Science.gov (United States)

    Akosionu, Odichinma; Virnig, Beth; Call, Kathleen T; Yuan, Jian-Min; Chanthanouvong, Sunny; Nguyen, Ruby H N

    2016-02-01

    Liver cancer incidence is increasing among Asian Americans. Laotians in the US have greater risk of liver cancer death compared to other Asian American groups. However, ethnicity is not the only disparity; Laotian men are at increased risk of liver cancer compared to Laotian women. Use of hepatitis B virus (HBV) vaccination and screening is low among Laotians. The impact of gender differences in attitudes and beliefs concerning HBV vaccination and screening is unknown. This secondary analysis of a cross-sectional community-based participatory research study. Although men were more likely to believe that infection with HBV is preventable, and treatable, causes liver cancer, and that healthy persons should be vaccinated, of those who thought people should get vaccinated, women were four times more likely to receive vaccine than men (adj. OR 4.0, CI 1.2-19). Understanding and addressing gender differences may increase HBV screening and vaccination uptake, thus reducing disparities within the Laotian community. PMID:25612922

  4. Occult hepatitis B virus infection and cryptogenic chronic hepatitis in an area with intermediate prevalence of HBV infection

    Institute of Scientific and Technical Information of China (English)

    Mohammad Javad Kaviani; Behzad Behbahani; Mohammad Jafar Mosallaii; Fatemeh Sari-Aslani; Seyed Alireza Taghavi

    2006-01-01

    AIM: To assess the possible role of occult HBV infection in the pathogenesis of chronic hepatitis in Iranian patients.METHODS: After exclusion of autoimmune, metabolic and viral etiologies, 104 consecutive adult patients with histologic and biochemical features of chronic hepatitis and negative HBsAg were enrolled in the study.Qualitative PCR with a sensitivity of 150 × 103 copies/L,using two primers for Pre-S and core regions was applied to measure presence of HBV DNA in serum of the patients.RESULTS: All 104 patients completed the study.Qualitative HBV DNA was positive in two patients (1.9%).CONCLUSION: Occult HBV infection has negligible role in the pathogenesis of cryptogenic chronic hepatitis in Iranian patients.

  5. Static structures and dynamics of hemoglobin vesicle (HBV) developed as a transfusion alternative.

    Science.gov (United States)

    Sato, Takaaki; Sakai, Hiromi; Sou, Keitaro; Medebach, Martin; Glatter, Otto; Tsuchida, Eishun

    2009-06-18

    Hemoglobin vesicle (HbV) is an artificial oxygen carrier that encapsulates solution of purified and highly concentrated (ca. 38 g dL(-1)) human hemoglobin. Its exceptionally high concentration as a liposomal product (ca. 40% volume fraction) achieves an oxygen-carrying capacity comparable to that of blood. We use small-angle X-ray scattering (SAXS) and dynamic light scattering (DLS) to investigate the hierarchical structures and dynamics of HbVs in concentrated suspensions. SAXS data revealed unilamellar shell structure and internal density profile of the artificial cell membrane for Hb encapsulation. The SAXS intensity of HbV at scattering vector q > 0.5 nm(-1) manifests dissolution states of the encapsulated Hbs in the inner aqueous phase of the vesicle having ca. 240 nm diameter. The peak position as well as the height and width of static structure factor of Hb before and after encapsulation are almost identical, demonstrating the preserved protein-protein interactions in the confined space. To overcome multiple scattering from turbid samples, we employed thin layer-cell DLS combined with the so-called bruteforce and echo techniques, which allows us to observe collective diffusion dynamics of HbVs without dilution. A pronounced slowdown of the HbV diffusion and eventual emergence of dynamically arrested state in the presence of high-concentration plasma substitutes (water-soluble polymers), such as dextran, modified fluid gelatin, and hydroxylethyl starch, can be explained by depletion interaction. A significantly weaker effect of recombinant human serum albumin on HbV flocculation and viscosity enhancement than those induced by other polymers is clearly attributed to the specificity as a protein; its compact structure efficiently reduces the reservoir polymer volume fraction that determines the depth of the attractive potential between HbVs. These phenomena are technically essential for controlling the suspension rheology, which is advantageous for versatile

  6. Cortical signature of patients with HBV-related cirrhosis without overt hepatic encephalopathy: a morphometric analysis

    OpenAIRE

    Xiu Wu; yuling Zhang

    2015-01-01

    Previous studies have shown that patients with hepatitis B virus-related cirrhosis (HBV-RC) without overt hepatic encephalopathy (OHE) are associated with a varying degree of cognitive dysfunction. Several resting-state functional magnetic resonance imaging (fMRI) studies have been conducted to explore the neural correlates of such cognitive deficits, whereas little effort has been made to investigate the cortical integrity in cirrhotic patients without OHE. Here, using cortical thickness, su...

  7. Optimization of competitively differentiated polymerase chain reaction in detection of HBV basal core promoter mutation

    Institute of Scientific and Technical Information of China (English)

    Xiao-Mou Peng; Lin Gu; Xue-Juan Chen; Jian-Guo Li; Yang-Su Huang; Zhi-Liang Gao

    2005-01-01

    AIM: To improve competitively differentiated polymerase chain reaction (CD-PCR) in detection of HBV basal core promoter mutation.METHODS: Recombinant plasmid of double point mutation A1762T/G1764A in basal core promoter of HBV constructed by site-directed mutagenesis was used as mutant control.To reveal the deficiency mechanism of CD-PCR, relationship between the circle number of PCR and the increased speed of products of each competitive primer was comparatively studied. Diversified amount of dNTPs and mutual primer of the competitive primers were tried to optimize CDPCR. Optimized CD-PCR was evaluated by detecting A1762T/G1764A mutation in recombinant plasmids and clinical sera from patients with HBV infection. RESULTS: The deficiency mechanism of CD-PCR was that the products of mismatched competitive primer grew fast when the amplification of matched primer entered into plateau stage, which led to decrease in or disappearance of the difference in the amount of their products. This phenomenon could be eliminated by reducing dNTPs to10 μmol/L and mutual primer to about 100 nmol/L. Optimized CD-PCR could detect both mutant and wild strain indepe ndent of the amount of templates and the number of PCRcycles. Its detection limit was 103 copies/mL, about 50 copies/reaction. About 10% of mutant DNAs among wild type DNAs could be detected. A1762T/G1764A mutant was detected in 41.8% (51/122) of patients with HBV infection, but not detected in controls with negative HBsAg. CONCLUSION: Optimized CD-PCR can detect mutation independent of the amount of initial templates and the number of PCR cycles.

  8. Status of Health related Quality of life between HBV and HCV Patients of Pakistan

    OpenAIRE

    Awan, Masood Sarwar; Waqas, Muhammad; Ali, Mumtaz; Aslam, Muhammad Amir

    2011-01-01

    The aim of the study is to explore the factors those differentiate health related quality of life (HRQOL) among hepatitis B (HBV) and hepatitis C (HCV) patients. Different public and private hospitals of Sargodha district were visited and 120 patients of hepatitis B and C were interviewed. World health related quality of life-BREF (WHOQOL-BREF) questionnaire was used to construct HRQOL instrument. Multiple regression analysis was performed to observe the collision of demographic, medica...

  9. Seroprevalences of HBV, HCV and HIV among Children who examined Before Elective Surgery in Mardin province

    OpenAIRE

    Tekin A et al.

    2011-01-01

    Objectives: The aim of this study was to investigate the seroprevalence of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among children who examined before elective surgery in Mardin province. Materials and Methods: Between 01 November 2008 and 30 April 2010, a total of 556 patients aged 0–16 years, who planned to be operated, were investigated for viral hepatitis seroprevalences in the Mardin Women and Pediatrics Hospital. Children’s blood samples w...

  10. Clinical and laboratory characteristics associated with dyslipidemia and liver steatosis in chronic HBV carriers

    Directory of Open Access Journals (Sweden)

    Angélica Luciana Nau

    2014-04-01

    Full Text Available Introduction Chronic hepatitis B virus (HBV infection and liver steatosis (LS are the most common causes of chronic liver disease, and their coexistence is frequently observed in clinical practice. Although metabolic syndrome is the main cause of LS, it has not been associated with HBV infection. The aims of this study were to describe the lipid profile and prevalence of LS among HBV carriers and to identify the characteristics associated with LS in this group. Methods This retrospective cross-sectional study included hepatitis B surface antigen (HBsAg-positive patients evaluated during 2011 and 2012. Results Of the 83 patients included, the mean age was 46.4±12.5 years, 53% were men, and 9.1% were hepatitis B e antigen (HBeAg -positive. These patients exhibited the following lipid profile: total cholesterol = 175.4±38.8mg/dL, low-density lipoprotein (LDL = 113.0±32.7mg/dL, and triglycerides = 91.1±45.2mg/dL. Their fasting glucose was 95.3±14.5g/dL, and fasting insulin was 6.1±5.9µIU/mL. Liver steatosis was observed on abdominal ultrasound in 11.3% of individuals. Factors associated with the presence of LS included higher levels of total cholesterol, prothrombin activity, fasting insulin, and body mass index (BMI as well as lower levels of aspartate aminotransferase (AST. Conclusions These findings suggest that LS in patients with chronic HBV appears to be a consequence of metabolic alterations and insulin action rather than of viral factors.

  11. Seroprevalence of HIV, HBV, HCV, and HTLV among Pregnant Women in Southwestern Nigeria.

    Science.gov (United States)

    Opaleye, Oluyinka Oladele; Igboama, Magdalene C; Ojo, Johnson Adeyemi; Odewale, Gbolabo

    2016-01-01

    Sexually transmitted infections (STIs) are major public health challenge especially in developing countries. This study was designed to determine the prevalence of Hepatitis B virus (HBV), Hepatitis C Virus (HCV), Human immunodeficiency virus (HIV), and Human T-cell lymphotropic Virus type I (HTLV-I) among pregnant women attending antenatal clinic, in Ladoke Akintola University Teaching Hospital, Osogbo, and South-Western Nigeria. One hundred and eighty two randomly selected pregnant women were screened for HBsAg, anti-HCV, anti-HIV and HTLV-1 IgM antibodies using commercially available ELISA kit. Of the 182 blood samples of pregnant women screened whose age ranged from 15-49 years, 13 (7.1%), 5 (2.7%), 9 (4.9%), and 44 (24.2%) were positive for HBsAg, anti-HCV, anti-HIV, and HTLV-1 IgM antibodies, respectively. The co-infection rate of 0.5% was obtained for HBV/HCV, HBV/HIV, HIV/HTLV-1, and HCV/HTLV-1 while 1.1% and 0% was recorded for HBV/HTLV-1 and HCV/HIV co-infections, respectively. Expected risk factors such as history of surgery, circumcision, tattooing and incision showed no significant association with any of the viral STIs (P > 0.05). This study shows that there is the need for a comprehensive screening of all pregnant women for HBsAg, anti-HCV, anti-HIV and HTLV-1 to prevent mother to child transmission of these viral infections and its attending consequences. PMID:25879258

  12. 乙肝病毒携带孕妇检出病毒阳性年龄及疫苗接种调查%Investigation on detection age of positive HBV and vaccine inoculation of HBV - infected pregnant women

    Institute of Scientific and Technical Information of China (English)

    陈红; 任群

    2011-01-01

    目的:了解乙型肝炎病毒母婴和父婴传播中垂直传播和水平传播的比例和乙肝病毒携带孕妇乙肝疫苗接种情况.方法:对父母也为乙肝病毒携带者的乙型肝炎病毒携带孕妇的乙肝病毒检出年龄进行调查,并对乙肝病毒携带孕妇乙肝病毒检出前乙肝疫苗接种情况也进行了调查.结果:①165例被调查乙肝病毒携带孕妇中,否认在检出乙肝病毒阳性前家庭有乙肝病毒接触史72例,占43.64%.有非家庭乙肝病毒接触史11例,占6.67%.家庭中有乙肝病毒携带者76例,占46.06%,其中母亲为乙肝病毒携带者42例,占25.45%,父亲为乙肝病毒携带者21例,占12.73%,丈夫为乙肝病毒携带者13例,占7.88%.做过外科手术6例,占3.64%.②母亲为乙肝病毒携带者加父亲为乙肝病毒携带者63例中,4例1岁以前检出乙肝病毒阳性,占6.35%,1岁以后检出乙肝病毒阳性59例,占93.65%,差异有统计学意义(X2=96.032,P=0.000).其中6例7岁以前检出乙肝病毒阳性,占9.52%,其余57例均在7岁以后检出乙肝病毒阳性,占90.48%,经统计学处理,7岁以前与7岁以后检出乙肝病毒阳性差异仍有统计学意义(X2=76.222,P=0.000).③165例被调查乙肝病毒携带孕妇中有98例明确自己检出乙肝病毒阳性前是否接种过乙肝疫苗,占被调查乙肝病毒携带孕妇的59.39%.其中检出乙肝病毒阳性前接种过乙肝疫苗者39例,占39.80%,但均未在检出前3年内接种乙肝疫苗.未接种过乙肝疫苗者59例,占60.20%.结论:乙肝病毒母婴传播和父婴传播中水平传播多于垂直传播.全程接种乙肝疫苗后不可能终生免疫,乙肝病毒密切接触者需要定期检测乙肝保护性抗体定量,及时加强免疫.%Objective: To understand the ratio of vertical transmission and horizontal transmission in mother - to - fetus transmission and father - to - fetus transmission of hepatitis B virus ( HBV ) and the vaccine inoculation situation of HBV

  13. The Experimental Study on Treating Transgenic HBV Mice with Recombined IL-2-PreS DNA Vaccine

    Institute of Scientific and Technical Information of China (English)

    李建远; 王海燕; 沈肖方; 王学波; 靳绍华; 刘芙君; 刘运祥

    2004-01-01

    The aim of this study is to investigate the feasibility and mechanism of hIL-2-preS DNA vaccine as prevention and therapeutic approach against Hepatitis B. Eukaryon expression vector involving hIL-2 and preS gene was constructed with recombinant technique and transferred into normal BALB/c mice and HBV transgenic mice (Tg-Mice) respectively. Tnen a series of detection were performed: detection of anti-preS2, HBs antibody and HBsAg in BALB/c mice and Tg-mice with ELISA, quantification of HBV DNA copies in HBV Tg-mice serum with real-time PCR, determination of hepatitis degree with immunopathological HE staining and detection of liver function. Anti-preS1 can be detected at 4th , 6th and 10th week in inoculated BALB/c mice. Injection with gene gun gained an advantage over muscular and subcutaneous injection since it acquired just 1/10 inoculation quantity (10μg/mouse). Highest expression of IgG2a at 4th week suggested Thl-mediated immune response, which facilitated HBV cleaning. Of all inoculated HBV Tg-mice, 80% of them showed anfi-preS2, HBs antibody positive and HBV DNA decreased, and 20% showed negative for HBsAg. HE staining to hepatic tissue showed obvious infiltration of inflammatory cells, swelling and granular degeneration of hepatocytes. In our study, IL-2-preS DNA vaccine which can provoke the humoral and cellular immune response and break the immune tolerance supports the designation and construction of new vaccine against HBV and specific immune remedy for HBV continuous infection.

  14. Omega-3 fatty acid improves the clinical outcome of hepatectomized patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma

    OpenAIRE

    Wu, Zhengshan; Qin, Jianjie; Pu, Liyong

    2012-01-01

    Omega-3 fatty acid supplemented total parenteral nutrition improves the clinical outcome of patients undergoing certain operations; however, its benefits for patients with hepatitis type B virus (HBV)-associated hepatocellular carcinoma (HCC) who have undergone hepatectomy are still not clear. The aim of this study was to evaluate the effect of omega-3 fatty acid supplemented total parenteral nutrition on the clinical outcome of patients with HBV-associated HCC who underwent hepatectomy at ou...

  15. Telbivudine (Sebivo in patients with hepatitis B virus (HBV chronic infection

    Directory of Open Access Journals (Sweden)

    Viola Sacchi

    2008-12-01

    Full Text Available Hepatitis B is the most common serious liver infection in the world, with about 350 million people who are infected with the hepatitis B virus (HBV and about 1 million deaths annually.Hepatitis B is characterized by an acute and a chronic phase, if the subject fails to produce adequate immune response.About 5-10% of adults infected with HBV go on to develop chronic infection and become chronic carriers (CHB; moreover, the liver damage, if not stopped, continues until cirrhosis or hepatocellular carcinoma. In the natural history of HBV infection, the most important event is HBeAg seroconversion, characterized by loss of HBeAg (a specific antigen of the virus and development of anti-HBe antibodies (HBeAg-positive patients. If the seroconversion has occurred early (when liver damage is not already significant and is maintained, long-term prognosis is excellent. The disease can follow a more aggressive course if active viral replication persists despite anti-HBe positivity. This state, characterized by continuing viral replication, has been termed as HBeAg-negative CHB, and is the most prevalent form in Italy. At the moment, there are 4 approved antiviral drug classes, with different antiviral efficacy, for the treatment of chronic hepatitis B: interferons, nucleoside analogues, nucleotide analogues, and cyclopents.The primary target of the treatment is a prolonged suppression of viral replication, in order to avoid long term complications and increase survival.

  16. Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Shi, Yang, E-mail: yangshi_xz@126.com; Song, Qingwei; Hu, Dianhe; Zhuang, Xiaohu; Yu, Shengcai

    2015-05-22

    Hepatocellular carcinoma (HCC) is one of the most common cancers and can be induced by chronic HBV infection. The role of HBV-specific immune responses in mediating tumorigenesis and HCC prognosis is debated. The effect of intratumoral microenvironment on tumor-infiltrating lymphocytes (TILs) is also unclear. Here, we examined resected tumor tissue from 36 patients with HBV-induced HCC. We categorized study cohort based on ex vivo IL-10 secretion by tumor cells into high IL-10-secreting (Hi10) and low IL-10-secreting (Lo10) groups, and found that the Lo10 group was less sensitive to TLR ligand stimulation. TILs from the Lo10 group contained higher frequencies of HBV-specific IFN-g-producing cells and total IFN-g-producing cells, and possessed higher proliferative capacity. Moreover, the proliferative capacity of TILs from the Hi10 group was negatively correlated with IL-10 secretion from tumor cells. Together, our data demonstrated that low IL-10-producing capacity in HBV-induced HCC tumors is associated with enhanced TIL activity. - Highlights: • We examined intratumoral IL-10 production in HBV-induced HCC. • We grouped HCC tumors into Hi10 and Lo10 groups based on their IL-10 production. • Lo10 groups had better IFN-g response by TILs. • Lo10 groups had better TIL proliferative capacity. • Lo10 group tumor cells were refractory to TLR ligand stimulation.

  17. Watershed Modeling of Nutrient Transport Covering the Country of Sweden - Scale Transfer in HBV-NP

    Science.gov (United States)

    Arheimer, B.; Andersson, L.

    2002-12-01

    Eutrophication of the Baltic Sea and its coastal zone is considered a serious environmental problem. The problems are mainly caused by excessive load of nitrogen (N) and phosphorus (P). To improve the situation new policies including watershed-based water management are implemented. However, this also demands watershed-based knowledge of nutrient transport proc-esses and appropriate tools for landscape planning. A watershed model (HBV-NP) that can be applied both on the local and the national scale has thus been developed to be used both for international reporting and scenario estimates for more efficient nutrient control strategies. The P part is presently developed within the Swedish Water Management Research Program (VASTRA), in which HBV-NP will be used for evaluation of best management practices, and for communication with local stake-holders. The model has recently been applied at the national scale for calculations of flow-normalized annual average of gross load, N retention and net transport, and source apportionment of the N load reaching the sea. In this application (called TRK) several submodels with different levels of process descriptions were linked together. Dynamic and detailed models were included for arable leaching (SOIL-N model), rainfall interpolation, atmospheric deposition (MATCH model), water balance (HBV), and nutrient transformation in groundwater, rivers and lakes (HBV-N). Based on landscape information in GIS, different leaching rates and emissions were assigned to the water discharge from similar landscape elements in 1000 subbasins covering Sweden. Scale transfer was mainly achieved through up-scaling procedures and by using the conceptual model approach for watershed hydrology, including variability parameters that are calibrated for regions. The modeled river flow and N concentrations were validated against time-series from several independent-monitoring stations. A similar national system is now under development for P, including

  18. acute onset Pancreatitis in the third trimester of Pregnancy in HBV Carrier Women taking telbivudine for Blocking Mother-to-Infant transmission

    Institute of Scientific and Technical Information of China (English)

    2014-01-01

    Acute pancreatitis in pregnancy (APIP) is rare and the reasons for APIP are biliary disease and congenital or acquired hypertriglyceridemia, which could occur during any trimester but more than 50% cases happened during the third trimester. In this report, one case of a young pregnant woman, a HBV carrier in her 37th week+5 d of gestation, was admitted to Emergency Department due to acute abdominal pain, vomiting and diarrhea. The patient was in antiretroviral treatment with telbivudine from 28 weeks of gestation to prevent mother-to-child transmission of HBV. Laboratory tests demonstrated hypertriglyceridemia, abdominal computed tomography scan revealed peripancreatic edema. Hyperlipidemic pancreatitits was primary diagnosed and the patient was admitted to the intensive care unit. Considering the possible role in the pathogenesis of pancreatitis, telbivudine was interrupted after birth giving. After supportive treatment, her condition gradually improved. Since it is the ifrst description of APIP during treatment with telbivudine, the association between pregnancy, hyperlipidemia, telbivudine and acute pancreatitis has been well investigated.

  19. Prevalence of HIV-1/2, HTLV-I/II, hepatitis B virus (HBV, hepatitis C virus (HCV, Treponema pallidum and Trypanosoma cruzi among prison inmates at Manhuaçu, Minas Gerais State, Brazil Prevalência do HIV-1/2, do HTLV-I/II, do vírus da hepatite B (HBV e C (HCV, do Treponema pallidum e do Trypanosoma cruzi entre presidiários em Manhuaçu, Minas Gerais, Brasil

    Directory of Open Access Journals (Sweden)

    Bernadette Corrêa Catalan-Soares

    2000-02-01

    Full Text Available The purpose of this study was to determine the seroprevalence of human immunodeficiency virus (HIV-1/2, human T-cell lymphotropic virus (HTLV-I/II, hepatitis B virus (HBV, hepatitis C virus (HCV, Treponema pallidum and Trypanosoma cruzi among 63 male prisoners in Manhuaçu, Minas Gerais, Brazil and to compare this with data from eligible blood donors. The positive results were as follows: 11/63 (17.5% for HBV, 5/63 (7.4% for syphilis, 4/63 (6.3% for HCV, 3/63 (4.8% for Chagas' disease, 2/63 (3.2% for HIV-1/2 and 1/63 (1.6% for HTLV-I/II. The seroprevalence in prisoners was higher than among blood donors, mainly for antibodies to HIV-1/2, HCV and HBV. This is probably due to low social economic level, illiteracy, higher proportion with a prior history of intravenous drug use and/or unsafe sexual behavior. Therefore, these prisoners constitute a high risk group and routine screening and counseling are recommended.O objetivo deste estudo foi determinar a oroprevalência do vírus da imunodeficiência humana (HIV-1/2, do vírus linfotrópico humano (HTLV-I/II, da hepatite B (HBV, da hepatitis C (HCV, do Treponema pallidum e do Trypanosoma cruzi em 63 presidiários do sexo masculino em Manhuaçu, Minas Gerais, Brasil e comparar com resultados de doadores de sangue. Os resultados positivos foram: 11/63 (17,5% para HBV, 5/63 (7,4% para sífilis, 4/63 (6,3% para HCV, 3/63 (4,8% para doença de Chagas, 2/63 (3,2% para HIV-1/2 e 1/63 (1,6% para HTLV-I/II. A soroprevalência em prisioneiros foi mais alta que entre doadores de sangue, principalmente para anticorpos anti-HIV-1/2, HCV e HBV. Isso se deve provavelmente ao baixo nível socio-econômico e de escolaridade, proporção elevada de história pregressa de uso de drogas endovenosas e/ou comportamento sexual de risco. Concluímos que prisioneiros constituem um grupo de alto risco para essas doenças e testes de triagem e aconselhamento são recomendados como rotina no ambiente carcerário.

  20. Recombination of IL18-HBV S Gene Vaccine to Resist Tumor and Hepatitis B%抗肿瘤和乙肝双效IL18-HBV S基因疫苗的构建

    Institute of Scientific and Technical Information of China (English)

    何淑雅; 薛志红; 任为; 刘映霞; 尹志华

    2001-01-01

    [Purpose] To find the combination function of 1L-18 and HBV S gene. [Method] 1L-18 cDNA was obtained by RT-PCR from human embryo liver tissue. And an eukaryote expression vector -pEGFP-N1/ IL-18 with a report gene which was expressing green fluorescene protein was constructed. Then the authors got the IL-18 cDNA by restriction enzyme and PCR. Because of its liverphagy and immunization, the authors used HBV S gene from an expression vector-pcDNA3.0/S and linked it with 1L-18 cDNA. [Result]This two genes were subcloned into an expression eukaryote vector-pIRES-EGFP and formed a new expression vector pIRES-EGFP-S-IL18 that would resist tumor and Hepatitis B.[Conclusion]The recombination of IL18-HBV S gene makes great progress in enhancing the immunity of HBV gene vaccine. It could play a basic role in resisted rumor and Hepatitis B.%[目的]探讨IL-18及乙肝病毒s基因(HBV s)的联合功效。[方法]从胎肝组织中抽提总RNA,RT-PCR扩增IL-18cDNA基因。从载体pcDNA3.0/S中限制性酶切获取HBV S基因,然后,将其与IL—18 cDNA一并亚克隆到真核表达质粒pIRES—EGFP中。[结果]构建了具有抗肿瘤及乙肝双重功效的IL18-HBV S乙肝基因疫苗。[结论]含有IL-18基因的HBv基因疫苗的构建为基因疫苗的功能和应用研究提供了基础。

  1. Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy.

    Science.gov (United States)

    Audsley, Jennifer; Robson, Christopher; Aitchison, Stacey; Matthews, Gail V; Iser, David; Sasadeusz, Joe; Lewin, Sharon R

    2016-01-01

    Background.  Advanced fibrosis occurs more commonly in human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected individuals; therefore, fibrosis monitoring is important in this population. However, transient elastography (TE) data in HIV-HBV coinfection are lacking. We aimed to assess liver fibrosis using TE in a cross-sectional study of HIV-HBV coinfected individuals receiving combination HBV-active (lamivudine and/or tenofovir/tenofovir-emtricitabine) antiretroviral therapy, identify factors associated with advanced fibrosis, and examine change in fibrosis in those with >1 TE assessment. Methods.  We assessed liver fibrosis in 70 HIV-HBV coinfected individuals on HBV-active combination antiretroviral therapy (cART). Change in fibrosis over time was examined in a subset with more than 1 TE result (n = 49). Clinical and laboratory variables at the time of the first TE were collected, and associations with advanced fibrosis (≥F3, Metavir scoring system) and fibrosis regression (of least 1 stage) were examined. Results.  The majority of the cohort (64%) had mild to moderate fibrosis at the time of the first TE, and we identified alanine transaminase, platelets, and detectable HIV ribonucleic acid as associated with advanced liver fibrosis. Alanine transaminase and platelets remained independently advanced in multivariate modeling. More than 28% of those with >1 TE subsequently showed liver fibrosis regression, and higher baseline HBV deoxyribonucleic acid was associated with regression. Prevalence of advanced fibrosis (≥F3) decreased 12.3% (32.7%-20.4%) over a median of 31 months. Conclusions.  The observed fibrosis regression in this group supports the beneficial effects of cART on liver stiffness. It would be important to study a larger group of individuals with more advanced fibrosis to more definitively assess factors associated with liver fibrosis regression. PMID:27006960

  2. Performance and diagnostic usefulness of commercially available enzyme linked immunosorbent assay and rapid kits for detection of HIV, HBV and HCV in India

    Directory of Open Access Journals (Sweden)

    Maity Susmita

    2012-11-01

    Full Text Available Abstract Background HIV, HBV and HCV pose a major public health problem throughout the world. Detection of infection markers for these agents is a major challenge for testing laboratories in a resource poor setting. As blood transfusion is an important activity saving millions of live every year, it also carries a risk of transfusion transmissible infections caused by these fatal blood borne pathogens if the quality of testing is compromised. Conventional ELISA is regarded as the mostly used screening technique but due to limitations like high cost, unavailability in many blood banks and testing sites, involvement of costly instruments, time taking nature and requirement of highly skilled personnel for interpretation, rapid tests are gaining more importance and warrants comparison of performance. Results A comparative study between these two techniques has been performed using commercially available diagnostic kits to assess their efficacy for detection of HIV, HBV and HCV infections. Rapid kits were more efficient in specificity with synthetic antigens along with high PPV than ELISA in most cases. Comparison between different ELISA kits revealed that Microlisa HIV and Hepalisa (J. Mitra & Co. Pvt. Ltd.; ERBA LISA HIV1 + 2, ERBA LISA Hepatitis B and ERBA LISA HCV (Transasia Bio-medicals Ltd. gives uniform result with good performance in terms of sensitivity, specificity, PPV, NPV and efficiency, whereas, Microlisa HCV (J. Mitra & Co. Pvt. Ltd., Microscreen HBsAg ELISA and INNOVA HCV (Span Diagnostics Ltd. did not perform well. Rapid kits were also having high degree of sensitivity and specificity (100% except in HIV Comb and HCV Comb (J. Mitra & Co. Pvt. Ltd.. The kit efficiency didn’t vary significantly among different companies and lots in all the cases except for HCV ELISA showing statistically significant variation (p  Conclusions ELISA is a good screening assay for markers of HIV, HBV and HCV infections. Rapid tests are useful for

  3. Clinical study on safety and immunogenicity of therapeutic dual-plasmid HBV DNA vaccine mediated by in vivo electroporation

    Directory of Open Access Journals (Sweden)

    Hai-yan YANG

    2013-03-01

    Full Text Available Objective  To evaluate the safety and immunogenicity of the therapeutic dual-plasmid HBV DNA vaccine mediated by electroporation (EP in vivo against the hepatitis B virus in healthy adult volunteers. Methods The enrolled 30 healthy volunteers were randomly divided into three dosage groups (10 volunteers in each group, namely: high-dose (4mg, middle-dose (2mg and low-dose (1mg groups. Volunteers received four intramuscular injections of HBV DNA vaccine mediated by in vivo EP at the 0, 4th, 12th and 24th week. Each dose group was further divided into 2 sub-groups (5 persons/per group with different EP frequencies, i.e. 36 and 60 volt. The changes in response was determined by physical diagnosis (ECG, chest X-ray, type-B ultrasound, lab findings (blood and urine routine, blood biochemistry, prothrombin time, thyroid function, tumor biomarkers, immunological variables (IFN-γ, ANA, anti-dsDNA Ab, serological variables pertaining to HBV (HBsAg, HBcAb, HBeAg, HBeAb, HBV DNA and serum anti-HBs status in volunteers before and after receiving EP mediated HBV DNA vaccination. Results The dual-plasmid HBV DNA vaccination mediated by in vivo EP was well tolerated in all healthy volunteers with a stable life signs. It was found that EP-mediated immunization of the therapeutic DNA vaccine against hepatitis B virus had a specific and obvious anti-HBs humoral immune response in one volunteer (17.22mU/ml. Four repeated intramuscular injections of the vaccine did not show any significant adverse effects in the receptors. Although mild elevation of serum ALT and enlarged spleen were found in one individual, the abnormalities disappeared spontaneously at the end of the trial. Conclusions EP-mediated dual-plasmid HBV DNA vaccine is safe and well tolerated with certain degree of humoral immunogenicity.

  4. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.

    Science.gov (United States)

    Dai, Shenglan; Zhuo, Meng; Song, Linlin; Chen, Xiaohua; Yu, Yongsheng; Zang, Guoqing; Tang, Zhenghao

    2016-07-01

    Predominant T helper cell type 1 (Th1) immune responses accompanied by boosted HBV-specific cytotoxic T lymphocyte (CTL) activity are essential for the clearance of hepatitis B virus (HBV) in chronic hepatitis B (CHB) patients. Ubiquitin (Ub) serves as a signal for the target protein to be recognized and degraded through the ubiquitin-proteasome system (UPS). Ubiquitinated hepatitis B core antigen (Ub-HBcAg) has been proved to be efficiently degraded into the peptides, which can be presented by major histocompatibility complex (MHC) class I resulting in stimulating cell-mediated responses. In the present study, lentiviral vectors encoding Ub-HBcAg (LV-Ub-HBcAg) were designed and constructed as a therapeutic vaccine for immunotherapy. HBcAg-specific cellular immune responses and anti-viral effects induced by LV-Ub-HBcAg were evaluated in HBV transgenic mice. We demonstrated that immunization with LV-Ub-HBcAg promoted the secretion of cytokines interleukin-2 (IL-2), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), generated remarkably high percentages of IFN-γ-secreting CD8(+) T cells and CD4(+) T cells, and enhanced HBcAg-specific CTL activity in HBV transgenic mice. More importantly, vaccination with LV-Ub-HBcAg could efficiently decreased the levels of serum hepatitis B surface antigen (HBsAg), HBV DNA and the expression of HBsAg and HBcAg in liver tissues of HBV transgenic mice. In addition, LV-Ub-HBcAg could upregulate the expression of T cell-specific T-box transcription factor (T-bet) and downregulate the expression of GATA-binding protein 3 (GATA-3) in spleen T lymphocytes. The therapeutic vaccine LV-Ub-HBcAg could break immune tolerance, and induce potent HBcAg specific cellular immune responses and therapeutic effects in HBV transgenic mice. PMID:26874581

  5. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.

    Science.gov (United States)

    Giray, Burcu Gurer; Emekdas, Gurol; Tezcan, Seda; Ulger, Mahmut; Serin, Mehmet Sami; Sezgin, Orhan; Altintas, Engin; Tiftik, Eyup Naci

    2014-07-01

    Recently, circulating miRNAs have been reported as promising biomarkers for various pathologic conditions including cancer. Certain microRNAs (miRNAs) have been shown early diagnostic potential for many types of cancer. The objective of this study was to investigate the potential of certain serum/plasma miRNAs as novel non-invasive biomarkers for early diagnosis of hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). For this reason, the expression levels of 24 miRNA (let-7c, miR-92a-3p, 423-5p, 150-5p, 223-3p, 125b-5p, 342-3p, miR-206, 122-5p, 375, 223-5p, 10a-5p, 23b-5p, 99a-5p, 23a-5p, 10a-3p, 122-3p, 125b-1-3p, 23b-3p, 125b-2-3p, 23a-3p, 92a-1-5p, 92a-2-5p, 99a-3p) were analyzed in plasma of patients with chronic hepatitis B, HBV-positive cirrhosis and HBV-positive HCC and compared with control group samples. Totally 94 plasma samples; 28 control and 66 patient plasma (24 CHB, 22 HBV-positive cirrhosis, 20 HBV-positive HCC) and were included in this study. The expression levels of 24 miRNAs were detected for all control and patient group plasma samples by qRT-PCR using BioMark™ 96.96 Dynamic Array (Fluidigm Corporation) system. The expression levels of miR-125b-5p were detected 2.85 fold, 2.46 fold and 1.89 fold (p = 0.01513, p = 0.0009440, p = 0.0001446) up regulated in CHB, HBV-positive cirrhosis and HBV-positive HCC, respectively when compared versus control group individually by Mann-Whitney U test. The expression levels of miR-223-3p were detected 5.55 fold, 13.88 fold and 12.65 fold (p = 0.01513, p = 0.0009440, p = 0.0001446) down regulated in same comparisons. When all groups were compared versus control group by one-way ANOVA test, the expression levels of miR-223-3p were also found statistically significant (p < 0.05). Although not statistically significant, miR-125b-5p tended to be upregulated. (p = 0.07192). These results significantly imply that miR-125b-5p and miR223-3p could be used as novel non-invasive biomarkers of HBV-positive HCC

  6. An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients

    OpenAIRE

    Stalke, Piotr; Rybicka, Magda; Wróblewska, Anna; Dreczewski, Marcin; Stracewska, Ewa; Smiatacz, Tomasz; Bielawski, Krzysztof Piotr

    2014-01-01

    Background Success in treating hepatitis B virus (HBV) infection with nucleoside analogues drugs is limited by the emergence of drug-resistant viral strains upon prolonged therapy. In addition to mutation patterns in the viral polymerase gene, host factors are assumed to contribute to failure of treatment in chronic HBV infections. The aim of this study was to analyze the correlation between efficacy of antiviral therapy and the prevalence of HBV pretreatment drug-resistant variants. We also ...

  7. Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression

    Institute of Scientific and Technical Information of China (English)

    Rosa; Zampino; Adriana; Boemio; Aldo; Marrone; Luciano; Restivo; Maria; Chiara; Fascione; Riccardo; Nevola; Luigi; Elio; Adinolfi; Nicola; Coppola; Carmine; Minichini; Mario; Starace; Evangelista; Sagnelli; Grazia; Cirillo; Emanuele; Miraglia; del; Giudice; Maria; Stanzione; Emanuele; Durante-Mangoni; Giovanna; Salzillo

    2014-01-01

    AIM:To evaluate steatosis,insulin resistance(IR)and patatin-like phospholipase domain-containing 3(PNPLA3) and their relation to disease progression in hepatitis B and C viruses(HCV-HBV) coinfected patients.METHODS:Three hundred and thirty patients with biopsy proven chronic hepatitis were enrolled:66 had HBV-HCV,66 HBV and 198 HCV infection.Prevalence of steatosis,IR and PNPLA3 polymorphisms and their relation to anthropometric,biochemical,virological and histological parameters were evaluated.RESULTS:Prevalence of steatosis in group HBV-HCV was similar to that in HCV(47.0% vs 49.5%,respec-tively);group HBV showed the lowest steatosis(33.3%).Group HBV-HCV had a lesser degree of steatosis than HCV(P = 0.016),lower HCV RNA levels(P = 0.025) and lower prevalence and degree of IR(P = 0.01).PNPLA3 polymorphisms were associated with steatosis.Group HBV-HCV showed higher levels of liver fibrosis than group HCV(P = 0.001),but similar to that ob-served in HBV group.In HBV-HCV group,liver fibrosis was not associated with steatosis,IR or PNPLA3.HBV infection was the independent predictor of advanced liver fibrosis.CONCLUSION:HBV-HCV co-infected patients have lower degree of hepatic steatosis,IR and HCV RNA than HCV mono-infected;co-infected patients showed a more rapid liver fibrosis progression that seems to be due to the double infection and/or HBV dominance.

  8. Study on the hepatitis B serum markers and the correlation between serum and milk HBV-DNA in HBV-infectious pregnant women%乙肝病毒携带产妇血清标志物模式与血清及乳汁HBV-DNA相关性研究

    Institute of Scientific and Technical Information of China (English)

    朱珉之; 杭双熊; 申红玉

    2014-01-01

    目的:通过检测分析乙肝病毒携带产妇血清学标志物与血清、乳汁HBV-DNA阳性率的关系,以及产妇血清与乳汁中HBV-DNA含量之间的相关性,旨在指导母乳喂养。方法选取96例乙肝病毒携带产妇,将其分为大三阳组(54例)、小三阳组(25例)、HbsAg和HbeAg均阳性组(8例)及HbsAg和HbcAb均阳性组(9例)。另选取12例乙肝两对半全阴的产妇作为对照组。ELISA法检测乙肝病毒携带产妇乙肝免疫血清学标志物,实时荧光定量PCR法分别检测产妇血清与乳汁中HBV-DNA含量,并对所有检测指标进行相关性分析。结果大三阳组产妇血清和乳汁HBV-DNA阳性率明显高于其他三组(P0.05)。根据乙型肝炎血清学标志物HBeAg是否阳性将96例产妇分为HBeAg阳性组(62例)和HBeAg阴性组(34例),血清HBeAg阳性产妇的血清和乳汁中HBV-DNA阳性率均明显高于HBeAg阴性产妇,差异具有统计学意义(P0.05). The HBV-DNA positive rates in serum and milk in HBeAg positive groups were obvious-ly higher than that in HBeAg-negative group (P<0.01). However, HBV-DNA in serum and milk were also detected in part of the HBeAg-negative pregnancy women. The HBV-DNA content in serum had positive relation with HBV-DNA content in milk (r=0.891, P<0.05). Conclusion In HBV- infectious pregnant women, it is found that the HBV-DNA positive rate in milk was less than that in serum, and the content of HBV-DNA in milk was increased along with that increased in serum. Therefore, it is more reliable to determine the risk of hepatitis B virus transmission from mother to infant by quantitative measurement of HBV-DNA in serum and milk. It is helpful in interrupting HBV trans-mission, deciding the mode of breast-feeding, and guiding breast-feeding, so as to decrease the infectious rate of baby.

  9. A Turbidity Test Based Centrifugal Microfluidics Diagnostic System for Simultaneous Detection of HBV, HCV, and CMV

    Directory of Open Access Journals (Sweden)

    Hung-Cheng Chang

    2015-01-01

    Full Text Available This paper presents a LAMP- (loop-mediated isothermal amplification- based lab-on-disk optical system that allows the simultaneous detection of hepatitis B virus, hepatitis C virus, and cytomegalovirus. The various flow stages are controlled in the proposed system using different balance among centrifugal pumping, Coriolis pumping, and the capillary force. We have implemented a servo system for positioning and speed control for the heating and centrifugal pumping. We have also successfully employed a polymer light-emitting diode section for turbidity detection. The easy-to-use one-click system can perform diagnostics in less than 1 hour.

  10. Using survey results regarding hepatitis B knowledge, community awareness and testing behavior among Asians to improve the San Francisco Hep B Free campaign.

    Science.gov (United States)

    Shiau, Rita; Bove, Fred; Henne, Jeff; Zola, Janet; Fang, Ted; Fernyak, Susan

    2012-04-01

    Asians are disproportionately affected by chronic hepatitis B (HBV) infection and its fatal consequences. The Hep B Free campaign was launched to eliminate HBV in San Francisco by increasing awareness, testing, vaccination and linkage to care. The campaign conducted 306 street intercept and telephone interviews of San Francisco Asians to assess current levels of HBV knowledge, testing behaviors and effectiveness of existing campaign media materials. One-third of respondents ranked HBV as a key health issue in the Asian community, second to diabetes. General HBV awareness is high (85%); however, a majority could not name an effective prevention method. Sixty percent reported having been tested for HBV; provider recommendation was the most often cited reason for testing. Respondents reported a high level of trust in their providers to correctly assess which health issues they may be at risk for developing and test accordingly, confirming that efforts to increase HBV testing among Asians must simultaneously mobilize the public to request testing and compel providers to test high-risk patients. Regarding community awareness, more than half reported hearing more about HBV recently; younger respondents were more likely to have encountered campaign materials and recall correct HBV facts. Assessment of specific campaign materials found that while upbeat images and taglines captured attention and destigmatized HBV, messages that emphasize the pervasiveness and deadly consequence of infection were more likely to drive respondents to seek education and testing. The campaign used survey results to focus efforts on more intensive provider outreach and to create messages for a new public outreach media campaign. PMID:21874365

  11. Extraction of protoporphyrin disodium and its inhibitory effects on HBV-DNA

    Institute of Scientific and Technical Information of China (English)

    Chao-Pin Li; Li-Fa Xu; Qun-Hong Liu; Chao Zhang; Jian Wang; Yu-Xia Zhu

    2004-01-01

    AIM: To explore an ideal method for extracting protoporphyrin disodium (PPN) from unanticoagulated animal blood, and to study the inhibitory effects of PPN on HBV-DNA duplication and its cytotoxicity to 2.2.15 cell strain.METHODS: Protoporphyrin methyl ester and other intermediate products were prepared with protoheme separated from protein hydrolysates of coagulated animal blood, which were finally made into PPN and detected quantitatively with an ultraviolet fluorescent analyzer.Ten μg/ml, 20 μg/ml, 40 μg/ml, 80 μg/ml and 160 μg/ml of PPN-aqueous solution were added into culture medium for 2.2.15 cells respectively. Eight days later, the drug concentration in supernatant from the culture medium was detected when inhibition rate of HBeAg, cell Survival rate when inhibition rate of HBeAg was 50% (ID50), and when survival cells in experimental group were 50% of those in control group (CD50), and the therapeutic index (TI) was also detected. PPN with different concentration of 10 μg/ml,20 μg/ml, 40 μg/ml, 80 μg/ml and 160 μg/ml was respectively mixed and cultivated with HepG2 2.2.15 cell suspension,and then the inhibition of PPN against HBV-DNA was judged by PCR.RESULTS: The extract of henna crystal was identified to be PPN. When the concentrations of PPN were 160 μg/ml and 80 μg/ml, the inhibition rates of HBeAg were 89.8% and 82.4%, and the cell survival rates were 98.7% and 99.2%.CONCLUSION: It is suggested that PPN can be extracted from unanticoagulated animal blood. PPN can inhibit HBV-DNA expression and duplication ih vitro, and has no cytotoxicity to liver cells. Further study and application of PPN are warranted.

  12. The HBV spatially distributed flash flood forecasting model - The Slovenia case study

    Science.gov (United States)

    Tsanis, I. K.; Grillakis, M. G.; Blöschl, G.; Pogačnik, N.

    2009-04-01

    The HBV distributed flash flood forecasting model which is in operational use in northern Austria is applied to a watershed in northwest Slovenia, a case study for the FP6 project HYDRATE. The selected watershed consists of 6 sub-basins with a total area of 646 Km2. Model setup and calibration was performed in this watershed and three long duration rainfall - runoff periods were simulated in order to examine the efficiency of the model. The selected periods included rainfall events that produced high outflows on the exit of the watershed, such as the September 2007 event that caused a flash flooding and severe damages to the towns of Zali Log and Zelezniki. The model uses 1km grid rainfall and temperature data of fifteen minute time intervals in order to simulate the rainfall - runoff process. Inverse distance weighting interpolation is used in order to generate the spatially distributed rainfall and temperature while the hydrological parameters are defined for each 1km grid cell that correspond to one hydrological response units (HRU - areas with analogous hydrogeological characteristics). The basic calibration of the HBV model is based on hydrological parameters of each HRU, parameters that control the rainfall - runoff process within the basin and non HRU parameters that control the river routing between the basins. The model performance is based on seven efficiency criteria that were selected as appropriate for long simulation periods, e.g. coefficient of determination R2 and Nash Sutcliffe efficiency E. The HBV model produced satisfactory results for the three rainfall periods and could be used as an operational model in Slovenia as well.

  13. Composition of inflammatory infiltrate and its correlation with HBV/HCV antigen expression

    Institute of Scientific and Technical Information of China (English)

    Bozena Walewska-Zielecka; Kazimierz Madalinski; Joanna Jablonska; Paulina Godzik; Joanna Cielecka-Kuszyk; Bogumila Litwinska

    2008-01-01

    AIM: To study the composition of liver inflammatory infiltrate in biopsy material from patients chronically infected with hepatotropic viruses and to evaluate the correlation of inflammatory infiltrate with hepatitis B virus (HBV) and hepatitis C virus (HCV) viral antigen expression in chronic B and C hepatitis.METHODS: The phenotype of inflammatory cells was evaluated by the EnVision system, using a panel of monoclonal antibodies. HBV and HCV antigens were detected with the use of monoclonal anti-HBs, poly-clonal anti-HBc and anti-HCV antibodies, respectively.RESULTS: The cellular composition of liver inflammatory infiltrate was similar in the patients with B and C hepatitis: ~50%-60% of cells were T helper lymphooltes. Approximately 25% were T cytotoxic lymphocytes; B lymphocytes comprised 15% of inflammatory infiltrate; other cells, including NK, totalled 10%. Expression of HLA antigens paralleled inflammatory activity. Portal lymphadenoplasia was found more often in hepatitis C (54.5%) than in hepatitis B (30.6%). Expression of HB-cAg was found more often in chronic B hepatitis of moderate or severe activity. Overall inflammatory activity in HBV-infected cases did not correlate with the intensity of HBsAg expression in hepatooltes. Inflammatory infiltrates accompanied the focal expression of HCV anti-gens. A direct correlation between antigen expression and inflammatory reaction in situ was noted more often in hepatitis C than B.CONCLUSION: Irrespective of the etiology and activity of hepatitis, components of the inflammatory infiltrate in liver were similar. Overall inflammatory activity did not correlate with the expression of HBsAg and HCVAg; HBcAg expression, however, accompanied chronic hepatitis B of moderate and severe activity.

  14. Characteristics of S gene mutation in patients with occult HBV infection

    Directory of Open Access Journals (Sweden)

    Jian-hong CHEN

    2015-04-01

    Full Text Available Objective To analyze characteristics of HBV S gene mutation in one patient with occult hepatitis B virus infection, who was positive for serum HBV DNA for long term, but negative for HBsAg in order to reveal the correlation between S gene mutation and development of OBI as well as the progression of the liver disease. Methods Four serum samples were collected at different time-points for the use of amplifying HBV S gene and performing cloning-sequencing. The representative S mutants were selected to construct recombinant vectors for phenotype analysis. Results Several S-gene mutational patterns were detected in the samples, including pre-S1 large fragment deletion, s126-127 "RPCMNCTI" insertion, sQ129N, s131-133 TSM→NST, and classical sG145R mutations. In sequential 4 samples, s131-133 TSM→NST mutation was detected in 0%, 26%, 59% and 74% of viral clones, respectively. The pre-S1 large fragment deletion was constantly found in the 4 serum samples, accounting for 26%, 17%, 15% and 21% of detected viral clones, respectively. Phenotypic analysis showed that sQ129N and s131-133 TSM → NST mutations reduced the affinity of the antibody to HBsAg and increased the secretion of virus particles. Compared with the wild-type strain, the replication capacity and surface antigen promoter Ⅱ (SPⅡ activity of large fragment-deleted (nt 3046-3177 deletion strain were decreased by 43.7% and 97.2%, respectively. In addition, sG145R-induced impairment to secretion capacity of viral particles was verified. Conclusions Clinical presentations of long-term OBI of this HBV-infected patient could be caused by multiple S-gene mutants. Some S-gene mutations influence viral phenotypic characteristics, which might closely be related to the progression of liver disease. DOI: 10.11855/j.issn.0577-7402.2015.03.02

  15. High Serum Levels of TGF-β in Iranians With Chronic HBV Infection

    OpenAIRE

    Khorramdelazad, Hossein; Hassanshahi, Gholamhossein; Nasiri Ahmadabadi, Behzad; Kazemi Arababadi, Mohammad

    2012-01-01

    Background The transforming growth factor-β (TGF-β) is an important cytokine with anti-inflammatory properties. Objectives The main purpose of this study was to compare the serum levels of TGF-β in a group of chronic HBV infected (CHB) patients as well as healthy individuals from South-East of Iran. Patients and Methods Sixty patients with CHB as well as sixty healthy individuals were enrolled in the study. ELISA technique was applied to measure the serum levels of TGF-β in both groups. Resul...

  16. Recombinant HBV vaccine enhances the rate of sustained virological response when early initiated after anti-HCV combination therapy.

    Science.gov (United States)

    Hanafy, Amr Shaaban; Farag, Alaa Ahmad; Hassanin, Hassan Mahmoud; Hassaneen, Ahmad Mahmoud

    2016-01-01

    The overall SVR rate for chronic hepatitis C genotype 4 using the Standard of care is 54.3%. HBV infection can be prevented by the administration of effective and safe vaccine. Evaluation of the vaccination-induced anti-HBs response rates in a cohort of HCV Egyptian patients after being exposed to antiviral combination therapy and the magnitude of its effect on the rate of SVR through its putative role in induction of crossed immunity. (A) 500 HCV patients who had completed the course of antiviral therapy and achieved ETR were retrospectively analyzed and received 20 μg of recombinant DNA vaccine for hepatitis B at time intervals (0, 1, and 4 months). The first dose of the vaccine was initiated one month post treatment. (B) Laboratory analysis: Included routine preliminary investigations to anti viral therapy and specific investigations as determination of anti-HBs antibodies 2 months following the third dose of vaccine. 433 patients showed protective response (86.6%), 67 patients were non-responders (13.4%) (P = 0.003). Adding HBV vaccine 1 month post-treatment increased SVR (400 patients, 80%) (χ(2)  = 40.3, P = 0.000). Diabetes affect response to HBV vaccine (P = 0.0001). Adding HBV vaccine to the post treatment care of patients with HCV after termination of antiviral therapy gain two benefits; protection from HBV and significant increase in rates of SVR. PMID:26147509

  17. Immunization with adenovirus LIGHT-engineered dendritic cells induces potent T cell responses and therapeutic immunity in HBV transgenic mice.

    Science.gov (United States)

    Jiang, Wenzheng; Chen, Ran; Kong, Xiaobo; Long, Fengying; Shi, Yaru

    2014-07-31

    LIGHT, a TNF superfamily member (TNFSF14), is a type II transmembrane protein expressed on activated T cells and immature dendritic cells (DCs). However, the expression of LIGHT on mature DCs is down-regulated. Recent studies demonstrated that LIGHT provides potent costimulatory activity for T cells, enhancing proliferation and the production of Th1 cytokines independently of the B7-CD28 pathway. Here, we evaluated the effectiveness of peptide-pulsed DC-mediated antiviral immunity in HBV transgenic mice and the immunoadjuvant effect of LIGHT. The bone marrow-derived DCs were modified in vitro with an adenovirus (Ad) vector expressing mouse LIGHT (Ad-LIGHT), the expression of costimulatory molecules was up-regulated and the secretion of cytokines IL-12 and IFN-γ increased. LIGHT-modified DCs enhanced allostimulation for T cells in mixed lymphocyte reaction (MLR). HBV peptide-pulsed DCs elicited HBV specific CD8+ T cell response and reduced the level of HBsAg and HBV DNA in sera of HBV transgenic mice. Importantly, LIGHT-modified DCs could induce stronger antiviral immunity. These results support the concept that genetic modification of DCs with a recombinant LIGHT adenovirus vector may be a useful strategy for antiviral immunotherapy. PMID:24951859

  18. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine

    International Nuclear Information System (INIS)

    CD8+ T cells play a critical role in protective immunity against Hepatitis B Virus (HBV). Epitope-based DNA vaccines expressing HBV-dominant CTL epitopes can be used as candidate vaccines capable of inducing cytotoxic T Lymphocytes (CTL) responses. A plasmid DNA encoding a CTL epitope of HBV core antigen, HBc18-27, was constructed. Intramuscular immunization of C57BL/6 mice with this DNA vaccine resulted in successful induction of HBV-specific CTL responses. In order to promote transportation of the peptide into endoplasmic reticulum (ER) to bind to MHC class I molecules for optimal class I antigen presentation, an ER targeting sequence (ERTS) was fused with the C18-27 encoding gene. ERTS fusion significantly enhanced specific CD8+ T cell responses in terms of CTL cytolysis as well as IFN-γ secretion. This enhancement was correlated with promoted epitope presentation on target cell surface. We report here an enhanced immunogenicity of an epitope-based DNA vaccine using an ER targeting signal sequence, which has significant implications for future design of therapeutic HBV vaccine

  19. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations

    Directory of Open Access Journals (Sweden)

    Schmit Jean-Claude

    2011-05-01

    . Conclusions Despite the existing national risk-reduction strategies implemented since 1993, high prevalence of HCV and HBV infections in injecting drug users is observed. Our study showed that implementing risk-prevention strategies, including immunisation remains difficult with PDUs. Improvement should be looked for by the provision of field healthcare structures providing tests with immediate results, advice, immunisation or treatment if appropriate.

  20. HBV相关慢加亚急性肝衰竭患者中Th17细胞、Treg细胞的变化及其与肝功能和HBV-DNA载量间的研究%Change of Th17 cell, Treg cell in patients with HBV-associated acute-on-chronic liver failure and its relationship with liver function and HBV-DNA load

    Institute of Scientific and Technical Information of China (English)

    沈敏; 林明强; 冯奇桃; 吕友凯; 李永武

    2016-01-01

    目的:通过检测乙型肝炎病毒(HBV)相关慢加亚急性肝衰竭(HBV-ACLF)患者外周血中的Th17细胞、Treg细胞的水平,探讨Th17、Treg细胞在HBV-ACLF发病机制中的作用。方法流式细胞术检测22例HBV-ACLF患者、24例慢性乙型肝炎患者(CHB)以及20例健康对照者(HC)外周血Th17、Treg细胞的频率,荧光定量PCR法检测患者外周血HBV-DNA水平,同时分析Th17细胞、Treg细胞、Th17/Treg与谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TB)及HBV-DNA载量间的相关性。结果 HBV-ACLF组患者的Thl7细胞、Treg细胞、Th17/Treg较CHB组和HC组明显增高,CHB组又较HC组Th17细胞、Treg细胞、Th17/Treg升高,差异均有统计学意义(P0.05). Conclusion Th17 and Treg may be in a balanced state in healthy people, and such state might be broken in patients with CHB and HBV-ACLF, which indicates that Th17 and Treg are involved in the occurrence and development of CHB and HBV-AVLF. Th17 cell could be used as an immunological marker for determination of the liver damage degree in HBV-ACLF. Th17, Treg have no correlation with the load of HBV-DNA.

  1. Prevalence of HBV and/or HDV markers using RIA in patients with chronic liver disease

    International Nuclear Information System (INIS)

    Sixty six with different chronic liver disease (CLD) were studied for the prevalence of HBV and/or HDV markers using radioimmunoassay. The total prevalence of HBV markers (i.e. when any of the markers is present) for chronic active hepatitis (CAH), post viral cirrhosis, chronic persistent hepatitis (CPH), cryptogenic cirrhosis, primary biliary cirrhosis (PBC), alcoholic cirrhosis, hepatocellular carcinoma (HCCA) and methyldopa induced chronic hepatitis were 6/13 (46.2%), 6/6 (100%), 7/9 (77.8%), 0/10, 0/2, 10/15 (66.7%), 7/10 (70%) and 0/1 respectively; whereas the total prevalence of anti-delta antibody was 0/13, 1/6 (16.7%), 3/9 (33.3%), 0/10 0/2, 0/15, 2/10 (20%) and 0/1 respectively, while the prevalence of anti-delta antibody for the control group was 4/102 (3.9%). Various patients with CLD, though they showed various viral markers yet they showed different pattern groups. 3 tabs

  2. CRYOGLOBULINEMIC VASCULITIS ASSOCIATED WITH HBV INFECTION: CLINICAL OBSERVATIONS AND LITERATURE REVIEW

    Directory of Open Access Journals (Sweden)

    N. V. Dunaeva

    2014-08-01

    Full Text Available Description of two clinical cases of chronic HBV hepatitis at cirrhotic stage associated with type III cryoglobulinemia manifested with symptoms of systemic vasculitis is presented in current article. There were no signs of HCV infection in both patients. In first case cutaneous vasulitis appeared after 19 years since serological finding of HBsAg and vasculitis progressed despite steroid therapy. Initiation of antiviral therapy (entecavir 0.5 g/day induced transient remission. After interruption of antiviral therapy vasculitis reappeared with several vasculitic ulcers on lower legs. Mild improvement of vasculitis was noted after repeated plasmapheresis, steroid and cytostatic treatment with addition of lamivudin. Despite therapy reactivation of HBV infection was detected. Lamivudin was changed to entecavir and rituximab was given in two 500 mg infusions. Combined antiviral and anti-CD20 treatment induced remission of cutaneous vasculitis and healing of leg ulcers. In other case vasculitis manifested after 21 years since detection of HBsAg with cutaneous purpura, arthritis and microhematuria. Entecavir 0.5 g/day induced rapid virological response and complete remission of symptoms related to vasculitis. Similar literature cases were reviewed and available treatment options in refractory cryoglobulinemic vasculitis were discussed.

  3. The implementation of the HBV model on the Sava River Basin

    International Nuclear Information System (INIS)

    The Swedish HBV model was used for modelling the Sava River discharge and modelling of snow cover over the Sava river watershed in Slovenia. The Sava River is the largest river in Slovenia and tributary of the Danube River, contributing to its largest runoff. It covers more than half of the territory of Slovenia, namely 10700 km2. The watershed is heterogeneous, mountainous in the upper parts and plain in the middle reach. There are also some karstic regions. The floods are caused by heavy rainfall in headwater mountain areas, especially in autumn. Some tributary flows can rise more than a hundred times in such events. For the purpose of flood forecasting the HBV model was set up for the whole watershed using the time step of 24 hours to calibrate the set of model parameters, which then used for recalibration of the model with time step of 1 hour. The watershed was divided to 26 subcatchments. Model input data are precipitation, potential evapotranspiration, and in case of climates with temperatures below zero, temperature data. Measured discharges are needed to calibrate, verify and up-date the model. Satisfactory calibration of the model was achieved, although the topography has strong influence on the meteorological happening in the catchement, especially in the upper stream of the Sava river, and small number of available raingauges.

  4. STUDY OF VIRAL MARKERS (HIV, HBV, HCV IN A TERTIARY CARE HOSPITAL

    Directory of Open Access Journals (Sweden)

    Samatha

    2015-10-01

    Full Text Available BACKGROUND: Viral infections are global health problems, affecting millions. Studies show wide variations in the prevalence patterns of the Human Immuno deficiency, Hepatitis B and Hepatitis C Virus infections. Prevalence of these infections may vary not only from country to country but also in different regions of the same country . The present study was designed to find out the sero - prevalence of HBV, HCV, and HIV infections in patients attending a tertiary care hospital. METHODS: A prospective study was conducted for a period of one year from April 2014 to March 2015. A total of 4 276 patients were screened for Hepatitis B surface Antigen ( HBsAg, anti HCV antibodies and anti HIV antibodies. Patients with symptoms or signs of these viral infections and the patients for routine pre - surgical evaluation, referred by the clinicians were included in the study. Age, sex and serological result data was analysed for these patients. The results were analysed by Chi - square statistics. RESULTS: The sero - prevalence of HBsAg was 2.5%, anti HCV antibodies was 0.63%, anti HIV antibodies was 1.73% whereas, co - infection of HBsAg with HIV was seen in only three patients. CONCLUSION: In the present study, the sero - prevalence of Hepatitis B Virus (HBV was higher than HIV and HCV infections. As these viral infections are dangerous and cause morbidity an d mortality, population based awareness & screening programmes are recommended to limit the further spread.

  5. Detection of Mutations Resistant to Lamivudine or Adefovir in HBV and Its Management

    Institute of Scientific and Technical Information of China (English)

    De-xing Jia; Jing Feng; Ping Li; Xiu-ying Lun; Xian-jie Yu

    2013-01-01

    Objective Nucleos(t)ide analogues (NAs) naïve chronic hepatitis B(CHB) patients were given rescue combination therapy after drug resistance to lamivudine or adefovir. Evolution of HBV mutation patterns and its impact on antiviral effects were studied. Methods Total of 142 naïve CHB patients treated with lamivudine were randomly divided into two groups when lamivudine resistance occurred. One group was added with adefovir, the other was switched to entecavir and adefovir. Seventy-two naïve CHB patients treated with adefovir were randomly divided into two groups when adefovir resistance occurred. One group was added with lamivudine, the other was added with entecavir. HBV polymerase reverse transcriptase mutations associated with resistance were analyed before and after 48 weeks of rescue therapy, respectively. Results The mutation patterns of M204V/I, M204V+L180M were predominantly found in CHB patients after lamivudine resistance. Meanwhile, the entecavir resistance mutation patterns were also detected. Therefore, patients with lamivudine resistance could develop more diverse drug resistance mutations if they were switched to entecavir and adefovir. The mutation patterns of rtA181 were predominantly found in CHB patients after adefovir resistance and rescure therapy with add-on entecavir was more effective than with add-on lamivudine Conclusions Resistance mutation analysis chould help to choose NAs, reduce resistance and ehance antiviral effects.

  6. Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection

    OpenAIRE

    Ling Li; Hie-Won Hann; Shaogui Wan; Hann, Richard S.; Chun Wang; Yinzhi Lai; Xishan Ye; Alison Evans; Ronald E Myers; Zhong Ye; Bingshan Li; Jinliang Xing; Hushan Yang

    2016-01-01

    Recent studies have demonstrated a potential link between circulating cell-free mitochondrial DNA (mtDNA) content and cancers. However, there is no study evaluating the association between circulating mtDNA as a non-invasive marker of hepatocellular carcinoma (HCC) risk. We conducted a nested case-control study to determine circulating mtDNA content in serum samples from 116 HBV-related HCC cases and 232 frequency-matched cancer-free HBV controls, and evaluate the retrospective association be...

  7. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study

    DEFF Research Database (Denmark)

    Weber, Rainer; Sabin, Caroline; Reiss, Peter; de Wit, Stephane; Worm, Signe W; Law, Matthew; Dabis, Francois; D'Arminio Monforte, Antonella; Fontas, Eric; El-Sadr, Wafaa; Kirk, Ole; Rickenbach, Martin; Phillips, Andrew; Ledergerber, Bruno; Lundgren, Jens

    2010-01-01

    Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals....

  8. The Knowledge, Attitude and Practices regarding HBV Infection of Married Women in the Reproductive Age Group living in Cantonment Area, Sunjawan, Jammu

    Directory of Open Access Journals (Sweden)

    Rashmi Sharma, C.L. Sharma, Ruchi Khajuria

    2004-07-01

    Full Text Available The present study was conducted to know the knowledge, attitude and practices of 300 marriedwomen in the reproductive age group living in the cantonment area Sunjawan, Jammu regardingHBV infection. Only 20% of the women were found aware of the mode of transmission of HBV.However, 50% of the women were having the misconceptions regarding mode of transmission ofHBV. 4% of women, 30% of children up to 5 years and 15% of children above 5 years were fullyimmunized with hepatitis B vaccine. 80% of children up to 5 years and 75% of children above 5years were fully immunized as per universal immunization programme. Hence, the results of thestudy clearly indicated the low immunization rate with vaccine against HBV than that under universalimmunization programme and further potentiated the need for implementation of therecommendations in 9th five year plan of India regarding introduction of immunization againstHBV in universal immunization programme at the earliest .

  9. MOLECULAR EPIDEMIOLOGY FEATURES OF HBV/HDV CO-INFECTION IN KYRGYZSTAN

    Directory of Open Access Journals (Sweden)

    A. V. Semenov

    2016-01-01

    Full Text Available One of the most serious health problems in the world are hepatotropic viruses that cause chronic liver disease. Hepatitis B virus is distributed globally; around 5% of the carriers are also infected with hepatitis delta virus. Co-infection or superinfection of hepatitis viruses B and D significantly associated with a much more severe liver disease, compared with infection only hepatitis B virus. However, examination of hepatitis virus B carriers for the presence of hepatitis D virus in most regions of the world is not mandatory. It should be noted that the complete genotype mapping of viruses hepatitis B and D isolated on the territory of the CIS and the countries of the former Soviet Union, there is not yet, despite the constantly ongoing works devoted genotyping hepatotropic virus in the territory of the Russian Federation and neighboring countries. Due to the fact that one of the prospective ways of spreading viruses is the “labor migration” the inhabitants of Central Asia in other countries, including the Russian Federation, there is a need to pay attention to the situation of viral hepatitis in the region. The aim of our study was to estimate the prevalence of genetic variants and characteristics of molecular epidemiology of chronic viral hepatitis co-infection B + D in Kyrgyzstan. The study involved 30 plasma samples from patients with chronic viral hepatitis B and D from different regions of Kyrgyzstan. Based on the phylogenetic analysis of the isolates showed that among patients examined HBV identified only D genotype. Based on the phylogenetic analysis of the isolates indicated that among the examined patients with chronic viral hepatitis B revealed only genotype D. It is shown prevalence of HBV subtype D1 (73.34% compared to the HBV subtype D2 (3.33% and D3 (23.33%. Revealed HDV genotype I with highly variable region of the gene encoding the delta antigen. The high similarity of some isolates with strains specific to neighboring

  10. 复制型HBV转基因小鼠的建立与应用%Establislunent and use of HBV- replication transgenic mice

    Institute of Scientific and Technical Information of China (English)

    孔祥平; 刘光泽; 易学瑞

    2011-01-01

    尽管有了有效的疫苗,但乙肝病毒(HBV)感染依然是全球性公共卫生问题,在我国形势尤为严峻.由于HBV的自然宿主仅限于人和黑猩猩,现有的模型都有不同的缺陷,因此关于其生物学及治疗方法 研究的诸多问题依然没有解决.复制型HBV转基因小鼠模型的建立,极大地提高了我们对HBV生活史、免疫生物学和肝脏病变的免疫发病机制的认识.本文简要介绍国际上由Francis V.Chisari实验室和国内由本实验室建立的复制型HBV转基因小鼠,以及利用该模型开展抗病毒药物和乙肝发病机制的研究工作.%Despite the existence of a preventive vaccinet hepatitis B virus (HBV) infection is still a major worldwide health problem, especially in China. As HBV naturally Despite of the existence of a preventive vaccine, hepatitis B virus CHBV) infection is still a major worldwide healthy problem, especially in China. As HBV naturally infects only human and chimpanzees, many issues pertaining to the biology and the therapeutic of HBV infection remain unresolved due to the limitation of the establishment of a HBV model. However, the establishment of HBV-replication transgenic mice has greatly improved our understanding of life cycle, immunobiology and pathogensis of HBV. The establishment of HBV transgenic mice and its use in assessing the antiviral potential of pharmacological agents and HBV immunopathogenesis are herewith briefly described in the present paper.

  11. Relationship Between Hepatic Steatosis and the Elevation of Aminotransferases in HBV-Infected Patients With HBe-Antigen Negativity and a Low Viral Load.

    Science.gov (United States)

    Enomoto, Hirayuki; Aizawa, Nobuhiro; Nishikawa, Hiroki; Ikeda, Naoto; Sakai, Yoshiyuki; Takata, Ryo; Hasegawa, Kunihiro; Nakano, Chikage; Nishimura, Takashi; Yoh, Kazunori; Ishii, Akio; Takashima, Tomoyuki; Iwata, Yoshinori; Iijima, Hiroko; Nishiguchi, Shuhei

    2016-04-01

    Nonalcoholic fatty liver disease has been suggested to be associated with alanine aminotransferase (ALT) elevation in hepatitis B virus (HBV)-infected patients with HBe antigen (HBeAg)-negativity and a low HBV-DNA level. However, few studies have evaluated the association according to histological findings of the liver.Among a total of 198 HBV-infected patients who received a percutaneous liver biopsy, we studied the histological and laboratory findings of HBeAg-negative patients without receiving nucleoside/nucleotide analogues treatment (N = 70) in order to evaluate whether hepatic steatosis and its related metabolic disorders were associated with an elevation in ALT levels in HBeAg-negative patients.In HBeAg-negative patients with a high serum HBV-DNA level (≥2000 IU/mL), the level of HBV-DNA was the only significant factor related to ALT elevation. However, in HBeAg-negative patients with a low HBV-DNA level, the serum ferritin level, and histologically observed hepatic steatosis were significantly associated factors with ALT elevation. When we evaluated 2 metabolic variables (serum ferritin and fasting insulin) that are suggested to be relevant to the presence of progressive disease in Japanese patients, we found that the rate of metabolic disorders was significantly higher among patients with a high ALT level and a low HBV-DNA level than it was among those with other conditions. The triglyceride level and the frequency of moderate or severe hepatic steatosis were significantly higher in patients with a low HBV-DNA level than in those with a high HBV-DNA level.Histologically proven hepatic steatosis and its related metabolic disorders are suggested to be involved in the elevation of aminotransferases of HBeAg-negative patients, particularly those with low HBV-DNA levels. PMID:27124068

  12. Association of Mutations in the Basal Core Promoter and Pre-core Regions of the Hepatitis B Viral Genome and Longitudinal Changes in HBV Level in HBeAg Negative Individuals: Results From a Cohort Study in Northern Iran

    OpenAIRE

    Besharat, Sima; Poustchi, Hossein; Mohamadkhani, Ashraf; Katoonizadeh, Aezam; Moradi, Abdolvahab; Roshandel, Gholamreza; Freedman, Neal David; Malekzadeh, Reza

    2015-01-01

    Background: Although certain HBV mutations are known to affect the expression of Hepatitis e antigen, their association with HBV viral level or clinical outcomes is less clear. Objectives: We evaluated associations between different mutations in the Basal Core promoter (BCP) and Pre-core (PC) regions of HBV genome and subsequent changes in HBV viral DNA level over seven years in a population of untreated HBeAg negative chronic hepatitis B (CHB) participants in Northeast of Iran. Materials and...

  13. HBV cccDNA 检测的研究进展

    Institute of Scientific and Technical Information of China (English)

    陆晖; 江建宁

    2008-01-01

    @@ 自1965年Blumberg发现澳大利亚抗原(HBsAg)以来,病毒性乙型肝炎(viral hepatitis B)有了划时代的研究进展.病毒性乙型肝炎主要流行于亚洲、非洲、南部欧洲和拉丁美洲.全世界约20亿人有既往或持续感染HBV,慢性HBV感染者达3~3.5亿,其中15%~25%最终死于肝衰竭、肝硬化或肝癌,年病死人数约100万;男女性病人的病死率分别约50%和15%.

  14. DNA immunization with fusion genes containing HCV core region and HBV core region

    Institute of Scientific and Technical Information of China (English)

    杨莉; 刘晶; 孔玉英; 汪垣; 李光地

    1999-01-01

    The eucaryotic expression plasmids were constructed to express the complete (HCc191) or the truncated (HCc69 and HCc40) HCV core genes, solely or fused with the HBV core gene (HBc144). These constructions were transiently expressed in COS cells under the control of the CMV promoter. The antigenicity of HBc and HCc could be detected in the expression products by ELISA and Western blot. The mice immunized with these expression plasmids efficiently produced the anti-HCc antibodies, and also anti-HBc antibodies when the plasmids contained the fusion genes. In addition, the antibodies induced by the fusion genes were more persistent than those induced by the non-fusion HCV core genes. These indicate that the fusion of HCc genes to HBc gene is in favor of the immunogenicity of HCc, while the immunogenicity of HBc is not affected.

  15. The hydrological response of the Ourthe catchment to climate change as modelled by the HBV model

    Directory of Open Access Journals (Sweden)

    T. L. A. Driessen

    2009-11-01

    Full Text Available The Meuse is an important river in western Europe, and almost exclusively rain-fed. Projected changes in precipitation characteristics due to climate change, therefore, are expected to have a considerable effect on the hydrological regime of the river Meuse. We focus on an important tributary of the Meuse, the Ourthe, measuring about 1600 km2. The well-known hydrological model HBV is forced with three high-resolution (0.088° regional climate scenarios, each based on one of three different IPCC CO2 emission scenarios: A1B, A2 and B1. To represent the current climate, a reference model run at the same resolution is used. Prior to running the hydrological model, the biases in the climate model output are investigated and corrected for. Different approaches to correct the distributed climate model output using single-site observations are compared. Correcting the spatially averaged temperature and precipitation is found to give the best results, but still large differences exist between observations and simulations. The bias corrected data are then used to force HBV. Results indicate a small increase in overall discharge for especially the B1 scenario during the beginning of the 21st century. Towards the end of the century, all scenarios show a decrease in summer discharge, partially because of the diminished buffering effect by the snow pack, and an increased discharge in winter. It should be stressed, however, that we used results from only one GCM (the only one available at such a high resolution. It would be interesting to repeat the analysis with multiple models.

  16. PCR-Based Molecular Diagnosis of Hepatitis Virus (HBV and HDV) in HCV Infected Patients and Their Biochemical Study

    Science.gov (United States)

    Anwar, Muhammad Ayaz; Raheel, Ummar; Badshah, Yasmeen; Akhtar, Hashaam; Tamanna, Kosar; Tahir, Muhammad; Sadaf Zaidi, Najam us Sahar

    2016-01-01

    Seroprevalence of HCV indicates that HCV is found in more than 10% of HBV- or HDV-infected patients worldwide leading to liver disease. Here we show HBV and HDV coinfection association with HCV infected Pakistani patients, study of disease severity, and possible interpretation of associated risk factors in coinfected patients. A total of 730 liver diseased patients were included, out of which 501 were found positive for HCV infection via PCR. 5.1% of patients were coinfected with HBV while 1% were coinfected with HBV and HDV both. LFTs were significantly altered in dually and triply infected patients as compared to single HCV infection. Mean bilirubin, AST, and ALT levels were highest (3.25 mg/dL, 174 IU/L, and 348 IU/L) in patients with triple infection while dual infection LFTs (1.6 mg/dL, 61 IU/L, and 74 IU/L) were not high as in single infection (1.9 mg/dL, 76 IU/L, and 91 IU/L). The most prominent risk factor in case of single (22%) and dual infection (27%) group was “reuse of syringes” while in triple infection it was “intravenous drug users” (60%). It is concluded that HBV and HDV coinfections are strongly associated with HCV infected Pakistani patients and in case of severe liver disease the possibility of double and triple coinfection should be kept in consideration. PMID:27366331

  17. Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection.

    Science.gov (United States)

    Troy, S B; Rossheim, A E B; Siik, J; Cunningham, T D; Kerry, J A

    2016-05-01

    Even after CD4 count recovery on antiretroviral therapy, HIV infection is associated with decreased response to most vaccines compared to the general population. Chronic infections with viruses such as cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV), which are more prevalent in HIV-infected populations, have been linked to immune dysfunction and decreased vaccine response in the general population. However, whether co-infection with these other viruses contributes to the decreased vaccine response seen in adults with well-controlled HIV infection is unknown. We conducted a secondary analysis of data and serum from adults with well-controlled HIV infection from an inactivated polio vaccine trial (224 subjects) and a pneumococcal conjugate vaccine study (128 subjects). We evaluated the association of CMV, HBV, or HCV co-infection with post-vaccination antibody levels using both univariate and multivariate analyses, controlling for factors such as age, race, CD4 count, comorbidities, smoking status, and baseline antibody levels. Ninety-three percent, 7%, and 14% of subjects were co-infected with CMV, HBV, and HCV respectively. On both univariate and multivariate analysis, neither CMV nor HCV co-infection were significantly associated with post-vaccination antibody levels to either vaccine. HBV co-infection was significantly associated with post-vaccination antibody concentrations for pneumococcal serotype 7F on univariate analysis and 6A on multivariate analysis, but the association was with higher antibody concentrations. In conclusion, co-infection with CMV, HBV, or HCV does not appear to contribute to the decreased vaccine response seen in adults with well-controlled HIV infection. PMID:26751638

  18. Characterization of the liver-draining lymph nodes in mice and their role in mounting regional immunity to HBV.

    Science.gov (United States)

    Zheng, Meijuan; Yu, Jiali; Tian, Zhigang

    2013-03-01

    The lymphatic system is important in mounting an immune response to foreign antigens and tumors in humans and animal models. The liver produces a large amount of lymph, and its lymphatic system is divided into three major components: the portal, sublobular and superficial lymphatic vessels. Despite the fact that mice are the most commonly used laboratory animals, detailed descriptions of the anatomical location and function of the lymph nodes (LNs) that drain the liver are surprisingly absent. In this study, we found that the portal and celiac LNs adjacent to mouse liver were stained with Evans blue within 5-8 min. Enhanced green fluorescence protein (EGFP)-positive cells from the liver also drained into the two aforementioned LNs. These data indicate that the portal and celiac LNs drain the mouse liver. Lymphadenectomy of the identified liver-draining LNs resulted in hepatitis B virus (HBV) persistence in immunocompetent mice compared with the sham group. In addition, the frequencies of CD8(+) T cells and dendritic cells (DCs) increased significantly in the liver-draining LNs after hydrodynamic injection of HBV plasmid. Liver-draining LN cells in HBV plasmid-injected mice also showed significant antigen-specific proliferation in response to stimulation with recombinant hepatitis B core antigen in vitro. Adoptive transfer of these cells into Rag1(-/-) mice induced a reduction in the serum concentration of hepatitis B surface antigen (HBsAg) compared to liver-draining LN cells in uninjected mice. Altogether our data characterize the liver-draining LNs and provide evidence that the liver-draining LNs induce an anti-HBV-specific immune response responsible for HBV clearance. PMID:23376862

  19. COOH-terminal deletion of HBx gene is a frequent event in HBV-associated hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    Xiao-Hong Liu; Jing Lin; Shu-Hui Zhang; Shun-Min Zhang; Mark A Feitelson; Heng-Jun Gao; Ming-Hua Zhu

    2008-01-01

    AIM:To investigate the hepatitis B virus (HBV) x gene (HBx) state in the tissues of HBV-related hepatocellular carcinoma (HCC) in Chinese patients and whether there were particular HBx mutations.METHODS:HBx gene was amplified and direct sequencing was used in genomic DNA samples from 20HCC and corresponding non-cancerous liver tissues from HBsAg-positive patients.HBV DNA integration and HBx deleted mutation were validated in 45 HCC patients at different stages by Southern blot analysis and polymerase chain reaction methods.RESULTS:The frequencies of HBx point mutations were significantly lower in HCC than their corresponding non-cancerous liver tissues (11/19 vs 18/19,P = 0.019).In contrast,deletions in HBx gene were significantly higher in HCC than their non-cancerous liver tissues (16/19 vs 4/19,P<0.001).The deletion of HBx COOH-terminal was detected in 14 HCC tissues.A specific integration of HBx at 17p13 locus was also found in 8 of 16 HCC,and all of them also exhibited full-length HBx deletions.Integrated or integrated coexistence with replicated pattern was obtained in 45.5% (20145)-56.8% (25145)tumors and 40.9% (18/45)-52.3% (23/45) non-tumor tissues.CONCLUSION:HBx deletion,especially the COOH-terminal deletion of HBx is a frequent event in HBV-associated HCC tissues in China.HBV integration had also taken place in partial HCC tissues.This supporting the hypothesis that deletion and probably integrated forms of the HBx gene may be implicated in liver carcinogenesis.

  20. A new multiparameter integrated MELD model for prognosis of HBV-related acute-on-chronic liver failure.

    Science.gov (United States)

    Luo, Yue; Xu, Yun; Li, Mingming; Xie, Ya; Gong, Guozhong

    2016-08-01

    Hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF) is one of the most deadly diseases. Many models have been proposed to evaluate the prognosis of it. However, these models are still controversial. In this study, we aimed to incorporate some characters into model for end-stage liver disease (MELD) to establish a new reliable and feasible model for the prognosis of HBV-ACLF.A total of 530 HBV-ACLF patients who had received antiviral therapy were enrolled into a retrospective study and divided into the training cohort (300) and validation cohort (230). Logistic regression analysis was used to establish a model to predict the 3-month mortality from the patients in the training cohort, and then, the new model was evaluated in the validation cohort.Except for MELD score, 4 other independent factors, namely degree of hepatic encephalopathy (HE), alpha-fetoprotein (AFP), white blood cell (WBC) count, and age, were important for the new model called HBV-ACLF MELD (HAM) model: R = 0.174 × MELD + 1.106 × HE - (0.003 × AFP) + (0.237 × WBC) + (0.103 × Age) - 11.388. The areas under receiver-operating characteristic curve of HAM in the training and validation cohort were 0.894 and 0.868, respectively, which were significantly higher than those of other 7 models. With the best cut-off value of -1.191, HAM achieved higher sensitivity and negative predictive value.We developed a new model that has a great prognostic value of the 3-month mortality of patients with HBV-ACLF. PMID:27559979

  1. 基于磁性纳米探针的乙肝前 S1抗原的快速磁性免疫层析方法的建立%Establishment of HBV rapid magnetic immunochromatographic method based on magnetic nanoprobe for Pre-S1 antigen

    Institute of Scientific and Technical Information of China (English)

    徐晓巍; 崔正权; 卢瑛; 贾鑫明; 王祎龙

    2016-01-01

    为了建立快速灵敏的乙肝磁性免疫层析检测方法,选用前S1抗原作为乙肝检测标志物,将前S1抗原的特异性单抗偶联到磁珠表面,制备了乙肝的特异性磁性纳米探针,并以此探针作为检测标记物制备了乙肝的磁性试纸条。采用乙肝临床血样,对所构建磁性试纸条的检测灵敏度、稳定性和重现性等检测性能进行了评价,并和市售的乙肝ELISA试剂盒进行了对比分析。与ELISA试剂盒的对比结果显示,研究所建立的乙肝磁性试纸条灵敏度较ELISA法高2倍,具有较好的稳定性(25℃可保存半年)和重现性;这两种方法对441份临床血样的检测结果一致性高达97%。研究可为今后乙肝的床边早期诊断产品开发提供技术支撑。%To establish a rapid and sensitive detection method for HBV in serum samples of people , in this study, PreS1 antigen was selected as markers for HBV detection .Specific antibody against PreS 1 was coupled onto the surface of magnetic beads to prepare mag-netic nanoprobe .HBV magnetic test strip labeled by magnetic nanoprobe was constructed .HBV clinical serum samples were used as detection samples .The detection performance of magnetic test strip including sensitivity , stability and repeatability was performed .The developed magnetic test strip was compared with commercially ELISA kit of HBV .Comparison results showed that the sensitivity of our test strip was two folds higher than ELISA method .Good stability ( can save half a year in 25 ℃) and reproducibility was assessed for the magnetic test strip .The consistency of these two methods was as high as 97%( n=441 ) .Our study can provide technological sup-port of point of care products for early diagnosis of HBV .

  2. Improving testing for hepatitis B before treatment with rituximab

    Science.gov (United States)

    Jopson, Laura; Ng, Sarah; Lowery, Matthew; Harwood, Jayne; Waugh, Sheila; Valappil, Manoj; McPherson, Stuart

    2016-01-01

    Aims/Objectives/Background Individuals with current or previous infection with the hepatitis B virus (HBV) can experience viral reactivation when treated with immunosuppression. Rituximab, an anti-CD20 antibody used to treat many diseases, has potent immunosuppressant effects with a high risk of causing HBV reactivation. Reactivation can range from elevated liver enzymes to acute severe hepatitis with liver failure and a significant mortality risk. HBV screening and appropriate use of prophylactic antiviral therapy can prevent reactivation. This work describes the introduction of a local policy for HBV testing in patients before rituximab treatment and assesses its impact. Methods and Results A baseline review (before policy introduction) of 90 patients showed that only 21 (23%) had hepatitis B surface antigen (HBsAg) and 17 (19%) had hepatitis B core antibody (anti-HBcAb) tested before receiving rituximab. Following introduction of the policy (on the basis of international guidelines), improved laboratory reporting protocols and targeted education sessions, two further reviews of HBV testing rates among patients being initiated onto rituximab were performed. There was a marked increase in pre-rituximab testing for HBsAg from 23 to 79% and for anti-HBcAb from 19 to 78%. Throughout the study period, a total of one (0.8%) HBsAg-positive and six (4.7%) anti-HBcAb-positive patients were identified. Conclusions This work clearly indicates that simple strategies can markedly improve appropriate HBV screening. In our cohort, 6% (of whom only 43% had recognized HBV risk factors) required antiviral prophylaxis, which emphasizes the importance of universal screening before rituximab. Reinforcement of the guidelines and ongoing education is needed to further increase testing rates. PMID:27388147

  3. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative

    Institute of Scientific and Technical Information of China (English)

    Lei Geng; Bing-Yi Lin; Tian Shen; Hua Guo; Yu-Fu Ye; Shu-Sen Zheng

    2015-01-01

    Anti-virus prophylactic therapy may be not nec-essary for the prevention of hepatitis B virus (HBV) recur-rence after HBV-related liver transplantation (LT). However, studies on completely stopping the hepatitis B immune globu-lin (HBIG) and nucleos(t)ide analogs (NUC) after LT are few. The aim of the current study was to evaluate the safety of anti-virus prophylaxis withdrawal in liver recipients whose serum hepatitis Be antigen (HBeAg) and HBV DNA are negative. We analyzed 190 patients undergone LT for HBV-related liver dis-ease from 2006 to 2012 and found that 10 patients completely stopped the HBIG and NUC due to poor compliance. These patients were liver biopsied and checked monthly with serum HBV markers, HBV DNA and liver function. Among the 10 patients, 9 did not show the signs of HBV recurrence after a mean follow-up of 51.6 months (range 20-73) after with-drawal of the HBIG and NUC. The average time from LT to the withdrawal of the anti-virus drug was 23.8 (13-42) months;one patient showed hepatitis B surface antigen-positive and detectable HBV DNA after stopping anti-virus drugs and this patient was successfully treated with entecavir. Our data sug-gested that complete withdrawal of anti-virus prophylaxis was safe and feasible for patients whose serum HBeAg and HBV DNA were negative at the time of LT.

  4. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative

    Institute of Scientific and Technical Information of China (English)

    Lei Geng; Bing-Yi Lin; Tian Shen; Hua Guo; Yu-Fu Ye; Shu-Sen Zheng

    2016-01-01

    Anti-virus prophylactic therapy may be not nec-essary for the prevention of hepatitis B virus (HBV) recur-rence after HBV-related liver transplantation (LT). However, studies on completely stopping the hepatitis B immune globu-lin (HBIG) and nucleos(t)ide analogs (NUC) after LT are few. The aim of the current study was to evaluate the safety of anti-virus prophylaxis withdrawal in liver recipients whose serum hepatitis Be antigen (HBeAg) and HBV DNA are negative. We analyzed 190 patients undergone LT for HBV-related liver dis-ease from 2006 to 2012 and found that 10 patients completely stopped the HBIG and NUC due to poor compliance. These patients were liver biopsied and checked monthly with serum HBV markers, HBV DNA and liver function. Among the 10 patients, 9 did not show the signs of HBV recurrence after a mean follow-up of 51.6 months (range 20-73) after with-drawal of the HBIG and NUC. The average time from LT to the withdrawal of the anti-virus drug was 23.8 (13-42) months;one patient showed hepatitis B surface antigen-positive and detectable HBV DNA after stopping anti-virus drugs and this patient was successfully treated with entecavir. Our data sug-gested that complete withdrawal of anti-virus prophylaxis was safe and feasible for patients whose serum HBeAg and HBV DNA were negative at the time of LT.

  5. Towards the complete eradication of mother-to-child HIV/HBV coinfection at Saint Camille Medical Centre in Burkina Faso, Africa

    Directory of Open Access Journals (Sweden)

    Denise Ilboudo

    2010-06-01

    Full Text Available The coinfection of HIV and hepatitis B virus (HBV and their vertical transmission constitute a public health problem in sub-Saharan countries of Africa. The objectives of this research are: i identify the pregnant women that are coinfected by HIV and HBV at Saint Camille Medical Centre; ii use three antiretroviral drugs (zidovudine, nevirapine and lamivudine to interrupt the vertical transmission of HIV and HBV from infected mothers; and iii use the PCR technique to diagnose children who are vertically infected by these viruses in order to offer them an early medical assistance. At Saint Camille Medical Centre, 115 pregnant women, aged from 19 to 41 years, were diagnosed as HIV-positive and, among them, 14 coinfected with HBV. They had at least 32 weeks of amenorrhoea and all of them received the HAART, which contained lamivudine. Two to six months after childbirth, the babies underwent PCR diagnosis for HIV and HBV. The results revealed that, among these mothers, 64.4% were housewives, 36.5% were illiterates, and only 1.7% had a university degree. The rate of vertical transmission of HIV and HBV was 0.0% (0/115 and 21.4% (3/14, respectively. The 3 mothers who transmitted the HBV to their children had all HBsAg, HbeAg, and HBV DNA positive. An antiretroviral therapy that in addition to zidovudine and nevirapine includes lamivudine could, as in the present study, block or reduce the vertical transmission in HIV positive pregnant women who are coinfected with HBV.

  6. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule

    Directory of Open Access Journals (Sweden)

    Collard Alix

    2010-10-01

    Full Text Available Abstract Background Combination vaccines improve coverage, compliance and effectively introduce new antigens to mass vaccination programmes. This was a phase III, observer-blind, randomized study of GSK Biologicals diphtheria-tetanus-whole cell pertussis vaccine combined with hepatitis B and Haemophilus influenzae type b vaccines, containing a reduced amount of polyribosyl-ribitol-phosphate (PRP and a DTPw component manufactured at a different site (DTPw-HBV/Hib2.5 [Kft]. The primary aim of this study was to demonstrate that DTPw-HBV/Hib2.5 [Kft] was not inferior to the licensed DTPw-HBV/Hib (Tritanrix(tm-HepB/Hiberix(tm vaccine or the DTPw-HBV/Hib2.5 vaccine, also containing a reduced amount of PRP, with respect to the immune response to the PRP antigen, when administered to healthy infants, according to the Expanded Programme for Immunization (EPI schedule at 6, 10 and 14 weeks of age. Methods 299 healthy infants were randomised to receive either DTPw-HBV/Hib2.5 [Kft] DTPw-HBV/Hib2.5 or DTPw-HBV/Hib according to the 6-10-14 week EPI schedule. Blood samples were analysed prior to the first dose of study vaccine and one month after the third vaccine dose for the analysis of immune responses. Solicited local and general symptoms such as pain, redness and swelling at the injection site and drowsiness and fever, unsolicited symptoms (defined as any additional adverse event and serious adverse events (SAEs were recorded up to 20 weeks of age. Results One month after the third vaccine dose, 100% of subjects receiving DTPw-HBV/Hib2.5 [Kft] or DTPw-HBV/Hib and 98.8% of subjects receiving DTPw-HBV/Hib2.5 vaccine had seroprotective levels of anti-PRP antibodies (defined as anti-PRP antibody concentration ≥0.15 μg/ml. Seroprotective antibody concentrations were attained in over 98.9% of subjects for diphtheria, tetanus and hepatitis B. The vaccine response rate to pertussis antigen was at least 97.8% in each group. Overall, the DTPw-HBV/Hib2.5 [Kft

  7. PIN1 genetic polymorphisms and the susceptibility of HBV-related hepatocellular carcinoma in a Guangxi population.

    Science.gov (United States)

    Huang, Li; Mo, Zhuning; Lao, Xianjun; Zhang, Xiaolian; Liu, Yanqiong; Sui, Jingzhe; Qin, Xue; Li, Shan

    2016-05-01

    Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (PIN1) plays a critical role in different signaling pathways, cell cycle progression and proliferation, and gene expression, and it has been found to overexpress in many tumor tissues. Recently, researchers have found that PIN1 gene polymorphisms may alter the function of protein and be associated with the risk of cancer. The present study analyzed three common polymorphisms in promoter regions (rs2233678 and rs2233679) and in exon2 (rs2233682) of the PIN1 gene in 254 patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and 235 healthy controls in a Guangxi study population to determine whether any relationship exists between the polymorphisms and the risk of HBV-related HCC. The results revealed that the rs2233679 TT genotype was associated with increased risk of HCC with HBV infection [odds ratio (OR) = 2.04, 95 % confidence interval (95 % CI) = 1.13-3.69, p = 0.019]. This association was stronger in men than in women (OR = 2.17, 95 % CI = 1.09-4.34, p = 0.028) as well as in men 50 years of age and older (OR = 3.91, 95 % CI = 1.29-11.80, p = 0.016); moreover, for alcohol drinkers, being a carrier of the PIN1 rs2233679 CT genotype had a moderately increased risk of HCC (OR = 3.98, 95 % CI = 1.02-15.57, p = 0.047). In contrast, people carrying the rs2233682 GA genotype and A alleles were 0.23 times more likely to develop HCC (OR = 0.23, 95 % CI = 0.06-0.87, p = 0.031 and OR = 0.23, 95 % CI = 0.06-0.87, p = 0.030). No such associations were found in the PIN1 rs2233678 polymorphisms between the HBV-related HCC cases and the controls. In addition, the haplotype GCA was found to be a high protection factor for HCC with HBV infection (OR = 0.14, 95 % CI = 0.03-0.62, p = 0.003). In conclusion, this study's findings suggest that the PIN1 rs2233679 TT genotype, the rs2233682GA genotype, and A alleles

  8. Simultaneous detection of HBV-DNA concentration and its melting temperature by improved fluorescent quantitative PCR%改良荧光定量PCR同步检测HBV-DNA含量及其熔解温度

    Institute of Scientific and Technical Information of China (English)

    赵友云; 高应林; 王春香; 乐惠荣

    2007-01-01

    目的 通过改进荧光定量聚合酶链反应(FQ-PCR)的单荧光标记,建立灵敏、特异的HBV-DNA含量及其熔解温度(Tm)的同步检测方法.方法 根据荧光标记物质的不同,将FQ-PCR分为TaqMan+SYBR Green I双标记(T+S组)、TaqMan探针单标记(T组)和SYBR Green I染料单标记(S组)三种,同时检测HBV-DNA已知浓度为108.48、105.70、103.70和<1×103.00(copies/ml)的血清中HBV-DNA含量及Tm,每组FQ-PCR检测每份血清时1次做5个平行管.结果 T+S组检测的HBV-DNA阳性血清均为阳性,其平均含量为108.55±0.32、105.79±0.29、103.81±0.30,与T组的108.49±0.31、105.69±0.30、103.72±0.25copies/ml对应浓度值取10对数比较,无统计学意义(t=0.31、0.54和0.27,P>0.05);与S组的108.41±0.35、105.21±0.34和103.26±0.26 copies/ml(不含未检出的两次血清)比较,除高浓度外,中低浓度有统计学意义(t=2.90和2.62,P<0.05).T+S组和S组阳性血清均出现明显熔解曲线,Tm分别为71.8℃、72℃和79.8℃,阴性血清未出现扩增曲线和Tm值.T+S组、T组和S组的灵敏度分别为102.70、102.70和103.00copies/ml.结论 改良的SYBR Green I和TaqMan探针双标记的FQ-PCR检测HBV-DNA时,兼有TaqMan探针标记FQ-PCR的灵敏度高、特异性强和SYBR Green I标记FQ-PCR的Tm分析的优点,能达到同步检测HBV-DNA含量及其Tm的目的 ,为HBV-DNA含量及其多态性分析,尤其是为HBV-DNA含量及其基因分型同步检测提供了新思路.

  9. Coinfecciones por HBV y HCV en pacientes HIV positivos en la "era HAART": nuevos desafíos Hbv and hcv co-infections in hiv positive patients in the "HAART era": new challenges

    Directory of Open Access Journals (Sweden)

    Natalia L. Laufer

    2007-02-01

    Full Text Available Las coinfecciones con virus de la hepatitis C (HCV y/o virus de la hepatitis B (HBV en pacientes infectados por el virus de la inmunodeficiencia humana (HIV son un hallazgo frecuente en virtud de las similares vías de transmisión que estos agentes presentan (sexual, parenteral y vertical. Desde el advenimiento del tratamiento antirretroviral de alta eficiencia (TARV se evidenció una marcada disminución en la morbi-mortalidad de los pacientes; sin embargo, ante la prolongación de su sobrevida, las complicaciones crónicas debidas a las coinfecciones con estos virus hepatotropos han cobrado importancia, convirtiéndose la enfermedad hepática en una de las primeras causas de morbi-mortalidad de los pacientes HIV positivos en los países desarrollados. Se disponen en la actualidad de nuevas terapias y métodos de diagnóstico y seguimiento para HBV y HCV, lo cual permite un mejor control de ambas coinfecciones.Co-infections with HIV and HCV/HBV are frequently found due to the similar routes of transmission (sexual, parenteral and vertical. Since the introduction of highly active antiretroviral therapy (HAART there has been a notably decrease in patients morbidity and mortality, nevertheless with the prolonged survival, many of these patients are at risk of developing chronic complication, secondary to the infection of hepatotropic viruses. End stage liver disease is one of the main causes of morbid-mortality among HIV patients in developed countries. Nowadays there are new available therapies, diagnostic and follow up techniques for HBV and HCV, what provides a better control of both co-infections.

  10. The ``Nordic`` HBV model. Description and documentation of the model version developed for the project Climate Change and Energy Production

    Energy Technology Data Exchange (ETDEWEB)

    Saelthun, N.R.

    1996-12-31

    The model described in this report is a version of the HBV model developed for the project Climate Change and Energy Production. This was a Nordic project aimed at evaluating the impacts of the Scandinavian countries including Greenland with emphasis on hydropower production. The model incorporates many of the features found in individual versions of the HBV model in use in the Nordic countries, and some new ones. It has catchment subdivision in altitude intervals, a simple vegetation parametrization including interception, temperature based evapotranspiration calculation, lake evaporation, lake routing, glacier mass balance simulation, special functions for climate change simulations etc. The user interface is very basic, and the model is primarily intended for research and educational purposes. Commercial versions of the model should be used for operational implementations. 5 refs., 4 figs., 1 tab.

  11. HIV-1 infection, but not syphilis or HBV infection, is a strong risk factor for anorectal condyloma in Asian population: A prospective colonoscopy screening study

    Directory of Open Access Journals (Sweden)

    Takeshi Nishijima

    2015-08-01

    Conclusions: HIV-1 infection, but not syphilis or HBV infection, was identified as a strong risk for anorectal condyloma. Anal HPV 16/18 was highly prevalent in patients with HIV-1 infection, especially in those with condyloma.

  12. Selection of affinity-improved neutralizing human scFv against HBV PreS1 from CDR3 VH/VL mutant library.

    Science.gov (United States)

    Chen, YanMin; Bai, Yin; Guo, XiaoChen; Wang, WenFei; Zheng, Qi; Wang, FuXiang; Sun, Dejun; Li, DeShan; Ren, GuiPing; Yin, JieChao

    2016-07-01

    A CDR3 mutant library was constructed from a previously isolated anti-HBV neutralizing Homo sapiens scFv-31 template by random mutant primers PCR. Then the library was displayed on the inner membrane surface in Escherichia coli periplasmic space. Seven scFv clones were isolated from the mutant library through three rounds of screening by flow cytometry. Competition ELISA assay indicates that isolated scFv fragments show more efficient binding ability to HBV PreS1 compared with parental scFv-31. HBV neutralization assay indicated that two clones (scFv-3 and 59) show higher neutralizing activity by blocking the HBV infection to Chang liver cells. Our method provides a new strategy for rapid screening of mutant antibody library for affinity-enhanced scFv clones and the neutralizing scFvs obtained from this study provide a potential alternative of Hepatitis B immune globulin. PMID:27255707

  13. Therapeutic potential of peripheral blood stem cell transplantation in one cirrhotic patient caused by HBV combined with HCV

    OpenAIRE

    Fan, Daiming; Han, Huohong; Han, Ying; He, Yuang-long; Liu, Jingmei; Wang, Jianhong; Yan, Li; Zhou, Xinmin

    2008-01-01

    Stem cell based therapy was very attractive in decompensated liver cirrhosis currently. The possible mechanism might be due to its potential to help tissue regeneration with minimally invasive procedures. Here we report the case of a 44-year-old man, infected by hepatitis B virus (HBV) combined with hepatitis C virus (HCV) for longer than 10 years, who eventually developed decompensated liver cirrhosis. After being infused with mobilized peripheral blood stem cells, the patient showed signifi...

  14. People with Multiple Tattoos and/or Piercings Are Not at Increased Risk for HBV or HCV in The Netherlands

    OpenAIRE

    Urbanus, Anouk T.; van den Hoek, Anneke; Boonstra, Albert; van Houdt, Robin; de Bruijn, Lotte J.; Heijman, Titia; Coutinho, Roel A; Prins, Maria

    2011-01-01

    Background Although published results are inconsistent, it has been suggested that tattooing and piercing are risk factors for HBV and HCV infections. To examine whether tattooing and piercing do indeed increase the risk of infection, we conducted a study among people with multiple tattoos and/or piercings in the Netherlands who acquired their tattoos and piercings in the Netherlands and/or abroad. Methods Tattoo artists, piercers, and people with multiple tattoos and/or piercings were recrui...

  15. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study

    OpenAIRE

    Asare Isaac; Adu-Gyamfi Clement; Boamah Isaac; Ampofo William K; Gbagbo Foster; Armah Henry B; Adjei Andrew A; Hesse Ian FA; Mensah George

    2008-01-01

    Abstract Background Prisons are known to be high-risk environments for the spread of bloodborne and sexually transmitted infections. Prison officers are considered to have an intermittent exposure potential to bloodborne infectious diseases on the job, however there has been no studies on the prevalence of these infections in prison officers in Ghana. Methods A national multicenter cross-sectional study was undertaken on correlates of human immunodeficiency virus (HIV), hepatitis B virus (HBV...

  16. Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies

    OpenAIRE

    Li, Jing; Du, Yun; Liu, Xian; Shen, Qian-cheng; Huang, Ai-Long; Zheng, Ming-Yue; Luo, Xiao-Min; Jiang, Hua-liang

    2012-01-01

    Aim: To investigate the molecular mechanisms underlying the influence of DNA polymerase from different genotypes of hepatitis B virus (HBV) on the binding affinity of adefovir (ADV). Methods: Computational approaches, including homology modeling, docking, MD simulation and MM/PBSA free energy analyses were used. Results: Sequence analyses revealed that residue 238 near the binding pocket was not only a polymorphic site but also a genotype-specific site (His238 in genotype B; Asn238 in genotyp...

  17. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation.

    Science.gov (United States)

    Sun, Hai-Hua; Zhou, Dong-Fang; Zhou, Jun-Ying

    2016-01-01

    Chronic hepatitis B virus (HBV) infection is the result of an inadequate immune response towards the virus. Dendritic cells (DCs), as the most efficient professional antigen-presenting cells (APCs), possess the strongest antigen presenting the effect in the body and can stimulate the initial T cell activation and proliferation. DCs of patients with chronic HBV infection are impaired, resulting in more tolerogenic rather than immunogenic responses, which may contribute to viral persistence. Recently, numerous methods have been developed to induce DCs maturation. To date, recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) combined with interleukin-4 (rhIL-4) has been a classic culture combination to DCs. The recently classified type III interferon group interferon-λ (IFN-λ) displays antiviral, antitumor, and immunoregulatory activity. In our laboratory, we demonstrate that IFN-λ1 combined with rhGM-CSF and rhIL-4 can significantly increase the expression of DC surface molecules and the secretion of interleukin-12 (IL-12) and interferon-γ (IFN-γ) in patients with chronic hepatitis B infection. In this review, we emphasize on the role of DCs in the immunopathogenesis of chronic HBV infection. Importantly, we systematic review that the latest update in the current status of knowledge on the methods of inducing DCs maturation in anti-HBV immunity. What's more, we conclude that IFN-λ1 combined with GM-CSF and IL-4 can induce DCs maturation, which could become a possibility to be applied to the autologus dendritic cell vaccine to treat chronic hepatitis B. PMID:26104380

  18. Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection.

    Science.gov (United States)

    Li, Ling; Hann, Hie-Won; Wan, Shaogui; Hann, Richard S; Wang, Chun; Lai, Yinzhi; Ye, Xishan; Evans, Alison; Myers, Ronald E; Ye, Zhong; Li, Bingshan; Xing, Jinliang; Yang, Hushan

    2016-01-01

    Recent studies have demonstrated a potential link between circulating cell-free mitochondrial DNA (mtDNA) content and cancers. However, there is no study evaluating the association between circulating mtDNA as a non-invasive marker of hepatocellular carcinoma (HCC) risk. We conducted a nested case-control study to determine circulating mtDNA content in serum samples from 116 HBV-related HCC cases and 232 frequency-matched cancer-free HBV controls, and evaluate the retrospective association between mtDNA content and HCC risk using logistic regression and their temporal relationship using a mixed effects model. HCC cases had significantly lower circulating mtDNA content than controls (1.06 versus 2.47, P = 1.7 × 10(-5)). Compared to HBV patients with higher mtDNA content, those with lower mtDNA content had a significantly increased risk of HCC with an odds ratio (OR) of 2.19 (95% confidence interval [CI] 1.28-3.72, P = 0.004). Quartile analyses revealed a significant dose-dependent effect (Ptrend = 0.001) for this association. In a pilot longitudinal sub-cohort of 14 matched cases-control pairs, we observed a trend of dramatically decreased mtDNA content in cases and slightly decreased mtDNA content in controls, with a significant interaction of case-control status with time (Pinteraction = 0.049). Our findings suggest that circulating mtDNA is a potential novel non-invasive biomarker of HCC risk in HBV patients. PMID:27063412

  19. 慢性乙型肝炎患者血清HBV DNA与e抗原含量的关系

    Institute of Scientific and Technical Information of China (English)

    马兰

    2010-01-01

    目的 探讨慢性乙型肝炎(简称乙肝)患者血清乙肝病毒脱氧核糖核酸(HBV DNA)含量与e抗生素原含量的关系.方法 采用定量聚合酶链反应(PCR)和美国Abbott微粒子酶免疫荧光法(MEIA)检测330例慢性乙肝患者血清HBV DNA含量和乙肝病毒标志物(HBV-M)含量.结果 乙肝e抗原(HBeAg)(+)/乙肝e抗体(抗-HBe)(-)血清180例,HBV DNA平均含量为(6.23±2.51)copy/mL,HBeAg平均含量为(1 311.8±1 035.2)peiu/mL;HBeAg(+)/抗-HBe(+)血清62例,HBV DNA平均含量为(5.06±1.32)copy/mL,HBeAg平均含量为(5.2±2.1)peiu/mL;HBeAg(-)/抗-HBe(+)血清88例,HBV DNA平均含量为(4.18±1.14)copy/mL,HBeAg平均含量为(0.02±0.01)peiu/mL.任意两组间比较,差异均有统计学意义.轻度慢性乙肝患者血清160例,HBVDNA平均含量为(6.41±2.32)copy/mL;中度慢性乙肝患者血清138例,HBV DNA平均含量为(5.32±1.44)cop-y/mL;重度慢性乙肝血清32例,HBV DNA平均含量为(4.24±1.12)copy/mL.轻、重度组间差异均有统计学意义.结论 血清HBeAg阳性组HBV DNA含量明显高于e系统双阳性组及e抗原阴性组(P<0.05),HBV DNA含量与HBeAg含量具有相关性.慢性乙肝随病变程度的加重,HBV DNA平均拷贝数下降.

  20. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection

    Institute of Scientific and Technical Information of China (English)

    Kazumoto Murata; Kazushi Sugimoto; Katsuya Shiraki; Takeshi Nakano

    2005-01-01

    AIM: To determine the predictive factors forhepatocellular carcinoma (HCC) development in patientsafter spontaneous or therapeutic HBeAg seroconversion.METHODS: In 48 patients who seroconverted to anti-HBe positive during follow-up, the background factors forHCC development were analyzed.RESULTS: HCC was developed in six patients duringfollow-up (average follow-up after HBeAg seroconversion:10.9±5.4 years). The incidence of HCC evaluated byKaplan-Meier analysis was significantly higher in patientswith abnormal aspartate aminotransferase (AST>40 IU/L) level, lower platelet counts (PLT<10×104/μL),lower albumin level (Alb<30 g/L), positive HBV-DNA or older age at seroconversion (>40 years). However, lower platelet count was the only predictive factor for HCC development shown by multivariate proportional-hazard analysis.CONCLUSION: Active hepatitis or advanced hepatitis at HBeAg seroconversion or progressive hepatitis even after HBeAg seroconversion would be the risk factors for HCC development. These predictive factors should be taken into account in determining the frequency of biochemical study or imaging studies for HCC surveillance.

  1. Clinical Significance on the Serologic Profiles of HBV Markers in Various Liver Diseases

    International Nuclear Information System (INIS)

    By radioimmunoassay, serologic markers of Hepatitis B Virus were studied in 44 patients with acute viral hepatitis, 10 patients with chronic persistent hepatitis, 10 patients with chronic active hepatitis, 44 patients with liver cirrhosis and 25 patients with primary hepatocellular carcinoma. The results were follows: 1) HBsAg was present in 77.2% of AVH, 40% of CPH, 80% of CAH, 55.1% of LC and 68% of PHC. In this HBsAg positive groups, all but one in liver cirrhosis had Anti-HBc. 2) Anti-HBs was most commonly detected in CPH and accompanied by Anti-HBc except one case in AVH. 3) Anti-HBc was the only marker detected in 11.4% of AVH, 20% of CPH, 20% of CAH, 16.3% of LC and 8% of PHC. 4) HBeAg was most commonly found in HBsAg-positive CPH but Anti-HBe was most frequently detected in PHC. 5) The absence of HBV markers was noted in 2.3% of AVH, 10% of CPH, 8% of PHC except CAH and LC.

  2. HBV X PROTEIN (HBX) INTERACTS WITH GENERAL TRANSCRIPTION FACTOR TFIIB BOTH IN VITRO AND IN VIVO

    Institute of Scientific and Technical Information of China (English)

    1999-01-01

    Objective.In order to demonstrate the binding of HBV X protein (HBX) with the general transcription factor TFIIB.Methods.In vitro glutathion S-transferase (GST)resin Pull-Down assay and Far-Western Blotting assay, in vivo Co-immunoprecipition assay were used.Results.The X199(51-99)domain of HBX is reponsible for HBX binding to TFIIB.While the d10 domain (125-295)of TFIIB is required for TFIIB binding to HBX.When the two basic amino acids(K) at position 178 and 189 of TFIIB were substituted by neutral amino acids(L),the binding of TFIIBK178L and K189L to HBX was siginificantly reduced. When the the basic amino acids were substituted by the acidic amino acids(E),the binding of TFIIB K178E and K189E to HBX were almost lost.In vitro results of HBX binding to TFIIB were further confirmed by in vivo co-immunoprecipitation assay.Our results also indicated that the Woodchuck hepatitis virus X protein (WHX)interacts with TFIIB.Conclusion.These results suggested that the communication between HBX and general transcription factor TFIIB is one of the mechanisms which account for its transcriptional transactivation.

  3. Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(tide resistance in treatment-naive patients with Chronic Hepatitis B in Central China

    Directory of Open Access Journals (Sweden)

    Youyun Zhao

    2016-04-01

    Full Text Available Abstract Objective There are a lot of disagreements in the studies on hepatitis B virus (HBV DNA polymerase mutation rate associated with nucleos(tide analogues (NAs in treatment-naive chronic hepatitis B (CHB patients. This is the first study aimed to investigate the prevalence of spontaneous HBV resistance mutations in Central China. Methods This study included treatment-naive patients with CHB from June 2012 to May 2015 receiving care at the Institute of Liver Disease in Central China. All patients completed a questionnaire covering different aspects, such as family medical history, course of liver disease, medication history, alcohol use, among others. Mutations in HBV DNA polymerase associated with NAs resistance were detected using INNO-LiPA assay. Results 269 patients were infected with HBV genotype B (81.4%, C (17.9%, and both B and C (0.7%. Mutations in HBV DNA polymerase were detected in 24 patients (8.9% including rtM204I/V (n = 6, rtN236T (n = 5, rtM250V (n = 2, rtL180M (n = 2, rtT184G (n = 1, rtM207I (n = 1, rtS202I (n = 1, rtM204V/I & rtL180M (n = 5, and rtM204I & rtM250V (n = 1. Conclusion Spontaneous HBV resistance mutations in HBV DNA polymerase were found in treatment-naive patients with CHB in Central China. These findings suggest that we should analyze HBV DNA polymerase resistance mutation associated with NAs before giving antiviral therapy such as lamivudine (LAM, adefovir (ADV, and telbivudine (LdT.

  4. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study

    International Nuclear Information System (INIS)

    There has been limited study on the effect of infection with different hepatitis C virus (HCV) genotypes on the risk of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) endemic regions of Asia. Hazard ratios of HCC development were estimated for HBV and HCV co-infected subjects among a community-based prospective cohort. HCV genotype was determined in HCV RNA-positive samples. Incident HCC cases were identified through linkage to the cancer registry. HCC incidence was 79 per 100,000 person-years in the study population (50 incident cases among 6,694 individuals within 63,170 person-years with an average of 9.4 years of follow-up); seroprevalence of HBsAg and anti-HCV was 5.2% and 5.6%. Adjusted hazard ratios of HCC by HBsAg positivity and anti-HCV positivity were 13.3 (CI: 7.3-24.4) and 6.7 (CI: 3.6-12.6). HRs of HBV and HCV monoinfection, and HBV/HCV coinfection were 17.1 (CI: 8.4-34.8), 10.4 (CI: 4.9-22.1) and 115.0 (CI: 32.5-407.3). Multiplicative synergistic effect of HBV/HCV coinfection on HCC risk was also observed (synergy index: 4.5, CI: 1.3-15.5). Infection with HCV genotype 1 (HR: 29.7, CI: 13.6-46.8) and mixed infection with genotype 1 and 2 (HR: 68.7, CI: 16.4-288.4) significantly elevated HCC risk, much higher than HBV infection. The effect of differences in HCV genotype and the multiplicative synergistic effect of HBV/HCV coinfection on HCC risk shown in the present study underline the need for comprehensive identification of hepatitis infection status in order to prevent and control HCC in this HBV endemic area

  5. [Seroconversion and immune response after anti-HBV vaccination in patients on chronic hemodialysis: comparison of two vaccines].

    Science.gov (United States)

    Polito, Pasquale; Di Lullo, Luca; Iannacci, Giuseppe Roberto; Cecilia, Annalisa; Galderisi, Cristina; Gorini, Antonio

    2011-01-01

    ESRD patients on hemodialysis (HD) have a high risk of HBV infections. Primary prevention through vaccination is a first choice to reduce the morbidity from HBV. Prevention can be accomplished by two types of vaccines. The aim of this study was to evaluate the serological response to HBV vaccination in a population of HD patients who were randomized to Fendrix or Engerix B according to common administration protocols. Ninety-two HD patients were randomized to Fendrix or Engerix B immunization protocols. Patients in the Fendrix arm received four intramuscular administrations of 20 micron g, while patients in the Engerix arm received three intramuscular administrations of 40 micron g with an optional booster dose at two months from the last administration in nonresponders. The seroconversion rates were higher in the Fendrix group than the Engerix group, with faster responses, higher titers and longer duration of immune memory. Fendrix seems to be more effective than the older vaccine, Engerix, especially in patients at high infection risk like those making up our study population. Other crucial factors for good outcomes in patient immunization were biological and dialysis age. This underlines the importance of early immunization protocols such as already discussed by many nephrologists. PMID:22028266

  6. Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China.

    Science.gov (United States)

    Yang, Shigui; Yu, Chengbo; Chen, Ping; Deng, Min; Cao, Qing; Li, Yiping; Ren, Jingjing; Xu, Kaijin; Yao, Jun; Xie, Tiansheng; Wang, Chencheng; Cui, Yuanxia; Ding, Cheng; Tian, Guo; Wang, Bing; Zhang, Xiaoyan; Ruan, Bing; Li, Lanjuan

    2015-01-01

    The hepatitis B prevalence rate in adults is still at a high to intermediate level in China. Our purpose was to explore the incidence rate and protective immune barrier against hepatitis B in adults in China. A sample of 317961 participants was multi-screened for hepatitis B surface antigens (HBsAg) in a large-scale cohort of the National Hepatitis B Demonstration Project. A total of 5401 persons were newly-infected, representing an incidence rate of 0.81 (95% CI: 0.77-0.85) per 100 person-years after adjusted by gender and age. History of acquired immune deficiency syndrome, birth prior to 1992, coastal residence, family history of HBV, and migrant worker status were significantly associated with higher incidence, while HBV vaccination and greater exercise with lower incidence. The hepatitis B surface antibody (HBsAb) positive rate was negatively correlated with the incidence rate of hepatitis B (r = -0.826). Linear fitting yielded an incidence rate of 1.23 plus 0.02 multiplied by HBsAb positive rate. The study firstly identified the HBsAg incidence rate, which was reduced to 0.1 per 100 person-years after vaccination coverage of about 64%. The protective immune barrier against hepatitis B needs to be established in individuals born prior to the advent of infant HBV vaccination. PMID:26655735

  7. Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling,docking and dynamics simulation studies

    Institute of Scientific and Technical Information of China (English)

    Jing LI; Yun DU; Xian LIU; Qian-cheng SHEN; Ai-long HUANG; Ming-yue ZHENG; Xiao-min LUO; Hua-liang JIANG

    2013-01-01

    Aim: To investigate the molecular mechanisms underlying the influence of DNA polymerase from different genotypes of hepatitis B virus (HBV) on the binding affinity of adefovir (ADV).Methods: Computational approaches,including homology modeling,docking,MD simulation and MM/PBSA free energy analyses were used.Results: Sequence analyses revealed that residue 238 near the binding pocket was not only a polymorphic site but also a genotypespecific site (His238 in genotype B; Asn238 in genotype C).The calculated binding free-energy supported the hypothesis that the polymerase from HBV genotype C was more sensitive to ADV than that from genotype B.By using MD simulation trajectory analysis,binding free energy decomposition and alanine scanning,some energy variation in the residues around the binding pocket was observed.Both the alanine mutations at residues 236 and 238 led to an increase of the energy difference between genotypes C and B (△△Gc-B),suggesting that these residues contributed to the genotype-associated antiviral variability with regard to the interaction with ADV.Conclusion: The results support the hypothesis that the HBV genotype C polymerase is more sensitive to ADV than that from genotype B.Moreover,residue N236 and the polymorphic site 238 play important roles in contributing to the higher sensitivity of genotype C over B in the interaction with ADV.

  8. Pokemon siRNA Delivery Mediated by RGD-Modified HBV Core Protein Suppressed the Growth of Hepatocellular Carcinoma.

    Science.gov (United States)

    Kong, Jing; Liu, Xiaoping; Jia, Jianbo; Wu, Jinsheng; Wu, Ning; Chen, Jun; Fang, Fang

    2015-10-01

    Hepatocellular carcinoma (HCC) is a deadly human malignant tumor that is among the most common cancers in the world, especially in Asia. Hepatitis B virus (HBV) infection has been well established as a high risk factor for hepatic malignance. Studies have shown that Pokemon is a master oncogene for HCC growth, suggesting it as an ideal therapeutic target. However, efficient delivery system is still lacking for Pokemon targeting treatment. In this study, we used core proteins of HBV, which is modified with RGD peptides, to construct a biomimetic vector for the delivery of Pokemon siRNAs (namely, RGD-HBc-Pokemon siRNA). Quantitative PCR and Western blot assays revealed that RGD-HBc-Pokemon siRNA possessed the highest efficiency of Pokemon suppression in HCC cells. In vitro experiments further indicated that RGD-HBc-Pokemon-siRNA exerted a higher tumor suppressor activity on HCC cell lines, evidenced by reduced proliferation and attenuated invasiveness, than Pokemon-siRNA or RGD-HBc alone. Finally, animal studies demonstrated that RGD-HBc-Pokemon siRNA suppressed the growth of HCC xenografts in mice by a greater extent than Pokemon-siRNA or RGD-HBc alone. Based on the above results, Pokemon siRNA delivery mediated by RGD-modified HBV core protein was shown to be an effective strategy of HCC gene therapy. PMID:26356810

  9. The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely.

    Science.gov (United States)

    Guo, Xiaoyan; Chen, Ping; Hou, Xiaohu; Xu, Wenjuan; Wang, Dan; Wang, Tian-Yan; Zhang, Liping; Zheng, Gang; Gao, Zhi-Liang; He, Cheng-Yi; Zhou, Boping; Chen, Zhi-Ying

    2016-01-01

    HBV covalently closed circular DNA (cccDNA) is drug-resistant and responsible for viral persistence. To facilitate the development of anti-cccDNA drugs, we developed a minicircle DNA vector (MC)-based technology to produce large quantity of recombined cccDNA (rcccDNA) resembling closely to its wild-type counterpart both in structure and function. The rcccDNA differed to the wild-type cccDNA (wtcccDNA) only in that it carried an extra 36-bp DNA recombinant product attR upstream of the preC/C gene. Using a procedure similar to standard plasmid production, milligrams of rcccDNA can be generated in common laboratories conveniently. The rcccDNA demonstrated many essential biological features of wtcccDNA, including: (1) undergoing nucleation upon nucleus entry; (2) serving as template for production of all HBV RNAs and proteins; (3) deriving virions capable of infecting tree shrew, and subsequently producing viral mRNAs, proteins, rcccDNA and infectious virions. As an example to develop anti-cccDNA drugs, we used the Crispr/Cas9 system to provide clear-cut evidence that rcccDNA was cleaved by this DNA editing tool in vitro. In summary, we have developed a convenient technology to produce large quantity of rcccDNA as a surrogate of wtcccDNA for investigating HBV biology and developing treatment to eradicate this most wide-spreading virus. PMID:27174254

  10. Cytokines, Lipid Peroxide and Nitric Oxide in Egyptian Hepatocellular Carcinoma on Top of HCV and HBV Infection

    Directory of Open Access Journals (Sweden)

    Osman E.E., Mabrouk F.M., Hassan H.A., Aboelyazed S.M

    2007-12-01

    Full Text Available Background and Aims: Many studies have shown the relative roles of hepatitis B and C viruses in hepato-carcinogenesis. The aim of this study is to define the independent and interactive roles of some cytokines namely, TNF , IL-6, IL-1 together with NO and TEARS in the genesis of HCC following the infection with such viruses. Patients and methods: Blood samples were taken from 58 patients with hepatocellular carcinoma and were divided into four groups: a 28 patients with HCV, b 10 patients with HBV, c 11 patients with B+C, d 9 patients without viral infection. In addition, 20 healthy subjects served as control group for each, TNF , IL-6, and IL-1 were measured using ELISA technique, in addition to NO and TBARs using chemical methods. Results: Patients with coinfection B-C viral infection showed the highest levels in studied parameters. Patients with HCV and HBV separately showed more or less similar results. However, patients without viral infection showed the least higher levels comparing to the control group. Conclusion: Cytokines in addition to NO and TEARS have a definite role in hepatic carcinogenesis. Coinfection with the two viruses carries a synergistic risk factor of hepatocellular carcinoma development. Depending on the results of the studied parameters HCV did not show predominancy on HBV. Further studies are needed to clarify the exact mechanism of carcinogenesis especially in HCV patients.

  11. The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely

    Science.gov (United States)

    Guo, Xiaoyan; Chen, Ping; Hou, Xiaohu; Xu, Wenjuan; Wang, Dan; Wang, Tian-yan; Zhang, Liping; Zheng, Gang; Gao, Zhi-liang; He, Cheng-Yi; Zhou, Boping; Chen, Zhi-Ying

    2016-01-01

    HBV covalently closed circular DNA (cccDNA) is drug-resistant and responsible for viral persistence. To facilitate the development of anti-cccDNA drugs, we developed a minicircle DNA vector (MC)-based technology to produce large quantity of recombined cccDNA (rcccDNA) resembling closely to its wild-type counterpart both in structure and function. The rcccDNA differed to the wild-type cccDNA (wtcccDNA) only in that it carried an extra 36-bp DNA recombinant product attR upstream of the preC/C gene. Using a procedure similar to standard plasmid production, milligrams of rcccDNA can be generated in common laboratories conveniently. The rcccDNA demonstrated many essential biological features of wtcccDNA, including: (1) undergoing nucleation upon nucleus entry; (2) serving as template for production of all HBV RNAs and proteins; (3) deriving virions capable of infecting tree shrew, and subsequently producing viral mRNAs, proteins, rcccDNA and infectious virions. As an example to develop anti-cccDNA drugs, we used the Crispr/Cas9 system to provide clear-cut evidence that rcccDNA was cleaved by this DNA editing tool in vitro. In summary, we have developed a convenient technology to produce large quantity of rcccDNA as a surrogate of wtcccDNA for investigating HBV biology and developing treatment to eradicate this most wide-spreading virus. PMID:27174254

  12. Comparison of the influence of different nucleic acid extraction methods on HBV DNA detection using quantitative fluorescence-PCR%不同核酸提取方法在HBV DNA荧光定量检测中的比较

    Institute of Scientific and Technical Information of China (English)

    李成德; 黄晓佳; 陈雄毅

    2010-01-01

    目的 研究不同核酸提取方法在HBV DNA荧光定量检测中的提取效率、重复性、抗干扰性及对扩增试剂的兼容能力.方法 运用两种具有不同启动温度的Taq酶的扩增试剂分别扩增经一步法、煮沸法和磁珠法提取HBV DNA强阳性血清的模板,比较不同提取方法对扩增试剂的兼容能力.采用3种方法提取3份HBV DNA含量不同的标本各10次,进行扩增,比较不同方法的提取效率和重复性;对HBV DNA阳性标本用HBV DNA阴性的黄疸血清和溶血液进行10倍稀释后分别用前述方法提取进行干扰试验.结果 3种提取方法中,磁珠法和煮沸法提取的模板对两种扩增试剂具有良好的兼容性;重复性比较以一步法最佳,磁珠法次之,煮沸法较差;提取效率比较以磁珠法最理想,一步法次之,煮沸法最差;对黄疸和溶血的抗干扰能力以磁珠法最佳,溶血对煮沸法有一定影响,在无5-羧基-X-罗丹明(5-ROX)校正的情况下,黄疸对一步法影响较大,有5-ROX校正系统分析则可以消除这种影响.结论 磁珠法具有良好的重复性和提取效率,对黄疸和溶血有较强抗干扰能力,对扩增试剂的兼容性好,是一种理想的核酸提取方法;相对而言,一步法快捷且重复性更佳.

  13. The correlation study of HBV serological index in neonate's venus, cord blood and mother's venus blood%新生儿静脉血与脐带血及孕妇静脉血HBV病原学标记物相关性研究

    Institute of Scientific and Technical Information of China (English)

    易为; 张禄雪; 胡玉红; 李明慧; 郝红晓; 王士俊; 姜秀娟; 张书凤; 宋淑静

    2013-01-01

    Objective In this study,we discussed the consistency and correlation of HBV serological indexes between neonates' venous blood and cord blood whose mothers had chronical HBV infection,as well as the correlation of thoses indexes with the mothers'.Method Chronically HBV infected mothers who were postive of both HBsAg and HBeAg and also had a HBV DNA virus load above 105copies/ml and their infants were enrolled.The mothers' venous blood were collected before delivery.The neonates' cord blood were collected at birth after removal of contaminants and disinfected with alcohol on the cord's surface,and the venous blood were collected before hepatitis B virus immune globin(HBIG) and hepatitis B vaccine were given.The levels of HBsAg,anti-HBs,HBeAg and anti-HBeAg were tested with Abbott microparticle chemiluminescence method (Abbott Laboratories,Abbott Architac i2000).HBV DNA quantification were tested by COBAS TagMan real-time PCR Assay.Results 383 mothers and their infants were enrolled.The positive rates of HBsAg in cord blood and venous blood were 61.2% and 63.9%.The positive rates of HBeAg level in cord blood and venous blood were 83.2% and 83.5%.The positive rates of HBV DNA level in cord blood and venous blood were 56.0% and 59.4%.The state of HBsAg,HBeAg and HBV DNA in cord blood and venous blood were consistency,and significant correlation was observed in their levels with correlation coefficients of 0.766,0.857,and 0.692,respectively (P < 0.000).Significant correlation of the HBeAg levels were observed between mothers' venous blood and neonates' venous blood,as well as neonates' cord blood with correlation coefficients of 0.362 and 0.352 (P < 0.000).However,there was no significant correlation of HBsAg levels between them (r =0.023,P =0.785 ; r =0.04,P =0.604).Conclusions The HBV serological index of neonate's cord blood could reflect the HBV serological indexes in venous blood because of the good correlation and consistency between them.%目的

  14. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

    Directory of Open Access Journals (Sweden)

    Hsu Chao Wei

    2012-12-01

    Full Text Available Abstract Background The aims of this study were to compare results from a Taiwanese sub-study of the GLOBE 2303 telbivudine study and evaluate the HBV DNA kinetics. Methods Forty-one Taiwanese patients were treated for an additional 2 years with telbivudine. Efficacy endpoints were the same as the GLOBE study. The correlations of reductions in HBV DNA levels at Week 24 were evaluated. Results All 7 HBeAg-positive patients with undetectable HBV DNA levels at Week 24 sustained this response at Year 4 with rates of ALT normalization 71%, HBeAg seroconversion 57%, and cumulative resistance 0%. Out of 16 HBeAg-negative patients with undetectable HBV DNA levels at Week 24, 11 (78% sustained this response at Year 4 with rates of ALT normalization 83% and cumulative resistance 8.7%. There were significant correlations between reductions of DNA of ≥5 log10 copies/mL at Week 24 with maintained PCR negativity at Years 2–4 and a lack of resistance at Year 2. Conclusions Long-term telbivudine efficacy in Taiwanese patients was comparable to the GLOBE 2303 study. A reduction in HBV DNA levels by ≥5 log10 copies/mL at Week 24 represented the optimal cut-off point, which may predict favourable outcomes in patients with high baseline HBV DNA levels. Trial registration ClinicalTrials.gov Identifier: NCT00142298 (http://clinicaltrials.gov/.

  15. 不同程度慢性乙型肝炎血脂与HBV DNA关系研究%Relationship between blood lipid levels and HBV-DNA in patients with different stages of chronic hepatitis B

    Institute of Scientific and Technical Information of China (English)

    颜华东; 高国生; 祝成亮; 盛吉芳

    2013-01-01

    目的 探讨慢性乙型肝炎患者不同血脂指标的表达水平及其与病情轻重和HBV DNA的关系.方法 收集2011年1月至2012年10月宁波市第二医院142例慢性乙型病毒性肝炎患者以及44名健康献血员血清,检测总胆固醇(TCHO)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(ApoAl)、载脂蛋白B(ApoB)、载脂蛋白E(ApoE)、脂蛋白a及HBV DNA,对检测结果进行统计学分析.结果 不同病情及不同HBVDNA栽量慢性乙型肝炎患者ApoE水平均显著高于正常对照组(P均<0.05);而其他各血脂指标均低于正常对照组(P均<0.05).ApoE含量与病情轻重呈正相关,而T-CHO、HDL-C、ApoA1则呈负相关.HDL-C、ApoA1含量与HBV DNA载量呈正相关,而T-CHO、LDL-C、ApoB、ApoE则呈负相关.结论 慢性乙型肝炎患者血脂水平受肝脏合成功能以及HBV本身等多种因素的影响.%Objective To investigate the correlations of dislipidemia with disease stages and HBV-DNA in patients with chronic hepatitis B (CHB). Methods Serum samples were collected from 142 CHB patients and 44 healthy controls at Ningbo Second Hospital from January 2011 to October 2012, and the levels of TCHO, HDL-C, LDL-C, ApoAl, ApoB, ApoE, lipo and HBV-DNA were detected. The detected data were statistically analyzed. Results Regardless of disease stages and viral loads, the serum ApoE level was higher in CHB patients than that in the healthy controls ( P < 0. 05 ) , while the levels of other indicators were lower (P < 0. 05 ). The serum ApoE concentration was correlated positively with disease progression, but the levels of T-CHO, HDL-C, and ApoAl were correlated negatively with disease stages. The serum ApoAl concentration was correlated positively with HBV-DNA,but the levels of T-CHO,LDL-C, ApoB and ApoE were correlated negatively with the viral loads. Conclusion Dislipidemia is affected multiple factors such as liver synthesis function and HBV-DNA in CHB

  16. Study on the risk factors related vertical transmission of HBV positive couples to their infant%父母双方乙型肝炎病毒感染垂直传播的危险因素研究

    Institute of Scientific and Technical Information of China (English)

    张荣莲; 王梅颖; 陈起燕; 修晓燕; 任坤海; 邱丽茵; 黄欣欣

    2012-01-01

    Objective To explore the risk factors and the rate of HBV vertical transmission from HBsAg-positive couple to their infant.Methods 46 families who had antenatal examination at Fujian Provincial Maternal and Child Health Hospital during August 2010 and November 2011 were chosen as research object.Cord blood was sampled after delivery for HBVM and HBV-DNA quantification.Those with HBV-DNA load ≥5 × 102 copies/ml were involved in the case group while those having <5 × 102 copies/ml were chosen as controls.Results The average positive rate of neonatal cord blood HBV-DNA was 45.7% (21/46),while the positive rates of cord blood HBsAg and HBeAg were 34.8%(16/46) and 23.9% (11/46) respectively.The positive rates of maternal serum HBV-DNA and paternal serum HBV-DNA were 52.2% (24/46) and 69.6% (32/46) respectively,with the positive rate of couple serum HBeAg as 39.1% (18/46) and 32.6%(15/46) respectively.Results from univariate analysis showed that hepatitis B surface markers,serum HBeAg-positive,serum HBV-DNA positive,and serum HBV-DNA load of the couples were risk factors to the HBV vertical transmission(x2=8.731,8.414,8.932,9.663,10.823,3.962,13.638,36.501 ;P<0.05).Data from the multivariate analysis showed that maternal serum HBV-DNA positive and paternal serum HBV-DNA load were risk factors to the HBV vertical transmission [OR= 17.6 (1.3-238.4) ;OR = 3.5 (1.6-7.6)].Serum HBV-DNA loads of the couples were positively correlated with the cord blood HBV-DNA load,while the load levels of the couple' s serum HBV-DNA were higher than cord blood HBV-DNA.There appeared dose-response relationship between couple' s serum HBV-DNA load level and the cord blood HBV-DNA load level.Results from the analysis of ROC curve showed that both maternal serum HBV-DNA load level (103 copies/ml) and paternal serum HBV-DNA load level (104 copies/ml) were demarcation points to better forecast the occurrence of vertical transmission of HBV,because there showed higher

  17. Relationship between the monocyte proportion in peripheral blood and the extent of liver lesion in patients infected with HBV

    Directory of Open Access Journals (Sweden)

    Da-gang WANG

    2012-08-01

    Full Text Available Objective To discuss the relationship between the monocyte proportion in peripheral blood and the extent of liver lesions in HBV patients. Methods The clinical data of HBV patients, which were definitely diagnosed from 2010 to 2011 in our hospital, were studied, including 197 cases with mild or moderate hepatitis (hepatitis group and 248 cases of cirrhosis (cirrhosis group. The data of 269 healthy people concurrently coming for physical examination served as control (control group. The peripheral blood were analyzed by Sysmex XE-2100 hematology analyzer. The real-time PCR was employed to quantitatively detect the HBV DNA in serum; ELISA was performed to determine the liver fibrosis indicators, including hyaluronic acid (HA, laminin (LN, type Ⅳcollegen (IV. C and type Ⅲprecollegen (PCⅢ. Liver biopsy was done in 390 patients, and the extents of liver inflammation (G0-G4 and hepatic fibrosis (S0-S4 were evaluated according to the “Program of Viral Hepatitis Prevention and Control”issued by Chinese Medical Association in 2000. Results The peripheral blood analysis revealed that the monocyte proportion were significantly higher in hepatitis group and cirrhosis group (8.93%±3.05% and 9.85%±3.61% than in control group (8.16%±1.88%, P < 0.01, and also in cirrhosis group than in hepatitis group (P < 0.01. The result of real-time PCR showed that the monocyte proportion was significantly higher in 239 patients with HBV DNA≥100U/ml (8.61%±2.83% than that in the 206 patients with HBV DNA < 100U/ml (8.12%±2.53%, P < 0.05. The ELISA results indicated that the levels of liver fibrosis indicators (HA, LN, IV.C, PCⅢ were significantly higher in cirrhosis group than in hepatitis group, and moreover, in the same group the higher of those indicators, the higher of monocyte proportion. The results of liver biopsy in 390 patients showed that the monocyte proportion significantly elevated along with aggravation of liver inflammation and fibrosis (P

  18. Interleukin-22 as a molecular adjuvant facilitates IL-17-producing CD8+ T cell responses against a HBV DNA vaccine in mice.

    Science.gov (United States)

    Wu, Bing; Zou, Qiang; Hu, Yanxin; Wang, Bin

    2013-10-01

    Interleukin-22 (IL-22) is mainly produced by activated Th1 cells, Th17 cells and NK cells and promotes anti-microbial defense, pro-inflammatory and tissue remodeling responses. However, its potential use as a vaccine adjuvant has not been tested. In this study, we tested if a DNA construct expressing IL-22 (pVAX-IL-22) could be used as a molecular adjuvant to enhance host immune responses induced by HBV DNA vaccination (pcD-S2). After immunizing mice with pcD-S2 combined with pVAX-IL-22, we didn't find enhancement of HBsAg-specific antibody responses in comparison to mice immunized with pcD-S2 alone. However, there was an enhancement of the level of IL-17 expression in antigen specific CD8(+) cytotoxic T lymphocytes (Tc17). By using CD8 T-cell knockout (KO) and IL-17 KO mice, Tc17 cells were found to be a dominant population driving cytotoxicity. Importantly, there was a correlation between pVAX-IL-22 enhancement of T lymphocytes and a reduction of HBsAg-positive hepatocytes in HBsAg transgenic mice. These results demonstrate that IL-22 might be used as an effective adjuvant to enhance cellular immune responses during HBsAg DNA vaccination since it can induce Tc17 cells to break tolerance in HBsAg transgenic mice. PMID:23941891

  19. HBV BCP区1762/1764和1896突变位点检测新技术研究%The Study on Mutation Locus Detection Technology of the HBV BCP Double Muta-tions with 1762/1764 and Precore Mutation with 1896

    Institute of Scientific and Technical Information of China (English)

    王泽; 唐景峰

    2014-01-01

    Objective:To establish a new method( MAMA-PCR)for the detection of mutations at 1762/1764 and 1896 in the BCP region and precore region of HBV using mismatch amplification and Fluorescent PCR and to evaluate this method with clinical samples. Method:a)Evaluate the parameters of the MAMA-PCR mutation detection method:to analyze the stability of reagents by reactions with three repeats using the wild-type and mutant reference as a template;to test the detection efficiency of the HBV hybrid infection using mutant and wild-type references with different mixing ratio. b)Compare the MAMA-PCR method with sequencing and commercialized mutation detection kits and evaluate the MAMA-PCR method. Results:Three tests of MAMA-PCR had good repeatability with a CV value of less than 5% and HBV infection samples which contained 1% mutation could be stably detected. In 132 HBV samples,sequencing meth-od identified 67 with 1762/1764 mutations,mutation detection kit identified 69,and MAMA-PCR identified 69. The detection rates were 50. 8%,52. 3%,and 52. 3%,respectively. Sequencing method identified 39 samples with 1896 mutation,mutation detection kit identified 41,and MAMA-PCR identified 42. The detection rates were 29. 5%, 31. 1%,and 31. 8%,respectively. Conclusions:The MAMA-PCR method is very stable. The mutation detection rate of MAMA-PCR is almost the same as commercialized kits,and is higher than sequencing. This new technology( MAMA-PCR)can be used in the fast detection of HBV BCP 1762/1764 double mutations and precore 1896 mutation in clinical samples.%目的:利用错配扩增和荧光PCR原理,建立一种针对HBV BCP区1762/1764和前C区1896突变位点的新型检测方法---错配扩增突变分析PCR法( MAMA-PCR),并对该方法进行临床评价。方法:a)MAMA-PCR突变检测方法性能评估:以野生和突变性阳性参考品作为模板检测3次,分析该方法稳定性;将突变型和野生型质控品梯度比例混合,分析该方法

  20. Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma.

    Science.gov (United States)

    Ye, Chao; Tao, Ran; Cao, Qingyi; Zhu, Danhua; Wang, Yini; Wang, Jie; Lu, Juan; Chen, Ermei; Li, Lanjuan

    2016-08-01

    Hepatocellular carcinoma (HCC) is a common solid tumor worldwide with a poor prognosis. Accumulating evidence has implicated important regulatory roles of epigenetic modifications in the occurrence and progression of HCC. In the present study, we analyzed 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) levels in the tumor tissues and paired adjacent peritumor tissues (APTs) from four individual HCC patients using a (hydroxy)methylated DNA immunoprecipitation approach combined with deep sequencing [(h)MeDIP-Seq]. Bioinformatics analysis revealed that the 5-mC levels in the promoter regions of 2796 genes and the 5-hmC levels in 507 genes differed significantly between HCC tissues and APTs. These differential genes were grouped into various clusters and pathways and found to be particularly enriched in the 'metabolic pathways' that include 'Glycolysis/gluconeogenesis', 'Oxidative phosphorylation' and 'Citrate cycle (TCA cycle)', implicating a potential role of metabolic alterations in HCC. Furthermore, 144 genes had both 5-mC and 5-hmC changes in HCC patients, and 10 of them (PCNA, MDM2, STAG1, E2F4, FGF4, FGF19, RHOBTB2, UBE2QL1, DCN and HSP90AA1) were enriched and interconnected in five pathways including the 'Cell cycle', 'Pathway in cancer', 'Ubiquitin mediated proteolysis', 'Melanoma' and 'Prostate cancer' pathways. The genome-wide mapping of 5-mC and 5-hmC in HCC tissues and APTs indicated that both 5-mC and 5-hmC epigenetic modifications play important roles in the regulation of HCC, and there may be some interconnections between them. Taken together, in the present study we conducted the first genome-wide mapping of DNA methylation combined with hydroxymethylation in HBV-related HCC and provided a series of potential novel epigenetic biomarkers for HCC. PMID:27221337

  1. Construction of exogenous multiple epitopes of helper T lymphocytes and DNA immunization of its chimeric plasmid with HBV pre-S2/S gene

    Institute of Scientific and Technical Information of China (English)

    Wen-Jun Gao; Xiao-Mou Peng; Dong-Ying Xie; Qi-Feng Xie; Zhi-Liang Gao; Ji-Lu Yao

    2004-01-01

    AIM: To design and construct an exogenous multiple epitope of helper T lymphocytes (HTL), and to evaluate its effect on anti-HBs response through DNA immunization.METHODS: Artificial HTL epitope, PADRE and four other HTL epitopes from different proteins were linked together using splicing by overlap extension to generate exogenous multiple epitopes of HTL, MTE5. pcMTE5 and pcHB weregenerated by cloning MTE5 and fragments of HBV pre-S2/S gene into mammalian expression plasmid pcDNA3. Four chimeric plasmids were constructed by cloning MTE5 into the region of pre-S2 gene (Bam HI), 5′ terminal of S gene (HincⅡ, Xba Ⅰ) and 3′ terminal of S gene (Acc Ⅰ) of pcHB respectively. BALB/c mice were used in DNA immunization of the recombinant plasmids. Anti-HBs was detected using Abbott IMx AUSAB test kits.RESULTS: The sequences of MTE5 and the 6 constructs of recombinant plasmids were confirmed to be correct by DNA sequencing. The anti-HBs response of the coinoculation of pcHB and pcMTE5 was much higher than that of the inoculation of pcHB only (136.7±69.1 mIU/mL vs 27.6±17.3 mIU/mL, P<0.01, t = -6.56). Among the 4 chimeric plasmids, only the plasmid in which MTE5 was inserted into the pre-S2 region had good anti-HBs response (57.54±7.68 mIU/mL), and had no significant difference compared with those of pcHB and the co-inoculation of pcHB and pcMTE5.CONCLUSION: Exogenous multiple epitopes of HTL had immune enhancement when they were co-inoculated with pre-S2/S gene or inoculated in the chimeric form at a proper site of pre-S2/S gene of HBV. It might suggest that it was possible to improve hepatitis B vaccine using exogenous multiple epitopes of HTL. The antibody responses were very low using DNA immunization in the study. Thus, the immune enhancement effect of exogenous multiple epitopes of HTL has to be confirmed and the effect on overcoming the drawback of the polymorphism of HLA Ⅱ antigens should also be evaluated after these chimeric plasmids are expressed

  2. Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial

    OpenAIRE

    Qu, Chunfeng; Chen, Taoyang; Fan, Chunsun; Zhan, Qimin; Wang, Yuting; Lu, Jianhua; Lu, Ling-ling; Ni, Zhengping; Huang, Fei; Yao, Hongyu; Zhu, Jian; Fan, Jian; Zhu, Yuanrong; Wu, Zhiyuan; Liu, Guoting

    2014-01-01

    Editors' Summary Background Hepatitis B is a life-threatening liver infection caused by the hepatitis B virus (HBV). HBV, which is transmitted through contact with the blood or other bodily fluids of an infected person, can cause both acute (short-term) and chronic (long-term) liver infections. Acute infections rarely cause any symptoms and more than 90% of adults who become infected with HBV (usually through sexual intercourse with an infected partner or through the use of contaminated needl...

  3. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life

    Directory of Open Access Journals (Sweden)

    Van Der Meeren Olivier

    2010-01-01

    Full Text Available Abstract Background Few studies have assessed long term persisting immunity against hepatitis B virus (HBV in children vaccinated during infancy with combined vaccines containing recombinant HBV surface antigen (HBs. We assessed antibody persistence and immune memory in children 4-5 years of age, previously vaccinated with four doses of combined hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™. Methods Immune memory was assessed in 301 children through administration of a challenge dose of monovalent HBV vaccine. Results At 4-5 years of age, 85.3% of subjects had persisting anti-HBs antibody concentrations ≥ 10 mIU/mL, rising to 98.6% after the HBV challenge dose. All but 12 subjects (95.8% achieved post-challenge anti-HBs concentrations ≥ 100 mIU/mL. The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations. An anamnestic response to the HBV vaccine challenge was observed in 96.8% of subjects, including 17/21 (81.0% of children with initially undetectable antibodies ( Conclusion The combined DTPa-HBV-IPV/Hib vaccine induced lasting immune memory against hepatitis B. Long term protection afforded by DTPa-HBV-IPV/Hib is likely to be similar to that observed following priming with monovalent HBV vaccines. Trial registration http://www.clinicaltrials.gov 106789 NCT00411697

  4. PRODUCTION IN PICHIA PASTORIS AND CHARACTERIZATION OF GENETIC ENGINEERED CHIMERIC HBV/HEV VIRUS-LIKE PARTICLES

    Institute of Scientific and Technical Information of China (English)

    Hong-zhao Li; Hong-ying Gang; Qiang-ming Sun; Xiao Liu; Yan-bing Ma; Mao-sheng Sun; Chang-bai Dai

    2004-01-01

    Objective To investigate the presentation of a neutralization epitope-containing peptide antigen of hepatitis E virus (HEV)on chimeric virus-like particles (VLPs) of hepatitis B surface antigen (HBsAg).Methods The gene fragment corresponding to amino acids (aa) 551-607 (HEnAg) of HEV capsid protein, which contains the only neutralization epitope identified to date, was fused via a synthetic glycine linker in frame with the gene of HBsAg.The resulted fusion gene was then integrated through transformation into the genome of Pichiapastoris under the control of a methanol-induced alcohol oxidase 1 (A OX 1) promoter and expressed intracellularly. The expression products in the soluble cell extracts were characterized by Western blot, ELISA, CsCl density gradient analysis, and electron microscopic visualization.Results The novel fusion protein incorporating HBsAg and the neutralization epitope-containing HEnAg was expressed successfully in Pichiapastoris with an expected molecular weight of approximately 32 kD. It was found to possess the ability to assemble into chimeric HBV/HEV VLPs with immunological, physical and morphological characteristics akin to HBsAg particles. Not only did the chimeric VLPs show high activity levels in a HBsAg particle-specific ELISA but they were also strongly immunoreactive with hepatitis E (HE) positive human serum in a HEV specific ELISA, indicating that HEnAg peptide fragments were exposed on VLP surfaces and would be expected to be readily accessible by cells and molecules of the immune system. Similarity between chimeric VLPs to highly immunogenic HBsAg particles may confer good immunogenicity on surface-displayed HEnAg.Conclusion The chimeric HBV/HEV VLPs produced in this study may have potential to be a recombinant HBV/HEV bivalent vaccine candidate.

  5. Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis.

    Directory of Open Access Journals (Sweden)

    Chih-An Shih

    Full Text Available Reactivation of HBV replication with an increase in serum HBV DNA and alanine aminotransferase (ALT activity has been reported in 20-50% of hepatitis B carriers undergoing cytotoxic chemotherapy for cancer treatment. Manifestation of HBV reactivation ranges from asymptomatic self-limiting hepatitis to severe progressive hepatic failure and fatal consequences.To investigate the risk of severe acute exacerbation of chronic HBV infection in HBsAg-positive cancer patients with solid tumors or hematological malignancies who underwent chemotherapy without antiviral prophylaxis.A retrospective review of charts was conducted for HBsAg-positive cancer patients in our institution who underwent chemotherapy and did not receive anti-viral prophylaxis between the periods of July 2007 to January 2013. We investigate the incidence of severe acute exacerbation of chronic HBV infection if these patients with a variety of solid tumors and hematological malignancies.A total of 156 patients (hematological malignancies: 16; solid tumors: 140 were included. The incidence of severe acute HBV exacerbation in the patients with hematological malignancy was higher than that in solid tumors (25.0% [4/16] vs 4.3% [6/140]; P = 0.005. Additionally, patients receiving rituximab-based chemotherapy had higher acute exacerbation rate than those with non-rituximab-based chemotherapy (40.0% vs 4.1%, P = 0.001. Among the patients with solid tumors, the incidences of severe acute exacerbation of chronic HBV in hepatocellular carcinoma, colorectal cancer, lung cancer, breast cancer, gynecological cancer, urological tract cancer, head/neck cancer and other solid malignancies were 2.3%, 4.0%, 7.1%, 9.0%, 16.7%, 6.7%, 0% and 0%, respectively.Severe acute exacerbation of chronic HBV infection may occur in HBsAg-positive patients with a variety of solid tumors who received chemotherapy without adequate anti-viral prophylaxis. Hematological malignancy and rituximab-based chemotherapy are

  6. The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely

    OpenAIRE

    Xiaoyan Guo; Ping Chen; Xiaohu Hou; Wenjuan Xu; Dan Wang; Tian-yan Wang; Liping Zhang; Gang Zheng; Zhi-liang Gao; Cheng-Yi He; Boping Zhou; Zhi-Ying Chen

    2016-01-01

    HBV covalently closed circular DNA (cccDNA) is drug-resistant and responsible for viral persistence. To facilitate the development of anti-cccDNA drugs, we developed a minicircle DNA vector (MC)-based technology to produce large quantity of recombined cccDNA (rcccDNA) resembling closely to its wild-type counterpart both in structure and function. The rcccDNA differed to the wild-type cccDNA (wtcccDNA) only in that it carried an extra 36-bp DNA recombinant product attR upstream of the preC/C g...

  7. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation

    Institute of Scientific and Technical Information of China (English)

    Tadeusz Wojciech Lapinski; Robert Flisiak; Jerzy Jaroszewicz; Ma3gorzata Michalewicz; Oksana Kowalczuk

    2005-01-01

    AIM: To analyze the effectiveness and safety of lamivudine treatment in patients with chronic HBV infection undergoing hemodialysis or after kidney transplantation, and to study the frequency of tyrosine - methionine - aspartate - aspartate (YMDD) mutation occurrence after lamivudine treatment.METHODS: We analyzed 91 patients with chronic hepatitis B, among whom, 16 patients underwent hemodialysis, 7patients had kidney transplantation and 68 patients had normal function of kidney. The hemodialysis patients were treated by lamivudine 300 mg/wk. Patients after kidney transplantation and patients with normal function of kidney were treated with lamivudine 100 mg/d. Therapy lasted for 12 mo. HBV-DNA, HBsAg, HBeAg and anti-HBe, and antiHCV antibodies were assessed in sera of patients. The analysis was performed before and 6 mo after the end of lamivudine treatment. Before, during and after the lamivudine therapy,the number of erythrocytes, leukocytes, platelets and hemoglobin concentration, ALT and AST activity, as well as bilirubin, urea and creatinine concentrations were analyzed in sera from patients.RESULTS: After the 12-mo lamivudine treatment, elimination of HBV - DNA was observed in 56% patients undergoing hemodialysis and in 53% patients with normal kidney function. Only 1 from 7 (14%) kidney-transplanted patients eliminated HBV-DNA. Furthermore, HBeAg elimination was observed in 36% hemodialysis patients, in 51% patients with normal function of kidneys and in 43% kidneytransplanted patients. Among the patients undergoing dialysis, no YMDD mutation was found after 12 mo of therapy, while it was detected in 9 patients (13%) with normal function of kidney and in 2 kidney-transplanted patients (29%, P<0.006). We did not observe significant side effects of lamivudine treatment in studied patients.CONCLUSION: Effectiveness of lamivudine therapy in dialysis patients is comparable with that in patients withnormal function of kidney. Lamivudine treatment is well

  8. Complement Factor 3 Could Be an Independent Risk Factor for Mortality in Patients with HBV Related Acute-on-Chronic Liver Failure

    Science.gov (United States)

    Zhang, Geng-lin; Zhang, Ting; Ye, Yi-nong; Liu, Jing; Zhang, Xiao-hong; Xie, Chan; Peng, Liang; Gao, Zhi-liang

    2016-01-01

    The complement is thought to be involved in the pathogenesis of multiple liver disorders. However, its role in patients with HBV related acute-on-chronic liver failure (HBV-ACLF) remains unclear. Serum levels of the third and fourth complement components (C3, C4) and complement function (CH50) were examined in this prospective, observational study. Associations between their expression and disease activity were analyzed. Survival was analyzed by Kaplan-Meier curves. Predictors of clinical outcome were determined by Cox regression analysis. C3, C4, and CH50 levels were significantly lower in HBV-ACLF patients compared to controls. C3, C4, and CH50 levels were negatively correlated with Tbil levels but positively associated with PTA levels. C3 levels were negatively associated with MELD-Na. C3 levels were significantly lower in HBV-ACLF patients who died compared to patients who survived. In a median hospital stay of 39 days, mortality occurred in 41 patients with a progressive increase based on C3 grade (P = 0.008). The actuarial probability of developing mortality was significantly higher in patients with low C3 grade compared to those with high C3 grade (P < 0.001). Multivariate Cox regression analysis showed that C3 levels were an independent predictor of mortality. Complement played a pathogenic role in HBV-ACLF patients and C3 was an independent predictor of mortality. PMID:27144164

  9. Seroprevalence of HIV, HBV, HCV and Syphilis in Blood Donors in Saurashtra Region of Gujarat: Declining Trends Over a Period of 3½ Years

    Directory of Open Access Journals (Sweden)

    Dhruva Gauravi A

    2012-04-01

    Full Text Available Background: Transfusion of blood and blood products is a life saving intervention and benefits innumerous patients worldwide. At the same time it could be an ominous mode of infection transmission to recipients. In 15 percent of total patients infected with HIV, blood transfusion has been the responsible mechanism of transmission. Methods: In this study, we aimed to access the prevalence and trend of HIV, HBV, HCV and Syphilis over the last 3½ years (January 2008 to June 2011 among the blood donors who came to donate blood at Blood Bank, P.D.U. Medical College & Hospital, Rajkot as well as in various blood donation camps organized by the same blood bank. Results: From the total of 30,178 blood donors, 711 (2.35% had serological evidence of infection with at least one pathogen, either of HIV, HBV, HCV or Syphilis. These included 131 (0.43% with HIV, 293 (0.97% with HBV, 124 (0.41% with HCV and 94 (0.31% with Syphilis. Moreover, significantly declining trends of HIV, HBV and Syphilis was observed over the study period. Conclusion: A substantial percentage of blood donors harbor HIV, HBV, HCV and Syphilis infections. Strict selection of blood donors and comprehensive screening of donors’ blood using standard methods are highly recommended to ensure the safety of blood for recipient.

  10. 隐匿性乙型肝炎病毒感染可通过密切接触传播%Occult HBV infection may be transmitted through close contact

    Institute of Scientific and Technical Information of China (English)

    胡莉萍; 方钟燎; 刘德平; 陈钦艳; Tim J. Harrison; 何翔; 王学燕; 李海; 谭超; 杨庆利

    2016-01-01

    Objective To search for the infectious source of hepatitis B virus from a child, who had received the standard vaccination regimen at birth and produced protective antibody. Methods Serum samples were obtained from a child and his parents. Sera were tested for HBV serological markers and viral loads. HBV DNA was extracted using phenol-chloroform .The surface gene of HBV was amplified by nested PCR and the amplicons were cloned and sequenced. Phylogenetic analysis was carried out using Mega 5.0 and Bioedit 7.0. Results Both parents had occult infections. Twelve, eleven and nine clones, from the father, mother and son, respectively, were sequenced. Serotypes adrq +, ayw1, ayw,ayr and genotype B, subgenotype C2, a recombinant B/C were identified in the father. Serotypes ayw1, adw2, adwq+ and genotype B, subgenotype C5 ,two recombinants B/C、a recombinant C/G were identified in the mother. The adrq + was the only serotype in son. Subgenotype C2 was the only genotype identified in son. A phylogenetic tree showed that all of the child’s sequences and most of the father’s sequences clustered together. However, none of mother’s sequences clustered with those of the child. The surface antigens gene from the child and his father had the same amino acid substitution patterns (T118K, T123N and G145A). Conclusions The father was the source of the son’s HBV infection, suggesting that occult HBV infection may be transmitted through close contact.%目的探索一名出生时乙肝疫苗免疫成功后仍感染乙肝病毒的小孩的感染来源。方法采集小孩及其父母的血标本进行HBV 血清学标志物和病毒载量检测,使用酚氯仿法提取HBV DNA,PCR扩增HBV S基因,将扩增产物进行克隆并测序,利用Mega 5.0和Bioedit 7.0对测序结果进行分析。结果父亲和母亲均为隐匿性乙型肝炎病毒感染,父亲、母亲、儿子的 PCR 产物分别获得12、11和9个克隆株。父亲克隆株的血清型为 adrq+,ayw1

  11. Test

    DEFF Research Database (Denmark)

    Bendixen, Carsten

    2014-01-01

    Bidrag med en kortfattet, introducerende, perspektiverende og begrebsafklarende fremstilling af begrebet test i det pædagogiske univers.......Bidrag med en kortfattet, introducerende, perspektiverende og begrebsafklarende fremstilling af begrebet test i det pædagogiske univers....

  12. Tissue donation and virus safety: more nucleic acid amplification testing is needed.

    Science.gov (United States)

    Pruss, A; Caspari, G; Krüger, D H; Blümel, J; Nübling, C M; Gürtler, L; Gerlich, W H

    2010-10-01

    In tissue and organ transplantation, it is of great importance to avoid the transmission of blood-borne viruses to the recipient. While serologic testing for anti-human immunodeficiency virus (HIV)-1 and -2, anti-hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), anti-hepatitis B core antigen (HBc), and Treponema pallidum infection is mandatory, there is until now in most countries no explicit demand for nucleic acid amplification testing (NAT) to detect HIV, hepatitis B virus (HBV), and HCV infection. After a review of reports in the literature on viral transmission events, tissue-specific issues, and manufacturing and inactivation procedures, we evaluated the significance of HIV, HCV, and HBV detection using NAT  in  donors of various types of tissues and compared our results with the experiences of blood banking organizations. There is a significant risk of HIV, HCV, and HBV transmission by musculoskeletal tissues because of their high blood content and the high donor-recipient ratio. If no effective virus inactivation procedure for musculoskeletal tissue is applied, donors should be screened using NAT  for  HIV, HCV, and HBV. Serologically screened cardiovascular tissue carries a very low risk of HIV, HCV, or HBV transmission. Nevertheless, because effective virus inactivation is impossible (retention of tissue morphology) and the donor-recipient ratio may be as high as 1:10, we concluded that NAT  should be performed for HIV, HCV, and HBV as an additional safety measure. Although cornea allografts carry the lowest risk of transmitting HIV, HCV, and HBV  owing to corneal physiology, morphology, and the epidemiology of corneal diseases, NAT  for  HCV should still be performed. If the NAT  screening of a donor for HIV, HCV, and HBV is negative, quarantine storage of the donor tissue seems dispensable. In view of numerous synergistic effects with transfusion medicine, it would be advantageous for tissue banks to cooperate with blood

  13. Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleukin-18 recombinant

    Institute of Scientific and Technical Information of China (English)

    陈建忠; 朱海红; 刘克洲; 陈智

    2004-01-01

    Objective: To investigate the effect of interleukin-18 (IL-18) on immune response induced by plasmid encoding hepatitis B virus middle protein antigen and to explore new strategies for prophylactic and therapeutic HBV DNA vaccines. Methods: BALB/c mice were immunized with pCMV-M alone or co-immunized with pcDNA3-18 and pCMV-M and then their sera were collected for analysing anti-HBsAg antibody by ELISA; splenocytes were isolated for detecting specific CTL response and cytokine assay in vitro. Results: The anti-HBs antibody level of mice co-immunized with pcDNA3-18 and pCMV-M was slightly higher than that of mice immunized with pCMV-M alone, but there was not significantly different (P>0.05). Compared with mice injected with pCMV-M, the specific CTL cytotoxity activity of mice immunized with pcDNA3-18 and pCMV-M was significantly enhanced (P0.05). Conclusion: The plasmid encoding IL-18 together with HBV M gene DNA vaccines may enhance specific TH1 cells and CTL cellular immune response induced in mice, so that IL-18 is a promising immune adjuvant.

  14. Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination.

    Science.gov (United States)

    Zhang, Wenjuan; Du, Xiaogang; Zhao, Gang; Jin, Huali; Kang, Youmin; Xiao, Chong; Liu, Mingyu; Wang, Bin

    2009-08-01

    Chemical compounds activating innate responses may present potential adjuvants for the vaccine development. Levamisole (LMS), demonstrated as a potent adjuvant for DNA and viral killed vaccines in our previous studies, may activate such responses. To confirm this notion, LMS combined with the recombinant HBsAg (rHBsAg) was investigated. Compared to the vaccination with rHBsAg alone, LMS could up-regulate the expressions of TLR7&8, MyD88, IRF7 and their downstream pro-inflammatory cytokines including IFN-alpha and TNF-alpha, which promote DCs activation. Strikingly, we find that the combination of LMS and alum adjuvant synergistically enhances immunogenicity of rHBsAg and leads to a robust cell-mediated response demonstrated by the higher level of IgG2a/IgG1, T cell proliferation, and importantly, a high level of antigen-specific CTL and IFN-gamma production within these activated CD8(+) T cells. The achieved robust responses are at a comparative level with CpG+alum used as a positive control adjuvant in mice. The combination of LMS+alum with rHBsAg may provide a cost-effective, safe, and effective therapy to treat those individuals chronically infected by HBV, since antigen-specific cellular immunity is implicated for the clearance of HBV chronic infection. PMID:19549606

  15. Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleukin-18 recombinant

    Institute of Scientific and Technical Information of China (English)

    陈建忠; 朱海红; 刘克洲; 陈智

    2004-01-01

    Objective:To investigate the effect of interleukin-18 (IL-18) on immune response induced by plasmid encoding hepatitis B virus middle protein antigen and to explore new strategies for prophylactic and therapeutic HBV DNA vaccines.Methods:BALB/c mice were immunized with pCMV-M alone or co-immunized with pcDNA3-18 and pCMV-M and then their sera were collected for analysing anti-HBsAg antibody by ELISA;splenocytes were isolated for detecting specific CTL response and cytokine assay in vitro.Results:The anti-HBs antibody level of mice co-immunized with pcDNA3-18 and pCMV-M was slightly higher than that of mice immunized with pCMV-M alone,but there was not significantly different (P>0.05).Compared with mice injected with pCMV-M, the specific CTL cytotoxity activity of mice immunized with pcDNA3-18 and pCMV-M was significantly enhanced (P0.05).Conclusion:The plasmid encoding IL-18 together with HBV M gene DNA vaccines may enhance specific TH1 cells and CTL cellular immune response induced in mice, so that IL-18 is a promising immune adjuvant.

  16. Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

    OpenAIRE

    Zeng, Zhen; Shi, Feng; Zhou, Lin; Zhang, Min-Na; Chen, Yan; Chang, Xiu-Juan; Lu, Yin-Ying; Bai, Wen-lin; Jian-hui QU; Wang, Chun-Ping; Wang, Hong; Lou, Min; Wang, Fu-Sheng; Ji-yun LV; Yang, Yong-Ping

    2011-01-01

    Background The programmed cell death-1 receptor/programmed cell death-1 ligand (PD-1/PD-L1) pathway plays a crucial role in tumor evasion from host immunity. This study was designed to evaluate the association between circulating PD-L1/PD-1 and prognosis after cryoablation in patients with HBV-related hepatocellular carcinoma (HCC). Methodology/Principal Findings In the present study, 141 HBV-related HCC patients were enrolled and of those 109 patients received cryoablation. Circulating PD-L1...

  17. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.

    Directory of Open Access Journals (Sweden)

    Gail V Matthews

    Full Text Available OBJECTIVE: Anti-HBe seroconversion and HBsAg loss are important therapeutic endpoints in patients with hepatitis B virus (HBV infection. Quantitative measures of hepatitis B surface antigen (qHBsAg and e antigen (qHBeAg have been identified as potentially useful indicators of therapeutic response in HBV monoinfection. The aim of this study was to examine serological change including quantitative biomarkers in HIV-HBV coinfected patients initiating HBV active antiretroviral therapy (ART. METHODS: HIV-HBV coinfected individuals from Thailand were followed for up to 168 weeks post ART. Rates and associations of qualitative serological change were determined. Longitudinal changes in qHBsAg and qHBeAg were measured and their utility as predictors of response examined. RESULTS: Forty seven patients were included of whom 27 (57% were HBeAg positive at baseline. Median CD4 count was 48 cells/mm(3. Over a median follow-up of 108 weeks 48% (13/27 lost HBeAg, 12/27 (44% achieved anti-HBe seroconversion and 13% (6/47 HBsAg loss. Anti-HBe seroconversion was associated with higher baseline ALT (p = 0.034, lower qHBsAg (p = 0.015, lower qHBeAg (p = 0.031 and greater HBV DNA decline to week 24 (p = 0.045. Sensitivity and specificity for qHBsAg and qHBeAg decline of >0.5 log at week 12 and >1.0 log at week 24 were high for both anti-HBe seroconversion and HBsAg loss. CONCLUSIONS: Rates of serological change in these HIV-HBV coinfected individuals with advanced immunodeficiency initiating HBV-active ART were high. Baseline and on treatment factors were identified that were associated with a greater likelihood of subsequent anti-HBe seroconversion, including both quantitative HBsAg and HBeAg, suggesting these biomarkers may have utility in this clinical setting.

  18. Persistence of HBV Vaccine’s Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran

    Directory of Open Access Journals (Sweden)

    Shahrzad Yazdanpanah

    2010-01-01

    Full Text Available Background and Aims: The duration of the protection of hepatitis B vaccination for infants and the necessity of a booster dose administration is unknown. The aim of the present study was to evaluate the persistence of seroprotection after hepatitis B virus (HBV vaccination in order to determine the necessity of a single booster dose in 5- to 7-year-old children.Methods: This clinical trial study was conducted from 2004 to 2005. The study population included all children aged 5 to 7 years old in the Kohgiloyeh and Boyerahmad province who had been vaccinated starting at birth with hepatitis B vaccine. Among these children, 729 were selected via a multiple-stage sampling method. Parents gave their informed consent, and blood specimens (3 ml were obtained from children. Hepatitis B surface antibody (HBsAb and hepatitis B surface antigen (HBsAg were determined by enzyme-linked immunosorbent assay (ELISA. Subjects with nonprotective titer levels (< 10 mIU/ml received a booster does of the DNA recombinant vaccine. Four weeks after the administration of a booster dose, the antibody to HBsAg (anti-HBs titer was measured. Data were analyzed using SPSS software, and analyses included chi-square, ANOVA, and independent-samples and paired-samples t-tests.Results: 615 children (84.4% had a protective antibody titer. The mean antibody titer was 230.5 ± 308.9 IU/ml, with a range of 10.6 to 1175 IU/ml. 15.6% of subjects had a nonprotective antibody titer, and the mean antibody titer was 4.97 ± 3.5 IU/ml. All subjects were HBsAg negative. No statistically significant differences were found by sex or by urban versus rural area of residence. The seroprotection rates significantly decreased by as the age of the children increased. Following the booster dose, 78.1 % of the children had a protective titer, and the mean titer significantly increased from 4.97 ± 3.5 at birth to 332.1 ± 402 IU/ml after the booster (P < 0.001. Conclusions: According to our results

  19. 广州市1324名吸毒人员HIV、 HBV、 HCV及梅毒感染状况调查%Investigation on infection status of HIV, HBV, HCV and syphilis among 1324 drug addicts in Guangzhou City

    Institute of Scientific and Technical Information of China (English)

    钟秋林; 刘展翅

    2012-01-01

    [Objective] To understand the infection status of HIV, HBV, HCV and syphilis among drug addicts in Guangzhou City provide the basis for developing the prevention and control measures of common infectious diseases among drug addicts in Guanj zhou. [ Methods] From July 2009 to June 2011, the venous blood samples were collected from 1 324 drug addicts in a detoxificatk center of Guangzhou city, and the anti-HIV , anti-HCV, HBsAg and syphilis antibody were tested. [ Results] Among 1 324 dnifc addicts, 74 cases were positive for anti-HIV with the positive rate of 4,2% f the positive rate of HBsAg was 12.2% , that of anti-HCV was 40.5% , and that of treponema pallidum particle agglutination assay (TPPA) was 6. 1%. 21.8% of drug addicts were dectected with two infectious diseases, and 2,2% were detected with three infectious diseases. [ Conclusion]The infection rates of HIV, HBV, HCV and syphilis among drug addicts in Guangzhou city are high, and it is important to pay attention to supervision, monitoring and education in this population.%目的 了解广州市吸毒人群HIV 、HBV 、HCV及梅毒感染状况,为制定针对该地区吸毒人群常见传染病的防治措施提供依据.方法 于2009年7月-2011年6月,抽取广州市某戒毒所收入的1324例吸毒人员静脉血,检测HIV 、HCV和梅毒抗体以及HBV表面抗原.结果 1324例吸毒人群中,HIV抗体阳性74例,阳性率4.2%;乙肝表面抗原阳性率12.2%,丙肝抗体阳性率40.5%,梅毒螺旋体明胶颗粒凝集试验(TPPA)阳性率6.1%. 21.8%的吸毒人员同时检出2种传染病,2.2%的吸毒者同时检出3种传染病.结论 广州市吸毒人群中HCV、HBV、梅毒及HIV仍存在较高的感染率,应继续重视对该人群的监管监测及宣传教育.

  20. Detection of serum hepatitis B virus large envelope protein and its relationship with viral replication%乙肝病毒外膜大蛋白检测及其对判定HBV DNA复制的意义

    Institute of Scientific and Technical Information of China (English)

    张红娟; 崔辰莹; 张洁; 王丽伟; 张雪丽

    2011-01-01

    目的 探讨血清乙肝病毒外膜大蛋白(LHBs)检测对于判定HBV DNA复制的临床意义.方法采用酶联免疫方法检测LHBs,Pre - S1和HBV M,采用实时荧光定量PCR法检测HBV DNA.结果(1)在HBeAg阳性血清中,HBV DNA与LHBs、Pre -S1之间的阳性率差异均无统计学意义(P>0.05);(2)在HBeAg阴性血清中,HBV DNA与LHBs的阳性率差异无统计学意义(P>0.05).HBV DNA与Pre -S1之间的阳性率差异有统计学意义(P<0.05);(3) 90份乙肝患者血清中LHBs水平与HBV DNA拷贝数呈良好相关性(r=0.918),Pre - S1水平与HBV DNA拷贝数的相关系数为0.765.结论 血清LHBs水平能反映HBV DNA复制程度,其与HBV DNA的相关性优于pre - S1,可作为评判HBV DNA复制新的血清学指标.%Objective To study the clinical significance of HBV large envelope protein in diagnosing viral replication in chronic hepatitis B patienis. Methods ELISA was used to measure the level of serum LHBs and pre -SI. HBV markers were detected by enzyme linked immunosorbenl assay. HBV DNA was detected using quantitative fluorescent PCR - Results In terms of the positive rale, there was no difference between HBV DNA and LHBs,but the difference was significant between HBV DNA and pre - SI as in HBeAk positive samples (P >0. 05). In HBeAg negative samples, both the posivite rate of HBV DNA and that of LHBs were 72. 22% . The difference between the rale of HBV DNA and that of pre - SI was significant ( P <0. 05). LHBs levels were correlated with the number of HBV DNA copies(r =0. 918) , and the correlation between HBV DNA and pre-SI was 0. 765. Conclusions The level of serum l,HBs can be used to estimate the state of viral replication and the correlation is superior to that of pre -SI. So it can be used as a new serologioal marker to delect viral replication.

  1. 治疗性双质粒HBV DNA疫苗的纯化与检定%Purification and Quality Control of Two Recombinant Plasmids as Therapeutic HBV DNA Vaccine

    Institute of Scientific and Technical Information of China (English)

    饶桂荣; 黄明; 杨富强; 莫国玉; 刘惠萍; 陈光明

    2007-01-01

    目的 研究双质粒HBV DNA疫苗(pS2.S和pFP)的纯化工艺,并建立质控标准.方法 首先对两工程菌(DHSα/pS2.S和DH5α/pFP)的高效发酵菌体采用碱裂解法进行质粒初提;然后通过三步柱层析(依次为分子筛层析、亲和层析、阴离子层析)进行质粒纯化,并检测质粒含量、超螺旋比例、内毒素等,最后对终产品质粒溶液进行全面质量检定.结果 质粒初提液通过分子筛层析后,去除了大量的RNA、宿主DNA、内毒素等,再经亲和柱纯化后获得了高比例的超螺旋质粒DNA,达95%,最后经阴离子柱层析有效去除内毒素,并浓缩了质粒,质粒得率为0.9~1.1 mg/g菌,质粒总回收率达78%.三批终产品全面质量检定均符合规定.结论 建立了稳定的双质粒HBV DNA疫苗(pS2.S和pFP)的纯化工艺及质量控制标准,为进一步研究奠定基础.

  2. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance

    Institute of Scientific and Technical Information of China (English)

    LI Min-wei; HOU Wei; WO Jian-er; LIU Ke-zhou

    2005-01-01

    Objectives: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. Methods: One hundred forty-one patients with lamivudine resistance after lamivudine treatment and 60 chronic hepatitis B patients without lamivudine treatment were enrolled in this study. The serum HBV DNA mutation was analyzed by sequence detection via polymerase chain reaction (PCR). The sequences of the same patient were analyzed before and after lamivudine treatment. Results: One hundred and nine lamivudine resistance patients had HBV YMDD (tyrosine-methionine-aspartate-aspartate) mutation. Among them, 45 patients had rtL 180M/M204V mutation (41.28%), 28patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%). There were 6 patients with rtL180M mutation in 32 lamivudine resistance patients. Sixty chronic hepatitis patients without lamivudine treatment had no mutations. Conclusions: HBV mutations, which play an important role in lamivudine resistance usually locate at polymerase gene 204 site; 180 site mutation was also observed in these patients. Evaluation of the anti-virus therapy by surveillance of the two sites mutations is of importance.

  3. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment

    NARCIS (Netherlands)

    H.G.M. Niesters (Bert); F. Zoulim (Fabien); C. Pichoud (Christian); M. Buti (Miquel); F. Shapiro; N. D'Heuvaert; L. Celis (Linda); J. Doutreloigne (Joke); E. Sablon (Erwin)

    2010-01-01

    textabstractHepatitis B virus (HBV) antiviral drug resistance mutations prevent successful outcome of treatment and lead to worsening of liver disease. Detection of its emergence permits opportune treatment with alternative drugs. Unfortunately, the use of newly approved antivirals, including adefov

  4. Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo.

    Science.gov (United States)

    Song, Linlin; Zhuo, Meng; Tang, Yuyan; Chen, Xiaohua; Tang, Zhenghao; Zang, Guoqing

    2014-11-01

    Therapeutic strategies based on an enhanced hepatitis B virus (HBV)-specific cytotoxic T lymphocyte (CTL) activity may eradicate HBV. We previously verified that a fusion protein ubiquitin (Ub)-hepatitis B core antigen (HBcAg)-cytoplasmic transduction peptide (CTP) can enter the cytoplasm of dendritic cells and enhance T cell response to generate HBV-specific CTLs efficiently in vitro. Ub, a marker of protein degradation, may promote the generation of peptides appropriate for major histocompatibility complex class I presentation. In the present study, the specific immune responses of the fusion protein Ub-HBcAg-CTP in BALB/c mice were evaluated and the underlying mechanisms were investigated. Results showed that Ub-HBcAg-CTP increased the anti-HBcAg titer and produced the cytokines IFN-γ and IL-2. This fusion protein also induced higher percentages of IFN-γ(+)CD8(+) cells and specific CTL responses. Ub-HBcAg-CTP could also upregulate the expressions of Jak2, Tyk2, STAT1, and STAT4 in T lymphocytes. In conclusion, Ub-HBcAg-CTP enhanced cellular and humoral immune responses and induced robust HBV-specific CTL activities in BALB/c mice. PMID:25135878

  5. The Associated Ion between the VDR Gene Polymorphisms and Susceptibility to Hepatocellular Carcinoma and the Clinicopathological Features in Subjects Infected with HBV

    Directory of Open Access Journals (Sweden)

    Xing Yao

    2013-01-01

    Full Text Available Aim. To evaluate the possible association between the vitamin D receptor (VDR, single-nucleotide polymorphisms (SNPs, and hepatocellular carcinoma (HCC in patients with chronic hepatitis B virus (HBV infection. Method. 968 chronic HBV infection patients were enrolled, of which 436 patients were diagnosed HCC patients, and 532 were non-HCC patients. The clinicopathological characteristics of HCC were evaluated. The genotypes of VDR gene at FokI, BsmI, ApaI, and TaqI were determined. Results. The genotype frequencies of VDR FokI C>T polymorphism were significantly different between HCC and non-HCC groups. HCC patients had a higher prevalence of FokI TT genotype than non-HCC subjects. With FokI CC as reference, the TT carriage had a significantly higher risk for development of HCC after adjustments with age, sex, HBV infection time, α-fetoprotein, smoking status, and alcohol intake. In addition, we also found that the TT genotype carriage of FokI polymorphisms were associated with advanced tumor stage, presence of cirrhosis, and lymph node metastasis. The SNP at BsmI, ApaI, and TaqI did not show positive association with the risk and clinicopathological features of HCC. Conclusion. The FokI C>T polymorphisms may be used as a molecular marker to predict the risk and to evaluate the disease severity of HCC in those infected with HBV.

  6. Active immunization against hepatitis B virus (HBV with low-doses of plasma-derived vaccine by intradermal route

    Directory of Open Access Journals (Sweden)

    Flair José Carrilho

    1989-04-01

    Full Text Available Schedule for vaccination against HBV infection has usually been based on three separate injections of 20 meg of the vaccine by intramuscular route. One of the main shortcomings to its use in large scale programs has been its high cost. Ninety out of 300 health workers were submitted to three injections of 2 meg of plasma-derived vaccine (PDV by intradermal (ID route on days 0, 30, and 180. Anti-HBs was detected in 74 (82.2% after the second dose and in 80 (88.9% after the third dose, a non-significant difference. However, levels above 10 times the cut-off were observed in 29 (32.2% and 77 (85.5%, respectively (p < 0.001. The results showed that a low-dose schedule is effective when used in health workers and should be tried with other risk groups.

  7. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

    Directory of Open Access Journals (Sweden)

    James S Cavenaugh

    Full Text Available BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs, encoding the surface antigen of HBV as therapy for chronic HBV. A secondary goal was to characterize the immune responses. METHODS: Firstly 32 HBV e antigen negative (eAg(- participants were randomly assigned to one of four groups: to receive vaccines alone, lamivudine (3TC alone, both, or neither. Later 16 eAg(+ volunteers in two groups received either 3TC alone or both 3TC and vaccines. Finally, 12 eAg(- and 12 eAg(+ subjects were enrolled into higher-dose treatment groups. Healthy but chronically HBV-infected males between the ages of 15-25 who lived in the western part of The Gambia were eligible. Participants in some groups received 1 mg or 2 mg of pSG2.HBs intramuscularly twice followed by 5×10(7 pfu or 1.5×10(8 pfu of MVA.HBs intradermally at 3-weekly intervals with or without concomitant 3TC for 11-14 weeks. Intradermal rabies vaccine was administered to a negative control group. Safety was assessed clinically and biochemically. The primary measure of efficacy was a quantitative PCR assay of plasma HBV. Immunity was assessed by IFN-γ ELISpot and intracellular cytokine staining. RESULTS: Mild local and systemic adverse events were observed following the vaccines. A small shiny scar was observed in some cases after MVA.HBs. There were no significant changes in AST or ALT. HBeAg was lost in one participant in the higher-dose group. As expected, the 3TC therapy reduced viraemia levels during therapy, but the prime-boost vaccine regimen did not reduce the viraemia. The immune responses were variable. The majority of IFN-γ was made by antigen non-specific CD16(+ cells (both CD3(+ and CD3(-. CONCLUSIONS: The vaccines were well tolerated but did not control HBV infection. TRIAL REGISTRATION: ISRCTN ISRCTN67270384.

  8. 乙型肝炎病毒相关线粒体致病机制研究进展%Progress in HBV related mitochondrial pathogenesis

    Institute of Scientific and Technical Information of China (English)

    杨松; 邢卉春; 成军

    2016-01-01

    线粒体是参与细胞内能量、细胞凋亡、免疫应答与细胞周期调控等的重要细胞器。在乙型肝炎病毒(hepatitis B virus,HBV)致病机制中,HBV主要通过HBx与HBsAg作用于线粒体。HBV可以影响线粒体途径的细胞凋亡,但HBV对线粒体凋亡的影响在不同环境下呈现不同的作用。HBV还可影响氧化应激损伤、细胞周期调控以及线粒体相关抗病毒免疫。HBV作用于线粒体,一方面为完成HBV生命周期创造有利的细胞内环境,另一方面会造成肝细胞损伤。阐明线粒体在HBV致病机制中的作用,进一步深入阐释HBV导致细胞损伤尤其是肝细胞癌发生的可能机制,可为相关药物研发提供新的靶位。%Mitochondria is an important cell organelle which is involved in energy metabolism, cell apoptosis, immune regulation and cell cycle regulation. In hepatitis B virus (HBV) pathogenesis, HBV interact with mitochondria through HBx and HBsAg. HBV may act on the mitochondria related intrinsic apoptosis, but the results are different in different situations. Besides, HBV is also related to oxygen stress injury, cell cycle regulation and antiviral immune response. Effect of HBV on mitochondria is to build the circumstance for HBV life cycle and cause liver injury. Further studies are needed to elucidate the role of mitochondria in HBV pathogenesis.

  9. Serum levels of macrophage migration inhibitory factor,Interleukin-17 and Interleukin-10 in patients with HBV-related liver disease%Serum levels of macrophage migration inhibitory factor, Interleukin-17 and Interleukin-10 in patients with HBV-related liver disease

    Institute of Scientific and Technical Information of China (English)

    YU Xiaohui; DUAN Huichun; WEI Wang

    2012-01-01

    Objective To study the potential role of macrophage migration inhibitory factor ( MIF),Interleukin-17 (IL-17) and lnterleukin-10 (IL-10) in the development of HBV-related liver disease.Methods 48 patients with chronic hepatitis B ( HBeAg negative and positive,24 cases; 21 cases of HBV-DNA negative and 27 cases of HBV-DNA positive),81 cases of hepatitis B patients with decompensated cirrhosis and 48 cases of primary liver cancer patients were collected as the experimental group,26 healthy people were as control group.Serum MIF,IL-17 and IL-10 were measured.Results MIF and IL-17 significantly increased,IL-10 significantly decreased in experimental group,compared with the control group ( P < 0.05 ),there was significant difference. In addition,there was no significant difference (P >0.05) between positive and negative of chronic hepatitis B.MIF,IL-17 and ALT levels were positively correlated ( r =0.693,P < 0.0 1 ; r =0.897,P < 0.001 ),IL-10 and ALT was negatively correlated ( r =-0.285,P =0.037).Conclusion These results indicated that MIF,IL-17 and IL-10 may participate in the pathological process of HBV-related liver disease,serum levels of MIF,IL-17 and IL-10 appear to reflect the severity of tissue injury in HBV-related liver disease.

  10. The silence of MUC2 mRNA induced by promoter hypermethylation associated with HBV in Hepatocellular Carcinoma

    Directory of Open Access Journals (Sweden)

    Ling Yang

    2013-01-01

    Full Text Available Abstract Background To evaluate the promoter methylation status of MUC2 gene and mRNA expression in patients with hepatocellular carcinoma. Methods We analyzed MUC2 methylation by MSP, and MUC2 mRNA by real-time PCR in 74 HCC. Results MUC2 mRNA were lower in HCC tissues (Mean -ΔCt = −4.70 than that in Non-HCC tissues (Mean -ΔCt = −2.98. Expression of MUC2 was elevated in only 23 (31.08% of the 74 HCC patients. MUC2 promoter was hypermethylated in 62.2% (46/74 of HCCs, and in only 18.9% (14/74 of non-tumor samples. MUC2 mRNA were lower in HCC patients with hypermethylation (Mean -ΔΔCt = −2.25 than those with demethylation (Mean -ΔΔCt = −0.22, and there is a decreased tendency for MUC2 mRNA in HCC patients with promoter hypermethylation (p = 0.011. There was a significantly correlation found between MUC2 mRNA and HBV and AFP in HCC. The loss of MUC2 mRNA and hypermethylation could be poor prognostic factors. After treated by 5-Aza-CdR and TSA, we found that MUC2 mRNA induced significantly in 7721, Huh7 and HepG2 cells. Conclusion The results suggested that MUC2 mRNA silenced by promoter hypermethylation is associated with high levels HBV in HCC.

  11. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation.

    Directory of Open Access Journals (Sweden)

    Guo-Ying Wang

    Full Text Available BACKGROUND: Neutrophil to lymphocyte ratio (NLR has been proposed to predict prognosis of hepatocellular carcinoma (HCC. However, the cut-off values are empirical. We determined the optimal cut-off value to predict HCC recurrence after liver transplantation (LT and further established a scoring model based on NLR. METHODOLOGY/PRINCIPAL FINDINGS: We analyzed the outcome of 101 HBV-associated HCC patients undergoing LT. Preoperative risk factors for tumor recurrence were evaluated by univariate analysis. By using ROC analysis, NLR≥3 was considered elevated. The disease-free survival (DFS and overall survival (OS for patients with high NLR was significantly worse than that for patients with normal NLR (the 5-year DFS and OS of 28.5% and 19.5% vs. 64.9% and 61.8%, respectively; P5 cm, tumor number >3, macrovascular invasion, AFP≥400 µg/L, NLR≥3, and HBV-DNA level >5 log10 copies/mL were preoperative predictors of DFS. Cox regression analysis showed macrovascular invasion, tumor number, and high NLR were independent prognostic factors. We then established a preoperative prognostic score based on multivariate analysis. Each factor was given a score of 1. Area under the ROC curve of the score was 0.781. All nine patients with score 3 developed recurrence within 6 months after LT. Of 71 patients without vascular invasion, three patients with both tumor number >3 and NLR≥3 developed recurrence within 14 months after LT while the 5-year DFS and OS for patients with a score of 0 or 1 were 68.1% and 62.8%, respectively. CONCLUSIONS/SIGNIFICANCE: Preoperative elevated NLR significantly increases the risk of recurrence in patients underwent LT for HCC. Patients with both NLR≥3 and tumor number >3 are not a good indication for LT. Our score model may aid in the selection of patients that would most benefit from transplantation for HCC.

  12. HIV, HCV, HBV, HSV, and syphilis prevalence among female sex workers in Tehran, Iran, by using respondent-driven sampling.

    Science.gov (United States)

    Moayedi-Nia, Saeedeh; Bayat Jozani, Zahra; Esmaeeli Djavid, Gholamreza; Entekhabi, Fatemeh; Bayanolhagh, Saeed; Saatian, Minoo; Sedaghat, Abbas; Nikzad, Rana; Jahanjoo Aminabad, Fatemeh; Mohraz, Minoo

    2016-04-01

    To find out the prevalence of HIV, HCV, HBV, HSV, and syphilis infections among female sex workers (FSWs) in Tehran, a cross-sectional study by using respondent-driven sampling (RDS) method was conducted. From December 2012 to April 2013 FSWs in Tehran were recruited. Inclusion criteria consisted of trading sex during the 12 months prior to this study and selling sex for at least 6 months in participants' lifetime. Among 161 consenting participants, 5% were infected with HIV. Moreover, 8.1% of FSWs were HCV positive, 37.9% were of HSV type1/type2, 1.2% of participants were infected with HBV, and none of the participants were infected with syphilis. HIV-positive participants were significantly more likely to be co-infected with HSV type1/type2, be younger, have more sexual partners and especially more clients during seven days prior to this study and report more history of having at least one of sexually transmitted infections symptoms in 12 months prior the study. In the multiple logistic regression analysis, being infected with HSV and also being under 25 years of age were found to be independently associated with HIV infection. Compared with the prevalence of HIV among general population of Tehran, relatively high prevalence of HIV and other viral infections among FSWs should be considered. All in all, it is critical to commence effective counter-measures for this high-risk group if the aim is to prevent spreading of these viruses to general population. PMID:26565671

  13. The Study of IgG Subclass Profiles of Anti-HBc in Populations with Different Status of HBV Infection

    Institute of Scientific and Technical Information of China (English)

    Yu-Yen Yang; Chi-Chiang Yang; Chien-Fu Huang; James Cheng-Chung Wei; Mei-Shang Ho; Lina Wang; Shyh-Jye Lin; Wei-Yu Tsai; Chien-Chou Lin; Fangling Xu

    2005-01-01

    To study IgG subclasses for the hepatitis B virus (HBV) core antigen (anti-HBc) in different populations, a comparison was made between 104 chronic carriers (60 male and 44 female) and 434 recovered individuals (247 male and 192 female). Biochemistry analyses of AST (aspartate aminotransferase) and ALT (alanine aminotransferase) were also performed. Among the 104 chronic carriers, 21 patients were found to be ALT and AST abnormal (> 25 IU/ml). After comparing these ALT and AST abnormal patients with other ALT and AST normal chronic carriers, no statistical difference was observed in the OD values of the anti-HBe (p > 0.05). The ELISA results showed the anti-HBc IgG subclass pattern was IgG1 > IgG3 > IgG4 in chronic carriers and IgG3 > IgG1 > IgG4 in recovered individuals (p < 0.05). This result suggests the IgG1/IgG3 ratio may be related with HBV status. However, in spite of the different anti-HBc IgG1/IgG3 patterns demonstrated in different populations, both anti-HBc IgG1 and IgG3 concentrations were significantly higher in chronic carriers (p < 0.05). Therefore, both the anti-HBc IgG1/IgG3 ratio and their amounts differed. They may play a significant role in chronic carriers and recovered individuals. The anti-HBc IgG subclass profiles of chronic carriers were not changed regardless of liver inflammation, and were independent of sex and age. Cellular & Molecular Immunology.

  14. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa.

    Science.gov (United States)

    Kania, D; Bekalé, A M; Nagot, N; Mondain, A-M; Ottomani, L; Meda, N; Traoré, M; Ouédraogo, J B; Ducos, J; Van de Perre, P; Tuaillon, E

    2013-12-01

    People screened for human immunodeficiency virus (HIV) using rapid diagnostic tests (RDTs) in Africa remain generally unaware of their status for hepatitis B (HBV) and hepatitis C (HCV) infections. We evaluated a two-step screening strategy in Burkina Faso, using both HIV RDTs and Dried Blood Spot (DBS) assays to confirm an HIV-positive test, and to test for HBV and HCV infections. HIV counselling and point-of-care testing were performed at a voluntary counselling and testing centre with HBV, HCV status and HIV confirmation using DBS specimens, being assessed at a central laboratory. Serological testing on plasma was used as the reference standard assay to control for the performance of DBS assays. Nineteen out of 218 participants included in the study were positive for HIV using RDTs. A fourth-generation HIV ELISA and immunoblot assays on DBS confirmed HIV status. Twenty-four out of 25 participants infected with HBV were found positive for hepatitis B surface antigen (HBsAg) using DBS. One sample with a low HBsAg concentration on plasma was not detected on DBS. Five participants tested positive for HCV antibodies were confirmed positive with an immunoblot assay using DBS specimens. Laboratory results were communicated within 7 days to participants with no loss to follow up of participants between the first and second post-test counselling sessions. In conclusion, DBS collection during HIV point-of-care testing enables screening and confirmation of HBV, HCV and HIV infections. Diagnosis using DBS may assist with implementation of national programmes for HBV, HCV and HIV screening and clinical care in middle- to low-income countries. PMID:23902574

  15. Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins

    Directory of Open Access Journals (Sweden)

    Aris Haryanto

    2015-11-01

    Full Text Available Bayer 41-4109 is heteroarylpyrimidine (HAP which has been identified as potent of HBV capsid assemblyinhibitor. The present study was to study effect of Bayer 41-4109 treatment on the intracellular localization ofEGFP-Core fusion proteins into HepG2 cells. Three recombinant plasmids of pEGFP-Core with single, double andtriple NLS of HBV core (EGFP-Core 1C, 2C and 3C and two recombinant plasmids with single and triple NLS ofSV-40 (EGFP-Core 1 and 3 SV-40 were used in this work. After transient transfected into HepG2 cells and treatedwith Bayer 41-4109, the intracellular localization of expressed fusion proteins from all plasmid constructions weredetermined and quantified under confocal laser microscope. Results shown that Bayer 41-4109 treatment in HepG2cells inhibited the nuclear localization of EGFP-Core with single of triple HBV core NLS. As well as the constructionsof expressed fusion protein with single and triple SV-40 NLS (EGFP-Core 1 and 3 SV-40 NLS showeddecreasing the nuclear localization after treated with Bayer 41-4109, even not as strong as EGFP-Core 1C and 3CNLS. Bayer 41-4109 has been identified as a potent inhibitors of HBV replication which has multiple effects on HBVcapsid assembly. It may inhibit virus replication by inducing assembly inappropriately and by misdirectingassembly decreasing the stability of normal capsids.Keywords: HBV capsid, Bayer 41-4109, EGFP-Core fusion protein, HepG2 cell

  16. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

    Directory of Open Access Journals (Sweden)

    Fabrizio Cantini

    2014-01-01

    Full Text Available Introduction. Antitumor necrosis factor-alpha (TNF-α agents are widely used for treatment of rheumatic and dermatological diseases. We conducted the systematic review and meta-analysis to assess the prevalence of HBV reactivation among patients treated with anti-TNF-α. Methods and Findings. A comprehensive literature search of MEDLINE, Scopus, and ISI Web of Knowledge databases was conducted. From 21 studies included in the systematic review, 9 included patients with occult chronic HBV infection and 6 included patients with overt infection while 6 addressed both groups. Based on 10 studies eligible for meta-analysis we report pooled estimate of HBV reactivation of 4.2% (95% CI: 1.4–8.2%, I2: 74.7%. The pooled prevalence of reactivation was 3.0% (95% CI: 0.6–7.2, I2: 77.1% for patients with occult infection, and 15.4% (95% CI: 1.2–41.2%, I2: 79.9% for overt infection. The prevalence of reactivation was 3.9% (95% CI: 1.1–8.4%, I2: 51.1% for treatment with etanercept and 4.6% (95% CI: 0.5–12.5%, I2: 28.7% for adalimumab. For subgroup of patients without any antiviral prophylaxis the pooled reactivation was 4.0% (95% CI: 1.2–8.3%, I2: 75.6%. Conclusion. Although HBV reactivation rate is relatively low in patients treated with anti-TNF-α for rheumatic and dermatological conditions, the antiviral prophylaxis would be recommended in patients with overt chronic HBV infection.

  17. Application of the HBV model for assessment of climate change impacts on the elements of hydrological cycle for the Struma River Basin

    International Nuclear Information System (INIS)

    The model used in this report is a version of the HBV model developed for the project Climate Change and Energy Production, a Nordic project aimed at evaluating the impacts of climate change on the water resources. It has a simple vegetation parametrization including interception, temperature based evapotranspiration. calculations, lake evaporation, lake routing, glacier mass balance simulation, special functions for climate change simulations etc. The HBV model, originally developed at the Swedish Meteorological and Hydrological Institute in the first half of the seventies (Bergstroem 1976) has gained widespread use for a large range of applications both in Scandinavia and beyond. It can be classified as a semi-distributed conceptual model. The version described in this report was developed for the Nordic project 'Climate change and Energy Production' (Saelthun 1996), as a synthesis of several versions used in the different Nordic countries. The main input variables are the average daily temperature, daily totals of the precipitation, the potential evapotranspiration and the daily discharges. The HBV model was applied for assessment of climate change impacts on the elements of hydrological cycle for the Struma river basin. The river Struma flows from North to South up to the Aegean Sea. Considerable part of the river basin is situated in northwest part of Bulgaria, heaving an area of more than 10 000 km2 and average elevation about 900m asl (cross-section Marino pole). The period of 16 years (1973-1988), four precipitation and temperature stations were used for the model parameters evaluation. The achieved value of R2 (Nash criterion) is 0.55. The climate change impact calculations (monthly values of temperatures change in oC and precipitation change in %) for two scenarios were used for the input data correction to the HBV model. The obtained results are promising and they show the potential possibility for the HBV model use to assess the climate change impacts

  18. Changes and Significance of peripheral Th17 cells and Treg cells in HBV infected patients%Th17细胞与 Treg 细胞在 HBV 感染患者中的检测意义

    Institute of Scientific and Technical Information of China (English)

    邓永佳; 张房英; 赖小丽

    2015-01-01

    Objective To investigate the changes of T helper 17 (Th17)cells and regulatory T (Treg)cells in the peripheral blood of hepatitis B virus(HBV)infected patients and their correlations with liver injury.Methods One hundred and nine cases of hepatitis B patients were chosen in our hospital from March 2010 to January 2013 and were divided into four groups in accordance with the condition of diseases.The peripheral blood of 32 asymptomatic HBV carriers (ASC group),47 chronic hepatitis B patients (CHB group),30 hepatocellular carcinoma patients (HCC group)and 30 healthy controls (control group)were collected.The percentages of Th17 and Treg cells were detected by flow cytometry.Alanine aminotransferase (ALT)and aspartate aminotransferase (AST)were detected by automatic biochemistry analyzer.Results Compared with control group,the percentages of both Treg and Th17 cells in the peripheral blood of ASC group were higher,but no statistical difference was detected (t =0.809,P >0.05 for Treg cells;t =1 .459,P >0.05 for Th17 cells, respectively).While significant increase of percentages of Treg cells and Th17 cells in CHB group and HCC group was found(t=2.988,7.569,P <0.05 for Treg cells;t=3.910,6.725,P <0.05 for Th17 cells,respectively).And Treg cells increase in HCC group was higher than that in CHB group (t=6.580,P <0.01).Treg cells and Th17 cells were correlated positively with ALT and AST(r=0.546,0.587,P <0.01 for Treg cells;r =0.546、0.617,P <0.01 for Th17 cells),and Th17 cell percentage was positively correlated with Treg cell percentage (r =0.487,P <0.01).The rate of Th17/Treg in control group was the lowest (0.15%±0.14%),while significantly higher Th17/Treg ratio in CHB group and HCC group were observed (t=2.015,5.056,P <0.05).Conclusion With the development of HBV infection,the percentages of Th17 and Treg cells increased.The destruetion of the immune balance leads to the increased of Th17 cells that induced immune injury and induce the inflammation of liver cells

  19. Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety

    Directory of Open Access Journals (Sweden)

    Rajesh Kumar

    2015-01-01

    Full Text Available Background: Transfusion-transmitted infections (TTIs are one of the biggest threats to blood transfusion safety. Nucleic acid testing (NAT in blood donor screening has been implemented in many countries to reduce the risk of TTIs. NAT shortens this window period, thereby offering blood centers a much higher sensitivity for detecting viral infections. Aims: The objective was to assess the role of individual donor-NAT (ID-NAT for human immunodeficiency virus-1 (HIV-1, hepatitis C virus (HCV and hepatitis B virus (HBV and its role in blood safety. Materials and Methods: A total of 32978 donations were tested for all three viruses using enzyme-linked immuno-sorbent assay (Vironostika ® HIV Ag-Ab, Hepanostika ® HCV ultra and hepatitis B surface antigen ultra by Biomerieux and ID-NAT using Procleix Ultrio plus ® Assay (Novartis Diagnostic, USA. All initial NAT reactive samples and serology nonreactive were retested in triplicate and NAT discriminatory assay for HIV-1, HCV and HBV were performed. Results: Of the 32978 samples, 43 (0.13% were found to be ID-NAT reactive but seronegative. Out of 43, one for HIV-1, 13 for HCV and 27 for HBV were reactive by discriminatory assays. There were two samples that were reactive for both HCV-HBV and counted as HCV-HBV co-infection NAT yield. The prevalence of these viruses in our sample, tested by ID-NAT is 0.06%, 0.71%, and 0.63% for HIV-1, HCV and HBV respectively. The combined NAT yield among blood donors was 1 in 753. Conclusion: ID-NAT testing for HIV-1, HCV and HBV can tremendously improve the efficacy of screening for protecting blood recipient from TTIs. It enables detection of these viruses that were undetected by serological test and thus helped in providing safe blood to the patients.

  20. SNP loci detection method based on HBV sequence%一种基于HBV序列的SNP位点检测方法研究

    Institute of Scientific and Technical Information of China (English)

    张琪; 刘立芳; 马磊; 贺建峰

    2014-01-01

    乙型肝炎病毒(Hepatitis B Virus,HBV)感染作为严重影响人类健康的疾病之一,是导致慢性肝脏疾病、肝硬化和肝癌的主要元凶。HBV由于其自身复制的特殊性,具有高变异特性,据研究表明HBV基因变异是HBV持续感染的根本原因。为了了解HBV的基因变异情况,检测HBV序列的SNP位点即单突变位点已广泛应用于大量的研究,所检测出的SNP位点对指导临床有重要意义。但是目前关于SNP位点检测的方法多因技术难度较高,费用大等不利因素而受到制约。因此,探讨一种基于计算机的SNP位点检测方法成为一种趋势。针对HBV序列的 SNP位点的特点,提出了一种基于最优风险与预防模型的HBV序列的SNP位点检测方法。方法首次应用于HBV序列的SNP位点检测,实验结果表明:该方法不仅有效地检测出HBV序列的X基因片段和前C区基因片段中已经报道的位点,而且还发现了一些新的SNP位点。与硬件检测SNP位点不同的是,所提出的计算机方法具有操作简单和费用低的优点,而且普通实验室和医疗机构均可以承受。%As one of the severe diseases, HBV(Hepatitis B Virus)infection is seriously affecting human health. This kind of virus infection is the main reason that leads to chronic liver disease, cirrhosis and liver cancer. Due to the particularity of HBV replication and high variability characteristics, related studies have revealed that the HBV gene mutation is the basic reason of persistent HBV infection. In order to understand the genetic variation of HBV, the SNP detection from HBV sequences has been widely applied in the large number of research, the detected SNP loci may contain great clinical significance. However, currently, the SNP loci detection methods are restricted by some negative factors, such as high technical difficulty, high expense and so on. Therefore, to explore a computer-based method for SNP loci

  1. 广州地区吸毒人员HBV、HCV感染流行病学特征%HBV and HCV infection among drug addicts in Guangzhou

    Institute of Scientific and Technical Information of China (English)

    熊华平; 花文峰; 王敏; 廖峭; 戎霞; 黄杰庭; 黄珂; 许茹; 付涌水

    2013-01-01

    Objective To investigate the infection rates and the impact of HBV and HCV infection among drug addicts in Guangzhou.Methods Questionnaire survey was conducted in this study.Blood samples from the drug addicts were collected.HBsAg and HCV antibodies were detected by ELISA assays.The correlation between infection and possible impact factors were analyzed by SPSS16.0 software.Results Of the 1 375 drug addicts,the percentage of HBV and HCV infection was 20.8% and 39.2%,respectively.106 cases (7.7%) were found to have HBV and HCV co-infection.412 cases were intravenous drug users (IDUs),in which the HBV and HCV infection rate was 24.5% and 84.5%,respectively.Elderly and those with a long history of drug addiction had a higher risk of having HBV and HCV infection.Conclusions Drug addiction,especially through the intravenous injection,is the risk factor of HBV and HCV infection.Age,the history of drug addiction,and intravenous drug injection are correlated with HBV and HCV infection.%目的 了解广州地区吸毒人员乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)的感染状况及其影响因素.方法 收集广州地区吸毒人员的血液标本,采用ELISA检测HBsAg及HCV抗体,并对吸毒人员采取统一调查表进行问卷调查,采用统计学方法进行相关性分析.结果 1 375名吸毒者HBV、HCV的感染率分别为20.8%、39.2%,HBV/HCV合并感染率为7.7%(106/1 375).其中采用静脉吸毒者HBV、HCV的感染率分别24.5%、84.5%,均高于非静脉吸毒者的19.2%、19.8%,差异有统计学意义(P<0.05).吸毒者年龄越大、吸毒时间越长越容易发生HBV或HCV感染.结论 吸毒尤其是静脉吸毒是HBV、HCV感染的高危因素.吸毒者年龄、吸毒时间长短及吸毒方式与HBV、HCV感染相关.

  2. "Know Hepatitis B:" A Multilingual Communications Campaign Promoting Testing for Hepatitis B Among Asian Americans and Pacific Islanders.

    Science.gov (United States)

    Jorgensen, Cynthia; Chen, Sherry; Carnes, C Amanda; Block, Joan; Chen, Daniel; Caballero, Jeffrey; Moraras, Kate; Cohen, Chari

    2016-01-01

    The "Know Hepatitis B" campaign was the first national, multilingual communications campaign to promote testing for hepatitis B virus (HBV) among Asian Americans and Pacific Islanders (AAPIs). This population comprises fewer than 5% of the total U.S. population but accounts for more than half of the up to 1.4 million Americans living with chronic HBV infection. To address this health disparity with a national campaign, CDC partnered with Hep B United, a national coalition of community-based partners working to educate AAPIs about hepatitis B and the need for testing. Guided by formative research, the "Know Hepatitis B" campaign was implemented in 2013 with a two-pronged communications strategy. CDC used available Chinese, Korean, and Vietnamese media outlets on a national level and relied on Hep B United to incorporate campaign materials into educational efforts at the local level. This partnership helped facilitate HBV testing among the priority population. PMID:27168659

  3. Development of a Novel, Ultra-rapid Biosensor for the Qualitative Detection of Hepatitis B Virus-associated Antigens and Anti-HBV, Based on “Membrane-engineered” Fibroblast Cells with Virus-Specific Antibodies and Antigens

    OpenAIRE

    Antonios Perdikaris; Nikos Alexandropoulos; Spiridon Kintzios

    2009-01-01

    A novel miniature cell biosensor detection system for the detection of Hepatis B virus (HBV)-associated antigens and anti-HBV is described. The biosensor is based on “membrane-engineered” Vero fibroblast cells immobilized in an alginate matrix. The membrane-engineering process involved the electroinsertion of anti-HBV specific antibodies (anti-HBs, anti-HBe) or antigens (HBsAg) in the membranes of the Vero cells. The attachment of a homologous antigen to the electroinserted antibody (or, resp...

  4. 治疗性双质粒HBV DNA疫苗工程菌的中试发酵工艺研究%Pilot Fermentation Procedure of Recombinant E. coli Strain Containing Two Plasmids as Therapeutic HBV DNA Vaccine

    Institute of Scientific and Technical Information of China (English)

    饶桂荣; 黄英; 王鹏; 何晓嫱; 杨富强; 莫国玉; 陈光明

    2007-01-01

    目的 研究双质粒HBV DNA疫苗工程菌的中试发酵工艺.方法 首先通过计算质粒拷贝数,检测工程菌DH5α/pS2.S和DH5α/pFP在传代过程中的遗传稳定性,通过摇瓶培养确定培养基组成,再在30 L发酵罐内,通过改变培养基成分、培养时间、补料方式,确定最佳发酵参数.并将确定的最佳发酵参数应用于50 L发酵罐连续3批中试规模的发酵,同时考察在发酵培养过程中质粒稳定性和超螺旋质粒DNA的比例.结果 工程菌DH5α/pS2.S和DH5α/pFP在连续传代30次后,质粒拷贝数保持稳定.确定最佳发酵参数为以甘油为碳源的培养基培养,梯度恒速流加方式补料,培养时间为10 h.通过3批稳定发酵,最终可获得湿菌58.0~71.8 g/L,质粒含量可达到1.11~1.58 mg/g菌,超螺旋质粒DNA的比例达93%以上.结论 已建立了稳定的双质粒HBV DNA疫苗工程菌中试发酵工艺,为进一步规模化生产奠定了基础.

  5. 妊娠后期拉米夫定抗病毒治疗HBV DNA高载量孕妇的母婴结局分析%Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B

    Institute of Scientific and Technical Information of China (English)

    江红秀; 韩国荣; 王翠敏; 季莹

    2012-01-01

    Ag)-positivity and highly viremic status.Methods A total of 256 pregnant women in the second or third trimester with monoinfected CHB,HBeAg-positivity,and HBV DNA > 6 log10 copies/mL were divided into two groups:lamivudme (lam) treatment (n =164) or no treatment (controls; n =92).All infants were treated with hepatitis B immune globin (HBIg; 200 IU) within 12 hrs of birth and 15 days later,and were given the recombinant HBV vaccine (20 μg) at 0,1 and 6 months.All infants were followed-up to at least seven months and hepatitis B surface antigen (HBsAg) and HBV DNA levels were used to determine perinatal transmission (PT) rates.The mothers' data from routine blood analysis,tests of hepatic and renal function,detection of HBV markers and HBV DNA were retrospectively analyzed to determine changes associated with the lam treatment.Correlations of lam treatment with HBV PT rate,alanine aminotransferase (ALT) normalization,adverse reactions,pregnancy complications,congenital deformities,and infants' growth/development were determined by statistical analyses.Results Prior to delivery,the lam-treated mothers had significantly lower HBV DNA levels (3.72 ± 1.78 vs.controls:7.83 ± 0.67 log10 c/ml; t=-22.359,P< 0.001).The rate of virological response in the lam-treated group was 97.56% (160/164).The lam-treated group had significantly higher ALT normalization rate (90.20% vs.controls:55.88%; x2 =13.349,P<0.001) and significantly lower HBeAg titer (957.73 ±458.42 vs.controls:1296.35 ± 383.14 S/CO; t=-5.410,P< 0.001).At birth,the infants from lam-treated mothers had significantly lower HBsAg-positivity (15.24% (25/164) vs.controls:30.43% (28/92); x2 =8.284,P=0.004).By 7-12 months after birth,none of the infants born to lamtreated mothers tested positive for HBsAg,compared to 8.70% (8/92) of the infants born to mothers in the control group (x2 =14.721,P< 0.001).None of the lam-treated mothers required treatment discontinuation due to adverse events or lam

  6. The Intrahepatic Expression and Distribution of BTLA and its Ligand HVEM in patients with HBV-related acute-on-chronic liver failure

    Directory of Open Access Journals (Sweden)

    Xu Huan

    2012-10-01

    Full Text Available Abstract Objective It has been demonstrated that signals from the inhibitory receptor B and T lymphocyte attenuator (BTLA are involved in regulating the pathogenesis of infectious diseases. However, the expression and anatomical distribution of BTLA and its ligand, the herpes virus entry mediator (HVEM, have not yet been determined in cases of HBV-related acute-on-chronic liver failure (HBV-ACLF patients. Methods In this study, the expression of BTLA and HVEM in liver tissues from HBV-ACLF, chronic hepatitis B (CHB patients and healthy individuals was analyzed by immunohistochemistry. Results The results of this analysis demonstrated that both molecules were observed in the HBV-ACLF samples and that their expression was chiefly in the infiltrating inflammatory cells and the damaged bile ducts. However, they were absent in liver sections from CHB patients and healthy controls. Immunofluorescence double-staining indicated that BTLA was found on CK-18+ epithelial cells, CD31+ endothelial cells, CD68+ macrophages, CD56+ NK cells, CD16+ monocytes, CD3+ , CD8+ T cells, and Foxp3+ regulatory T cells (Treg. By contrast, HVEM expression was restricted to CK18+ epithelial cells and CD68+ macrophages. Moreover, the expression of several members of the B7 superfamily, including PD-L1, PD-L2, B7-H3 and B7-H4, was also detected in these liver tissues, and these proteins were co-expressed with HVEM. Interestingly, the expression of fibrinogen-like protein 2 (FGL2, a virus-induced procoagulant molecule, was also found in liver sections from HBV-ACLF, this molecule also co-expresses with BTLA and HVEM. Conclusions These results suggest that BTLA-HVEM signaling is likely to affect the pathogenesis of HBV-ACLF, a clear understanding of the functional roles of these proteins should further elucidate the disease process. Virtual slides The virtual slide(s for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8080806838149123

  7. The level of knowledge of, attitude toward and emphasis given to HBV and HCV infections among healthcare professionals: Data from a tertiary hospital in Turkey

    Directory of Open Access Journals (Sweden)

    Ayhan Hilmi Cekin

    2013-02-01

    Full Text Available Objectives: To evaluate the level of knowledge of, to investigate the attitudes toward, and to determine the emphasis given to the national prevalence of HBV/HCV infections among healthcare professionals. Materials and Methods: A total of 206 healthcare professionals (mean (SD age: 37.0 (6.3 years; 86.9% – females including medical laboratory technicians (N = 54 and nurses (N = 152 employed in the Antalya Training and Research Hospital, Antalya, Turkey. Laboratory (N = 53, operating room (N = 41 and in-patient clinic (N = 112 staff were included in this descriptive study. A 33-questionnaire composed of questions related to their level of knowledge and attitudes toward HBV/HCV infections, the sources of their knowledge of HBV/HCV infections and the emphasis given to the national and global importance of the diseases was administered via a face–to-face interview method with each subject; participation was volunteer based. Results: The participants working in the in-patient clinic (18.0 (3.2 had the highest mean (SD knowledge level compared to the laboratory (16.4 (3.1, p < 0.05 and operating room (17.0 (2.8, p < 0.05 staff. The participants from the in-patient clinic (44.6% had a more advanced level of knowledge compared to the participants working in the laboratory (27.8%, p < 0.05 and the operating room (30.0%, p < 0.05. Most of the subjects (60.7% had education concerning HBV/HCV infections in the past. There was no signifi cant difference between the hospital units in terms of the attitudes of healthcare workers (HCWs toward HBV/HCV infections and the level of education concerning them. Conclusions: Our fi ndings revealed a moderate level of knowledge in most HCWs, regardless of their exposure to risk. While the highest knowledge scores and vaccination rates were noted among the in-patient clinic staff, there was no signifi cant difference between the hospital units in terms of the attitudes of HCWs towards a patient or a colleague with an

  8. 慢性乙型肝炎免疫清除期甲胎蛋白与HBV DNA清除的相关性研究%Correlation between serum alpha-fetoprotein level and HBV DNA clearance in immune clearance phase of patients with chronic hepatitis B

    Institute of Scientific and Technical Information of China (English)

    庞晓鹰; 徐洪涛; 杨秀珍; 咸建春; 沈美龙

    2014-01-01

    目的:探讨乙型肝炎免疫清除期,甲胎蛋白(AFP)与HBV DNA清除之间的相关性。方法收集处于免疫清除期发病2周内AFP升高5倍以上患者共58例,分为非抗病毒治疗组(下称观察组)31例和核苷(酸)类似物抗病毒治疗组(下称阳性对照组)27例,另取同期住院AFP阴性首次发病的慢性乙型肝炎核苷(酸)类似物抗病毒患者30例作为阴性对照组。分析影响HBV DNA清除率的相关因素。结果阳性对照组及阴性对照组患者均行抗病毒治疗,HBV DNA定量与各临床数据之间均无相关性,观察组HBV DNA定量与各指标之间的关系结果显示,AFP与HBV DNA清除具有显著相关性(r=0.8420,P=0.018),以下依次为ALT(r=0.7888,P=0.027)和总胆红素(TBil)(r=0.7816,P=0.032)。HBsAg(r=0.0480,P=0.413)和HBeAg(r=0.3356,P=0.191)与HBV DNA清除无显著相关性。结论对乙型肝炎免疫清除期AFP升高5倍以上患者,可先进行密切病情观察,根据病情需要进行抗病毒治疗。%Objectives To investigate the relationship between serum alpha-fetoprotein level and HBV DNA clearance in immune clearance phase of patients with chronic hepatitis B (CHB). Methods Total of 58 cases with CHB, who were in immune clearance phase and the serum alpha-fetoprotein level>5 upper limits of normal in two weeks since disease onset were enrolled. Among which 31 cases received non-antiviral therapy as experimental group, and 27 cases received antiviral therapy as positive control group. While other 30 cases with CHB who were in immune clearance phase and the serum alpha-fetoprotein level were normal in two weeks since disease onset, were enrolled as negative control group. And the correlation factors of HBV DNA clearance were analyzed, respectively. Results There were no signiifcant correlation between HBV DNA clearance and other data in patients who received antiviral therapy in positive and negative

  9. Unconfirmed reactive screening tests and their impact on donor management

    International Nuclear Information System (INIS)

    To determine the percentage of false positive testing for transfusion transmitted infections (TTIs) using immunochromatographic test (ICT) as first line of screening tests and its effect on loss of volunteer blood donors. Over a period of three months, samples from blood bags of donors undergoing phlebotomy at teaching hospital blood banks in Lahore were screened for human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) by immunochromatographic tests. Those found positive on initial screening were re-tested by ELISA method at the screening laboratory of the Institute of Haematology and Blood Transfusion Service, Punjab. Lahore. Out of a total of 62090 voluntary blood donors, 469 donors were found to be initially reactive for either HIV, HBV or HCV. Amongst these 96 (0.15%) blood donors were found to have tested falsely positive for HIV, HBV or HCV as compared to testing by ELISA. False positive testing rate of 0.15% or 96 out of a total of 62090 donors is rather small in terms of loss of voluntary donors and appropriate utilization of available resources. Although immunochromatographic testing is not the gold standard, however it serves an important purpose of initial donor screening. (author)

  10. Sensitivity Analysis of a Conceptual HBV Raınfall-Runoff MODEL Using Eumetsat Snow Covered Area Product

    Science.gov (United States)

    Akyurek, Z.; Surer, S.; Parajka, J.

    2014-12-01

    HBV is a conceptual hydrological model extensively used in operational hydrological forecasting and water balance studies. In this study, we apply the HBV model on the upper Euphrates basin in Turkey, which has 10 624 km2 area. The Euphrates basin is largely fed from snow precipitation whereby nearly two-thirds occur in winter and may remain in the form of snow for half of the year. We analyze individual sensitivity of the parameters by calibrating the model using the Multi-Objective Shuffled Complex Evolution (MOSCEM) algorithm. The calibration is performed against snow cover area (SCA) in addition to runoff data for the water years 2009, 2010, 2011, 2012 and 2013. The SCA product has been developed in the framework of the European Organization for the Exploitation of Meteorological Satellites (EUMETSAT), Satellite Application Facility on Support to Operational Hydrology and Water Management (H-SAF) Project. The product is generated by using data from Spinning Enhanced Visible and InfraRed Imager (SEVIRI) instrument making observations from a geostationary satellite Meteosat Second Generation (MSG). In the previous study evaluation of the model was done with commonly used statistical performance metrics (Nash-Sutcliffe) for high and low flows, volume error and root mean square error (RMSE). In this study signature metrics, which are based on the flow duration curve (FDC) are used to see the performance of the model for low flows. In order to consider a fairly balanced evaluation between high and low flow phases we divided the flow duration curve into segments of high, medium and low flow phases, and additionally into very high and very low phases. Root mean square error (RMSE) is used to evaluate the performance in these segments. The sensitivity analysis of the parameters around the calibrated optimum points showed that parameters of the soil moisture and evapotranspiration (FC, beta and LPrat) have a strong effect in the total volume error of the model. The

  11. Hepatocellular Carcinoma Metastasis to the Orbit in a Coinfected HIV+ HBV+ Patient Previously Treated with Orthotopic Liver Transplantation: A Case Report

    Directory of Open Access Journals (Sweden)

    S. Guerriero

    2011-01-01

    Full Text Available Hepatocellular carcinoma rarely metastasizes to the orbit. We report a 45-year-old male, HBV+, HIV+, with a past history of a liver transplant for ELSD (end-stage liver disease with hepatocellular carcinoma and recurrent HCC, who presented with proptosis and diplopia of the left eye. CT scans of the head revealed a large, irregular mass in the left orbit causing superior and lateral destruction of the orbital bone. Biopsy specimens of the orbital tumor showed features of metastatic foci of hepatocellular carcinoma. Only 16 other cases of HCC metastasis to the orbit have been described in literature, and this is the first case in a previously transplanted HIV+, HBV+ patient.

  12. The Prevalence and Risk Factors of Hepatitis Delta Virus in HIV/HBV Co-Infected Patients in Shiraz, Iran, 2012

    Directory of Open Access Journals (Sweden)

    Mohammad Motamedifar

    2015-09-01

    Full Text Available Evidence has shown that liver disease caused by hepatitis viruses can be more aggressive and severe in HIV infected subjects. Therefore, the present cross-sectional study aimed to evaluate the seroprevalence of HDV infection among HIV/HBV co-infected clients in Shiraz, southwest Iran. In this study, 178 patients co-infected with HBV and HIV individuals were enrolled. The diagnosis of HIV infection was documented based on serological assays. The demographic and complementary data were collected by a questionnaire. HBsAg and HDV Ab were detected by commercial quantitative enzyme linked immunosorbent assay kits according to the manufacturer’s instructions. Alanine aminotransferase (ALT and aspartate aminotransferase (AST were also measured. The mean age of the participants was 37.4±7.4 years (range 22-63. 175 (98.4 % patients were male and 3 (1.6 % were female. Among 178 patients co-infected with HIV/HBV, 35 cases (19.7%, 95% CI: 14%-25% were anti-HDV‏ positive and 143 (80.3% were negative for anti-HDV. HDV exposure in HIV/HBV co-infected patients was associated with blood transfusion (P=0.002, OR: 14.3 and prison history (P=0.01, OR: 2.31 but not with age, marital status, unsafe sex contact, and injection drug abuse. Our data showed a relatively high prevalence of HDV infection in HIV infected population in Shiraz, Iran. The high frequency of HDV Ab in patients with blood transfusion and prison history reveals that HDV transmission occurs more frequently in the parental route than sexual contacts; therefore, blood screening for HDV diagnosis in the high-risk group is recommended.

  13. 比较三种定性PCR法在HBV母婴传播研究中HBV-DNA检测分析及临床意义

    Institute of Scientific and Technical Information of China (English)

    金春子; 邵明明; 李萍; 贾卉

    2005-01-01

    目的用3种定性PCR法对乙肝病毒血清学指标阳性的晚孕妇女、新生儿血清及初乳中检测HBV-DNA,并比较及分析其结果和意义.方法用PCR-电泳法和PCR-杂交梳法同时对90份标本进行HBV-DNA检测,对其中45份标本同时用3种PCR法进行HBV-DNA检测.结果 90份标本中PCR-电泳法HBV-DNA阳性率为11.1%,PCR-杂交梳法阳性率为54.4%;其中45份标本用3种PCR法检测结果,PCR-电泳法、PCR-酶免法及PCR-杂交梳法阳性率分别为8.9%、11.1%.57.8%.经统计学处理,PCR-电泳法与PCR-酶免法结果比较无统计学差异(P>0.05),而PCR-杂交梳法分别与PCR-电泳法、PCR-酶免法结果比较均有高度显著性差异(P0.005).结论 PCR-杂交梳法较PCR-电泳法和PCR-酶免法具有更敏感、特异、简单、无EB(溴化乙锭)生物污染及抗产物污染等优点,是最佳的定性PCR法,最适合用于乙肝病毒母婴传播的诊断.

  14. Association between Waste Management and HBV among Solid Municipal Waste Workers: A Systematic Review and Meta-Analysis of Observational Studies

    OpenAIRE

    Carmela Romana Natalina Corrao; Angela Del Cimmuto; Carolina Marzuillo; Emanuele Paparo; Giuseppe La Torre

    2013-01-01

    Aim. To conduct a systematic review of this relationship using available published observational studies in the field of solid municipal waste treatment. Methods. The review of the scientific literature was based on Medline and Scopus databases up to December 2012, using the keywords HBV, waste, solid, treatment, workers, disposal, and refuse in different combinations. Results. 160 studies were found and checked. Finally, 5 observational studies were considered suitable, all cross-sectional. ...

  15. Patient with hepatocellular carcinoma related to prior acute arsenic intoxication and occult HBV: epidemiological, clinical and therapeutic results after 14 years of follow-up

    OpenAIRE

    Casanovas-Taltavull, Teresa; Ribes, Josepa; Berrozpe, Ana; Jordan, Sara; Casanova, Aurora; Sancho, Concha; Valls, Carles; Bosch, F. Xavier

    2006-01-01

    Little is known about the long-term survivors of acute arsenic intoxication. We present here a clinical case report of a man with chronic hepatitis B virus (HBV) infection who developed hepatocellular carcinoma four years after acute arsenic poisoning. HBsAg was detected in serum in 1990 when he voluntarily donated blood. In 1991, the patient suffered from severe psychological depression that led him to attempt suicide by massive ingestion of an arsenic-containing rodenticide. He survived wit...

  16. Abnormal Liver Stiffness Assessed Using Transient Elastography (Fibroscan®) in HIV-Infected Patients without HBV/HCV Coinfection Receiving Combined Antiretroviral Treatment

    OpenAIRE

    Han, Sang Hoon; Kim, Seung Up; Kim, Chang Oh; Jeong, Su Jin; Park, Jun Yong; CHOI, JUN YONG; Kim, Do Young; Ahn, Sang Hoon; Song, Young Goo; Han, Kwang-Hyub; Kim, June Myung

    2013-01-01

    Background and Aims Liver stiffness measurement (LSM) using transient elastography (Fibroscan®) can identify individuals with potential underlying liver disease. We evaluated the prevalence of abnormal LSM values as assessed using LSM and its predictors in HIV-infected asymptomatic patients receiving combined antiretroviral treatment (cART) without HBV/HCV coinfection. Methods We prospectively recruited 93 patients who had consistently been undergoing cART for more than 12 months at Severance...

  17. Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina Faso

    OpenAIRE

    Bonnard, Philippe; Sombié, Roger; Lescure, Francois-Xavier; Bougouma, Alain; Guiard-Schmid, Jean Baptiste; Poynard, Thierry; Calès, Paul; Housset, Chantal; Callard, Patrice; Pendeven, Catherine Le; Drabo, Joseph; Carrat, Fabrice; Pialoux, Gilles

    2010-01-01

    Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis B. In Burkina Faso, liver biopsy (LB) remains the “gold standard” method for this purpose. Access to treatment might be simpler if reliable alternative techniques for LF evaluation were available. The hepatitis B virus (HBV)-infected patients who underwent LB was invited to have liver stiffness measurement (Fibroscan) and serum marker assays. Fifty-nine patients were enrolled. The performance of each techniqu...

  18. Seroprevalence of HIV, HBV, HCV and Syphilis in Blood Donors in Saurashtra Region of Gujarat: Declining Trends Over a Period of 3½ Years

    OpenAIRE

    Dhruva Gauravi A; Agravat Amit H; Pujara Krupal M

    2012-01-01

    Background: Transfusion of blood and blood products is a life saving intervention and benefits innumerous patients worldwide. At the same time it could be an ominous mode of infection transmission to recipients. In 15 percent of total patients infected with HIV, blood transfusion has been the responsible mechanism of transmission. Methods: In this study, we aimed to access the prevalence and trend of HIV, HBV, HCV and Syphilis over the last 3½ years (January 2008 to June 2011) among the blood...

  19. Sequece-dependent cleavage of HBV DNA by combining with triple helix-forming oligodeoxyribonucleotides modified with manganese porphyrin in vitro%卟啉锰修饰的TFO结合并切割HBV-DNA片段体外的实验研究

    Institute of Scientific and Technical Information of China (English)

    光丽霞; 袁发焕; 奚敏; 赵聪敏; 刘立; 温恩懿; 艾友萍

    2005-01-01

    目的观察卟啉锰修饰的螺旋寡核苷酸(TFO)在体外结合并切割HBV-DNA片段的能力.方法以卟啉锰、吖啶修饰TFO末端;在37℃pH7.4体外环境中,使卟啉锰、吖啶修饰的TFO与32P标记的HBV-DNA片段结合,以凝胶滞留试验、酶足迹和切割试验观察其结合的亲和性、特异性以及切割HBV-DNA片段的能力.结果卟啉锰、吖啶修饰的TFO可与HBV靶序列结合成三链DNA,解离常数(Kd)为3.5×10-7mol/L,相对亲和力为0.008,并具有序列特异性.在KHSO5存在的情况下,卟啉锰、吖啶修饰的TFO可切割靶DNA,切割部位为三链DNA形成区.结论在有KHSO5存在的情况下,卟啉锰-TFO-吖啶化合物可定点切割靶HBV-DNA.

  20. Experimental study of triplex-forming oligonucleotide targeted to the initiator of S gene of HBV labeled with 125I

    International Nuclear Information System (INIS)

    This study is used to investigate the feasibility of employing the Iodogen method to label triplex-forming oligonucleofide (TFO) targeted to the initiator of the S gene of HBV with 125I. A 17-mer oligonucleotides sequence was synthesized and grafted at the 5' terminal with a tyramine group. Radioiodination of the tyramine-TFO with 125I was then performed using the Iodogen method. After TFO was labeled with 125I using the Iodogen method, the labeling rate, the radiochemical purity, stability and bioactivity were determined, respectively. The results show that the radiolabeling rate and the radiochemical purity were 93% and 99%, respectively; and the radiochemical purity is more than 90% in vitro at -20 degree C on the 5th day after labeling; and the rate of 125I-tyramine-TFO binding to HepG2.2.15 cells was (37.2 ± 1.4)% and statistically different from the rate of HepG2 (p<0.5). Hence, it is concluded that the labeling of oligonucleotides conjugated with tyramine using the Iodogen method is successful and is characterized with a high labeling rate, high stability, and a low loss of bioactivity of the labeled agent. (authors)

  1. Experimental study of triplex-forming oligonucleotide targeted to the initiator of S gene of HBV labeled with 125Ⅰ

    Institute of Scientific and Technical Information of China (English)

    2006-01-01

    This study is used to investigate the feasibility of employing the Iodogen method to label triplex-forming oligonucleotide (TFO) targeted to the initiator of the S gene of HBV with 125Ⅰ. A 17-mer oligonucleotides sequence was synthesized and grafted at the 5' terminal with a tyramine group. Radioiodination of the tyramine-TFO with 125Ⅰwas then performed using the Iodogen method. After TFO was labeled with 125Ⅰ using the Iodogen method, the labeling rate, the radiochemical purity, stability and bioactivity were determined, respectively. The results show that the radiolabeling rate and the radiochemical purity were 93% and 99%, respectively; and the radiochemical purity is more than 90% in vitro at -20℃ on the 5th day after labeling; and the rate of 125Ⅰ-tyramine-TFO binding to HepG2.2.15cells was (37.2±1.4) % and statistically different from the rate of HepG2 (p<0.5). Hence, it is concluded that the labeling of oligonucleotides conjugated with tyramine using the Iodogen method is successful and is characterized with a high labeling rate, high stability, and a low loss of bioactivity of the labeled agent.

  2. Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi

    OpenAIRE

    Liao, Xiwen; Han, Chuangye; Qin, Wei; Liu, Xiaoguang; Yu, Long; Lu, Sicong; Chen, Zhiwei; Zhu, Guangzhi; Su, Hao; Mo, Zengnan; Qin, Xue; Peng, Tao

    2016-01-01

    Objective: The genome-wide association approach was employed to explore the association between single nucleotide polymorphisms (SNPs) and TP53 expression in the HBV-related hepatocellular carcinoma (HCC) of Chinese patients in Guangxi. Methods: 403 HBV-related HCC patients were recruited into this study and classified according to the TP53 expression in the cancer by immunohistochemistry. DNA was extracted from the cancer and genotyped with the Human ExomeBeadChip 12v1-1 system; quality cont...

  3. Evaluation of disinfecting effect of 5% sodium hypochlorite solution diluted to 2:100 along with the use of disposable covers on HBV contaminated dental office surfaces and equipments

    OpenAIRE

    Arami S; Tavassoti Kheiri M.; Hasani Tabayabaie M.; Yasini E.; Pahlavan A; Ghavam M.; Mirzaie M; Kermanshah H.; Forootan Sh.; Ahrabi S.; Tabatabaian M.; Mahrokh L.

    2008-01-01

    Background and Aim: The efficiency of disinfecting materials and procedures in removal of contamination from dental surfaces and equipments is essential. In authors' previous study, daily use of 2:100 dilution of 5% sodium hypochlorite in water and disposable covers were recommended since HBV contamination was found on semi-critical parts of the operative dentistry department. The aim of this study was to evaluate the HBV contamination following application of the recommended procedures....

  4. Polymorphism attribution of cSNPs in cancer-related genes located in loss regions with a high frequency of HCC between HBV and health groups

    Institute of Scientific and Technical Information of China (English)

    WANG Juan; NI Hong; CHEN Li; CHEN Chengbin; SONG Wenqin

    2007-01-01

    Cancer-related genes harbored in the loss regions containing a high frequency of hepatocellular carcinoma (HCC) were selected.Related information was gathered and the coding single nucleotide polymorphism (cSNP) sequences were obtained from the single nucleotide polymorphism (SNP) database.The appropriate primers and oligonucleotide probes were then designed in accordance with the SNP sites,and subsequently,the gene chips for detecting SNPs were constructed.Genomic DNA was extracted from blood samples of healthy controls and from patients with HBV infection.The sequences,including the SNPs,were amplified via polymerase chain reaction (PCR) and labeled using digoxigenin deoxyuridine tri-phosphate (Dig-dUTP).The labeled products were then hybridized with the SNP chips.Results confirmed that the differences in allele frequencies of three SNPs EGFL3 (rs947345),Caspase9 (rs2308950),and E2F2 (rs3218171) were distinct between HBV-infected patients and controls,suggesting that these SNPs ocuring in high frequency in HBV-infected individuals may be associated with susceptibility to HCC.

  5. Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.

    Science.gov (United States)

    Visvanathan, Kumar; Dusheiko, Geoff; Giles, Michelle; Wong, May-Ling; Phung, Nghi; Walker, Susan; Le, Suong; Lim, Seng Gee; Gane, Ed; Ngu, Meng; Hardikar, Winita; Cowie, Ben; Bowden, Scott; Strasser, Simone; Levy, Miriam; Sasaduesz, Joe

    2016-02-01

    Hepatitis B during pregnancy presents unique management issues for both the mother and fetus. These include the lack of a current cohesive strategy for treatment and follow-up of mothers and their babies; the uncertain risk of postpartum HBV flares; the lack of randomised trial data on the safety and efficacy of antiviral treatment in pregnancy; the lack of head-to-head studies comparing different antivirals in pregnancy; and the lack of epidemiologic information regarding infection across different populations globally. This position paper provides a comprehensive review of the management of women with HBV infection prior to conception, throughout each stage of pregnancy and postpartum, as well as recommendations and clinical approaches for the follow-up of children born to infected mothers, based on available evidence in the literature and recommendations from international experts. Prevention of perinatal transmission is an important component of global efforts to reduce the burden of chronic HBV since vertical transmission is responsible for most of the chronic infection worldwide. PMID:26475631

  6. Association between Waste Management and HBV among Solid Municipal Waste Workers: A Systematic Review and Meta-Analysis of Observational Studies

    Directory of Open Access Journals (Sweden)

    Carmela Romana Natalina Corrao

    2013-01-01

    Full Text Available Aim. To conduct a systematic review of this relationship using available published observational studies in the field of solid municipal waste treatment. Methods. The review of the scientific literature was based on Medline and Scopus databases up to December 2012, using the keywords HBV, waste, solid, treatment, workers, disposal, and refuse in different combinations. Results. 160 studies were found and checked. Finally, 5 observational studies were considered suitable, all cross-sectional. The pooled proportion of HBs-Ag considering all the studies was 11% (95% CI: 5–21%, and considering the high quality studies only, this proportion was 14% (95% CI: 6–24%. The pooled proportion of HBs-Ab positivity among waste workers considering all the studies was 14.2% (95% CI: 1.4–37.2%, and considering the high quality studies only, this proportion was 24% (95% CI: 18–30%. The pooled proportion of HBc-Ab positivity among waste workers considering all the studies was 24% (95% CI: 6–49%. The pooled estimation of the risk of HBV positivity (HBsAg among exposed was OR = 2.39 (95% CI: 0.88–6.52. Conclusion. In conclusion, waste workers need to be vaccinated against HBV infection since they are at risk of acquiring this infection through the exposure to potentially infected waste.

  7. The theoretical and practical knowledge of nurses and midwives regarding to the hepatitis-B virus (HBV) vaccination: a cross-sectional study in Konya--Turkey.

    Science.gov (United States)

    Cetinkaya, Senay

    2014-03-01

    The aim of our cross-sectional study was to investigate the factors that affected Hepatitis-B Vaccination (HBV) knowledge of the nurses and midwives, serving at various medical facilities as part of the primary healthcare services in Konya, Turkey. The study was conducted during March 01-31, 2004, including 127 consentient nurses and midwives (out of 161) serving at 22 different healthcare centers in the region. In the survey, their source of information with regards to HBV vaccination varied from continuing education programs (37%) to book or brochure reading (11.8%), and their formal nursing education (11%). A statistically significant relationship was found between the number of years employed in this profession and knowledge of Hepatitis markers that are done prior to the beginning of vaccination calendar (p = 0.01) (p < 0.05). Majority (74.8%) of the participants reported that they gave information to families about potential side effects of HBV vaccination. In conclusion we have suggested that a special training program should be given to nurses and midwives that included topics like Hepatitis markers, vaccine administration techniques, doses, proper record taking, briefing individuals and families. PMID:24851596

  8. Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations

    International Nuclear Information System (INIS)

    To investigate the performance of the commercial Roche COBAS AmpliScreen assay, and demonstrate whether the COBAS AmpliScreen human immunodeficiency virus-1 (HIV-1) test, v1.5, and COBAS AmpliScreen hepatitis C virus (HCV) v 2.0 for screening for HIV-1 and HCV RNA in the donated blood units from which plasma mini pools were collected, by nucleic acid amplification technology (NAT), could detect the positive pools and reduce the risk of transmission of infections for those routinely tested by serological assays. The study was performed on 3288 plasma samples collected from blood donors in a period of 13 months, from August 2004 to August 2005, at Al-Hada Armed Forces Hospital, Molecular Pathology Laboratory, Taif, Kingdom of Saudi Arabia. The samples were tested by the reverse transcriptase polymerase chain reaction (RT-PCR) after RNA extraction (this represents the major method in NAT assays), in parallel with the routine serological testing to detect qualitatively for HIV-1 and HCV. The NAT assays that include an automated COBAS AmpliPrep system for RNA extraction and COBAS Amplicor Analyzer using AmpliScreen kits for RT-PCR assays, and the routine serological screening assays for the detection of the HIV-1 and HCV RNA in the plasma samples from the blood donors have shown to be a reliable combination that would meet our requirements. The collected data further confirms the results from the serological assays and enables us to decrease the residual risk of transmission to a minimum with the finding of no seronegative window period donation. The results demonstrate that out of 3288 samples, the percentages of RT-PCR (NAT) negative blood donations that were also confirmed as seronegative were 99% for HCV, and 99.1% for HIV-1. The modified combined systems (automated COBAS AmpliPrep system for RNA extraction and COBAS Amplicor Analyzer using AmpliScreen kits for RT-PCR assays) for NAT screening assays has allowed the release of all blood donations supplied in the

  9. Development of a Novel, Ultra-rapid Biosensor for the Qualitative Detection of Hepatitis B Virus-associated Antigens and Anti-HBV, Based on “Membrane-engineered” Fibroblast Cells with Virus-Specific Antibodies and Antigens

    Directory of Open Access Journals (Sweden)

    Antonios Perdikaris

    2009-03-01

    Full Text Available A novel miniature cell biosensor detection system for the detection of Hepatis B virus (HBV-associated antigens and anti-HBV is described. The biosensor is based on “membrane-engineered” Vero fibroblast cells immobilized in an alginate matrix. The membrane-engineering process involved the electroinsertion of anti-HBV specific antibodies (anti-HBs, anti-HBe or antigens (HBsAg in the membranes of the Vero cells. The attachment of a homologous antigen to the electroinserted antibody (or, respectively, of the antibody to the electroinserted antigen triggered specific changes to the cell membrane potential that were measured by appropriate microelectrodes, according to the principle of the Bioelectric Recognition Assay (BERA. The sensor was used for screening 133 clinical blood serum samples according to a double-blind protocol. Considerably higher sensor responses were observed against HBV-positive samples, compared with responses against negative samples or samples positive for heterologous hepatitis viruses such as Hepatitis C (HCV virus. Detection of anti-HBs antibodies was made possible by using a biosensor based on immobilized Vero cells bearing the respective antigen (HBsAg. The observed response was rapid (45 sec and quite reproducible. Fluorescence microscopy observations showed that attachment of HBV particles to cells membrane-engineered with anti-HBs was associated with a decrease of [Ca2+]cyt. The perspectives for using the novel biosensor as a qualitative, rapid screening, high throughput assay for HBV antigens and anti-HBs in clinical samples is discussed.

  10. Hepatitis B vaccine effectiveness in coping with global HBV genotype diversity%乙型肝炎疫苗应对全球乙型肝炎病毒基因多态性的有效性

    Institute of Scientific and Technical Information of China (English)

    陈奕; 许国章

    2012-01-01

    Recombinant hepatitis B vaccines are safe and effective methods for prevention of hepatitis B.Recombinant HBV vaccines are of the A2 genotype; one of ten known genotypes whose distribution varies globally.Preclinical and clinical studies demonstrate cross-protection by A2 vaccines against non-A2 HBV genotypes.Available data show that current HBV A2 vaccines are highly effective in preventing infection and clinical disease caused by all known HBV genotypes.%基因重组乙型肝炎(乙肝)疫苗是预防乙肝的安全有效方法.乙肝病毒(HBV)具有基因多态性,目前已知共有10个基因型,全球所用的乙肝疫苗为A2基因型重组乙肝疫苗.临床前实验和临床试验结果表明,HBV A2疫苗对非A2基因型感染具有交叉防御作用,能够有效预防所有已知HBV基因型所造成的感染和临床疾病.

  11. Comparison of real-time polymerase chain reaction with the COBAS Amplicor test for quantitation of hepatitis B virus DNA in serum samples

    Institute of Scientific and Technical Information of China (English)

    Ming Shi; Yong Zhang; Ying-Hua Zhu; Jing Zhang; Wei-Jia Xu

    2008-01-01

    AIM: To compare the clinical performance of a real-time PCR assay with the COBAS Amplicor Hepatitis B Virus (HBV) Monitor test for quantitation of HBV DNA in serum samples. METHODS: The reference sera of the Chinese National Institute for the Control of Pharmaceutical and Biological Products and the National Center for Clinical Laboratories of China, and 158 clinical serum samples were used in this study. The linearity, accuracy, reproducibility, assay time, and costs of the real-time PCR were evaluated and compared with those of the Cobas Amplicor test. RESULTS: The intra-assay and inter-assay variations of the real-time PCR ranged from 0.3% to 3.8% and 1.4% to 8.1%, respectively. The HBV DNA levels measured by the real-time PCR correlated very well with those obtained with the COBAS Amplicor test (r = 0.948). The real-time PCR HBV DNA kit was much cheaper and had a wider dynamic range. CONCLUSION: The real-time PCR assay is an excellent tool for monitoring of HBV DNA levels in patients with chronic hepatitis B.

  12. Relationship of human leukocyte antigen class Ⅱ genes with the susceptibility to hepatitis B virus infection and the response to interferon in HBV-infected patients

    Institute of Scientific and Technical Information of China (English)

    Yong-Nian Han; Jin-Long Yang; Shui-Gen Zheng; Qun Tang; Wei Zhu

    2005-01-01

    AIM: To study the relationship of human leukocyte antigen (HLA)-DRB1 and -DQB1 alleles with the genetic susceptibility to HBV infection and the response to interferon (IFN) in HBV-infected patients.METHODS: Low-resolution DNA typing kit was used to determine HLA-DR-1 and -DQB1 genes in 72 patients with chronic hepatitis B (CHB) and HLA-DRB1 in 200 healthy people ready to donate their bone marrow in Shanghai.Among CHB patients, 35 were treated with IFNα-1b for 24 wk.RESULTS: The frequencies of HLA-DRB1*06, DRB1*08and DRB1*16 alleles in 72 patients were higher than in 200 healthy people (2.08% vs0%, OR = 3.837, P= 0.018;11.11% vs5.50%, OR = 2.148, P= 0.034; and 6.94% vs 3.00%, OR = 0.625, P = 0.049, respectively); whereas that of DRB1*07 allele was lower (2.78% vs 7.75%,OR = 0.340, P = 0.046). The frequency of HLA-DRB1* 14allele was higher in 11 responders to IFN compared with 24 non-responders (18.18% vs2.08%, OR = 10.444,P = 0.031), whereas that of DQB1*07 allele was inverse (9.09% vs 37.50%, OR = 0.167, P= 0.021).CONCLUSION: The polymorphism of HLA class Ⅱ may influence the susceptibility to HBV infection and the response to IFN in studied CHB patients. Compared with other HLA-DRB1 alleles, HLA-DRB1*06, DRB1*08, and DRB1*16 may be associated with chronicity of HBV infection, HLA-DRB1*07 with protection against HBV infection, and HLA-DRB1*14 allele may be associated with a high rate of the response of CHB patients to IFN treatment.Compared with other HLA-DQB1 alleles, HLA-DQB1*07 may be associated with low response rate to IFN.

  13. Automated nucleic acid amplification testing in blood banks: An additional layer of blood safety

    Directory of Open Access Journals (Sweden)

    Pragati Chigurupati

    2015-01-01

    Full Text Available Context: A total of 30 million blood components are transfused each year in India. Blood safety thus becomes a top priority, especially with a population of around 1.23 billion and a high prevalence rate of human immunodeficiency virus (HIV, hepatitis B virus (HBV and hepatitis C virus (HCV in general population. Nucleic acid amplification testing (NAT in blood donor screening has been implemented in many developed countries to reduce the risk of transfusion-transmitted viral infections (TTIs. NAT takes care of the dynamics of window period of viruses and offers the safest blood pack for donation. Aims: The aim of this study is to show the value of NAT in blood screening. Settings and Design: Dhanavantari Blood Bank, Rajahmundry, Andhra Pradesh, India. Subjects and Methods: Over a period of 1 year from January 2012 to December 2012, a total number of 15,000 blood donor samples were subjected to tests for HIV, HBV, and HCV by enzyme-linked immunosorbent assay (ELISA method and 8000 ELISA nonreactive samples were subjected for NAT using multiplex polymerase chain reaction technology. Results: Of the 15,000 donors tested, 525 were seroreactive. In 8000 ELISA negative blood samples subjected to NAT, 4 donor samples were reactive for HBV. The NAT yield was 1 in 2000. Conclusions: NAT could detect HIV, HBV, and HCV cases in blood donor samples those were undetected by serological tests. NAT could interdict 2500 infectious donations among our approximate 5 million annual blood donations.

  14. 乙型肝炎肝硬化患者病毒基因型与滤泡辅助性T淋巴细胞及白细胞介素-21的关系和意义%Relationship between viral genotypes and follicular helper T lymphocyte and interleukin-21 and its significancein patients with HBV-induced hepatic cirrhosis

    Institute of Scientific and Technical Information of China (English)

    顾锡炳; 朱银芳; 王娟华; 华忠; 陆忠华; 杨小娟; 徐月琴

    2014-01-01

    目的 探讨乙型肝炎肝硬化患者不同HBV基因型与外周血滤泡辅助性T淋巴细胞(Tfh)及白细胞介素-21 (IL-21)的关系和意义.方法 59例人白细胞抗原(HLA)-A2阳性的乙型肝炎肝硬化患者作HBV基因型检测,比较B、C基因型感染者之间Tfh、IL-21的差别,并探讨其意义.结果 59例乙型肝炎肝硬化患者中,C基因型36例(61.02%),B基因型22例(37.29%),B、C混合型1例(1.69%),C基因型外周血Tfh水平(2.89%±1.44%),低于B基因型(4.65%±1.37%),t=3.01,P<0.01,IL-21水平(14.62±2.12 ng/L),低于B基因型(32.27±11.25 ng/L),=4.12,P<0.01,HBV特异性细胞毒性T淋巴细胞(CTL)水平(0.17%±0.02%),低于B基因型(0.37%±0.03%),t=3.12,P<0.01,HBV DNA水平(6.95±0.75log10拷贝/ml),高于B基因型(5.02 ±0.36log10拷贝/ml),=3.03,P<0.01.结论 与乙型肝炎肝硬化B基因型感染者相比,C基因型感染者的外周血Tfh水平较低,引起IL-21和HBV特异性CTL水平降低,导致HBV DNA水平较高.%Objective To explore relationship between different HBV genotypes and peripheral blood follicular helper T lymphocyte (Tfh) and interleukin-21 (IL-21) and its significance in patients with HBV-induced hepatic cirrhosis.Methods HBV genotypes were tested in 59 cases of cirrhotic hepatitis B with positive human leukocyte antigen (HLA)-A2,differences of Tfh and IL-21 between patients infected with genotype B and genotype C were compared and its significance was investigated.Results In 59 cases of cirrhotic hepatitis B,36 cases (61.02%) were infected with genotype C,22 cases (37.29%) were infected with genotype B and 1 case (1.69%) was infected with genotype B and C.Peripheral blood Tfh level of genotype C was(2.89% ± 1.44%),lower than that of genotype B (4.65% ± 1.37%),t =3.01,P <0.01,IL-21 level of genotype C was (14.62 ± 2.12 ng/L),lower than that of genotype B (32.27 ± 11.25ng/L),t =4.12,P <0.01,HBV specific cytotoxic T lymphocyte(CTL)level of

  15. HBV S基因变异与临床疾病的关系%The correlationship between heptatitis B surface antigen gene mutations and clinical diseases

    Institute of Scientific and Technical Information of China (English)

    许正锯; 潘兴南; 魏开鹏; 杨环文; 李树清; 黄志杰

    2013-01-01

    Objective To investigate the correlationship between heptatitis B surface antigen gene mutations and clinical diseases in patients with chronic hepatitis B in Quanzhou area. Methods Surface gene region of 43 patients with chronic HBV infection was amplified by PCR and mutations were analyzed after sequencing. Results Among 43 chronic HBV infected patients, the distributions of genetypes were B (29/43, 67.44%) and C (14/43, 32.56%), while that of subtypes were adw (28/43, 65.12%), adr (14/43, 32.56%) and ayw (1/43, 0.02%), respectively. Total of amino acid 32 (aa) mutations of hepatitis B surface antigen (HBsAg) were observed in these patients. The most common aa mutations including sY200F, sM2131, sI126T and sF85C, which were usually found in patients with hepatitis failure. Nineteen (19/43, 44.19%) aa mutations and 12 substitutions were found in HBV major hydrophilic region. The mutation of aal26 was the most common (7/23, 30.43%) mutation in MHR region, and there after was aal40 (3/23, 13.04%). sT126I/A mutation was found in 2 (2/29, 6.90%) cases with genotype B, while sI126T mutation was found in 5 (5/14, 35.71%) cases with genotype C. The mutation rate of aal26 in patients with genetype C was significantly higher than that of genetype B (χ2= 5.753, P 0.05). The mutation rate of surface antigen gene in "a" determinant was higher in patients with liver failure than that of chronic hepatitis B (χ2= 4.268, P < 0.05). Conclusions The most common genotype of HBV in Quanzhou area are B (adw) and C (adr). Some HBV surface antigen gene mutations were correlated with HBV genotype heterogeneity, which may be correlated with serious liver disease.%目的 探讨泉州地区乙型肝炎病毒(HBV)慢性感染者HBV S基因变异与临床疾病的关系.方法 采用PCR产物直接测序技术对43例慢性HBV感染者的HBV S区进行序列测定及分析.结果 43例慢性HBV感染者中共检出基因B型29例(29/43,67.44%),C型14例(14/43,32.56%);血清学分型adw型28

  16. The Ultramicrostructural Changes of the Placentae in the Patients Transmitting of HBV from Mother to Fetus%乙肝病毒母婴垂直传播胎盘超微结构变化

    Institute of Scientific and Technical Information of China (English)

    王爱莉; 戴笙; 初兆荣; 王淑英

    2001-01-01

    目的通过对乙肝病毒(HBV)母婴垂直传播者胎盘超微结构的观察,探讨HBV母婴垂直传播的细胞学机制。方法用ELISA双抗夹心法对孕妇静脉血及其胎儿脐血、新生儿静脉血进行HBV检测。对5例发生HBV母婴垂直传播者胎盘用JEM-1200EM透射电镜观察超微结构变化。结果HBV双抗原阳性孕妇60%发生HBV母婴垂直传播。HBV母婴垂直传播胎盘的超微结构改变有:胎盘合体细胞内核糖体增多,微绒毛增多、变形,合体细胞变性坏死;胎盘屏障中毛细血管基底膜增厚、纤维蛋白样物沉积,合体细胞间隙、胞浆、细胞核内见多种病毒样颗粒。结论HBV可感染胎盘合体细胞并且在其中复制,从而使胎儿在宫内被感染。%Objective By observing the placental ultramicrostructure in thefetuses infected by HBV in uterus from their mothers, to investigate the cellular mechanism of HBV transmitting. Methods HBV was determined in mother' serum,cord serum and neonatal serum with ELISA. Five patients'placentae ultramicrostructure of which HBV was transmitted to the fetuses were observed with JEM-1200EM. Results The HBV transmitting rate from mother to fetus in HBV antigens both positive women was 60%. The changes of HBV transmitting placentae include the increasing of ribosome and shape changes of microvilli, the trophoblastic necrosis, the capillary basal lamina in placenta barrier thickness with fibrin-like substance deposits and the exsistance of HBV-like particles in cell spaces, plasma and nuclears. Conclusions HBV can be transmitted from mother to fetus in uterus by infecting and duplicating in the syncytial trophoblast.

  17. 线粒体M亚型预测乙型肝炎后肝癌风险性的研究%Prediction of mitochondrial haplotype M haplogroup for risk of HBV-hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    何宏涛; 徐卓; 李杰; 郭占军

    2012-01-01

    Objective To study hepatitis B virus (HBV) related mitochondrial DNA D-loop region gene mutations and their role in the development of hepatocellular carcinoma ( HCC). Methods Mitochondrial DNA (mtDNA) of peripheral blood.tumor,and/or adjacent non-tumor tissue from 49 hepatitis B virus-related patients,and from 38 controls with normal hepatic hemangioma liver mitochondria were examined for single nucleotide polymorphisms( SNPs) and mutations in the D-loop region. Results The mitochondrial haplotypes under the M haplogroup with a defining 489C polymorphism were detected in 27 cases (55. 1 % ) of HBV-HCC and in 15 cases (39. 5%) of controls. Combination of subtype M and other polymorphisms can predict the risk of HCC. Frequencies of the 489T/152T,489T/523A,and 489T/525C haplotypes were significantly reduced in HBV-HCC patients compared with those of controls(all P <0. 05). Mutations in the D-loop region were detected in 21 HBV-HCC patients. Conclusion Mitochondrial haplotypes may differentially predispose patients to HBV-HCC. Mutations of the mitochondrial D-loop sequence may relate to HCC development.%目的 研究乙型肝炎后肝癌(HBV-HCC)组织线粒体DNA D-loop区基因的突变情况及其在肝癌发生发展中的作用.方法 提取49例HBV-HCC患者的肝癌组织,癌旁组织和血液中的线粒体DNA,以38例肝血管瘤患者的正常肝组织及血液线粒体为对照,用测序法测定线粒体D-loop的单核苷酸多态性(single nucleotide polymorphisms,SNPs)和变异.结果 将489C定义为M亚型,HBV- HCC患者27例(55.1%)和对照组15例(39.5%)含有此亚型.结合M亚型和其他位点多态性可以预测肝癌的风险.489T/152T,489T/523A和489T/525C与HBV-HCC发病风险呈负相关(均P<0.05).21例HBV-HCC患者D-loop中存在变异.结论 不同的线粒体亚型有不同的肝癌易感性,D-loop变异可能促进肝癌的发展.

  18. Risk of HBV transmission between breast-fed and artificial fed infants with HBV mothers after immunoprophylaxis: A Meta-analysis%乙肝病毒携带母亲喂养方式对阻断免疫后婴儿母婴传播影响Meta分析

    Institute of Scientific and Technical Information of China (English)

    汪娟; 李筱青; 冯晨晨; 马岩; 黄芬; 陈红; 叶冬青

    2011-01-01

    目的 探讨对婴儿采取免疫措施后,乙肝病毒(HBV)携带母亲采用不同的喂养方式对母婴HBV传播的影响.方法 检索PubMed、Medline、Embase、Cochrane图书馆、中国期刊全文数据库、维普中文科技期刊数据库和万方数据库等,对免疫干预后比较母乳喂养和人工喂养婴儿HBV感染率的前瞻性研究进行Meta分析.结果 10篇随机对照试验满足纳入条件进入Meta分析,其中母乳喂养组婴儿873例,人工喂养组751例.在对婴儿进行免疫于预后,母乳喂养组与人工喂养组的6~ 12月龄婴儿乙肝表面抗原或HBV DNA阳性率差异无统计学意义(7个研究:OR=0.86,95%CI=0.51 ~1.45,P=0.56;I2 =0,P=0.99);母乳喂养组与人工喂养组6~12月龄婴儿的乙肝表面抗体阳性率差异无统计学意义(8个研究:OR=0.98,95% CI=0.69~1.40,P=0.93;I2 =0,P=0.99).结论 HBV携带者母亲采用不同的喂养方式对免疫于预措施阻断母婴HBV传播没有影响,HBV携带产妇母乳喂养并不增加HBV母婴传播的风险.%Objective To compare the risk of hepatitis B vims (HBV) transmission between breastfeeding group and artificial feeding group in infants with HBV mothers after combination immunoprophylaxis. Methods Comprehensive computerized literature search of PubMed, Medline, EMBASE, Cochrane Library, National Science Digital Library, and China Biological Medicine Database were conducted. A meta-analysis of prospective studies exploring the role of breastfeeding in mother to child transmission (MTCT) of HBV in infants who had HBV mothers was performed. Results Ten Randomized controlled trials (RCT) were included, involving 751 infants in the breastfeeding group and 873 infants in the artificial feeding group. There was no significant differences of positive rates of HBsAg/HBV DNA(OR=0.86,95%Cl=0.51-1. 45,P=0.56;l2 =0,P=0.99) and surface antibodies(OR=0.98,95%Cl=0.69-1.40,P=0.93;I2 =0,P = 0.99) among the infants by different feeding patterns

  19. Risk factors of prognosis for patients with HBV related liver failure and the prognosis model%乙型肝炎相关肝功能衰竭患者预后危险因素及预后模型建立

    Institute of Scientific and Technical Information of China (English)

    汤伟亮; 谢青; 赵钢德; 董志霞; 项晓刚; 王晖; 周惠娟; 桂红莲; 郭斯敏; 庄焱

    2011-01-01

    目的 探讨影响乙型肝炎相关肝衰竭患者预后的危险因素并建立其预后模型.方法 回顾性收集2006年6月至2008年12月在我科收治的178例乙型肝炎相关肝衰竭患者的临床资料.采用x 2和t检验和非参数检验进行单因素分析,Logistic回归进行多因素分析.结果 年龄、腹水、感染、消化道出血、肝性脑病、肝肾综合征、甲胎蛋白、PT、WBC、TBil、DBil、Cr、BUN、血清钠在生存组与死亡组之间差异均有统计学意义(P<0.05).Logistic多因素分析进一步显示,肝性脑病、感染、PT、TBil是影响乙型肝炎相关肝衰竭患者预后的独立危险因素.同时对所得出的独立危险因素建立该人群的预后判断模型,通过计算预后指数并绘制ROC曲线,计算其曲线下面积(AUC)为0.931(95%CI:0.893~0.970).其评估价值优于CTP分级(0.862)、MELD评分(0.807)及MELD-Na评分(0.774).结论 肝性脑病、感染、PT、TBil是影响乙型肝炎相关肝衰竭患者预后的独立危险因素.建立的预后模型能够较为准确地预测乙型肝炎相关肝衰竭患者的短期预后,是一个较为理想的乙型肝炎相关肝衰竭预后评估系统.%Objective To investigate the risk factors of the prognosis for HBV related liver failure and thus to establish a prognosis model. Methods Retrospective analysis of the clinical data of 178 patients with HBV related liver failure in Ruijin hospital from June 2006 to December 2008. Quantitative data were analyzed by using t test and rank test, and qualitative data were analyzed by using Chi-square test. Then Logistic regression analysis was used for selecting the independent risk factors of the prognosis for HBV related liver failure. Based on independent risk factors from Logistic regression analysis, prognostic model for the patients with HBV related liver failure was established. Results The differences of age, ascites, infection, upper gastrointestinal bleeding, hepatic

  20. Analysis of HBV genotype distribution and its association with liver cirrhosis in Xinjiang Uygur Autonomous Region,China%新疆地区HBV基因分型构成特点及其与肝硬化的相关性分析

    Institute of Scientific and Technical Information of China (English)

    王晓忠; 王燕; 马燕; 郭峰; 庄小芳

    2014-01-01

    目的:探讨新疆地区HBV基因分型构成特点及其与肝硬化之间的关系。方法收集2011年10月至2013年6月新疆维吾尔自治区中医医院收治的慢性HBV感染者1018例。其中检测出基因型、资料完整的828例。根据实验室检查及彩超或CT结果将患者分为慢性乙型肝炎组、肝硬化组、原发性肝癌组。采用PCR法对HBV基因分型,运用列联卡方、秩和检验、多因素Logistic回归分析等方法对HBV基因型与临床病情及相关慢性肝病结局进行分析。结果828例患者中,以C型为主,占总样本的54.11%(448/828),B型占25.15%(200/828),D型占16.18%(134/828);各基因型病情程度构成差异无统计学意义(H=0.1689,P>0.05);116例肝硬化患者中基因C型占20.84%,与B型和D型相比较差异均有统计学意义(χ2值分别为25.486、20.947,P值均为0.000);乙型肝炎病程10年以上、基因C型、HBV DNA高病毒载量、ALT>ULN进入回归模型(P<0.05)。其中基因C型与肝硬化的相关度最高(OR=2.819,95%CI:1.582~5.021)。结论新疆地区HBV基因分型以C型为主,其次为B型、D型。基因C型是HBV相关肝硬化患者的独立危险因素。%Objective To investigate the distribution of hepatitis B virus (HBV)genotypes among patients in Xinjiang Uygur Autonomous Region,China,and to explore its association with liver cirrhosis.Methods HBV genotypes of 1018 hepatitis B patients were determined by PCR analysis.The relationship of HBV genotype with clinical outcomes and relevant chronic liver diseases was assessed by contingency chi-square test,Kruskal-Wallis test,and multivariate unconditional logistic regression analysis.Results Among the 828 patients whose HBV genotyping was completed in this study,type C was the major genotype and the percentage was 54.11%(448/828),25.15%(200/828) had type B,and 16.18%(134/828)had type D.Among the

  1. Study on in vitro inhibiting effect of Rabdosia Serra in anti-HBV%溪黄草抗乙型肝炎病毒体外抑制作用研究

    Institute of Scientific and Technical Information of China (English)

    庞琼; 胡志立

    2016-01-01

    Objective To provide an important scientific basis for verifying the in vitro anti-HBV activity of single herb Rabdosia Serra. Methods 50%ethanol extract of Rabdosia Serra was dispensed as certain concentrations. The HepG2.2.15 cel-lular model was adopted to conduct the cellular toxicity test and HBsAg and HBeAg enzyme-linked immunosorbent ssay(ELISA). Results IC50 was 4.275 mg/mL,IC50 of crude extract of Rabdosia Serra on HBsAg was 2.250 mg/mL,which on HBeAg was 2.150 mg/mL,the therapeutic index(TI)<2. Conclusion The crude extract of Rabdosia Serra has the effect for in vitro inhibiting HBV.%目的:为证实溪黄草单味药具有体外抗乙型肝炎病毒活性提供重要的科学依据。方法将溪黄草50%乙醇提取物配置成一定药物浓度,拟采用HepG2.2.15细胞模型进行细胞毒试验和乙型肝炎表面抗原(HBsAg)、乙型肝炎e抗原(HBeAg)酶联免疫检测。结果半数细胞抑制时其浓度为4.275 mg/mL,溪黄草粗提物对HBsAg的半抑制浓度(IC50)为2.250 mg/mL,对HBeAg的IC50为2.150 mg/mL,治疗指数小于2。结论溪黄草粗提物具有抑制体外乙型肝炎病毒的作用。

  2. 慢性乙型肝炎病毒携带产妇母乳喂养安全性研究%Safety of Breast-Feeding Carried out by Chronic HBV Carriers

    Institute of Scientific and Technical Information of China (English)

    陈琦; 谭布珍; 丰颖; 唐丽娟; 胡辉

    2011-01-01

    Objective To explore the safety of breast-feeding carried out by chronic HBV carriers. Methods HBV infectious markers were detected in umbilical cord blood and colostrum of 145 chronic HBV carrier mothers. Meanwhile, HBV DNA in 52 newborns with HBsAg (+) mothers. either breast-fed or formula-fed, was detected at 0, 7, and 12 months after born. Results HBV infectious markers were found to be positive in the umbilical cord blood in 136 out of the 145 HBV infectious marker - positive cases. The intrauterine HBV - infectious rate was 94% . HBV infectious markers were found to be positive in the colostrum in 32 out of the 145 cases with HBV infectious markers ( HBV - infectious rate : 22% ), 12 with HBsAg +) mothers ( positive rate: 23% ) and 20 with HBeAg ( + ) mothers ( positive rate: 83% ). No statistical differences between the breast - fed group and the formula - fed group of newborns with HBsAg + mothers were noted with respect to HBV -DNA positive rate of newborns at 0,7, and 12 months after born. Conclusion Breast feeding could he carried out hy HBsAg +) chronic HBV carriers and comhined immunization should be performed in the infants at the same time. The colostrum of HBeAg ( + ) mothers is highly infectious and is not suitable for breast - feeding.%目的 探讨乙型肝炎(乙肝)病毒携带产妇母乳喂养的安全性.方法 对145例静脉血乙肝病毒血清标志物阳性的孕产妇进行脐血及母乳乙肝病毒血清标志物检测,同时对52例单纯乙肝病毒表面抗原(HBsAg)阳性产妇母乳喂养组及人工喂养组的新生儿出生时、出生7个月及12个月时进行静脉血乙肝病毒DNA(HBV-DNA)检测.结果 145例静脉血乙肝病毒标志物阳性产妇中136例新生儿脐血乙肝病毒标志物阳性,乙肝宫内感染率为94%;有32例母乳中乙肝病毒标志物阳性[其中母血HBsAg阳性者12例,阳性检出率为23%;母血乙肝病毒e抗原(HBeAg)阳性者或HBsAg和HBeAg同时阳性者20

  3. Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion

    OpenAIRE

    Panigrahi Rajesh; Biswas Avik; Datta Sibnarayan; Banerjee Arup; Chandra Partha K; Mahapatra Pradip K; Patnaik Bharat; Chakrabarti Sekhar; Chakravarty Runu

    2010-01-01

    Abstract Background Occult hepatitis B virus (HBV) infection might transmit viremic units into the public blood supply if only hepatitis B surface antigen (HBsAg) testing is used for donor screening. Our aim was to evaluate the prevalence of occult HBV infection among the HBsAg negative/antiHBc positive donations from a highly HIV prevalent region of India. Methods A total of 729 HBsAg negative donor units were included in this study. Surface gene and precore region were amplified by in house...

  4. HBV mother-to-child transmission block-agreement and controversy%乙型肝炎病毒母婴传播阻断的共识与争议

    Institute of Scientific and Technical Information of China (English)

    陈巍; 丁洋; 盛秋菊; 窦晓光

    2011-01-01

    慢性乙型肝炎因其严重的不良临床结局如肝硬化或肝细胞癌而成为严重的公共卫生问题,而母婴传播是导致慢性HBV感染的最主要原因.尽管HBV阳性孕妇所生的新生儿在出生后24h之内应用了乙型肝炎疫苗和乙型肝炎免疫球蛋白(HBIG)进行联合免疫阻断,仍然有大约10%左右的新生儿感染了HBV,特别是高病毒载量的孕妇.本文将就HBV母婴传播的特点、目前在阻断措施方面达成的共识和存在的争议进行论述.%Hepatitis B virus (HBV) infection is one of the most severe public issue due to its serious harmful clinical outcomes such as cirrhosis or HCC. The mother - to - child transmission (MTCT, vertical transmission) is the main cause leading to chronic HBV infections. Though joint HBV immune prophylaxis with hepatitis B vaccine and hepatitis B immunoglobulin ( HBIG) are given within 24hrs after birth for all neonates whose mothers are HBV positive, about 10% of them suffer from HBV infection in their early life, even in pregnant women with a high HBV DNA serum load. This paper discusses the thesis concerning on agreement and controversy regarding the MTCT.

  5. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.

    Science.gov (United States)

    Kuhns, Mary C; Busch, Michael P

    2006-01-01

    Serologic testing for hepatitis B virus (HBV) surface antigen (HBsAg) and antibody to HBV core antigen (anti-HBc) has historically been the foundation of blood screening, while HBV nucleic acid testing (NAT) was recently developed to detect HBsAg-negative, anti-HBc-negative blood units donated during early acute infection. Comparison data on seroconversion panels using HBsAg assays of varying sensitivities and pooled- or single-sample NAT, along with viral load estimates corresponding to HBsAg assay detection limits, have provided information on the theoretical benefits of NAT relative to HBsAg. Model-derived estimates have generally been predictive of the yields of DNA-positive, HBsAg-negative window period blood units detected in a number of studies from Europe, Japan, and the US. Studies indicate that the added benefit of pooled-sample NAT is relatively small in areas of low endemicity, with greater yields in areas highly endemic for HBV. Single-sample NAT would offer more significant early window period closure and could prevent a moderate number of residual HBV transmissions not detected by HBsAg assays; however, no fully automated single-sample HBV NAT systems are currently available.Even single-sample HBV NAT may not substitute for anti-HBc screening, as indicated by studies of donors with isolated anti-HBc who have extremely low DNA levels undetectable by standard single-sample NAT and who have been associated with transfusion-transmitted HBV. Moreover, HBsAg testing may still be needed even in the setting of combined anti-HBc and NAT screening. HBsAg-positive units from donors in the chronic stage of infection may contain very low or intermittently detectable DNA levels that single-sample NAT would miss. Although such donors are usually anti-HBc reactive and would be interdicted by anti-HBc screening, some lack anti-HBc. Extensive parallel testing will be needed to determine whether single-sample NAT in combination with anti-HBc might be sufficient to

  6. Genomic Methylation Inhibits Expression of Hepatitis B Virus Envelope Protein in Transgenic Mice: A Non-Infectious Mouse Model to Study Silencing of HBV Surface Antigen Genes

    Science.gov (United States)

    Graumann, Franziska; Churin, Yuri; Tschuschner, Annette; Reifenberg, Kurt; Glebe, Dieter; Roderfeld, Martin; Roeb, Elke

    2015-01-01

    Objective The Hepatitis B virus genome persists in the nucleus of virus infected hepatocytes where it serves as template for viral mRNA synthesis. Epigenetic modifications, including methylation of the CpG islands contribute to the regulation of viral gene expression. The present study investigates the effects of spontaneous age dependent loss of hepatitis B surface protein- (HBs) expression due to HBV-genome specific methylation as well as its proximate positive effects in HBs transgenic mice. Methods Liver and serum of HBs transgenic mice aged 5–33 weeks were analyzed by Western blot, immunohistochemistry, serum analysis, PCR, and qRT-PCR. Results From the third month of age hepatic loss of HBs was observed in 20% of transgenic mice. The size of HBs-free area and the relative number of animals with these effects increased with age and struck about 55% of animals aged 33 weeks. Loss of HBs-expression was strongly correlated with amelioration of serum parameters ALT and AST. In addition lower HBs-expression went on with decreased ER-stress. The loss of surface protein expression started on transcriptional level and appeared to be regulated epigenetically by DNA methylation. The amount of the HBs-expression correlated negatively with methylation of HBV DNA in the mouse genome. Conclusions Our data suggest that methylation of specific CpG sites controls gene expression even in HBs-transgenic mice with truncated HBV genome. More important, the loss of HBs expression and intracellular aggregation ameliorated cell stress and liver integrity. Thus, targeted modulation of HBs expression may offer new therapeutic approaches. Furthermore, HBs-transgenic mice depict a non-infectious mouse model to study one possible mechanism of HBs gene silencing by hypermethylation. PMID:26717563

  7. EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma

    Science.gov (United States)

    Han, Chuangye; Liao, Xiwen; Qin, Wei; Yu, Long; Liu, Xiaoguang; Chen, Gang; Liu, Zhengtao; Lu, Sicong; Chen, Zhiwei; Su, Hao; Zhu, Guangzhi; Lu, Zili; Liu, Zhiming; Qin, Xue; Gui, Ying; Mo, Zengnan; Li, Lequn; Peng, Tao

    2016-01-01

    This study was to explore the association between gene variants and p21 expression and investigate the TP53-independent p21 regulation in hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) patients from Guangxi by genome-wide association study. 426 HBV-related HCC patients were enrolled. Results showed that, after quality control, a total of 21,643 SNPs were identified in 107 p21 positive and 298 p21 negative patients. The variants of epidermal growth factor receptor (EGFR; rs2227983 and rs6950826) and spectrin repeat containing, nuclear envelope 2 (SYNE2; rs8010699, rs4027405 and rs1890908) were associated with p21 expression. Moreover the haplotype block (rs2227983 and rs6950826, r2 = 0.378) in EGFR and the haplotype block in SYNE2 (rs8010699 was in strong LD with rs4027405 and rs1890908 (r2 = 0.91 and 0.70, respectively)) were identified, and the haplotype A-G of EGFR and haplotype G-A-A of SYNE2 were significantly associated with p21 expression (P < 0.01). rs4027405 and rs1890908 were significantly associated with overall survival, and patients with AG/GG genotypes of SYNE2 gene had a worse overall survival (P = 0.001, P = 0.002). Our findings indicate that variants of EGFR and SYNE2 play an important role in p21 regulation and are associated with the clinical outcome of HBV-related HCC in a TP53-indenpdent manner. PMID:27502069

  8. Assessing liver function in patients with HBV-related HCC: a comparison of T{sub 1} mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI

    Energy Technology Data Exchange (ETDEWEB)

    Ding, Ying; Rao, Sheng-Xiang; Chen, Caizhong; Li, Renchen; Zeng, Meng-Su [Zhongshan Hospital of Fudan University, Department of Radiology, 180 Fenglin Road, Xuhui District, Shanghai (China)

    2015-05-01

    To compare the potential of T{sub 1} mapping on gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) for assessing liver function in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). One hundred consecutive patients with known HBV-related HCCs were included. T{sub 1} relaxation time and apparent diffusion coefficient (ADC) of the liver were measured, and the reduction rate of T{sub 1} relaxation time (∇%) was calculated. T{sub 1} relaxation time measurements were compared with ADC values according to the Model for End-Stage Liver Disease (MELD) score. Hepatobiliary phase (HBP) and ∇% of T{sub 1} relaxation time measurements showed significant correlations with MELD score (rho = 0.571, p < 0.0001; rho = -0.573, p < 0.0001, respectively). HBP and ∇% of T{sub 1} relaxation time were significantly different between good (MELD ≤8) and poor liver function (MELD ≥9) (p < 0.0001 for both). Areas under the receiver operating characteristic curves (AUCs) of T{sub 1} relaxation time for HBP (AUC 0.84) and ∇% (AUC 0.82) were significantly better than for ADC (AUC 0.53; p < 0.0001). T{sub 1} mapping on Gd-EOB-DTPA-enhanced MRI showed promise for evaluating liver function in patients with HBV-related HCC, while DWI was not reliable. HBP T{sub 1} relaxation time measurement was equally accurate as ∇% measurement. (orig.)

  9. EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma.

    Science.gov (United States)

    Han, Chuangye; Liao, Xiwen; Qin, Wei; Yu, Long; Liu, Xiaoguang; Chen, Gang; Liu, Zhengtao; Lu, Sicong; Chen, Zhiwei; Su, Hao; Zhu, Guangzhi; Lu, Zili; Liu, Zhiming; Qin, Xue; Gui, Ying; Mo, Zengnan; Li, Lequn; Peng, Tao

    2016-01-01

    This study was to explore the association between gene variants and p21 expression and investigate the TP53-independent p21 regulation in hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) patients from Guangxi by genome-wide association study. 426 HBV-related HCC patients were enrolled. Results showed that, after quality control, a total of 21,643 SNPs were identified in 107 p21 positive and 298 p21 negative patients. The variants of epidermal growth factor receptor (EGFR; rs2227983 and rs6950826) and spectrin repeat containing, nuclear envelope 2 (SYNE2; rs8010699, rs4027405 and rs1890908) were associated with p21 expression. Moreover the haplotype block (rs2227983 and rs6950826, r(2) = 0.378) in EGFR and the haplotype block in SYNE2 (rs8010699 was in strong LD with rs4027405 and rs1890908 (r(2) = 0.91 and 0.70, respectively)) were identified, and the haplotype A-G of EGFR and haplotype G-A-A of SYNE2 were significantly associated with p21 expression (P < 0.01). rs4027405 and rs1890908 were significantly associated with overall survival, and patients with AG/GG genotypes of SYNE2 gene had a worse overall survival (P = 0.001, P = 0.002). Our findings indicate that variants of EGFR and SYNE2 play an important role in p21 regulation and are associated with the clinical outcome of HBV-related HCC in a TP53-indenpdent manner. PMID:27502069

  10. Intrauterine vertical transmission of HBV via pathway of peripheral blood mono-nuclear cells%外周血单个核细胞介导的HBV宫内垂直传播

    Institute of Scientific and Technical Information of China (English)

    周娜; 王健

    2014-01-01

    Objective:To study the HBV infection in peripheral blood mononuclear cells in mediating the role of mother -to-child transmission of hepatitis B virus.Methods: The peripheral blood mononuclear cells ( PBMCs ) in maternal and cord blood mononuclear cells ( CBMCs ) in newborns were conventionally isolated by Ficoll-Hypaque medium.The loads of HBV-DNA in peripheral blood of maternal and cord blood of newborns were both detected by PCR .Results:The clinical data showed that the positive detection rates of HBV-DNA in serum and PBMCs of pregnant women with HBeAg (+) were 100.00%( 25/25 ) and 72.00%( 18/25),and the positive detection rates of HBV-DNA in the neonatal umbilical cord blood serum and CBMCs were 60.00%(15/25) and 44.00%(11/25),respectively.There were significantly difference between HBeAg (+) and HBeAg(-) in the pregnant women (P<0.05 ).The positive detection rates of HBV-DNA in neonatal umbilical cord blood serum and CBMCs were higher in the group with high HBV loads (more than 106copies/ml) in PBMCs than those of low HBV loading group (102-103copies/ml).The significantly difference was explored between the two groups.Conclusion: Mononuclear cells can not only be infected by HBV , but also play a critical role in the intrauterine vertical transmission of HBV via the pathway transmitted from PBMCs in pregnant women to CBMCs in newborns.%目的:探讨HBV感染外周血单个核细胞在介导乙肝病毒母婴传播中的作用。方法:以Ficoll-Hypaque常规分离、纯化孕妇外周血单个核细胞( PBMCs )和新生儿脐血单个核细胞( CBMCs ), PCR法检测孕妇外周血和新生儿脐血HBV-DNA。结果:HBeAg(+)孕妇血清和PBMCs内HBV-DNA检出率分别为100.00%(25/25)和72.00%(18/25),其新生儿脐血血清和CBMCs内HBV-DNA检出率分别为60.00%(15/25)和44.00%(11/25),与 HBeAg (-)组相比差异有显著性( P<0.05)。 PBMCs内HBV高复制组其新生儿脐血及CBMCs

  11. A prospective study of hepatitis B virus markers in patients with chronic HBV infection from Brazilian families of Western and Asian origin

    Directory of Open Access Journals (Sweden)

    F.J. Carrilho

    2005-09-01

    Full Text Available The purpose of the present study was to determine the frequency of hepatitis B virus (HBV markers in families of HBsAg-positive patients with chronic liver disease. Serum anti-HBc, HBsAg and anti-HBs were determined by enzyme immunoassay and four subpopulations were considered: genetically related (consanguineous and non-genetically related (non-consanguineous Asian subjects and genetically related and non-genetically related Western subjects. A total of 165 and 186 relatives of Asian and Western origin were enrolled, respectively. The occurrence of HBsAg and anti-HBs antibodies was significantly higher (P < 0.0001 in family members of Asian origin (81.8% than in family members of Western origin (36.5%. HBsAg was also more frequent among brothers (79.6 vs 8.5%; P < 0.0001, children (37.9 vs 3.3%; P < 0.0001 and other family members (33.9 vs 16.7%; P < 0.0007 of Asian than Western origin, respectivelly. No difference between groups was found for anti-HBs, which was more frequently observed in fathers, spouses and other non-genetic relatives. HBV infection was significantly higher in children of Asian than Western mothers (P < 0.0004. In both ethnic groups, the mothers contributed more to their children's infection than the fathers (P < 0.0001. Furthermore, HBsAg was more frequent among consanguineous members and anti-HBs among non-consanguineous members. These results suggest the occurrence of vertical transmission of HBV among consanguineous members and probably horizontal sexual transmission among non-consanguineous members of a family cluster. Thus, the high occurrence of dissemination of HBV infection characterizes family members as a high-risk group that calls for immunoprophylaxis. Finally, the study showed a high familial aggregation rate for both ethnic groups, 18/19 (94.7% and 23/26 (88.5% of the Asian and Western origin, respectively.

  12. Upregulation of miRNA-130a Represents Good Prognosis in Patients With HBV-Related Acute-on-Chronic Liver Failure: A Prospective Study.

    Science.gov (United States)

    Zheng, Qing-Fen; Zhang, Jing-Yun; Wu, Ju-Shan; Zhang, Ying; Liu, Mei; Bai, Li; Zhang, Jin-Yan; Zhao, Jing; Chen, Yu; Duan, Zhong-Ping; Zheng, Su-Jun

    2016-02-01

    Prompt and accurate prediction of the outcome is the key to make correct medical decision and to reduce the mortality in patients with HBV-related acute-on-chronic liver failure (ACLF). Increasing evidence have certified that small, noncoding microRNAs (miRNAs) play critically regulatory roles in the pathogenesis of liver diseases. However, it remains unclear whether and how miRNAs involve in the prognosis of ACLF.Microarray analysis was performed to characterize the miRNA expression profiles in liver tissues from 1 HBV-related ACLF patient and 1 matched healthy control. Nine miRNAs with at least 5 folds difference between these 2 persons were picked out. The present prospective study involving 39 HBV-related ACLF patients including 20 recovered and 19 nonrecovered patients, which include death (n = 9) and liver transplantation (n = 10). The serum expression of these miRNAs detected by quantitative real-time Polymerase Chain Reaction (qRT-RCR) was then compared between the 2 groups. Moreover, the correlation between the serum miRNAs and the prognostic indexes for ACLF was analyzed.The result of microarray analysis showed 9 miRNAs had different expression in liver tissues of ACLF patient compared with healthy control (upregulated: miRNA-130a, -21, -143, and -200a; downregulated: miRNA-486-5p, -192, -148a, -122, and -194). Unlike the expression profiles in liver tissue, 8 serum miRNAs except miRNA-194 were markedly upregulated in ACLF patients (P < 0.05). Remarkably, the serum expression of miRNA-130a and miRNA-486-5p was higher in recovered than nonrecovered ACLF patients (P < 0.05). Especially, the serum miRNA-130a was negatively correlated with international normalized ratio, prothrombin time, Model for End-Stage Liver Disease score, and positively correlated with prothrombin time activity. The AUC for recovered versus nonrecovered patients of miRNA-130a was 0.741 (P = 0.02).miRNA-130a might be a useful prognosis biomarker in patients with HBV

  13. Study on the risk factors of HBV infection among spouses of HBsAg carriers%乙型肝炎病毒表面抗原携带者配偶感染乙型肝炎危险因素调查

    Institute of Scientific and Technical Information of China (English)

    王青; 徐佳薇; 姚宁

    2014-01-01

    目的:了解乙型肝炎病毒(HBV )表面抗原(HBsAg )携带者配偶 HBV感染状况及影响因素,探讨其有效的防控策略,降低HBV性接触传播的风险。方法采用1∶2病例对照研究设计,运用ELISA对2005年全国乙型肝炎血清学调查中重庆市18~59岁人群HBsAg携带者的配偶、健康人群的配偶开展HBV血清学(HBsAg、抗-HBc、抗-HBs)检测。结果病例组(HB-sAg携带者)HBsAg阳性率(14.8%)明显高于对照组(健康人群的配偶,7.5%),P<0.01;女性配偶其HBsAg阳性率随结婚年限增加呈上升趋势;多因素分析发现,配偶为HBsAg携带者、不使用安全套是HBsAg感染的危险因素。结论 HBsAg携带者配偶感染HBV风险高;性接触传播中,女性较男性更容易感染乙型肝炎,提倡婚前体检,采取安全性行为或配偶及时接种乙型肝炎疫苗等有效措施以降低 HBV性接触传播。%Objective To investigate the risks of HBV infection among the spouses of HBV surface antigen (HBsAg)carriers and to find out effective control strategies on hepatitis B control and prevention .Methods To use case-control study(1∶2) including spouses of HBsAg carriers aged 18 -59 years-old from the nationwide sero-epidemiological survey for Hepatitis B in Chonqing province in 2005 ,and the spouses of the healthy(HBsAg negative persons)as the control groups ,adopt euzymelinked immunosor-bent assay(ELISA) to carry out the sero-epidemiological testing (HBsAg ,anti-HBc ,anti-HBs) for Hepatitis B .Results The posi-tive rate of HBsAgamong the spouses of HBsAg carriers (14 .8% ) was higher than the rate of spouse among the healthy (7 .5% ) , with difference statistically significant (P<0 .01) ,the positive rate of HBsAg in female spouse was uptrend as the marriage age grown ,multiple factor analysis found that the risks of HBV infection among the spouses were their spouse with HBsAg and without condom when the sexual

  14. Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HbsAg%重组质粒与重组蛋白共免疫诱导HBsAg特异性T细胞免疫抑制

    Institute of Scientific and Technical Information of China (English)

    杜小刚; 王军朋; 康有敏; 王肖; 赵干; 王宾

    2009-01-01

    [Objective] To explore a new therapeutic strategy against acute hepatitis B and fulminant hepatitis B, we studied effect of co-immunization with HBV DNA and HBsAg on the T cell proliferation reaction. [Methods] We immunized the BALB/ c mice with HBV DNA vaccine (pcDS2) plus HBsAg by intramuscular injection. The immunization was performed on week 0, 2 and 4. The anti-HBs(IgC)antibody titer, T lymphocyte proliferation reaction , and the expression of IL-10 and Foxp3 in CD3 + T cell were detected on week 6. [Results] The anti-HBs IgC titer induced by pcDS2 plus HBsAg group was higher than that induced by pcDS2, or HBsAg alone. Compared to mice immunized with pcDS2, or HBsAg alone, the stimulated index (SI) of T cell proliferation induced by the pcDS2 plus HBsAg group tested by MTT methods decreased. Besides, the immune suppression of T cell proliferation response induced by co-immunization group was further confirmed by flow cytometry. Finally, the expression of IL-10 and Foxp3 in CD3+ T cell was up-regulated in the co-immunization group significantly. [Conclusion] The co-immunization of HBV DNA vaccine and HBsAg can induce the humoral immune response, but cannot induce antigen specific T cell proliferation reaction. Besides, the immune suppression induced by co-immunization may be correlated with the expression of IL-10 and Foxp3.%[目的]为了探索治疗急性乙型肝炎和爆发性乙型肝的新策略,本研究将HBV DNA疫苗和相应抗原的蛋白质分子联合免疫小鼠,旨在探讨联合免疫对小鼠抗原特异性T细胞增殖反应的影响.[方法]我们将HBV DNA疫苗(pcDS2)和相应抗原蛋白质分子(HBsAg)联合免疫BALB/c小鼠;分别在第0、2和4周进行免疫,在第6周用ELISA方法检测抗-HBs IgG效价,MTr和流式细胞仪检测T细胞增殖反应及流式细胞仪检测细胞因子表达水平.[结果]pcDs2和HBsAg联合免疫组小鼠的抗-HBs水平显著提高;免疫小鼠的T细胞体外经HBsAg刺激后,联

  15. Pathogenic and clinical characteristics of hepatitis B virus (HBV) pre-existing mutations related to adefovir dipivoxil (ADV) among ADV treatment-naive patients with chronic HBV infection%阿德福韦酯相关位点预存病毒变异的病原学及临床特征分析

    Institute of Scientific and Technical Information of China (English)

    毛海芳; 胡爱荣; 蒋素文; 丁世雄; 翁彭剑; 胡耀仁; 梁晓岳

    2013-01-01

    Objective To understand the pathogenic and clinical characteristics of HBV pre-existing mutations related to ADV among ADV treatment-naive patients with chronic HBV infection. Methods The gene re-sistance mutations of HBV P region in 211 ADV treatment-naive patients were analyzed by gene sequencing, meanwhile the HBV genotypes as well as HBV serum markers and HBV DNA levels were also determined. All patients were divided into pre-existing mutation group and non-mutation group based on the above data. Results Out of 211 patients, 9 were found to have pre-existing mutations related to ADV and 4 of them had ill-formed usage of other antiviral drugs except for ADV. rtN238T mutation was found to be the dominant one (44. 44%) , and multi-sites mutation (55. 56%) and mutation co-existence with wild strain (88. 89%) were al-so popular. The constituent ratios of males and end-stage liver diseases in pre-existing mutation group were higher than those in non-mutation group (P = 0. 013, <0. 001) . The average age of patients was 45. 9± 10. 5 years in pre-existing mutation group and 35. 6±10. 2 years old in non-mutation group (t=2. 978, P = 0. 003) . There were no statistically significant differences of constituent ratio of HBeAg, HBV genotypes and HBV DNA levels between the two groups. Conclusions There may be .some cases with pre-existing muta-tions in ADV treatment-naive patients, and these pre-existing mutations may be related to ill-formed usage of antiviral drugs. Male patients and patients with longer history of HBV infection are more likely to have pre-ex-ist 年个 mutations. It is important for patients to accept normative antiviral treatment in order to prevent re-sistance and avoid salvage therapy.%目的 了解慢性乙型肝炎病毒(HBV)感染者抗病毒治疗前阿德福韦酯(ADV)相关位点预存病毒变异的发生情况以及临床特点.方法 采用基因测序的方法对211例拟行抗病毒治疗的慢性HBV感染者的血清样本进行P区病

  16. Breaking the external inducements of immune tolerance to HBV in hepatitis B patients%打破乙肝病毒感染免疫耐受的外部诱因研究

    Institute of Scientific and Technical Information of China (English)

    曾庆磊; 李春霞; 王霞; 徐光华

    2011-01-01

    Aim To investigate the breaking of external inducements of immune tolerance to HBV in hepatitis B patients. Methods The levels of HBV M、HBV DNA、ALT and so on in HBV carriers were determined and then check the quantity of to filtrate control group who were live in immune tolerant phase, and to filtrate control group who were in immune reactive phase, then ask the outside inducement of the patients respectively. Results The quantity of HBV DNA、HBeAg and ALT in control group was (7.58±2.46)×107copies/ml、188.11 ±.54.52PEI U/ml and 28.64±1S.11U/L respectively; and in case group was (3.67±1.79)×1O4copies/ml、69.18±32.72 PEI U/ml and 102.43±37.65U/L respectively.Drinking, tire, stay up late, drugs that damage liver were the main outside inducement for the break of the immune tolerant phase of HBV infected patients. Conclusions HBV carriers who were in immune tolerant phase should avoid these outside inducements in order to live longtime in this phase.%目的 探讨打破乙肝病毒(hepatitis B virus,HBV)感染免疫耐受的外部诱因.方法 收集HBV携带者进行HBV血清学标志物(HBV M)定量、HBV DNA定量、肝功能等检测,筛分免疫耐受HBV感染者(对照组)和免疫再活动HBV感染者(病例组),详细询问两组间可能存在不同的外部诱固.结果 对照组HBV DNA定量为(7.58±2.46)×107copies/ml,HBeAg定量为(188.11+54.52)PEI U/ml,ALT为(28.64±15.11)U/L;病例组HBV DNA定量为(3.67±1.79)×104copies/ml,HBeAg定量为(69.18±32.72)PEI U/ml,ALT为(102.43±37.65)U/L.发现饮酒、劳累、熬夜、损肝药物等是打破免疫耐受的外部诱因(P<0.01).结论 处于免疫耐受期的HBV携带者如避免饮酒、劳累、熬夜、损肝药物等因素的干扰,或可较长时间的停留在免疫耐受期.

  17. A 3' UTR SNP in COL18A1 is associated with susceptibility to HBV related hepatocellular carcinoma in Chinese: three independent case-control studies.

    Directory of Open Access Journals (Sweden)

    Xiaopan Wu

    Full Text Available BACKGROUND: Accumulated evidences indicate that single nucleotide polymorphisms (SNP in angiogenesis and tumorigenesis related genes are associated with risk of Hepatocellular carcinoma (HCC. COL18A1 encodes the precursor of endostatin, which is a broad-spectrum angiogenesis inhibitor, and we speculate that SNPs in COL18A1 may be associated with susceptibility to HCC. METHODS AND FINDINGS: We carried out a 2-stage association study in 3 independent case-control groups in a total of 1067 chronic hepatitis B (CHB patients and 808 hepatitis B virus (HBV related HCC patients in Han Chinese. Four SNPs which can represent all potential functional SNPs with MAF>0.1 recorded in HapMap database were genotyped using TaqMan methods. Levels of total COL18A1 mRNA were also examined using quantitative real-time RT-PCR. We found that rs7499 located in 3'-UTR to be strongly associated with HBV related HCC (P(combined = 0.0000005, OR = 0.72, 95%CI = 0.63-0.82. COL18A1 mRNA expression was significantly decreased as the disease progressed (P = 0.000026. CONCLUSION: These findings indicate that COL18A1 rs7499 may contribute to the risk of HCC in Han Chinese.

  18. Inter-observer variability in histopathological assessment of liver biopsies taken in a pediatric open label therapeutic program for chronic HBV infection treatment

    Institute of Scientific and Technical Information of China (English)

    Marek Woynarowski; Joanna Cielecka-Kuszyk; Andrzej Ka(l)u(z)y(n)ski; Aleksandra Omulecka; Maria Sobaniec-(L)otowska; Julian Stolarczyk; Wojciech Szczepa(n)ski

    2006-01-01

    AIM: To our knowledge, the inter-observer variability of the liver biopsy findings in HBV-infected children have not been studied as yet. Hence, we aimed to compare different pathologist's assessment of grading and staging in liver biopsies obtained from children prior to interferon treatment.METHODS: We collected 920 biopsies from 11 medical centers. The biopsies were independently reviewed by 6 pathologists from academic centers who assessed Batts-Ludwig score for grading and staging. Satisfactory agreement among observers was defined as at least 60% of observers having the same opinion. Satisfactory dispersion between maximal and minimal score for the same biopsy specimen was defined as a maximum 1 point.RESULTS: Satisfactory inter-observer agreement for grading was obtained in 51.6% and for staging in 75.7% of biopsies. Satisfactory dispersion for grading scores was observed in 44.5% and for staging in 72.7% of cases.CONCLUSION: Our study demonstrates that: (1)pathologists differ in their assessment of grading and staging of liver biopsies; (2) inter-observer variability for staging is lower than that for grading; and (3) regardless of the inter-observer variability of assessments, the majority of children with chronic HBV infection have mild to moderate inflammation and mild to moderate fibrosis.

  19. Patient with hepatocellular carcinoma related to prior acute arsenic intoxication and occult HBV: Epidemiological, clinical and therapeutic results after 14 years of follow-up

    Science.gov (United States)

    Casanovas-Taltavull, Teresa; Ribes, Josepa; Berrozpe, Ana; Jordan, Sara; Casanova, Aurora; Sancho, Concha; Valls, Carles; Bosch, F Xavier

    2006-01-01

    Little is known about the long-term survivors of acute arsenic intoxication. We present here a clinical case report of a man with chronic hepatitis B virus (HBV) infection who developed hepatocellular carcinoma four years after acute arsenic poisoning. HBsAg was detected in serum in 1990 when he voluntarily donated blood. In 1991, the patient suffered from severe psychological depression that led him to attempt suicide by massive ingestion of an arsenic-containing rodenticide. He survived with polyneuropathy and paralysis of the lower limbs, and has been wheelchair-bound since then. During participation in a follow-up study conducted among HBV carriers, abdominal ultrasound detected a two-centimeter liver mass consistent with hepatocellular carcinoma. The tumor was confirmed by computed tomography (CT) and magnetic resonance image (MRI). Because of his significant comorbidity, the patient received palliative treatment with transarterial lipiodol chemoembolization (TACE) on three occasions (1996, 1997 and 1999). At his most recent visit in May 2005, the patient was asymptomatic, liver enzymes were normal and the tumor was in remission on ultrasound. PMID:16610011

  20. Prediction of hepatocellular carcinoma risk in chronic hepatitis B and C: review of findings in REVEAL-HBV/HCV study%乙型及丙型肝炎患者发生肝细胞癌的风险预测:REVEAL-HBV/HCV研究的回顾

    Institute of Scientific and Technical Information of China (English)

    杨怀壹; 李美璇; 陈建仁

    2011-01-01

    乙型肝炎病毒(HBV)及丙型肝炎病毒(HCV)的慢性感染是肝细胞癌(HCC)的主要致病原因.全球约有3亿5千万人为HBV的慢性感染者;HCV慢性感染者则有2亿人.全球每年约有50万人死于乙型肝炎引起的HCC,另有25万人死于丙型肝炎引起的HCC.乙型肝炎慢性感染者,其血中HBV DNA及ALT持续处于高水平是HCC最重要的预测因子.其他的危险因子还包括HBV C基因型、HBV基础核心促进子A1762T/G1764A双突变、男性、老年、肝癌家族史、酗酒习惯、以及与HCV或人类免疫不全病毒的合并感染等.根据REVEAL-HBV研究的资料,我们发展出简单易用的列线图,可利用非侵入性的临床特征准确地预测慢性乙型肝炎患者发生HCC的风险.丙型肝炎慢性感染患者发生HCC最重要的预测因子包括高血中HCV RNA水平、高ALT水平、HCV基因型以及老年等.REVEAL-HCV研究案例中,与HCV RNA水平低于检测范围且低ALT水平者相比,HCV RNA可测得、高ALT水平且感染第一型病毒的案例具有最高的HCC发生风险,其多变项调整后的风险比值(95%CI)为21.87(5.09~93.95),这些发现对于慢性丙型肝炎的临床处置具有重要的意义.%Both hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes of hepatocellular carcinoma (HCC).An estimated 350 million people worldwide are living with chronic HBV infection, and 200 million with chronic HCV infection.Each year, an estimated 500 000 people die of HCC caused by chronic HBV infection, and another 200 000 HCC cases caused by chronic HCV infection.The most important predictors of HCC risk in persons who have chronic HBV infection are persistently elevated serum levels of HBV DNA and alanine aminotransferase (ALT).Other HCC risk predictors for chronic hepatitis B patients include HBV genotype C infection, HBV basal core promoter A1762T/G1764A mutants, male sex, older age, family HCC history, habitual alcohol consumption, and co-infection with

  1. Establishment and detection of HBV transgenic mice with YMDD mutation%YMDD突变株HBV转基因小鼠的制备及检测

    Institute of Scientific and Technical Information of China (English)

    尤玉琴; 陈阳述; 刘光泽; 杨富强; 陈媚娟; 李秀梅; 周军辉; 孔祥平

    2011-01-01

    Objective To establish the hepatitis B virus (HBV) transgenie mice with YMDD mutation, and provide an animal model for research of HBV prevention and therapeutic approach. Methods 1. 3 copies HBV genome containing YMDD mutation associated with lamivudine resistance was injected into the zygote of FVB/N female mice by microinjection. Integration and passage of exogenous gene in transgenie mice was confirmed by PCR, The expression of HBsAg in liver and kidney tissues in transgenie mice was identified by ELISA and immunohistochemistry. Results A total of 3401 zygotes were injected and 269 Fo pups were bora PCR analysis indicated that 33 out of 269 pups were positive, and the integrating rate of exogenous gene was 12.3% in Fo. Fluorescent quantitative PCR showed that HBV DNA was weakly positive in serum samples in 9 transgenie mice, less than 103 copies/ml The expression of HBsAg in transgenie mice was observed in liver and kidney tissues by immunohistochemistry, and it was higher in kidney than in liver. The target gene was detected by PCR in 27.6% of 47 F1 offsprings. The expression of HBsAg could be observed in liver and kidney tissues in F1, which was similar to that in F0. Conclusion 1. 3 copies HBV transgenie mice model containing YMDD mutation associated with lamivudine resistance is successfully produced by microinjection, and HBsAg expression can be transmitted through germline cells.%目的 建立YMDD耐药突变株HBV转基因小鼠,为乙肝防治研究提供转基因动物模型.方法 采用受精卵显微注射法,将带有YMDD突变的对拉米夫定有耐药性的1.3拷贝HBV基因注入FVB/N单细胞受精卵的原核内,制备YMDD耐药突变株HBV转基因小鼠.采用PCR检测外源基因的整合和传代情况,采用ELISA和免疫组化等方法 检测HBsAg在肝、肾中的复制和表达情况.结果 注射受精卵3401枚,产269只F0代仔鼠,PCR阳性33只,外源基因的整合率12.3%.9只转基因鼠血清HBVDNA弱阳性,拷贝数低于103

  2. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

    OpenAIRE

    Kovari, Helen; Sabin, Caroline A; Ledergerber, Bruno; Ryom, Lene; Worm, Signe W; Smith, Colette; Phillips, Andrew; Reiss, Peter; Fontas, Eric; Petoumenos, Kathy; De Wit, Stéphane; Morlat, Philippe; Lundgren, Jens D.; Weber, Rainer

    2013-01-01

    Background. Liver diseases are leading causes of death in HIV-positive persons since the widespread use of combination antiretroviral treatment (ART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus co-infections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality.Methods. All patients of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study without HCV or HBV co-infection were prospectively f...

  3. Analysis of primary carcinoma of the liver of two semi hepatitis B and anti-HCV test results%探析原发性肝癌乙肝两对半及抗-HCV检测结果

    Institute of Scientific and Technical Information of China (English)

    任爱英

    2015-01-01

    目的:对原发性的肝癌乙肝两对半和抗-HCV 的检测结果进行临床分析,探讨乙型肝炎(HBV)和丙型肝炎(HCV)的感染模式和原发性肝癌之间的关系。方法:收治原发性的肝癌乙肝患者130例,于早晨抽取患者空腹静脉血5 mL,并采用酶联免疫法对乙肝两对半和抗-HCV 进行检测,观察检测结果。结果:130例患者中,HBV 的感染率96.15%(112/130),HCV 的感染率16.92%(22/130),HBV 与 HCV 的双重感染率10.77%(14/130)。结论:HBV 的感染很有可能是造成原发性的肝癌发生的主要因素,并对于HBV和HCV的双重感染也必须加以重视。%Objective:To analyze the primary carcinoma of the liver of two semi hepatitis B and anti -HCV test results,discussing the relationship between infection mode of Hepatitis B virus(HBV)and hepatitis C virus(HCV)and the primary hepatocellular carcinoma.Methods:130 patients with primary liver cancer Hepatitis B were selected,in the morning drawing fasting blood 5 mL, and using ELISA for hepatitis B two pairs of semi-detection and anti-HCV,observing the test results.Results:Among the 130 patients,HBV infection rate of 96.15%(112/130),HCV infection rate of 16.92%(22/130) HBV and HCV double infection rate of 10.77%(14/130).Conclusion:HBV infection is likely to be the main factors contributing to the occurrence of primary liver cancer, and for HBV and HCV co-infection must also be valued.

  4. Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory.

    Science.gov (United States)

    Lowe, Christopher F; Merrick, Linda; Harrigan, P Richard; Mazzulli, Tony; Sherlock, Christopher H; Ritchie, Gordon

    2016-01-01

    Sanger sequencing or DNA hybridization have been the primary modalities for hepatitis B (HBV) resistance testing and genotyping; however, there are limitations, such as low sensitivity and the inability to detect novel mutations. Next-generation sequencing (NGS) for HBV can overcome these limitations, but there is limited guidance for clinical microbiology laboratories to validate this novel technology. In this study, we describe an approach to implementing deep pyrosequencing for HBV resistance testing and genotyping in a clinical virology laboratory. A nested PCR targeting the pol region of HBV (codons 143 to 281) was developed, and the PCR product was sequenced by the 454 Junior (Roche). Interpretation was performed by ABL TherapyEdge based on European Association for the Study of the Liver (EASL) guidelines. Previously characterized HBV samples by INNO-LiPA (LiPA) were compared to NGS with discordant results arbitrated by Sanger sequencing. Genotyping of 105 distinct samples revealed a concordance of 95.2% (100/105), with Sanger sequencing confirming the NGS result. Resistance testing by NGS was concordant with LiPA in 85% (68/80) of previously characterized samples. Additional mutations were found in 8 samples, which related to the identification of low-level mutant subpopulations present at <10% (6/8). To balance the costs of testing for the validation study, reproducibility of the NGS was investigated through an analysis of sequence variants at loci not associated with resistance in a single patient sample. Our validation approach attempts to balance costs with efficient data acquisition. PMID:26537448

  5. 重组8型腺相关病毒介导HBV急性感染树鼩模型建立%Establishment of a tree shrew model of acute hepatitis B virus infection by transduction with a recombinant adeno-associated virus 8 carrying 1.3 copies of HBV genome

    Institute of Scientific and Technical Information of China (English)

    曾扬; 吴小红; 胡靓雅; 刘晨风; 于虹; 郭彦; 周勇; 孙世惠; 周育森

    2013-01-01

    目的 利用重组8型腺相关病毒介导1.3拷贝HBV基因组(1.3HBV,ayw亚型)在树鼩肝脏表达,建立HBV急性感染树鼩模型.方法 通过大腿内侧静脉注射将携带有1.3 HBV的重组8型腺相关病毒(recombinant adeno-associated virus 8,rAAV8-1.3HBV)导入树鼩肝脏,通过ELISA检测树鼩血清中HBsAg、HBeAg、HBsAb、HBeAb、HBcAb,荧光定量PCR检测树鼩肝脏和血清中HBV DNA,全自动生化分析仪检测血清中ALT水平,并观察感染后肝脏的病变情况.结果 HBV感染主要血清标志物1~2周内均检测阳性;30 d后肝组织仍可检测到病毒抗原阳性细胞;55 d时肝组织HBV DNA拷贝数仍可达到104~105;树鼩血清中HBV DNA拷贝数持续一个月高于正常组;肝组织炎细胞略增多,血清ALT水平持续升高.结论 rAAV8所携带的HBV基因组高效专一导入树鼩肝细胞并复制表达,成功建立HBV急性感染树鼩模型,为进一步探索rAAV8树鼩慢性感染模型打下一定的基础.%Objective To establish a tree shrew model of acute hepatitis B virus infection by injection of a recombinant adeno-associated virus 8 vector carrying 1.3 copies of HBV genome (ayw subtype) (rAAV8-1.3 HBV)into the liver of tree shrews.Methods Serum and liver tissues were collected at indicated times after i.v.injection of rAAV8-1.3 HBV into the tree shrews.The HBsAg,BeAg,HBsAb,HBeAb,HBcAb,ALT and HBV virus load were examined by ELISA and real-time PCR,respectively.The expression of HBcAg and pathological changes in the liver were also observed after the rAAV8-1.3 HBV infection.Results Markers of serum HBV were all positive 2 weeks after and HBcAg-positive hepatocytes were even detected in the liver 55 days after rAAV8-1.3 HBV injection.The copies of HBV DNA in liver reached 104-105 at 55 days after rAAV8-1.3HBV injection.Serum HBV DNA could be detected for over one month.Mild pathological changes with elevated ALT were observed after rAAV8-1.3 HBV injection.Conclusions A tree shrew

  6. Development of an English as a second language curriculum for hepatitis B virus testing in Chinese Americans.

    Science.gov (United States)

    Coronado, Gloria D; Taylor, Vicky; Acorda, Elizabeth; Hoai Do, H; Thompson, Beti

    2005-12-15

    Chinese Americans are at disproportionately high risk of liver cancer. A major risk factor for liver cancer in Asia is infection with hepatitis B virus (HBV): Approximately 80% of liver cancers are linked to HBV, and chronic carriers of HBV are > 100 times more likely to develop liver cancer compared with noncarriers. However, many adults, particularly those who have immigrated to the U.S., remain untested and therefore unvaccinated or unmonitored for the disease. Chinese Americans are mostly foreign born, and more recent arrivals face multiple social and health challenges. Many require special attention from public health professionals because of low levels of acculturation and difficulties learning English. It has long been established that an English as a Second Language (ESL) curriculum can teach immigrant adults and their family's important life skills, such as job training and citizenship. The authors report on their plans to develop and pilot test a culturally appropriate curriculum that will motivate Chinese ESL students to obtain a blood test for the detection of the HBV. PMID:16270314

  7. 乙肝疫苗联合乙肝免疫球蛋白预防HBeAg阴性的HBV感染母亲母婴传播的效果评估%Evaluation for Effects of Routine Administration of Hepatitis B Vaccine and Hepatitis B Immunoglobulin on Preventing Mother-to-Infant Transmission of HBV-infected Mothers with Negative HBeAg

    Institute of Scientific and Technical Information of China (English)

    芮燕京; 宋文英; 陈洁; 周乙华; 胡娅莉; 王志群

    2013-01-01

    目的:评价乙型肝炎(简称乙肝)疫苗联合乙肝免疫球蛋白(HBIG)常规免疫预防措施在阻断HBeAg阴性的乙肝病毒(HBV)感染母亲母婴传播的临床效果,观察分娩方式和喂养方式对HBV母婴传播的影响.方法:对2004年1月至2012年3月在本院分娩的231例HBsAg阳性但HBeAg阴性母亲及其252例儿童随访,记录母亲孕期HBIG使用情况、分娩方式、子女出生后免疫预防措施和喂养方式,并采血检测相关指标;199例儿童曾检测脐血HBV标志物.结果:16.08%儿童脐血HBsAg阳性,但所有252例儿童随访时(3.3±2.3岁)HBsAg和抗-HBc均阴性,抗-HBs阳性率74.21%.孕期使用HBIG和未使用HBIG母亲的子女抗-HBs阳性率分别为65.22%和73.33%(x2=1.797,P>0.05).剖宫产组和自然分娩组母亲的儿童抗-HBs阳性率分别为76.85%和72.22%(x2=0.69,P>0.05).111例儿童为母乳喂养,65例人工喂养,76例混合喂养,抗-HBs阳性率分别68.47%、78.46%和78.95%(x2=3.417,P>0.05).结论:HB-sAg阳性但HBeAg阴性孕妇的子女经正规免疫预防后,几乎无HBV感染;脐血HBsAg阳性不能确定母婴感染;孕妇孕晚期使用HBIG、分娩和喂养方式对HBV母婴传播和新生儿对乙肝疫苗的抗体应答无影响.%Objective:To investigate the effect of hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) in routine application to prevent mother-to-infant transmission of HBV-infected mothers with negative HBeAg,and to clarify whether HBIG in pregnancy women,different delivery modes,or feeding practices have an impact on perinatal HBV infection.Methods:Totally 231 HBsAg-positive with HBeAg-negative mothers and their 252 children,born January 2004 to March 2012,were followed-up.Relevant information such as administration of hepatitis B vaccine and HBIG in infants,delivery modes and feeding practices was collected.HBV serologic markers in cord blood were tested in 199 newborn infants.Results:Children's average age was 3.3

  8. Frequency and genotypic distribution of GB virus C (GBV-C among Colombian population with Hepatitis B (HBV or Hepatitis C (HCV infection

    Directory of Open Access Journals (Sweden)

    Carrilho Flair J

    2011-07-01

    Full Text Available Abstract Background GB virus C (GBV-C is an enveloped positive-sense ssRNA virus belonging to the Flaviviridae family. Studies on the genetic variability of the GBV-C reveals the existence of six genotypes: genotype 1 predominates in West Africa, genotype 2 in Europe and America, genotype 3 in Asia, genotype 4 in Southwest Asia, genotype 5 in South Africa and genotype 6 in Indonesia. The aim of this study was to determine the frequency and genotypic distribution of GBV-C in the Colombian population. Methods Two groups were analyzed: i 408 Colombian blood donors infected with HCV (n = 250 and HBV (n = 158 from Bogotá and ii 99 indigenous people with HBV infection from Leticia, Amazonas. A fragment of 344 bp from the 5' untranslated region (5' UTR was amplified by nested RT PCR. Viral sequences were genotyped by phylogenetic analysis using reference sequences from each genotype obtained from GenBank (n = 160. Bayesian phylogenetic analyses were conducted using Markov chain Monte Carlo (MCMC approach to obtain the MCC tree using BEAST v.1.5.3. Results Among blood donors, from 158 HBsAg positive samples, eight 5.06% (n = 8 were positive for GBV-C and from 250 anti-HCV positive samples, 3.2%(n = 8 were positive for GBV-C. Also, 7.7% (n = 7 GBV-C positive samples were found among indigenous people from Leticia. A phylogenetic analysis revealed the presence of the following GBV-C genotypes among blood donors: 2a (41.6%, 1 (33.3%, 3 (16.6% and 2b (8.3%. All genotype 1 sequences were found in co-infection with HBV and 4/5 sequences genotype 2a were found in co-infection with HCV. All sequences from indigenous people from Leticia were classified as genotype 3. The presence of GBV-C infection was not correlated with the sex (p = 0.43, age (p = 0.38 or origin (p = 0.17. Conclusions It was found a high frequency of GBV-C genotype 1 and 2 in blood donors. The presence of genotype 3 in indigenous population was previously reported from Santa Marta region in

  9. 原发性肝癌患者T淋巴细胞亚群变化及其与CTCs、TTV及HBV-DNA的关系%Changes of T lymphocyte subsets and its relationship with CTCs, TTV and HBV-DNA in patients with primary hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    陈佳佳; 万磊; 刘建军; 阚和平

    2016-01-01

    [Abstract]Objective To investigate the changes of T cell immune function in patients with hepatocellu-lar carcinoma(HCC)and its relationship with circulating tumor cells (CTCs), total tumor volume (TTV) and hepatitis B virus (HBV-DNA). Methods Peripheral blood of 45 patients with HCC was collected, and pe-ripheral blood of 45 normal adults was taken as control. CD3+T cells, CD4+T cells and CD4+/CD8+ratio were determined by flow cytometry. CTCs in the blood were detected by CanPatrolTM. The maximum diameter of tu-mor, quantitative hepatitis B virus (HBV-DNA) and other clinical pathological parameters were collected. The HCC patients were divided into high level group and low level group according to the rate of CD4+/CD8+, CTCs, TTV and HBV-DNA level. Results Compared with the healthy control, the percentage of CD3+T cells, CD4+T cells and the rate of CD4+/CD8+in HCC patients were significantly decreased(P0.05). The CD4+/CD8+ratio was positively correlated with TTV (P0.05). Conclusions The immune function of T cells in patients with HCC was disor-dered, and the immune function of T cells was significantly decreased. The immune function of T cell had a close relationship with CTCs and TTV in patients with HCC.%Objective To investigate the changes of T cell immune function in patients with hepatocellu-lar carcinoma(HCC)and its relationship with circulating tumor cells (CTCs), total tumor volume (TTV) and hepatitis B virus (HBV-DNA). Methods Peripheral blood of 45 patients with HCC was collected, and pe-ripheral blood of 45 normal adults was taken as control. CD3+T cells, CD4+T cells and CD4+/CD8+ratio were determined by flow cytometry. CTCs in the blood were detected by CanPatrolTM. The maximum diameter of tu-mor, quantitative hepatitis B virus (HBV-DNA) and other clinical pathological parameters were collected. The HCC patients were divided into high level group and low level group according to the rate of CD4+/CD8+, CTCs, TTV and HBV-DNA level. Results Compared

  10. Hepatitis B core antibody testing in Indian blood donors: A double-edged sword!

    Directory of Open Access Journals (Sweden)

    R N Makroo

    2012-01-01

    Full Text Available Background: Until lately, anti-HBc antibodies were considered an effective marker for occult Hepatitis B virus (HBV infection and have served their role in improving blood safety. But, with the development of advanced tests for HBV DNA detection, the role of anti-HBc in this regard stands uncertain. Materials and Methods: Anti-HBc and HBsAg ELISA and ID-NAT tests were run in parallel on donor blood samples between April 1, 2006 and December 31, 2010 at the Department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi. A positive ID-NAT was followed by Discriminatory NAT assay. Results: A total of 94 247 samples were tested with a total core positivity rate of 10.22%. We identified nearly 9.17% of donors who were reactive for anti-HBc and negative for HBsAg and HBV DNA. These are the donors who are potentially non-infectious and may be returned to the donor pool. Conclusion: Although anti HBc testing has a definite role in improving blood safety, centers that have incorporated NAT testing may not derive any additional benefit by performing anti-HBc testing, especially in resource-limited countries like ours.

  11. The results of nucleic acid testing in remunerated and non-remunerated blood donors in Lithuania

    Science.gov (United States)

    Kalibatas, Vytenis; Kalibatienė, Lina

    2014-01-01

    Background In Lithuania, governmentally covered remuneration for whole blood donations prevails. Donors may choose to accept or reject the remuneration. The purpose of this study was to compare the rate of nucleic acid testing (NAT) discriminatory-positive markers for human immunodeficiency virus-1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV) in seronegative, first-time and repeat, remunerated and non-remunerated donations at the National Blood Centre in Lithuania during the period from 2005 to 2010. Materials and methods All seronegative whole blood and blood component donations were individually analysed by NAT for HIV-1, HBV and HCV. Only discriminatory-positive NAT were classified. The prevalence of discriminatory-positive NAT per 100,000 donations in the donor groups and the odds ratios comparing the remunerated and non-remunerated donations were determined. Results Significant differences were observed for HBV NAT results: 47.42 and 26.29 per 100,000 remunerated first-time and repeat donations, respectively, compared to 10.6 and 3.58 per 100,000 non-remunerated first-time and repeat, seronegative donations, respectively. The differences were also significant for HCV NAT results: 47.42 and 51.99 for remunerated first-time and repeat donations, respectively, compared to 2.12 and 0 per 100,000 non-remunerated first-time and repeat, seronegative donations, respectively. No seronegative, discriminatory-positive NAT HIV case was found. The odds of discriminatory HBV and HCV NAT positive results were statistically significantly higher for both first-time and repeat remunerated donations compared to first-time and repeat non-remunerated donations. Discussion First-time and repeat remunerated seronegative donations were associated with a statistically significantly higher prevalence and odds for discriminatory-positive HBV and HCV NAT results compared to first-time and repeat non-remunerated donations at the National Blood Centre in Lithuania. PMID

  12. Association of ABO and Rh blood groups to HBV, HCV infections among blood donors in a blood bank of tertiary care teaching hospital in Southern India: A retrospective study

    Directory of Open Access Journals (Sweden)

    Sreedhar Babu KV

    2015-07-01

    Conclusion: In this study conducted to determine the predominant blood group antigen and its association with HBV and HCV seroreactivity, there was no association between blood group antigens with these infections. [Int J Res Med Sci 2015; 3(7.000: 1672-1676

  13. Tagosodes orizicolus (Muir, 1926), vector del "virus de la hoja blanca del arroz" (HBV) en la República Argentina (Homoptera-Delphacidae)

    OpenAIRE

    Mariani, Roxana; Ana M. M. de Remes Lenicov

    2001-01-01

    La especie Tagosodes orizicolus es el vector natural más importante del "Virus de la Hoja Blanca" (HBV) del arroz (Oryza sativa) en América Central y del Sur; esta enfermedad virósica sólo ataca a gramíneas y produce grandes pérdidas en los cultivos de arroz. En esta contribución se enuncian e ilustran los caracteres diagnósticos morfológicos más relevantes y se aportan nuevos datos acerca de la distribución geográfica en la República Argentina y países limítrofes y las plantas hospedantes....

  14. Development of an in-House TaqMan Real-Time PCR-Based Method to Detect Residual Host Cell DNA in HBV Vaccine.

    Science.gov (United States)

    Paryan, Mahdi; Khodayar, Mana; Kia, Vahid; Mohammadi-Yeganeh, Samira; Kaghazian, Hooman

    2016-06-01

    Biological therapeutic products such as recombinant hepatitis B virus (HBV) vaccine, produced by microbial fermentation in complex media, should be evaluated for host cell DNA contamination in purification steps. Eliminating these contaminations increases the efficacy of the vaccine and decreases its side effects. The objective of the present study is to trace the residual host cell DNA (HCD) in recombinant HBV vaccine by developing a TaqMan Real-Time PCR method which is more sensitive, specific, and reproducible than traditional methods such as Picogreen analysis and Threshold DNA assay. Primers and a probe were designed for the most highly conserved regions of Pichia pastoris genome. To determine the specificity of the assay, in addition to performing a BLAST for the primers and the probe in NCBI nucleotide database, 20 different human genomes and 8 bacterial and viral genomes were used. Moreover, serial dilutions of plasmids, from 10(2) to 10(7) copies/μL (from 0.00064 to 6.4 pg/μL), were prepared to find the sensitivity and the limit of detection (LOD) of the assay. Using 28 different genome samples, the specificity of the assay was determined to be 100 %. In addition, the sensitivity and LOD of the method was 0.39 × 10(-5) pg/μL. Moreover, the reproducibility of the assay based on intra- and inter-assay was 1.03 and 1.06 %, respectively. Considering the suitable specificity and sensitivity, ease of use, relatively low cost, and rapidity of the assay, it can be a reproducible and sensitive method to examine recombinant vaccines for P. pastoris residual DNA. PMID:26861732

  15. Identification of a natural mutant of HBV X protein truncated 27 amino acids at the COOH terminal and its effect on liver cell proliferation

    Institute of Scientific and Technical Information of China (English)

    Hang ZHANG; Xiao-dong ZHANG; Chang-liang SHAN; Nan LI; Xuan ZHANG; Xue-zhi ZHANG; Fu-qing XU; Shuai ZHANG; Li-yan QIU; Li-hong YE

    2008-01-01

    Aim:To identify mutants of the hepatitis B virus (HBV) X (HBx) gene and inves-tigate the effect of the natural mutant on liver cell proliferation. Methods:We identified natural mutants of the HBx gene from 188 sera and 48 tissues of Chinese patients infected with HBV by PCR, respectively. Based on the identification of the mutants ofHBx gene, we cloned the fragments of the mutants into the pcDNA3 vector. The biological activities of the mutants were investigated. Results:We identified a natural mutant of the HBx gene with deletion from 382 to 401 base pairs from 3 sera out of 188 patients, which resulted in the expression deletion of the HBx protein from the 128th amino acid at the COOH terminal. The similar mutant with deletion from 382 base pair at the COOH terminal was identified from 5 cases of genomes out of 48 hepatocellular carcinoma tissues. Regarding the biological activities of the mutant, we found that the mutant of the HBx protein failed to induce apoptosis by transient transfection, but promoted proliferation of human liver immortalized L-O2 cells by stable transfection, compared with the wild-type HBx protein. The data showed that the proliferation of the mutant stably-trans-fected L-O2-X-Sera cells and fragment stably-transfected L-O2-X△127 cells was enhanced by the BrdU incorporation assay and flow cytometry analysis. Lu-ciferase reporter gene assay showed that the transcriptional activities of NF-kB, survivin, and human telomerase reverse transcriptase were upregulated, and West-ern blot analysis revealed that the expression levels of c-Myc and proliferating cell nuclear antigen (PCNA) were upregulated in the cells. Conclusion:Our find-ings suggest that the natural HBx mutant truncated 27 amino acids at the COOH terminal promotes cell proliferation.

  16. DNA疫苗诱导健康小鼠抗-HBs产生的实验研究%Humoral immune response induced by HBV DNA vaccine in healthy mice

    Institute of Scientific and Technical Information of China (English)

    杨富强; 陈光明; 何晓嫱; 吴乐园; 谢宗法; 黄英; 李治刚

    2001-01-01

    目的 初步评价DNA疫苗诱导健康小鼠体液免疫应答效果。方法 应用基因重组技术构建编码乙型肝炎病毒(HBV)中蛋白(preS2+S)及人白细胞介素融合蛋白(FP)基因真核表达质粒(pS2.S/pFP),按不同剂量一次性及联合应用肌内注射免疫小鼠。结果 HBV DNA疫苗(pS2.S)高(100μg/只)、中(50μg/只)、低(10 μg/只)三组剂量一次性免疫健康C57BL/6小鼠均能在2周诱导抗HBs产生,抗体效价随时间延长而增长。血清抗体水平比较,高剂量组(82.9±30 0)mIU/ml较中剂量组(42.2±25 6)mIU/ml、低剂量组(24.6±7.5)mIU/ml差异分别具显著性(P<0.05)及非常显著性(P<0.01)。以后的4、8、14周高、中剂量组间差别缩小,但二者较低剂量组差异均具非常显著性(P<0.01)。低剂量组(1Oμg/只)的pS2-S与pFP联合免疫,于2、4周诱导组内全部(100%)健康小鼠抗体产生,而相同剂量的pS2.S+pcDNA3.1组仅分别为60%及80%。联合免疫组2周血清抗体水平(115 6±21 6)mIU/ml较pS2.S+pcDNA3.1组(21.0±7 7)mIU/ml差异有显著性(P<0 05)。结论 本室构建的HBV DNA疫苗能有效诱导正常小鼠体液免疫应答;联合接种白细胞介素融合蛋白质粒能有效增强DNA疫苗的免疫效果。%Objective To evaluate the humoral immunity induced by HBV DNA vaccine in healthy mice. Method Two eukaryotic expressed plasmids namely pS2. S and pFP, encoding HBV middle protein ( preS2 + S) or cytokine fusion protein by genetic recombinant technique and immunized the healthy mice by direct intramuscular injection. Results In the healthy C57BL/6 mice, serum anti-HBs appeared at the 2nd week after DNA vaccination, and quantitative comparison of the serum Ab level revealed a significant (P <0.05 ) or very significant( P<0.01 ) difference between the high dose group(82.9 ± 30.0) mIU/ml and the median dose(42.2 ± 25.6) mIU/ml or the lower dose (24.6± 7.5) mIU/ml respectively. During the long term follow

  17. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

    Directory of Open Access Journals (Sweden)

    Thomas H King

    Full Text Available Chronic hepatitis B infection (CHB is characterized by sub-optimal T cell responses to viral antigens. A therapeutic vaccine capable of restoring these immune responses could potentially improve HBsAg seroconversion rates in the setting of direct acting antiviral therapies. A yeast-based immunotherapy (Tarmogen platform was used to make a vaccine candidate expressing hepatitis B virus (HBV X, surface (S, and Core antigens (X-S-Core. Murine and human immunogenicity models were used to evaluate the type and magnitude of HBV-Ag specific T cell responses elicited by the vaccine. C57BL/6J, BALB/c, and HLA-A*0201 transgenic mice immunized with yeast expressing X-S-Core showed T cell responses to X, S and Core when evaluated by lymphocyte proliferation assay, ELISpot, intracellular cytokine staining (ICS, or tumor challenge assays. Both CD4+ and CD8+ T cell responses were observed. Human T cells transduced with HBc18-27 and HBs183-91 specific T cell receptors (TCRs produced interferon gamma (IFNγ following incubation with X-S-Core-pulsed dendritic cells (DCs. Furthermore, stimulation of peripheral blood mononuclear cells (PBMCs isolated from CHB patients or from HBV vaccine recipients with autologous DCs pulsed with X-S-Core or a related product (S-Core resulted in pronounced expansions of HBV Ag-specific T cells possessing a cytolytic phenotype. These data indicate that X-S-Core-expressing yeast elicit functional adaptive immune responses and supports the ongoing evaluation of this therapeutic vaccine in patients with CHB to enhance the induction of HBV-specific T cell responses.

  18. Drinking in male HBV carriers in the outpatient department%门诊男性乙型肝炎病毒携带者饮酒情况的调查

    Institute of Scientific and Technical Information of China (English)

    邹艳波; 蒋冬梅; 曾烂漫

    2012-01-01

    目的:了解门诊男性乙肝病毒携带者饮酒情况、特点及与情绪的关系,为饮酒干预提供依据.方法:应用一般情况调查表、酒精使用障碍筛查量表(AUDIT)、焦虑自评量表(SAS)、抑郁自评问卷(BDI)对980例门诊男性乙肝病毒携带者进行问卷调查.结果:近1年有饮酒经历者544人,饮酒率为58.18%,其中适度饮酒354人(37.86%),危险及有害饮酒168人(17.97%),酒依赖22人(2.35%).在不同年龄、文化程度、职业、收入、症状组间,危险有害/酒依赖(AUDIT 7~26分)构成比存在差异(P<0.05).在AUDIT不同组间(适度、危险有害、酒依赖),酒依赖组SAS总分高于常模(35.95±11.55 vs 29.78±0.46,P=0.020);酒依赖组的SAS总分和BDI总分(35.95±11.55和10.45±8.95)明显高于适度饮酒组(29.65±7.97和6.35±5.65)和危险有害饮酒组(29.68±7.06和6.44±5.27).结论:年龄30~49岁、小学及以下/本科及以上文化程度、干部/专业人员、收入高、症状重的男性乙肝病毒携带者的危险有害/酒依赖(AUDIT 7~26分)构成比高.男性乙肝病毒携带者中酒依赖组焦虑和抑郁情绪明显高于适度饮酒组和危险有害饮酒组.%Objective: To understand the relation among drinking, characteristics and emotion in outpatient male carriers with hepatitis B virus (HBV), and to provide reference for alcohol intervention. Methods: We used alcohol use disorders identification test (AUDIT), self-rating anxiety scale (SAS), and Beck depression inventory (BDI) to investigate 980 male HBV carriers in the outpatient department. Results: The questionnaires were responded by 544 people with drinking experience for nearly a year (drinking rate 58.18%). The prevalence of moderate drinking was 37.8% (354 patients), hazardous and harmful drinking 17.97% (168 patients) and alcohol dependence 2.35% (22 patients). In groups with different ages, education levels, occupations, income and symptoms, the constituent ratio of the

  19. Evaluation of HBsAg, anti-HCV, anti-HIV and VDRL test results in blood donors

    OpenAIRE

    Deveci, Özcan; Tekin, Alicem; Günbay, Seda Sibel; Kılıç, Dilek; KAYGUSUZ, Sedat; Ağalar, Canan; Özer, Türkan Toka

    2011-01-01

    Objectives: The most frequently encountered complication in the transfusion of blood and blood products are transmitted infections from these products. Infections caused by hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) remain the leading most important health problems in the transfusion of blood and blood products worldwide. Therefore, screening tests such as HBsAg, anti-HCV, anti-HIV, and RPR or VDRL for Treponema pallidum are mandatory tests to loo...

  20. Clinical significance of detecting the serum pre-S1 antigen and HBV-DNA in patients with heptatitis B virus%乙型病毒性肝炎不同血清学模式前S1抗原、乙型肝炎病毒-DNA和肝功能指标的关系

    Institute of Scientific and Technical Information of China (English)

    刘敏; 李娜; 张云; 马骢

    2010-01-01

    目的 检测乙型肝炎病毒 (HBV)感染者不同血清学模式前S1抗原(pre-S1-Ag)、HBV-DNA和乙型肝炎抗原、抗体含量,结合血清肝功能(丙氨酸转氨酶ALT、天冬氨酸转氨酶AST)分析病毒性肝炎临床诊断、病情判断和预后.方法 用酶联免疫吸附试验(ELISA)检测94例HBV感染者血清中pre-S1-Ag和乙型肝炎抗原、抗体,用荧光定量-聚合酶联反应(FQ-PCR)方法检测HBV-DNA含量,用全自动生化分析仪检测血清ALT和AST指标.结果 HBsAg(+)、HBeAg(+)、HBcAb(+)模式的pre-S1-Ag检出率为79.4%,HBV-DNA检出率为97.1%,肝功能异常的为94.1%;HBsAg(+)